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Ac    acetyl 
AcOH    acetic acid 
ADME-Tox   absorption, distribution, metabolism, excretion, and toxicity 
ADU    Affective Disorders Unit 
APCI    atmospheric pressure chemical ionization 
AUC    area under the concentration-time curve 
BBB    blood brain barrier 
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Boc    tert-butoxycarbonyl 
BSA    bovine serum albumin 
Bu    butyl 
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cAMP   3',5'-cyclic adenosine monophosphate 
CDCl3   deuterated chloroform 
cGMP   3',5'-cyclic guanosine monophosphate 
CH2Cl2   dichloromethane 
CH3CN   acetonitrile 
CL    clearance 
Cmax    maximum drug concentration 
compd   compound 
COPD   chronic obstructive pulmonary disease 
c-Pr    cyclopropyl 
dba    dibenzylideneacetone 
DBU    1,8-diazabicyclo[5.4.0]undec-7-ene 
DDCL   Drug Discovery Chemistry Laboratories 
DIEA    N,N-diisopropylethylamine 
DMA    N,N-dimethylacetamide 
DME    1,2-dimethoxyethane 
DMF    N,N-dimethylformamide 
DMSO   dimethyl sulfoxide 
DPPA    diphenylphosphoryl azide 
dppf    1,1'-bis(diphenylphosphino)ferrocene 
DTT    dithiothreitol 
EDCI    1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EDTA   ethylenediaminetetraacetic acid 
ee    enantiomeric excess 
EGTA   ethylene glycol tetraacetic acid 
EHNA   erythro-9-(2-hydroxy-3-nonyl)adenine 
ER    efflux ratio 
ESI    electrospray ionization 
Et    ethyl 
EtMgBr   ethylmagnesium bromide 
Et3N    triethylamine 
Et2O    diethyl ether 
EtOAc   ethyl acetate 
EtOH    ethanol 
F    bioavailability 
Fcx    frontal cortex 
GCDC   glycochenodeoxycholate 
GDP    guanosine diphosphate 
gem    geminal 
Gln    glutamine 
Gly    glycine 
GPCR   G protein-coupled receptor 
GTP    guanosine triphosphate 
HATU   1-(bis(dimethylamino)methylene)-1H-1,2,3-triazolo[4,5-b]pyridinium- 
3-oxid hexafluorophosphate 
HBA    hydrogen bond acceptor 
HBD    hydrogen bond donor 
HCl    hydrogen chloride 
HIP    hippocampus 
His    histidine 
HLM    human liver microsomes 
HMBC   heteronuclear multiple bond correlation 
HOBt    1-hydroxybenzotriazole 
HOSA   hydroxylamine-O-sulfonic acid 
HPLC   high-performance liquid chromatography 
HTS    high throughput screening 
IBMX   3-isobutyl-1-methylxanthine 
IC50    50% inhibitory concentration 
Ile    isoleucine 
i-Pr    isopropyl 
i-Pr2O   diisopropyl ether 
iv    intravenous 
KHMDA   potassium hexamethyldisilazide 
KP    brain-to-plasma ratio 
LC–MS   liquid chromatography–mass spectrometry 
LC–MS/MS   liquid chromatography tandem mass spectrometry 
LE    ligand efficiency 
Leu    leucine 
LipE    lipophilic efficiency 
m-CPBA   m-chloroperoxybenzoic acid 
MDR1   multidrug resistance protein 1 
Me    methyl 
MeMgBr   methylmagnesium bromide 
MeOH   methanol 
Met    methionine 
MgCl2   magnesium chloride 
MgSO4   magnesium sulfate 
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MRT    mean residence time 
Ms    methanesulfonyl 
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NaHCO3   sodium hydrogen carbonate 
NaOH   sodium hydroxide 
Na2SO4   sodium sulfate 
NBS    N-bromosuccinimide 
ND    not determined 
NDI    novelty discrimination index 
NH3    ammonia 
NMDA   N-methyl-D-aspartic acid 
NMR    nuclear magnetic resonance 
NO    nitric oxide 
NOE    nuclear Overhauser effect 
NOR    novel object recognition 
NOS    nitric oxide synthase 
NT    not tested 
NTA    nitrilotriacetic acid 
PAH    pulmonary arterial hypertention 
PD    pharmacodynamic 
PDB    protein data bank 
Pd/C    palladium on carbon 
PDE    phosphodiesterase 
PFC    prefrontal cortex 
P-gp    P-glycoprotein 
Ph    phenyl 
Phe    phenylalanine 
PKA    protein kinase A 
PKG    protein kinase G 
po    per os 
POC    proof of concept 
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Pr    propyl 
RHS    right-hand side 
RLM    rat liver microsomes 
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SAR    structure-activity relationship 
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Ser    serine 
SPA    scintillation proximity assay 
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TBS    tris-buffered saline 
TEA    triethylamine 
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TFA    trifluoroacetic acid 
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TLC    thin layer chromatography 
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TPSA    topological polar surface area 
Tyr    tyrosine 
Vdss    volume of distribution 






欲・認知機能などに重い障害をきたす精神疾患である. その有病者数は, 全世界で 2100 万人
以上 (WHO, 2017 年)1, 本邦において約 79.5 万人 (厚生労働省, 2008 年)2 と推定されてお
り, 世界人口のおよそ 1% が罹患する頻度の高い疾患といえる 3. その症状は, (1) 幻覚, 幻
聴, 妄想, 思考の混乱, 異常行動などを特徴とする「陽性症状」, (2) 感情・意欲の減退, 引き
こもり, 無関心などに代表される「陰性症状」, (3) 記憶力・理解力・注意力・情報処理能力








神病薬: 例えば, クロルプロマジン, ハロペリドール)6,7 と第二世代抗精神病薬 (非定型抗精
神病薬: 例えば, オランザピン, クエチアピン, リスペリドン, アリピプラゾール)8−12 に分類
される (Figure 1)13,14. 第一世代抗精神病薬は中脳辺縁系のドパミン D2 受容体に拮抗的に作
用し, 陽性症状に対して改善効果を示す一方で, 認知機能障害や陰性症状には効果が薄く, 
また黒質線条体や視床下部・下垂体の D2 受容体にも拮抗的に働くため, 錐体外路症状, 高プ
ロラクチン血症などの副作用の発現が問題となっている15,16. 第二世代抗精神病薬は, 第一世




外路症状, 高プロラクチン血症などの副作用が軽減すると考えられている17,18. しかしながら, 
第二世代抗精神病薬は, 脂質代謝異常, 体重増加, 過鎮静, 低血圧など依然として発生頻度の





Figure 1. Structures of selected examples of currently approved typical or first-generation 
antipsychotics and atypical or second-generation antipsychotics. 
 
3',5'-環状アデノシン一リン酸 (3',5'-cyclic adenosine monophosphate, cAMP) および 3',5'-




において重要な役割を果たしている. これらは, それぞれアデニル酸シクラーゼ20 あるいは
グアニル酸シクラーゼ21 が活性化することによって産生される. アデニル酸シクラーゼの活
性化は, Gs タンパク質注1) と共役する受容体にホルモンや神経伝達物質などの生理活性物質
が結合することで引き起こされる. 一方, グアニル酸シクラーゼは一酸化窒素合成酵素 
(nitric oxide synthase, NOS) によって産生される一酸化窒素 (nitric oxide, NO) により活性化さ
れる. 生成した cAMP および cGMP はそれぞれタンパク質リン酸化酵素 A (protein kinase A, 
PKA) あるいはタンパク質リン酸化酵素 G (protein kinase G, PKG) といった cAMP あるいは 
cGMP 依存性タンパク質リン酸化酵素の活性化を経て細胞内シグナルが伝達された後, 標的
遺伝子の転写活性化によって様々な生理作用を示す. 
ホスホジエステラーゼ (phosphodiesterase, PDE) は cAMP や cGMP といった環状ヌク
レオチドの 3'−リン酸エステル結合部位の加水分解を選択的に触媒し, それぞれ不活性な 
5'-AMP あるいは 5'-GMP に変換する酵素である (Figure 2)22. これまでに 21 種類の遺伝子
がクローニングされ, 組織あるいは細胞における局在性, 酵素化学的性質, アミノ酸配列の
相同性および触媒活性の制御機構などに基づいて, PDE1 から PDE11 まで 11 種類のファミ
リーに分類されている. それぞれのファミリーにはアミノ酸配列の相同性の高い 1 から 4 
つのアイソザイムが存在する．また基質特異性に基づいて23, PDE ファミリーは 3 つのカテ
ゴリー: (1) cAMP のみを基質とする PDE (PDE4, PDE7, および PDE8), (2) cGMP のみを基
                                                     
注 1) G タンパク質は α, β および γ サブユニットから成るヘテロ三量体タンパク質であり, 7 回膜貫通型受容体 
(G タンパク質共役型受容体 (G protein-coupled receptor, GPCR)) に共役するタンパク質である. α サブユニットの
機能および遺伝子の相違により, Gs, Gi, Gq, Gt などのサブファミリーに分類される. アゴニストが GPCR に結
合すると α サブユニットに結合しているグアノシン二リン酸 (guanosine diphosphate, GDP) とグアノシン三リン
酸 (guanosine triphosphate, GTP) の交換反応が起こり, GTP 結合型 α サブユニットと β, γ サブユニットに解離
する. これらのサブユニットは, それぞれ標的タンパク質や酵素を活性化し, シグナルを下流へと伝達する. α サ
ブユニット が Gs タンパク質の場合, GPCR の活性化を経て遊離した GTP 結合型 α サブユニットがアデニル
酸シクラーゼと結合することで活性化を引き起こし cAMP が産生される. 
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質とする PDE (PDE5, PDE6, および PDE9), (3) cAMP および cGMP の両方を基質とする二
重基質 PDE (PDE1, PDE2, PDE3, PDE10, および PDE11) に分類される. 
 
 
Figure 2.  Hydrolysis of cyclic nucleotiede substrates by PDEs. 
 
これまでに PDE3−5 を標的とする  PDE 阻害剤が , 急性心不全 , 慢性閉塞性肺疾患 
(chronic obstructive pulmonary disease, COPD), 男性性機能障害や肺動脈性肺高血圧症 
(pulmonary arterial hypertension, PAH) などの治療薬として上市され, 臨床応用が進められてい
る (Figure 3)24. 上述のように末梢を標的とする PDE 阻害剤が臨床で大きな成功を収めてい







Figure 3.  Structures of selected examples of currently approved PDE inhibitors. Of these, the PDE3 
inhibitors milrinone, olprinone, and cilostazol have been approved for the short-term treatment of 
congestive heart failure25 and the treatment of intermittent claudication,26 respectively. The PDE4 
inhibitor roflumilast has entered the market as an oral treatment for reducing the risk of exacerbations 
in patients with chronic obstructive pulmonary disease (COPD), who also have chronic 
bronchitis.27−29 Another PDE4 inhibitors apremilast and crisaborole have been approved for the 
treatment of psoriasis and psoriatic arthritis,30 and the treat ment of atopic dermatitis,31 respectively. 
The PDE5 inhibitors sildenafil, tadalafil, vardenafil, avanafil, udenafil, mirodenafil, and lodenafil are 
now marketed for the treatment of erectile dysfunction.24,32 Sildenafil and tadalafil have also been 
approved as treatments for pulmonary arterial hypertension (PAH);33 moreover, the latter has also 




PDE2A は cAMP および cGMP の両基質を加水分解する二重基質酵素である. また, 
PDE2A は脳部位に高発現しており, 中でも学習および記憶形成に重要な領域である前頭皮
質, 海馬, 線条体, 扁桃体に多く存在しているのに対し, 末梢領域での発現は脳部位に比べて
少ないことが報告されている39,40. したがって脳部位を標的とする場合, PDE2A を阻害する
ことによる末梢部位への薬理的影響は少ないことが期待でき, 副作用軽減の観点から魅力的
な発現分布と考えられる24,41,42. また, 環状ヌクレオチドを介したシグナル伝達に関する前臨
床研究において, 細胞内 cAMP および cGMP 濃度の上昇によって, シナプス伝達および長
期増強 (long-term potentiation) の増大を引き起こすことが報告されている43,44. また, cGMP 
および cAMP はそれぞれ短期記憶および長期記憶の形成に重要な役割を果たしていること
が知られている45. これらの結果から, PDE2A 阻害薬は学習・記憶に関連する脳部位での細胞
内 cAMP あるいは cGMP 濃度を高め神経回路を活性化することによって, 精神疾患や神経
変性疾患における認知機能障害を改善する治療薬になる可能性が期待されている. 一方で, 
PDE には上述のように 11 種類のファミリーが存在し, それぞれに特異的な組織発現や細胞
内局在, そして基質特異性を示すことから, 各種 PDE は生体内の様々な細胞内シグナル伝
達において重要な生理的役割を果たしていることが知られている. したがって, PDE 阻害薬
の臨床開発において, PDE 選択性の確保は, 標的とする PDE の薬理学的特性を明らかにし, 
他の PDE 阻害に基づく副作用を回避・軽減するという観点から極めて重要といえる. 
  これまでに PDE2A 阻害薬の探索は複数の製薬企業で活発に行われてきており, 数多く
の関連特許ならびに論文が報告されている (Figure 4)46−54. しかしながら, 多くの化合物は, 
PDE2A に対する阻害活性, PDE ファミリー選択性, 中枢移行性を含めた薬物動態など, いず
れかのプロファイルで課題を有しており, 当社で PDE2A 阻害薬の合成研究が開始された 
2010 年までに臨床開発に至った化合物は ND-7001 のみであった47. ND-7001 は第 I 相臨床
試験まで進んだものの, 社内の評価において PDE2A 阻害活性および PDE 選択性ともに不
十分なプロファイル (PDE2A IC50 = 190 nM, 3 倍の PDE 選択性) であったため, 本化合物を
用いた非臨床 POC (proof of concept) の検証は困難であった. このような状況下において, 最
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近 Pfizer 社より強力な PDE2A 阻害活性, 優れた PDE ファミリー選択性, 良好な中枢移行
性を併せ持つ臨床候補化合物 (PF-05180999) が報告された51,52. 本化合物は, 統合失調症, そ
の後片頭痛治療薬を指向して第 I 相臨床試験が実施されたが, 2014 年に臨床開発の中止が
報告されている (理由は不明). また 2014 年には Janssen 社より, 良好な PDE2A 阻害活性
と PDE 選択性を有するツール化合物注2), [1,2,4]トリアゾロ[4,3-a]キノキサリン誘導体 1 が
報告されている 48,49. 一方 , 2002 年に  Bayer 社より世界に先駆けて特許公開された 
BAY-60-755046 は, PDE2A 阻害薬の非臨床研究における重要なツール化合物として広く用い
られており, PDE2A の生理的役割の解明に大きく貢献してきた55,56. しかしながら本化合物
の経口吸収性, さらに中枢移行性は極めて低いことが報告されており, これまでに報告され
ている in vivo 作用が PDE2A の阻害作用に基づくものかどうかに関しては議論の余地ある
問題となっていた53,57. 
  このような背景のもと, 著者らは, 非臨床および臨床において PDE2A が統合失調症な
どの認知機能障害を改善する有望な標的分子であることを実証するべく, 構造独自性が高く, 
高活性・高選択性で, 高い経口吸収性および中枢移行性を示す PDE2A 阻害薬の探索研究を
開始した. 
                                                     














PDE2A IC50: 4.7 nMa (0.86 nMb)















ND-7001, Neuro3D (now Evotec)
PDE2A IC50: 50 nMa (190 nMb)











PDE2A IC50: 10 nMa
PDE selectivity: >210xa vs. PDE11A
PF-05180999, Pfizer
PDE2A IC50: 1 nMa
PDE selectivity: 2000xa vs. PDE10A
a data from literature
b data generated at Takeda  
Figure 4.  Representative structures and profiles of reported selective PDE2A inhibitors. 
 
以下に各章の概要を示す. 
【第 1 章】 ハイスループットスクリーニング (high through-put screening, HTS) で見出され
たヒット化合物 2 の PDE2A 阻害活性と PDE ファミリー選択性の向上を指向して, (1) ピ
ラゾロ[1,5-a]ピリミジン環母核上への置換基導入, (2) アミドリンカー部位の変換, (3) α-分岐
ベンジルアミン部位の変換を行った. その結果, PDE2A 阻害活性がおよそ 160 倍向上し, 
PDE3A 阻害と比較して 180 倍の良好な PDE2A 選択性を示すリード化合物 10a (IC50 = 24 
nM) を見出した (Scheme 1). また X 線共結晶構造解析の結果, 化合物 10a が PDE2A の触
媒ドメインに特徴的な結合様式で結合していることを明らかにした. さらに, 本化合物のマ
ウスへの経口投与によって脳内 cGMP 含量を有意に上昇させることを確認し, 本化合物が 
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in vivo 試験用ツール化合物, ならびにその後の最適化研究のリード化合物として有用である





【第 2 章】 本章では, 化合物 10a と PDE2A との X 線共結晶構造解析の情報を活用して, 
さらなる活性および PDE ファミリー選択性の向上とケモタイプの拡充を目指した. 第 1 章
で見出した化合物 10a のピラゾロ[1,5-a]ピリミジン環は PDE ファミリー共通の基質結合部
位である Gln859 と CH−O の弱い水素結合で相互作用していることが明らかになったこと
から, Gln859 と明確な水素結合が形成可能な新規骨格を種々設計・合成し, 活性に対する影
響を検討した. その結果, 対応するピラゾロ[1,5-a]ピリミジン誘導体 31 よりも PDE2A 阻
害活性が約 6 倍向上した新規骨格化合物, 2-オキソ-2,3-ジヒドロピリド[2,3-b]ピラジン誘導
体 32 を見出すことに成功した. 続いて, 化合物 32 を新たなリード化合物として, α-分岐ベ
ンジルアミン部位の変換および 2-オキソ-2,3-ジヒドロピリド[2,3-b]ピラジン環母核上への置
換基導入を中心に行い, PDE2A との新たな相互作用の獲得および PDE2A に特徴的な空間の
充填により活性および PDE ファミリー選択性の向上を目指した. 同時に, 良好な中枢移行
性を獲得する上で重要な物理化学的および物性パラメータを指標とした構造最適化検討を行
った結果, 非常に強力な PDE2A 阻害活性 (IC50 = 0.61 nM) ならびに PDE1A に対して 4100 
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倍の極めて高い PDE ファミリー選択性を示す化合物 42a を見出すことに成功した. 本化合
物は, ラットおよびマウスにおいて良好な経口吸収性および中枢移行性を示し, マウスにお
ける経口投与によって脳内 cGMP 含量を有意に上昇させた. またラットにおける新奇物体
認知試験 (novel object recognition test) および受動的回避試験 (passive avoidance test) におい
て, 有意な認知機能の亢進および改善作用を示し, 既存の抗精神病薬で認められる錐体外路
症状・高プロラクチン血症・耐糖能異常などの副作用の懸念の少ない化合物であることを明
らかにした. その後, 化合物 42a は臨床候補化合物 (開発コード番号: TAK-915) として選出







【第 3 章】 本章では, 高い PDE2A 阻害活性および PDE ファミリー選択性かつ中枢移行
性に優れた TAK-915 バックアップ化合物の創出を目指した. 第 1 章および第 2 章の合成
研究の過程で見出された化合物 118 および 31 に特徴的な部分構造を組合わせることで 
TAK-915 とは異なる構造, そして P-糖タンパク質 (P-glycoprotein, P-gp)注3),注4) による排出の
懸念の少ない新規リード化合物 119 を見出すことに成功した. さらなる PDE2A 阻害活性
および PDE ファミリー選択性の向上を指向して, 化合物 10a の X 線共結晶構造解析の情
報を基に化合物 119 のピラゾロ[1,5-a]ピリミジン環 5 および 6 位への置換基導入を検討し
た結果, TAK-915 と同等の PDE2A 阻害活性 (IC50 = 0.51 nM) と PDE ファミリー選択性 
(PDE1A 阻害作用に対して 5300 倍) を示すピラゾロ[1,5-a]ピリミジン誘導体 122b を見出
すことに成功した. また, この過程でピラゾロ[1,5-a]ピリミジン環 5 位に窒素原子で結合し
たヘテロ 5 員環を導入することにより, ラット in vivo クリアランスと in vitro 光毒性ポテ
ンシャルの両プロファイルが大きく改善されることも見出した. 化合物 122b は, ラットへ
の経口投与によって用量依存的かつ有意に脳内 PDE2A の占有率および cGMP 含量を上昇
させるとともに, 受動的回避試験において認知機能改善効果を示すことを明らかにした. こ
れらの詳細を第 3 章で述べる. 
 
 
                                                     
注 3) P-糖タンパク質をコードする遺伝子は MDR1 (mutidrug resistance protein 1) と呼ばれる. 良好な中枢移行性を
確保するためには, 薬物を脳内から排出するトランスポーターである P-gp の基質にならないことが重要である. 
P-gp の基質として脳から排出されやすいか否かは, P-gp 過剰発現細胞膜を用いた膜透過性試験の結果から算出
された P-gp による排出比 (P-gp or MDR1 efflux ratio) を用いて見積もる. P-gp による排出比 (B to A/A to B) は, 
P-gp 過剰発現細胞膜を用い, 吸収方向および排出方向, それぞれの単位面積当たりの透過速度を測定し, それら
の値を用いて算出する. 
注 4) 上市されている中枢薬および非中枢薬で P-gp による排出比を比較した研究によると, 薬物が脳に到達する
ためには, 排出比は 2.5 未満が理想的であるとされている 58. 本論文における P-gp 基質の判断基準として, 排









第 1 章 PDE2A 選択的阻害活性を有するリード化合物の創製 
 
第 1 節 ヒット化合物の同定とリード化合物創出を指向した薬物設計戦略 
  独自性の高い PDE2A 阻害薬を創出するに当たり, 著者らは, 社内化合物ライブラリー
を用いた HTS を実施した結果, ピラゾロ[1,5-a]ピリミジン骨格を有するヒット化合物 2 を
見出した (Figure 1-1(A)). 化合物 2 の PDE2A 阻害活性および PDE ファミリー選択性は, 
それぞれ 3.8 µM, 1.3 倍 (vs. PDE4D) と十分なものではなかったものの, 構造活性相関 
(structure activity relationship, SAR) を取得しやすいアミド構造を有していたこと, また良好な
経口吸収性や中枢移行性を指向する上で重要な指標である分子量 (molecular weight, MW) や
二次元極性表面積 (topological polar surface area, TPSA) 等の物性パラメータ注5) が小さな値で
あったことから, 最適化検討を推し進める上で構造変換の余地が大きく良質なヒット化合物
と考えられた. さらに化合物 2 は, ピラゾロ[1,5-a]ピリミジン環 4 位の窒素原子とアミド
部位の NH が分子内水素結合を形成することによってそれぞれの塩基性および HBD 性が
マスクされていると推察されることから, 中枢薬を指向した合成展開を行う上で有利である
と考えられた. 上述の考察を踏まえ, 著者らは, 主に PDE2A 阻害活性の向上を目指し, ヒッ
ト化合物 2 の構造変換を開始した. 
  本研究を開始した当初は, 化合物 2 と PDE2A タンパクとの X 線共結晶が得られてい
なかったことから , 非選択的  PDE 阻害剤である  3-イソブチル -1-メチルキサンチン 
(3-isobutyl-1-methylxanthine, IBMX)59 (Figure 1-2) と PDE2A の結晶構造を鋳型とする分子モ
                                                     
注 5) 経口投与可能な低分子医薬品の分子構造に基づく物性パラメータの範囲は, リピンスキーの法則 (Lipinski's 
rule of 5)60 に基づいて以下の 4 条件 (1. MW ≤ 500, 2. cLog P (脂溶性指標) ≤ 5, 3. 水素結合受容体 (hydrogen 
bond acceptor, HBA) 数 ≤ 10, 4. 水素結合供与体 (hydrogen bond donor, HBD) 数 ≤ 5) を満たすことが望ましいと
されている. また, Hitchcock らは良好な中枢移行性の獲得には TPSA < 90, 2 ≤ clogP ≤ 5, MW < 500 および HBD 








Figure 1-1.  (A) Structure and profile of pyrazolo[1,5-a]pyrimidine hit 2 from a high-throughput 
screen. The presumed intramolecular hydrogen bond is indicated in red. (B) SAR approach. 
 
 
Figure 1-2.  Structure of non-specific PDE inhibitor, IBMX. 
 
  まず化合物 2 をFigure 1-1 (B) に示す 3 つのフラグメントに分け (1. 母核, 2. アミドリ
ンカー部位, 3. α-分岐ベンジルアミン部位), Figure 1-3 で概説する合成戦略に従って各フラグ
メントの構造活性相関を取得した. 
戦略 1 ピラゾロ[1,5-a]ピリミジン環への置換基導入の許容性を検証する目的で, ピラゾロ
[1,5-a]ピリミジン環上 2, 5, 6 および 7 位にメチル基の導入を検討する. 
戦略 2 アミド部位のカルボニル基および NH が PDE2A 阻害活性に与える影響を検証す




戦略 3 ピラゾロ[1,5-a]ピリミジン環 4 位の窒素原子とアミド部位の NH の分子内水素結
合の活性発現に対する重要性を検証するために, アミド部位 NH のメチル化 (戦略 2), およ
びピラゾロ[1,5-a]ピリミジン環 4 位窒素原子の炭素原子への変換, あるいは分子内水素結合
を形成していると考えられる部位で新たに環形成させた誘導体を検討する. 
戦略 4 パラレル合成を活用して網羅的に α-分岐ベンジルアミン部位の変換を実施する. 
 
 
Figure 1-3.  Synthetic strategies of compound 2. 
 
第 2 節 生物活性と構造活性相関 
  ピラゾロ[1,5-a]ピリミジン環 2, 5, 6 および 7 位に置換基を導入した結果を Table 1-1 
に示す． ピラゾロ[1,5-a]ピリミジン環 2 位にメチル基を導入 (3a) すると活性が大きく減弱
する一方で, 5 位メチル置換体 3b は活性が保持することが分かった. 化合物 3a で見られ
た活性の減弱は, 2 位メチル基の導入によって近傍のアミドカルボニル基との立体反発が生
じ, 活性コンフォメーションに影響を及ぼしたためと考えられる. 一方, 6 位メチル置換体 
3c は無置換体 2 と比較して約 8 倍の活性の向上が認められた. また, 5 位および 7 位の両
部位にメチル基を導入したジメチル誘導体 3d は, 5 位メチル体 (3b) と比べて活性が低下





以上の結果を踏まえ, PDE2A 阻害活性の向上が認められた 6 位置換体について引き続き詳
細な検討を行った. その結果, 6 位クロロ体 (3e), シクロプロピル体 (3f), フェニル体 (3g) 
は 6 位メチル体 (3c) と比較して, いずれも活性が減弱することが明らかとなった. これら
の結果は, 6 位周辺がメチル基を許容できる程度の小さな空間であることを示唆するものと
考えられる. 以上のように, ピラゾロ[1,5-a]ピリミジン環上置換基の構造活性相関の結果, 6 
位メチル置換体 3c が良好なリガンド効率 (ligand efficiency, LE)注6) を保持しつつ, 最も強い 
PDE2A 阻害活性を示すことが明らかとなった. 
  
                                                     
注 6) リガンド効率は, 標的タンパク質と相互作用するリガンドの非水素原子一つ当たりの Gibbs エネルギーと
して定義される. 分子量が異なる化合物同士の活性を比較するのに用いられる指標である. また, 良質なリード
化合物を選定する上で重要な指標となる. 
 
リガンド効率 = ΔG/水素以外の原子数 ~ −RT ln(IC50)/水素以外の原子数 
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Table 1-1.  In Vitro Activities for Substituted Pyrazolo[1,5-a]pyrimidine Derivatives 
 
compd R2 R5 R6 R7 PDE2A IC50 (µM)a LEb 
2 H H H H 3.8 (3.0−4.7) 0.32 
3a Me H H H 16 (13−19) 0.27 
3b H Me H H 2.2 (1.8−2.7) 0.32 
3c H H Me H 0.49 (0.43−0.57) 0.36 
3d H Me H Me 7.0 (4.8−10) 0.28 
3e H H Cl H 1.4 (1.3−1.7) 0.33 
3f H H c-Pr H 1.0 (0.92−1.1) 0.31 
3g H H Ph H 23 (18−31) 0.22 
a IC50 values (95% confidence intervals given in parentheses) were calculated from percent inhibition 
data (duplicate, n = 1). All values are rounded to two significant digits. b Ligand Efficiency (LE) = 
−1.37LogIC50/number of heavy atoms. 
 
  続いて, アミド結合部位の構造活性相関を検証した (Figure 1-4). アミドカルボニル基の
除去 (4), アミド NH のメチル化 (5), アミドカルボニル基のスルホニル基への変換 (6) の
いずれも PDE2A 阻害活性が大きく減弱した. これらの結果から, アミドカルボニル基は水
素結合受容体として PDE2A のアミノ酸残基と何らかの相互作用に関与している一方で, ア
ミド NH はピラゾロ[1,5-a]ピリミジン環 4 位窒素原子との分子内水素結合を介して活性コ
ンフォメーションを固定化していることが示唆された. そこで, 分子内水素結合の重要性を
検証する目的で, ピラゾロ[1,5-a]ピリミジン環 4 位窒素原子を CH に変換した化合物 (7) 
と分子内水素結合を形成していると推定される部位で新たに環形成した化合物 (8) を設計し, 
合成を行った (Figure 1-5). その結果, 化合物 7 は予想通り活性が消失したのに対し, 化合物 
8 は活性の低下が認められたものの 21 µM の阻害活性を示すことが明らかとなった. これ
らの結果は, 本系統の誘導体において, 分子内水素結合による立体配座の固定化が活性発現







Figure 1-4.  Effect of the amide linker connecting the pyrazolo[1,5-a]pyrimidine core and 
p-methoxyphenyl moiety on PDE2A inhibitory activity. 
 
 
Figure 1-5.  Analog designed to test the involvement of intramolecular hydrogen bonding in PDE2A 
inhibitory activity. The intramolecular hydrogen bond is depicted as a red arc in compound 2. 
 




性相関を Table 1-2 に示した. また, 対照化合物として p-メトキシフェニル誘導体 3c の活
性も Table 1-2 に掲載した. 化合物 3c のパラ位メトキシ基を除去した無置換体 9a は, お
よそ 7 倍の活性の減弱が認められた. この結果は, パラ位メトキシ基が近傍の空間を効果的




鎖のエチル基 (9a) をメチル基に変換した化合物 9b は活性が 6 倍減弱し, 化合物 3c のエ
チル分岐側鎖をさらに除去した化合物 9d は活性が大きく低下した. さらに, 化合物 9a の
分岐エチル基末端炭素を隣接するフェニル基のオルト位で環化させたインダン誘導体 (9c) 
では 9 倍の活性の低下が認められた. これらの結果は, 分岐アルキル側鎖が PDE2A 阻害活
性を発現する上で重要な役割を果たしていることを示唆しており, 本側鎖が PDE2A のポケ
ットを効果的に充填するとともに, フェニル基を活性発現に有利な空間配置に誘起している
と考えられる. 一方, 化合物 9d のパラ位メトキシ基をメタ位 (9e), あるいはオルト位 (9f) 
に移すと活性が消失したことから, フェニル基上の置換様式も PDE2A 阻害活性に重要であ
ることが明らかとなった. また, パラ位置換基であるメトキシ基 (9d) をトリフルオロメトキ
シ基 (9g) に変換すると, およそ 9 倍活性が向上した. 一般に, トリフルオロメトキシフェ
ニル構造を有する化合物は C=C−O−CF3 の二面角が直交する配座が安定なのに対して, メト
キシフェニル構造を有する化合物ではフェニル基, 酸素原子, メチル基の炭素原子が同一平





座の違いが生じるものと考えられている64. これらのことから, 化合物 9g で認められた活性


































(33−74) 9g  
6.1 
(3.6−10) 
a IC50 values (95% confidence intervals given in parentheses) were calculated from percent inhibition 
data (duplicate, n = 1). All values were rounded to two significant digits. 
 
 
Figure 1-6.  A difference in conformational preferences (dihedral angles θ of Ca−Cb−O−Cc) between 
the methoxyphenyl and trifluoromethoxyphenyl groups. 
 
  次に, これまで述べてきた構造活性相関研究の知見を基に, 活性向上において重要な知
見, すなわち, ① ピラゾロ[1,5-a]ピリミジン環 6 位へのメチル基の導入, ② 末端トリフル
21 
 
オロメトキシ基への変換をそれぞれ組み合わせた化合物 (10) を設計し合成した結果, PDE2A 
阻害活性が相加的に向上することが明らかとなった (IC50 = 0.053 µM). 続いて, 光学活性体
の PDE2A 阻害活性および PDE ファミリー選択性に対する影響を検証するために, 化合物 
10 の光学分割を実施した. その結果, (R)-体 10a はラセミ体 10 と比べて活性が約 2 倍向
上し, (S)-体である 10b は 10 µM の濃度においても活性を示さないことが明らかとなった 
(Table 1-3). なお, ユートマー 10a注7) の絶対立体配置は, 後述する PDE2A との X 線共結晶
構造解析により決定した. また, (R)-体 10a は PDE3A に対して 180 倍, PDE10A に対して 
310 倍, その他の PDE ファミリーに対しては 420 倍以上の良好な選択性プロファイルを示
すことも明らかとなった (Table 1-4). 
  
                                                     




Table 1-3.  In Vitro Activity Profiles of 38 and Its Enantiomers 10a and 10b 
 
compd stereo PDE2A IC50 (µM)a 
10 rac 0.053 (0.047−0.059) 
10a Rb 0.024 (0.022−0.027) 
10b Sb >100 
a IC50 values (95% confidence intervals given in parentheses) were calculated from percent inhibition 
data (duplicate, n = 1). All values are rounded to two significant digits. b Absolute configuration 
assigned based on the stereochemistry of the bound conformation in the crystal structure of 10a (see 
Figure 1-6). 
 
Table 1-4.  In Vitro PDE Selectivity Profile of 10a 
PDE subtypes IC50 (µM)a selectivity ratiob 
PDE1A >10 >420 
PDE2A3 0.024 − 
PDE3A 4.2 180 
PDE4D2 >10 >420 
PDE5A1 >10 >420 
PDE6AB >10 >420 
PDE7B >10 >420 
PDE8A1 >10 >420 
PDE9A2 >10 >420 
PDE10A2 7.4 310 
PDE11A4 >10 >420 
a IC50 values were calculated from percent inhibition data (duplicate, n = 1). All values are rounded to 





第 3 節 化合物 10a と PDE2A の X 線共結晶構造解析 
  これまで述べてきたように, ヒット化合物 2 を端緒化合物とした合成展開により良好
な活性と PDE 選択性を示す化合物 10a を見出すことに成功した. 本化合物の結合様式を明
らかにするために, 10a と PDE2A の X 線共結晶構造解析を実施した. その結果, Figure 1-7 
(A) および 1-7 (B) に示すように, 化合物 10a が PDE2A の触媒ドメインに結合しているこ
とが明らかとなった. また上述の構造活性相関と一致して, アミド部位の NH はピラゾロ
[1,5-a]ピリミジン環 4 位窒素原子と分子内水素結合を形成し, 活性コンフォメーションの固
定化に寄与していることを確認することができた. さらに, 10a のベンジルアミン部位の絶
対立体配置は R 体と決定した. この X 線共結晶構造解析によって, 化合物 10a と PDE2A 
との相互作用が明らかとなった. 以下に特筆すべき相互作用についてまとめる. 
1. ピラゾロ[1,5-a]ピリミジン環 7 位の水素原子は PDE ファミリー共通の基質結合部位で
ある Gln859 と CH−O の擬似的水素結合 (C−O の距離: 3.2 Å)65 を介して相互作用して
いる. 
2. アミドカルボニル基は Tyr655 と水分子を介した水素結合のネットワークを形成すると
ともに, さらにもう一つ別の水分子と水素結合を形成している. この知見は, カルボニル
基を除去した場合 (化合物 3c → 化合物 4, Figure 1-4) に大幅に活性が減弱した結果と
矛盾のないものといえる. 
3. ピラゾロ[1,5-a]ピリミジン環は上に位置する Phe862, 下に位置する Ile826 とそれぞれ 
π−π ならびに CH−π の相互作用を形成している (Figure 1-7 (B)). 
4. ピラゾロ[1,5-a]ピリミジン環 6 位メチル基は Leu858 側鎖とファンデアワールスの相互
作用をしている. メチル基を許容しているポケットの大きさは限られており, この部位の
メチル基をより大きな置換基に変換すると活性が減弱した結果と一致する (Table 1-1, 
3e−3g). 
5. 分岐エチル側鎖は Ile826, Phe830, His656, Tyr655 で囲まれた脂溶性空間を占めている. 
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6. p-トリフルオロメトキシフェニル基は PDE2A タンパクとの結合によって新たに形成さ
れた脂溶性空間を効果的に充填している. 最近になって Zhu らは, この空間がこれまで
報告されている他の PDE の X 線共結晶構造解析において認められず, PDE2A に特徴
的な空間である可能性を報告している48,66. したがって, 化合物 10 で確認された良好な 
PDE ファミリー選択性は, PDE2A に特徴的な本空間を利用することによってもたらされ
ているのではないかと考えられる. また, トリフルオロメトキシ基はフェニル基に対して
エネルギー的に有利な直交型の立体配座で脂溶性空間を占有していることが明らかとな
った. フェニル基と同一平面上に位置する傾向の強いメトキシフェニル誘導体 3c と比
べて, トリフルオロメトキシフェニル誘導体 10 は脂溶性相互作用の増加に加えて, 結合







Figure 1-7.  X-ray crystal structure of 10a bound in the PDE2A catalytic site (PDB 5XKM) viewed 
from the top (A) and the entrance of the catalytic site (B). The key hydrogen bonding interactions of 
10a with PDE2A and the intramolecular hydrogen bond in 10a are indicated by red and yellow dotted 
lines, respectively.  
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第 4 節 化合物 10a の in vitro および薬物動態プロファイル 
  化合物 10a の in vitro (Table 1-5) および薬物動態プロファイル (Table 1-6) を示す. 化
合物 10a は分子量, TPSA, リガンド効率, 脂溶性効率 (Lipophilic efficiency, LipE)注8) などの
点で良好な物理化学的性質注9) を有していた. また, ヒト, ラット, マウスいずれの種におい
ても良好な代謝安定性プロファイルを示し, P-gp の基質の可能性が低く (MDR1 efflux ratio = 
0.43), 高い中枢移行性を示すことが期待された. 本化合物をラットおよびマウスに 0.3 mg/kg 
の静脈内投与をしたところ, 比較的大きなクリアランス (CLtotal) および分布容積 (Vdss) を示
したが , 1 mg/kg の経口投与において , それぞれ  15% および  34% の生物学的利用率 
(bioavailability, F) と 58.7 ng·h/mL および 132.6 ng·h/mL の血中濃度−時間曲線下総面積値 
(AUC0−8h) を示した. さらに, 前述の P-gp 基質性の結果と一致し, ラットおよびマウスにお
ける最高血中濃度到達時間 (Tmax) 付近 (化合物投与後 2 時間 (ラット) および 1 時間 (マ
ウス)) の脳内と血漿中の薬物濃度比 Kp はそれぞれ 2.9 と 2.6 で良好な値を示し, 血液脳
関門 (blood brain barrier, BBB) を通過して脳内に移行することを確認した. 以上の結果から, 




                                                     




脂溶性効率, LipE = pIC50 – log D 
注9) リード化合物の MW や TPSA などの物性パラメータは以降の最適化検討における構造変換により増加する
傾向があることから, 上限とされる値 (注5 参照) よりも小さい方が望ましいと考えられている. 一方, LE や 
LipE 値に関しては, 現在上市されている医薬品の前臨床開発段階時 (ヒットやリード化合物選出時) の各パラメ




Table 1-5.  Calculated Physicochemical Properties and In Vitro Profiles for Representative Lead 10a 
 
property value 
PDE2A IC50 0.024 µM 
MW 378 




PDE selectivity 180-fold (vs. PDE3A) 
HLMd <1 µL/min/mg 
RLMe 36 µL/min/mg 
MLMf 27 µL/min/mg 
MDR1 ratiog 0.43 
a Log D value at pH 7.4.68 b LE (ligand efficiency) = −1.37LogIC50/number of heavy atoms. c LipE 
(lipophilic efficiency) = pIC50 – Log D. d Metabolic stability in human liver microsomes. e Metabolic 
stability in rat liver microsomes. f Metabolic stability in mouse liver microsomes. g MDR1 efflux ratio 
in P-gp overexpressing cells. 
 
Table 1-6.  Pharmacokinetic Properties and Kp Values of 10aa 
species 
iv (0.1 mg/kg) po (1 mg/kg) 









rat 43.9 3953 15.9 1.7 58.7 15.4 2.9 
mouse 43.2 4363 44.8 0.7 132.6 33.9 2.6 
a Rat or mouse cassette dosing at 0.1 mg/kg, iv and 1 mg/kg, po (non-fasted). Average of three rats. 
b Total clearance. c Volume of distribution at steady state. d Maximum plasma concentration. e Time of 
maximum concentration. f Area under the plasma concentration vs. time curve (0−8 h). g Oral 




第 5 節 化合物 10a の in vivo 薬理評価 
  PDE2A 阻害作用による薬力学マーカー (pharmacodynamic (PD) marker)注10) に対する影
響を検証するために, 化合物 10a をマウスに経口投与 (10, 30, 100 mg/kg) し, PDE2A が高
発現している部位 (前頭葉, 線条体, 海馬)39,40 における cGMP および cAMP 含量を測定し
た (Figure 1-8 (A) と 1-8 (B)). その結果, 10a は上述の全ての部位における cGMP 含量を 
30 mg/kg から用量依存的かつ有意に増加させた. 一方 cAMP 量については, 前頭葉のみ 
100 mg/kg の用量で僅かな増加が認められた. PDE2A は cGMP および cAMP の両方を加水
分解することが報告されているが, 化合物 10a のみならず, これまでに報告されている 
BAY 60-755055, erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA)69, 化合物 1 (Figure 3)48 などの他
の PDE2A 阻害薬でも同様に cAMP よりも cGMP の濃度上昇に対してより強い効果を示す
傾向が認められている. この理由は現時点で不明であるが, PDE2A は本来 cAMP よりも 
cGMP に対して高い親和性 (低い Km 値) を示すこと70,71, また cAMP に対してより親和性
の強い PDE1, 4, 7, 8, 10 などの他の PDE ファミリーが共局在することによって, PDE2A 阻
害による cAMP の分解抑制作用が相殺されている可能性が考えられる22,39. 以上の結果から, 








                                                     
注 10) 薬物が実際に標的分子に到達して想定メカニズムに基づいた作用を示しているかどうかの指標として使わ




Figure 1-7.  Increase in mouse brain cGMP (A) and cAMP (B) levels 30 min after oral 
administration of compound 10a at 10, 30, and 100 mg/kg to ICR mice. The prefrontal cortex (PFC), 
striatum (STR), and hippocampus (HIP) were isolated after microwave irradiation. Data are presented 





第 6 節 化合物の合成 
  置換ピラゾロ[1,5-a]ピリミジン-3-カルボン酸 15 は, Scheme 1-1 に示したように, ピラ
ゾロ[1,5-a]ピリミジン環の構築およびエステル部位の加水分解の 2 工程で合成された. すな
わち, 酸性あるいは中性条件下, 5-アミノ-1H-ピラゾール 11 を種々の 1,3-ジカルボニル等価
体 12a−c と縮合させた後, 得られたピラゾロ[1,5-a]ピリミジン 13a−c をアルカリ加水分解
に付すことで対応するカルボン酸 15a−c を得た (Route A). 一方 15e は, ピラゾロ[1,5-a]ピ
リミジン骨格がアルカリ加水分解の条件下で不安定であったため, 環構築の前にエステルの
加水分解を実施することで合成した (Route B). また 15d,f は, 市販のカルボン酸 14b を出
発原料に用い, 対応する 1,3-ジカルボニル等価体 12d,f との縮合反応によって合成した. 
 
Scheme 1-1.  Synthesis of Substituted Pyrazolo[1,5-a]pyrimidine-3-carboxylic Acids 15a−fa 
 
a Reagents and conditions: (a) 12a or 12b, AcOH, 70−90 °C, 0.5−16 h, 69−87% (for 13a and 13b); 
12c, toluene, 100 °C, 16 h, 68% (for 13c); (b) 1 M or 2 M NaOH aq., MeOH, THF, 50−60 °C, 3 
h−overnight, 80−87% (for 15a−c); (c) 2 M NaOH aq., EtOH, reflux, 20 h, (taken on crude) (for 14a); 
(d) 12d or 12e or 12f, EtOH, AcOH, 80−100 °C, 1.5−2 h, 68% (for 15d), 64% (2 steps from 11) (for 
15e), 75% (for 15f). 
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  α-分岐ベンジルアミン 19, 21a, 21b, 22a, 22b は Scheme 1-2 記載の方法で合成した. カ
ルボン酸 16 を Weinreb アミド 17 へ変換した後, エチルグリニャール試薬を作用させてケ
トン 18b を合成した. 市販の 18a はチタンテトライソプロポキシド共存下, メチルアミン
とのイミン形成, 続く水素化ホウ素ナトリウムによる還元によって N-メチルベンジルアミ
ン 19 に導いた. また, 18a,b はヒドロキシアミン 塩酸塩を作用させてオキシム 20a,b とし, 
続いて粗生成物を水素添加の条件に付しベンジルアミン 21a,b を合成した. ベンジルアミン 
21a,b は塩酸塩とすることで結晶化させて 22a,b を得た. 
 
Scheme 1-2.  Synthesis of RHS Benzylamine Moieties 19, 21a, 21b, 22a, and 22ba 
 
a Reagents and conditions: (a) oxalyl chloride, cat. DMF, THF, rt, 4 h, then 
N,O-dimethylhydroxylamine hydrochloride, Et3N, DMA, rt, 16 h, 30%; (b) EtMgBr, THF, 0 °C, 2 h, 
86%; (c) MeNH2, Ti(Oi-Pr)4, MeOH, rt, 5 h, then NaBH4, rt, overnight, 25%; (d) hydroxylammonium 
chloride, Et3N, EtOH, 80 °C, 3−4 h, (taken on crude); (e) H2, 10% Pd/C, MeOH or EtOH, rt, overnight, 




  化合物 2, 3a−e, 5, 7, 9a−g, 10, 11 は, 市販品あるいは Scheme 1-1 で合成した置換ピラゾ
ロ[1,5-a]ピリミジン-3-カルボン酸 15 と Scheme 1-2 で合成した右骨格ベンジルアミン 21 
あるいは 22 を縮合させて合成した. また, 光学活性体 10a,b は ラセミ体 10 のChiralpak 
AD カラムを用いた光学分割により取得した (Scheme 1-3). 
 
Scheme 1-3.  Synthesis of Pyrazolo[1,5-a]pyrimidine Derivatives 2, 3a−e, 5, 7, 9a−g, 10, and 11a 
 
a Reagents and conditions: (a) EDCI·HCl, HOBt·H2O, Et3N or none, DMF, rt, 2 h−4 days, 44−98%; 
(b) EDCI, HOBt, DIEA, DMF, rt, overnight, 28−84%; (c) HATU, DIEA, DMF, rt, overnight, 52%; (d) 




  6 位シクロプロピルおよびフェニルピラゾロ[1,5-a]ピリミジン誘導体 3f および 3g は
対応するボロン酸との鈴木－宮浦クロスカップリング反応72,73 により合成した (Scheme 1-4). 
 
Scheme 1-4.  Synthesis of Pyrazolo[1,5-a]pyrimidine Derivatives 3f and 3ga 
 
a Reagents and conditions: (a) cyclopropylboronic acid, Pd(OAc)2, Cy3P, KOt-Bu, toluene, 100 °C, 16 
h, 10% (for 3f); phenylboronic acid, Pd(PPh3)4, K2CO3, DME, water, 150 °C (microwave), 20 min, 




  アミドカルボニル基をメチレン基あるいはスルホンに置換した誘導体 4 および 6 は, 
Vilsmeire 試薬73 あるいはクロロスルホン酸を用いた 6-メチルピラゾロ[1,5-a]ピリミジン 
(23) への位置選択的なホルミル化あるいはクロロスルホニル化によりホルミル体 24 および
クロロスルホニル体 25 へ変換した後, ベンジルアミン 22a との還元アミノ化反応あるい
はスルホンアミド化反応により標的化合物 4 および 6 を合成した (Scheme 1-5). 
 
Scheme 1-5.  Synthesis of Pyrazolo[1,5-a]pyrimidine Derivatives 4 and 6a 
 
a Reagents and conditions: (a) POCl3, DMF, 0 °C to rt, 3 h, 82%; (b) 22a, NaBH(OAc)3, AcOH, Et3N, 
CH3CN, rt, overnight, 88%; (c) chlorosulfonic acid, 80 °C, 2 h, 26%; (d) 22a, DIEA, CH3CN, rt, 
overnight, 97%. 
 
  3 環性化合物 8 は Scheme 1-6 記載の方法で合成した. ピリジン 26 を出発原料に用い, 
ヒドロキシアミン-O-スルホン酸による N-アミノ化反応, 続くプロピオル酸メチルとの 1,3-
双極子付加環化反応によって, 所望のピラゾロ[1,5-a]ピリジン環化体 27a および その位置
異性体 27b をそれぞれ 29% および 16% の収率で得た. 続いて, Dess−Martin 試薬75 によ
る一級アルコールの酸化反応, ベンジルアミン 21a との還元アミノ化反応, そしてエステル





Scheme 1-6.  Synthesis of 4,5-Dihydro-3H-pyrazolo[4,5,1-ij][1,6]naphthyridin-3-one Derivative 8a 
 
a Reagents and conditions: (a) hydroxylamine-O-sulfonic acid, NaHCO3, water, MeOH, 0 °C to 50 °C, 
16 h, then methyl propiolate, K2CO3, 0 °C to rt, 2 h, 29%; (b) 
1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one (Dess−Martin periodinane), CH3CN, 0 °C to 
rt, 2.5 h, (taken on crude); (c) 21a, NaBH(OAc)3, AcOH, CH3CN, 0 °C to rt, 16 h, 79%; (d) 1 M 




第 7 節 結語 
以上述べてきたように, HTS ヒット化合物 2 からのリード創出を指向した構造変換に
より, 強い PDE2A 阻害活性および PDE ファミリー選択性を有する新規 PDE2A 阻害薬リ
ード化合物 10a の創出に成功した. ヒット化合物 2 からのリード創出の過程において, ア
ミド部位の NH とピラゾロ[1,5-a]ピリミジン環 4 位窒素原子が互いに分子内水素結合を形
成し, 活性コンフォメーションを固定化していること, またピラゾロ[1,5-a]ピリミジン環 6 
位へのメチル基の導入, および右末端フェニル基上の置換基変換 (p-メトキシ基からトリフ
ルオロメトキシ基への変換) が PDE2A 阻害活性および PDE ファミリー選択性の向上にお
いて重要な役割を果たしていることを明らかにした. 化合物 10a は薬物動態試験により経
口吸収性および中枢移行性に優れることが示され, マウスへの経口投与において脳内 cGMP 
含量の有意な増加作用を示した. これらは, 10a が in vivo 経口ツール化合物および今後の
最適化研究のリード化合物として有用であることを支持する結果といえる. 一方で, 臨床候
補化合物の選択という観点においては, 化合物 10a の in vivo 有効用量および PDE ファミ
リー選択性 (180 倍  vs. PDE3A) は不十分であり , 以降の最適化検討においてさらなる 




第 2 章 高活性・高選択性・高い中枢移行性を示す PDE2A 阻害薬の創製：臨床候
補化合物 TAK-915 の創出 
 
第 1 節 研究背景 
  第 1 章では, リード化合物の取得を目指して, 社内化合物ライブラリーから見出された 
HTS ヒット化合物 2 を端緒とした構造変換を実施し, 良好な PDE2A 阻害活性と PDE フ
ァミリー選択性, そして薬物動態プロファイルを兼ね備えたリード化合物, ピラゾロ[1,5-a]
ピリミジン誘導体 10a を見出すことに成功した. 本化合物は上述の良好な in vitro および 
in vivo プロファイルを反映し, マウスへの経口投与によって, PDE2A が高発現している脳
部位において用量依存的かつ有意な cGMP 含量の上昇作用を示した. しかしながら, 本化
合物の in vivo 有効用量 (30 mg/kg, po) における高い血中暴露量および PDE ファミリー選
択性 (180 倍 vs. PDE3A) は臨床候補化合物の選択という観点から依然不十分であり, 臨床
において PDE2A の機能を解明し創薬標的としての有用性を検証するとともに, 他の PDE 
やそれ以外のオフターゲットに起因する副作用を回避するためにも, さらなる PDE2A 阻害
活性および PDE ファミリー選択性の向上が必要と考えられた. 序論でも論じたように, 11
種類の PDE ファミリーは基質特異性, 発現分布, 触媒活性の制御の仕方などが異なってお
り, それぞれが生体内の様々な組織の細胞内シグナル伝達の調節を行うことで多彩な生理作
用を発揮していることが知られている. 例えば, 心臓や血管平滑筋などに発現する PDE1 や 
PDE3 の阻害は, 血管拡張作用や頻脈など循環器系への影響が懸念され,76,77 網膜に存在する 
PDE6 の阻害は, 視覚異常が報告されている 78−80. したがって, PDE ファミリー選択性の確
保は , 副作用の回避に極めて重要と考えられる . これらの点を踏まえ , 著者らは , より 
PDE2A 阻害活性が強く (PDE2A IC50 < 5 nM), PDE 阻害作用の選択性に優れ (>1000 倍以上), 
かつ良好な中枢移行性を示す化合物の探索を進めることにした . リード化合物  10a の 
PDE2A 阻害活性および PDE ファミリー選択性向上を目指して, 著者らは, PDE2A/化合物 
10a 複合体の X 線共結晶構造情報 (Figure 1-7) に基づいた薬物設計を行った. また, 設計
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化合物の中枢移行性を高い確率で確保するために, TPSA および HBD の数, および P-gp 
基質性を指標とした合成展開を実施することとした. 
 
第 2 節 X 線共結晶構造情報に基づいた薬物設計戦略 
  化合物 10a のさらなる PDE2A 阻害活性および PDE ファミリー選択性向上を達成す
るためには, PDE2A タンパクとの新たな相互作用の獲得と他の PDE ファミリーには存在し
ない PDE2A に特徴的な空間を利用する必要があると考えた. そこで, Figure 1-7 に示した 
X 線共結晶構造情報に基づいて, 以下の 4 つの薬物設計戦略を立案した (Figure 2-1). 
 
戦略 1 第 1 章の第 3 節により, ピラゾロ[1,5-a]ピリミジン環 7 位の水素原子は PDE フ
ァミリー共通の基質結合部位である Gln859 と弱い擬似的水素結合を介して相互作用してい
ることが明らかとなった. 本結果に基づき, Gln859 と明確に水素結合が形成できる新たな母
核を探索し, 活性の向上を図る. この骨格変換によって, 活性の向上が期待できるのみなら
ず, 化合物の新規性や構造多様性を高め, 最適化研究における成功確率向上に繋がることが
期待される. 
戦略 2 p-トリフルオロメトキシフェニル基は, 他の PDE ファミリーではこれまで存在が
確認されていない PDE2A に特徴的な脂溶性空間を占有していることが分かっている. そこ
で, この脂溶性空間を充填する最適な置換基を導入することにより, PDE2A 阻害活性の向上
と PDE ファミリー選択性の向上を同時に図る. この際, トリフルオロメトキシ基のアルコ
キシ酸素の必要性や適切な置換様式についても検証する. 
戦略 3 リガンド結合サイトのマグネシウムや亜鉛金属イオンの周辺には, 極性アミノ酸残
基である His656 や Glu829, さらには水分子が多く存在する. また, 分岐エチル側鎖は溶媒側
に面しており, この周辺は比較的大きな親水性領域と考えられた. これら His656 や Glu829 





戦略 4 第 1 章・第 2 節の検討で明らかになったように, ピラゾロ[1,5-a]ピリミジン環 6 
位へのメチル基の導入によって活性および選択性が大幅に向上した. 戦略 1 で新たに見出
した母核近傍の空間を効果的に充填する, あるいは PDE 間で異なるアミノ酸残基を狙い適




Figure 2-1.  Drug design strategies to improve PDE2A inhibitory activity and PDE selectivity. 
 
第 3 節 新規母核の探索に向けた薬物設計戦略：戦略 1 
  化合物 10a のさらなる活性の向上を目指すに当たって, 著者らは, 10a のピラゾロ
[1,5-a]ピリミジン環と Gln859 の相互作用である擬似的水素結合に着目した . 一般的に 
CH−O の擬似的水素結合は X−H···Y (X, Y = N or O) で表される古典的な水素結合に比べて
弱い結合のため, Gln859 と古典的な水素結合を介して相互作用することができれば活性の向
上が期待できると考えた. 一方で, PDE2A ような cAMP と cGMP の両基質を加水分解する 
PDE の二重基質性を説明する分子メカニズムの一つとして「グルタミン スイッチ」が提唱
されている (Figure 2-2)81,82. これは, cAMP および cGMP の両基質を認識するために, PDE 
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ファミリー共通の基質結合部位である Gln 側鎖 (PDE2A の場合は Gln859) が自由に回転
するというものである. 上述の明確な水素結合による相互作用と「グルタミン スイッチ」の
分子メカニズムを考慮して, Gln859 と明確な水素結合が形成可能な新規骨格を設計した 
(Figure 2-3). その際, ピラゾロ[1,5-a]ピリミジン誘導体で認められている分子内水素結合の
重要性も考慮して, アミド部位の NH と分子内水素結合が形成できるよう新規骨格の適切
な位置に HBA として機能する窒素原子の導入を行った. また, P-gp による排出の懸念の少
ない化合物を見出すべく, 化合物設計の段階で TPSA や HBD 数などの物理化学的な指標
も考慮に入れた. これまでの報告によると, P-gp による排出を抑制するためには, TPSA お
よび HBD 数はそれぞれ < 90 Å2, そして < 2 (すなわち, 0 か 1) で定義される範囲内で薬
物設計を行うことが推奨されている 61,62. 分子内水素結合が認められるケモタイプでは, そ
の結合の強さによって見かけの TPSA および HBD 数が変化すると考えられ, 例えば, 強固
に分子内水素結合を形成する場合には, アミド部位の NH および母核の塩基性部位が完全
にマスクされ, 見かけの TPSA および HBD 数はそれぞれ約 20 Å2 と 1 つ減少すると見
なすことができる 83. 以上の考察を踏まえ, 本章で論じる薬物設計は, 中枢移行性を指向し
た 2 つの指標から定義されるケミカルスペースの範囲内 (TPSA < 90 + 20 = 110 Å2, HBD 数 
< 2 + 1 = 3)61,62,83 で実施することとした. 
 
 
Figure 2-2.  Glutamine switch mechanism proposed to explain the accommodation of both cyclic 





Figure 2-3.  Drug design concepts (A)−(D) to identify new alternatives to the 
pyrazolo[1,5-a]pyrimidine core. 
 
第 4 節 生物活性と構造活性相関：戦略 1 
  新規に設計, 合成した 2 環性骨格の PDE2A 阻害活性に対する影響を Table 2-1 にま
とめた. 合成した全ての誘導体の TPSA は, 化合物設計の段階で第 3 節で設定した 110 Å2 
未満の範囲内に収まるよう考慮した. また, 対照化合物としてピラゾロ[1,5-a]ピリミジン誘
導体 10 および 31 のデータも Table 2-1 に掲載した. Gln859 と cGMP 様の結合様式で水
素結合が形成可能な 3,4-ジヒドロピリド[2,3-b]ピラジン-2(1H)-オン誘導体 32 はピラゾロ
[1,5-a]ピリミジン誘導体 31 に比べ, 高い PDE2A 阻害活性を示した. しかしながら, 化合
物 32 の 3,4-ジヒドロピリド[2,3-b]ピラジン-2(1H)-オン環は, 片方の環が飽和環になってお
り, ピラゾロ[1,5-a]ピリミジン誘導体 31 と比べて, 環上下に位置する Phe862 と Ile826 と
の π−π および CH−π 相互作用が減弱している可能性が考えられた. そこで, さらなる活性
の向上を狙って, 化合物 32 のラクタム構造と化合物 31 の芳香族性を併せ持つ 1,5-ナフチ
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リジン-2(1H)-オン誘導体 33 を設計した. その結果, 期待通り 33 は誘導体 32 よりも約 4 
倍強い活性を示した. 本結果は, Gln859 との相互作用のみならず, 2 環性骨格の上下に位置
する Phe862 および Ile826 との相互作用の両方が活性発現に重要であることを示唆するも
のである. 一方, cAMP 様の結合様式と同様に Gln859 側鎖の −NH2 との水素結合を期待し
たピラゾロ[1,5-b][1,2,4]トリアジン誘導体 34 はピラゾロ[1,5-a]ピリミジン誘導体 10 と比
べて, 活性が大きく減弱した. また, 化合物 33 の逆アミド構造を有するラクタム誘導体 35 
も cAMP 様の結合様式を期待したが, 活性の増強には至らなかった. 活性が低下した原因
として, Gln859 の側鎖と相互作用が可能な適切な位置に HBA あるいは HBD を配置でき
ていない可能性も否定できないものの, Gln859 の側鎖自体が前述の「グルタミン スイッチ」
で提唱される自由な回転ができない可能性も考えられる. 実際, Figure 1-6 (A) で示した化合
物 10a の X 線共結晶構造解析では, Gln859 側鎖のカルボニル基は隣接する Tyr827 側鎖
のフェノール性水酸基と水素結合を形成していることが示唆されている. したがって, 化合
物 34 および 35 は, この水素結合ネットワークの切断によるエネルギー損失を上回る新た
な相互作用が獲得できなかった結果, 活性が低下したのではないかと推察できる. 続いて, 
良好な活性が認められた化合物 32 の母核上の塩基性窒素原子を CH に置換した誘導体 36 




誘導体を上回る強い PDE2A 阻害活性を示す誘導体 32 および 33 を見出すことに成功し
た. しかしながら, その後の化合物評価において, 33 は母核環構造に起因すると考えられる
強い in vitro 光毒性ポテンシャルを示したのに加え, 32 に比べて酸性度の高いラクタム 
N−H のプロトンを有しているため中枢移行性が低いことも判明した. 以上の結果から, 化




















































a See Figure 2-3. b IC50 values (95% confidence intervals given in parentheses) were calculated from 
percent inhibition data (duplicate, n = 1). All values are rounded to two significant digits. 
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第 5 節 化合物 32 の光学分割と in vitro 活性および PDE ファミリー選択性 
  活性の向上が認められた化合物 32 の光学分割を実施し, 光学活性体の PDE2A 阻害活
性および PDE ファミリー選択性に対する影響を検証した (Table 2-2). その結果, 光学異性
体 32a が IC50 = 66 nM の阻害活性を示し, もう一方の異性体 32b は 100 µM の濃度におい
ても阻害活性を示さなかった. この結果は, PDE2A タンパクが厳密にリガンドの絶対立体配
置を認識していること示唆していると考えられる. また 32a は, ラセミ体 32 と同様の選択
性プロファイルを示すことが明らかとなった (PDE1A に対して 30 倍, PDE3A に対しては 




Table 2-2.  In Vitro Activity Profiles of 32 and Its Enantiomers 32a and 32b 
 
compd stereo PDE2A IC50 (nM)a 
32 rac 78 (61−98) 
32a eutomer 66 (46−93) 
32b distomer >100000 
 
 32 32a 
PDE subtypes IC50 (nM)a selectivity ratiob IC50 (nM)a selectivity ratiob 
PDE1A 3200 41 2000 30 
PDE2A3 78 − 66 − 
PDE3A 8100 100 4200 64 
PDE4D2 >10000 >130 >10000 >150 
PDE5A1 9800 130 >10000 >150 
PDE6AB >10000 >130 >10000 >150 
PDE7B >10000 >130 >10000 >150 
PDE8A1 >10000 >130 >10000 >150 
PDE9A2 >10000 >130 >10000 >150 
PDE10A2 >10000 >130 >10000 >150 
PDE11A4 >10000 >130 >10000 >150 
a IC50 values were calculated from percent inhibition data (duplicate, n = 1). All values are rounded to 





第 6 節 p-トリフルオロメトキシフェニル部位の最適化：戦略 2 
  さらなる PDE2A 阻害活性および PDE ファミリー選択性の改善を目的として, フェニ
ル基上置換基の変換を実施した (Table 2-3). Figure 1-7 に示した X 線共結晶構造情報から, 
PDE2A サブタイプに特徴的な本空間は脂溶性側鎖で囲まれ, 大きさも限られていることが
示唆されていることから, コンパクトな脂溶性置換基を中心に導入の検討を行った. 第 1 章
のピラゾロ[1,5-a]ピリミジン誘導体の構造活性相関と同様に, p-トリフルオロメトキシ基 
(32) をメトキシ基 (37a) に変換すると活性が約 8 倍減弱することが分かった. 活性が大き
く低下した要因として, (1) 活性コンフォメーションでは, フェニル基とパラ位置換基が直交
型の立体配座で充填していることが明らかとなっており, 一般的にフェニル基と同じ平面に
位置する立体配座がエネルギー的に最も有利なメトキシ基は PDE2A タンパクに結合する
際に構造変化が必要となり, エントロピー損失が生じたこと 63, また (2) 脂溶性が低下 
(ΔLog D = 0.83) することによって PDE2A の脂溶性側鎖とのファンデアワールス相互作用
が低下した点が挙げられる. 一方, トリフルオロメトキシ基 (32) とは異なる 3 次元構造を
有するトリフルオロメチル基 (37b) やシクロプロピル基 (37c) は 32 と同等の阻害活性を
示したものの, PDE ファミリー選択性は低下する傾向が認められた. これらの結果から, 置
換基の 3 次元構造, あるいはフェニル基に直結したトリフルオロメトキシ基の酸素原子が 
PDE ファミリー選択性に重要な役割を果たしていると考えられる. また窒素原子で結合し
たアゼチジン誘導体 37d の阻害活性は約 8 倍減弱した. 続いて, トリフルオロメトキシ基
の最適な置換位置を検証するため, フェニル基のメタ位およびオルト位にトリフルオロメト
キシ基を有する誘導体 (37e, 37f) を合成したが, いずれも活性は大きく減弱した. メタ位お
よびオルト位近傍の空間の大きさが限られている, あるいはオルト位の置換基導入によって
分岐エチル側鎖を含む近傍の置換基と立体反発が生じ, 活性コンフォメーションに影響を及





その結果, オルト位にフルオロ基を導入したオルト置換体 37h は活性が低下する傾向を示
したのに対し, メタ置換体 37g は 42 nM の強い PDE2A 阻害活性を示すことが明らかとな
った. 以上の検討結果から, 化合物 32 と同等以上の PDE2A 阻害活性を示すフェニル置換




Table 2-3.  SAR of the RHS Phenyl Group 
 
compd Ar PDE2A IC50 (nM)a PDE selectivityb Log Dc 
32 
 
78 (61–98) 41-fold (PDE1A) 3.61 
37a 
 
610 (480–780) NTd 2.78 
37b 
 
72 (46–110) 4.2-fold (PDE1A) 3.45 
37c 
 
80 (64–100) 4.4-fold (PDE1A) 3.75 
37d 
 
500 (410–590) NTd 3.13 
37e 
 
4100 (3400–4900) NTd NT 
37f 
 
8100 (5500–18000) NTd 3.52 
37g 
 
42 (33–52) 15-fold (PDE1A) 3.67 
37h 
 
210 (160–290) 28-fold (PDE1A) 3.83 
a IC50 values (95% confidence intervals given in parentheses) were calculated from percent inhibition 
data (duplicate, n = 1). All values are rounded to two significant digits. b Minimum selectivity 
(rounded to two significant digits) over other PDEs. The least selective PDE was given in parenthesis. 




第 7 節 分岐エチル側鎖の変換：戦略 3 
  リガンド結合サイトに存在するマグネシウムおよび亜鉛金属イオン周辺の極性アミノ酸
残基や水分子との相互作用を目指して, 分岐エチル側鎖に極性官能基の導入を検討した 
(Table 2-4). メトキシメチル基を有する誘導体 38a は PDE2A 阻害活性および PDE ファミ
リー選択性ともに大きく改善するとともに, この変換によって脂溶性も大きく低減 (ΔLog D 
= 0.66) できることが明らかとなった. また, 一炭素増炭したメトキシエチル誘導体 38b は, 
化合物 32 と比べて活性は保持されたものの, PDE ファミリー選択性は低下する傾向を示し
た. さらに, 38a のエーテル酸素原子をメチレン基に置換した 38c は 10 倍以上の活性の減
弱が認められた. これらの結果から, エーテル酸素原子が PDE2A タンパクと新たな相互作
用を形成していることが示唆されたため, さらに他の極性官能基の導入を検討した. その結
果, 一級アルコール誘導体 38d は 32 と比較して, 活性および PDE ファミリー選択性が保
持するに留まったが, 対応する三級アルコール誘導体 38e は活性および PDE 選択性共に
改善することが明らかとなった. 化合物 38e の gem-ジメチル基の導入によって結合周りの
回転が抑制され, その結果, コンフォメーションが固定化され活性および選択性が向上した
のではないかと推察した. また, 極性のさらに高いスルホン誘導体 38f でも良好な活性と選
択性を示すことが明らかとなった. これらの結果は, この位置が極性アミノ酸残基や水分子
に囲まれ, 溶媒側に面した親水性の空間であることと矛盾のない結果と考えられる. 一方で, 
極性官能基の導入によって  TPSA あるいは  HBD 数の増加が認められている . 化合物 
38d−f は当初設定した TPSA あるいは HBD 数のいずれかの目標値 (TPSA < 110 Å2, HBD 
数 < 3) を逸脱しており, 実際のところ P-gp 基質の傾向が強いことが明らかとなった. こ
の結果は, TPSA および HBD の数が P-gp の基質認識性を予測する上で重要な因子であり, 
我々が設定したこれら指標の目標値が妥当であることを支持するものといえる. 以上の検討
結果より, PDE2A 阻害活性と PDE ファミリー選択性の向上および脂溶性の低減を同時に実













32 −Et 78 (61−98) 41-fold (PDE1A) 3.61 84 0.53 
38a −CH2OMe 19 (15−24) 310-fold (PDE1A) 2.95 93 0.68 
38b −CH2CH2OMe 62 (37−100) 14-fold (PDE5) 3.09 93 0.77 
38c −n-Pr 250 (190−330) NTe 4.05 84 0.59 
38d −CH2OH 65 (35−120) 54-fold (PDE1A) 2.16 104 2.8 
38e −C(Me)2OH 24 (18−33) 150-fold (PDE1A) 2.54 104 2.8 
38f −CH2SO2Me 29 (22−38) 220-fold (PDE1A) 1.91 118 26 
a IC50 values (95% confidence intervals given in parentheses) were calculated from percent inhibition 
data (duplicate, n = 1). All values are rounded to two significant digits. b Minimum selectivity 
(rounded to two significant digits) over other PDEs. The least selective PDE was given in parenthesis. 
c Log D values at pH 7.4. d MDR1 efflux ratios in P-gp overexpressing cells. e Not tested. 
 
第 8 節 新規母核への置換基導入：戦略 4 
  全 PDE ファミリーのアミノ酸配列の比較によって, 3,4-ジヒドロピリド[2,3-b]ピラジン
-2(1H)-オン環が占有すると考えられる空間近傍のアミノ酸残基  (例えば  PDE2A では 
Tyr827, Leu858, Met847 が 3,4-ジヒドロピリド[2,3-b]ピラジン-2(1H)-オン環近傍に存在する









た 3,4-ジヒドロピリド[2,3-b]ピラジン-2(1H)-オン環上の置換基探索を行った (Table 2-5). 6 
位 (39a) および 8 位 (39c) にメチル基を導入すると, 共に活性が減弱する傾向を示したの
に対し, 7 位メチル置換体 39b は 2 倍の活性向上に加え, 1100 倍の優れた PDE ファミリ
ー選択性を示すことが明らかとなった. これらの結果を受けて, 以後 3,4-ジヒドロピリド
[2,3-b]ピラジン-2(1H)-オン環 7 位への置換基導入を詳細に検討することとした. メチル基
よりも脂溶性が高く, かつ嵩高いシクロプロピル基 (39d) を導入すると, PDE2A 阻害活性
および選択性の向上が認められた. 一方, メチル基と同程度の原子サイズを有し, 電子求引
性基のクロロ基 (39e) を導入すると, 活性・選択性共に悪化する傾向を示した. 本結果は, ク
ロロ基の導入によって母核の電子密度が低下し, 上下に位置する Phe862/Ile826 との π−π 
および CH−π 相互作用が減弱したためと推察された. 以上のことから, 7 位への置換基導入
は受容体ポケットの充填と母核の電子密度の調節という 2 つの効果によって活性発現に寄
与している可能性が示唆された. 一方で, 化合物 39b および 39d などの 7 位アルキル誘
導体は 数 nM オーダーの強い阻害活性と優れた選択性を示したものの, 高い脂溶性に懸念
が持たれた. 一般的に脂溶性の高い分子は, 非特異的相互作用に基づく毒性発現のリスクが
高くなることが報告されている 86−88. そこで, 脂溶性の増加が小さなアルコキシ基の導入を
検討した結果, 7 位メトキシ誘導体 39f は, 対応するシクロプロピル誘導体 39d と同等の
活性と 2 倍以上改善した PDE ファミリー選択性を示すことが分かった. しかしながら, さ
らに嵩高いイソプロポキシ誘導体 39g は, 大幅な活性の低下が認められた. 以上の検討を経
て見出された化合物 39f は, 一般の中枢薬と比べると高い TPSA (102 Å2) を有しているに
も関わらず, P-gp の排出比は問題のない良好な値を示した. 前節と同様に, 分子内水素結合













38a H 19 (15−24) 310-fold (PDE1A) 2.95 93 0.68 
39a 6-Me 40 (31−52) 50-fold (PDE1A) 3.38 93 0.63 
39b 7-Me 8.7 (7.6−10) 1100-fold (PDE5) 3.35 93 1.0 
39c 8-Me 85 (67−110) NTe 3.16 93 0.74 
39d 7-c-Pr 3.5 (3.0−4.1) 1300-fold (PDE3A) 3.85 93 1.0 
39e 7-Cl 33 (30−36) 210-fold (PDE5) 3.74 93 0.58 
39f 7-MeO 2.8 (2.6−3.1) 2700-fold (PDE5) 3.20 102 1.3 
39g 7-iPrO 77 (66−90) NTe 3.94 102 1.1 
a IC50 values (95% confidence intervals given in parentheses) were calculated from percent inhibition 
data (duplicate, n = 1). All values are rounded to two significant digits. b Minimum selectivity 
(rounded to two significant digits) over other PDEs. The least selective PDE was given in parenthesis. 
c Log D values at pH 7.4. d MDR1 efflux ratios in P-gp overexpressing cells. e Not tested. 
 
第 9 節 化合物 39f およびその周辺誘導体の光学分割と光学活性体の in vitro 評価 
  化合物 39f は目標 (PDE2A 阻害活性 IC50 < 5 nM, PDE selectivity > 1000 倍) とする強
力な PDE2A 阻害活性と優れた選択性を示したことから光学分割を実施した. また, 化合物 
39f の p-トリフルオロメトキシフェニル基部位を, 第 7 節の検討で見出した 37b および 
37g の右末端フェニル基部位に変換した誘導体も同時に合成し, 光学分割を実施した. 各光
学活性体の PDE2A 阻害活性, PDE ファミリー選択性およびその他 in vitro プロファイルを 
Table 2-6 に示した. 光学分割体 40a, 41a, 42a は, それぞれ対応するもう片方の光学活性体
よりも PDE2A に対して高い結合阻害活性を示した. 化合物 40a は強力な阻害活性 (IC50 = 
1.6 nM) および PDE ファミリー選択性 (PDE1A に対して 3300 倍) を示したのに対し, 化
合物 41a は期待した活性 (IC50 = 7.2 nM) および選択性 (PDE1A に対して 83 倍) を示さな
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かった. 一方, 化合物 42a は合成した中で最も良好な活性 (IC50 = 0.61 nM) および PDE フ
ァミリー選択性 (PDE1A に対して 4100 倍, 各 PDE ファミリーに対する IC50 値は Table 
2-7 参照) を示すことが明らかとなった . また , 酵素・G タンパク質共役型受容体  (G 
protein-coupled receptor, GPCR)・核内受容体・イオンチャンネル・トランスポーターを含む合
計 96 種類のオフターゲット選択性試験 (Eurofins Panlabs 社) の結果, 化合物 42a は 下記 
6 種類のターゲットを除く 90 種類のターゲットに対して, 極めて高い選択性を有すること
が判明した. 一方, 10 μM の濃度において 50% 以上の阻害活性を示した 6 種類のターゲッ
ト (アセチルコリンエステラーゼ: 99%, 5-リポキシゲナーゼ: 70%, CB1 カンナビノイド受容
体: 60%, PDE5: 59%, L 型カルシウムチャンネン: 54%, 血液凝固因子 Xa ペプチダーゼ: 
51%) のうち, 最も強い阻害活性を示したアセチルコリンエステラーゼに関して社内で精査
試験を実施したところ, IC50 値にして 3.9 μM の酵素阻害活性を示した. 以上のことから, 
化合物 42a は各種の PDE ファミリー (4100 倍以上) のみならず, 他の広範なターゲット





Table 2-6.  In Vitro Profiles and Physicochemical Properties of Analogs 40a−b, 41a−b, 42a−ba 
 




40a R 1.6 (1.4−1.9) 3300-fold (PDE1A) 3.19 102 1.5 
40b S 39000 (28000−54000) − − − − 
41a NDf 7.2 (6.4−8.0) 83-fold (PDE1A) 3.03 93 0.79 
41b NDf 21000 (10000−42000) − − − − 
42a R 0.61 (0.53−0.70) 4100-fold (PDE1A) 3.32 102 0.87 
42b S 910 (720−1200) − − − − 
a Racemic compounds were chirally separated and each enantiomer was profiled. The absolute 
configurations of 40b and 42a were determined as S and R, respectively, via single crystal X-ray 
analysis of the corresponding RHS benzylamine precursors (see the Experimental Section). b IC50 
values (95% confidence intervals given in parentheses) were calculated from percent inhibition data 
(duplicate, n = 1). All values are rounded to two significant digits. c Minimum selectivity (rounded to 
two significant digits) over other PDEs. The least selective PDE was given in parenthesis. d Log D 




Table 2-7.  PDE Selectivity Profile of 42a 
PDE subtypes IC50 (nM)a selectivity ratiob 
PDE1A 2497 4100 
PDE2A3 0.61 − 
PDE3A >30000 >49000 
PDE4D2 14882 24000 
PDE5A1 >30000 >49000 
PDE6AB >30000 >49000 
PDE7B >30000 >49000 
PDE8A1 >30000 >49000 
PDE9A2 >30000 >49000 
PDE10A2 >30000 >49000 
PDE11A4 >30000 >49000 
a IC50 values were calculated from percent inhibition data (duplicate, n = 1). All values are rounded to 
two significant digits. b Selectivity ratio (rounded to two significant digits) = PDE''X'' IC50/PDE2A 
IC50. 
 
第 10 節 化合物 42a の薬物動態プロファイル 
  化合物 42a のラットおよびマウス薬物動態試験の結果を Table 2-8 に示す. 化合物 
42a はラットおよびマウスの肝ミクロソームにおいては比較的高いクリアランスを示し, ヒ
ト肝ミクロソームにおいては低いクリアランス値を示した. 化合物 42a をラットおよびマ
ウスに 0.3 mg/kg の静脈内投与をしたところ, ラットにおいて比較的大きなクリアランスお
よび分布容積を示したが, 1 mg/kg の経口投与においては, それぞれ 57% および 56% の良
好な生物学的利用率と 242.5 ng·h/mL および 1076.8 ng·h/mL の血中濃度−時間曲線下総面積
値を示した. さらに, ラットおよびマウスにおける最高血中濃度到達時間付近 (化合物投与
後 2 時間) の脳内と血漿中の薬物濃度比 Kp はそれぞれ 1.01 と 0.91 で, 高い TPSA を示
したにも関わらず, 良好な中枢移行性を示した. この結果は, 先の P-gp 過剰発現細胞膜を





Table 2-8.  PK Parameters and Kp Values of 42a in Rat and Mousea 
 rat mouse human 
Metabolic stabilityb (μL/min/mg) 84 73 33 
CLtotalc (mL/min/kg) 39.3 8.6 − 
Vdssd (mL/kg) 3429 1602 − 
Cmaxe (ng/mL) 64.2 201.0 − 
Tmaxf (h) 1.7 1.7 − 
AUC0−8hg (ng·h/mL) 242.5 1076.8 − 
Fh (%) 56.7 55.6 − 
Kpi 1.01 0.91 − 
a Cassette dosing at 0.1 mg/kg, iv and 1 mg/kg, po (non-fasted). Average of three rats or mice. 
b Metabolic stability was determined by incubation with liver microsomes. c Total clearance. 
d Volume of distribution at steady state. e Maximum plasma concentration. f Time of maximum 
concentration. g Area under the plasma concentration vs time curve (0−8 h). h Oral bioavailability. 




第 11 節 化合物 42a と PDE2A の X 線共結晶構造解析 
  化合物 42a と PDE2A との X 線共結晶構造を Figure 2-4 に示す. 本結晶構造解析によ
り, 化合物 42a が化合物 10a と同様の結合様式で PDE2A の触媒ドメインに結合している
ことが示された. また 3,4-ジヒドロピリド[2,3-b]ピラジン-2(1H)-オン環のラクタム NH は予
想通り, cGMP 様の結合様式で Gln859 側鎖のカルボニル基と水素結合を形成し, 一方で母
核は上下の Phe862 と Phe830/Ile826 と π−π および CH−π の相互作用を介して安定化して
いることが分かった. また, 母核 7 位のメトキシ基は活性および PDE ファミリー選択性に
対して, 以下の 2 つの重要な役割をしていると推察している. 1 つ目は, 電子供与性基とし
て母核の電子密度を高め, Phe862 や Phe830/Ile826 との π−π および CH−π の相互作用を増
強していると考えられる. 2 つ目は, 7 位メトキシ基が近傍の Tyr827, Leu858, Met847 で囲ま
れた小さな脂溶性空間を効果的に充填し活性向上に寄与していると考えられる . また 
PDE2A ポケットでは, メトキシ基が伸びる方向に脂溶性の Leu858 側鎖が存在するため効
果的なファンデアワールス相互作用が形成されるのに対し, PDE1A ポケットでは, Leu858 に
対応するアミノ酸残基がより極性の高い Ser416 であるため効果的な相互作用が獲得できず, 
その結果 PDE1A との選択性が向上したと考えられる. さらに ウレア部位のカルボニル基
は, 化合物 10a のアミドカルボニル基と同様に, Tyr655 の水酸基と水分子を介した水素結合
ネットワークを形成すると同時に, 別の水分子とも水素結合を形成していることが明らかと
なった. 一方, ウレアの NH は予想通り母核上の窒素原子と分子内水素結合を形成している
ことも明らかとなった. また, 分岐メトキシメチル基は紙面下側の溶媒側方向 (Figure 2-4 
(B)) を向いているにも関わらず, 予想した水分子や近傍のアミノ酸残基との明確な相互作用
は確認できなかった. しかしながら, 興味深いことに, メトキシメチル側鎖の酸素原子はウ
レア NH と前述の分子内水素結合とは別の新たな分子内水素結合の形成に関与しているこ







Figure 2-4.  X-ray crystal structure of 42a bound in the PDE2A catalytic site (PDB 5VP0) viewed 
from the top (A) and the entrance of the catalytic site (B). The key hydrogen bonding interactions of 





第 12 節 化合物 42a の in vivo 薬理評価 
  化合物 42a の PDE2A 阻害作用による PD マーカーに対する影響を確認するために, 
化合物 42a をマウスに経口投与し, 前頭葉, 線条体ならびに海馬の cGMP および cAMP 含
量を測定した. その結果, 化合物 42a は用量依存的に各脳部位の cGMP 含量を増加させ, 特
に海馬においては, 1 mg/kg の用量から有意な変化を示した (Figure 2-5 (A)). 一方 cAMP に関
しては, 前頭葉において 10 mg/kg の高用量でのみ有意な増加を示したが, その増加量は限定
的であった. また, その他の脳部位においては cAMP に対して影響を及ぼさなかった (Figure 
2-5 (B)). これらの結果は, 化合物 10a ならびに既存の PDE2A 阻害薬を用いた知見とよく一
致した 48,55,69. さらに, 化合物 42a による認知機能亢進作用を検証するために, ラットを用い
た新奇物体認知試験を実施した 89. 新奇物体認知試験は獲得試行と保持試行で構成されており, 
獲得試行において 2 つの同一物体を探索させた後, 一定時間経過後の保持試行において, 片
方の物体を新規な物体に置き換えて動物の探索行動の変化を見る試験である. 動物は獲得試
行と保持試行の間隔が短いとき, 新奇性のある物体により長い探索行動を示し, その嗜好性は
時間の間隔を広げていくことにより消失する. このことから, 新奇物体認知試験の行動変化は, 
獲得試行時の物体への記憶を反映していると考えられている. 化合物 42a をラットに経口投
与し, 2 時間後に 3 分間の獲得試行を行い, さらに獲得試行から 48 時間後, 3 分間の保持試
行を行った. ここでは, 獲得試行および保持試行の物体への探索時間, ならびに保持試行の新
奇物体選択率 (NDI = novel object interaction/total interaction × 100) を算出した. 化合物 42a の
経口投与は, すべての用量 (0.01, 0.1 ならびに 1 mg/kg) において獲得試行の探索時間に影響を
及ぼさなかった (Figure 2-6 (A)). 獲得試行から 48 時間後, 対照群の新奇物体と既知物体への
探索時間が同程度となり, 物体への記憶が低下することを確認した (Figure 2-6 (B)). 一方, 獲
得試行前に化合物 42a を投与した薬物群は, 0.1 mg/kg の用量から新奇物体への探索時間の有
意な増加が認められた. また, 1 mg/kg の用量で, 新奇物体選択率 (NDI) において有意な変化
が認められた (Figure 2-6 (C)). これらのことから, 化合物 42a が脳内の cGMP 含量の増加を
介し, 認知機能の亢進作用を示すことが示唆された. 続いて, 統合失調症モデル動物を用いた 
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in vivo 薬効試験を実施した. NMDA (N-methyl-D-aspartic acid) 受容体拮抗薬のフェンサイクリ
ジンやケタミンが統合失調症様の症状を惹起することから, NMDA 受容体機能低下が統合失
調症の病態に関与している可能性が示唆されている. この仮説に基づき, NMDA 受容体拮抗
薬である  MK-801 ((5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine) 
により惹起された認知機能障害モデル 90,91 を用いて, 化合物 42a のラットにおける受動的回




傾向が強くなる. 実際に MK-801 (0.1 mg/kg) をラットに皮下投与すると, 対照群 (control 
group) に対して認知機能の障害作用が認められた  (Figure 2-7, 対照群  vs. 溶媒投与群 
(vehicle group)). 一方, 化合物 42a の経口投与 (3 および 10 mg/kg) により, MK-801 により
惹起された認知機能障害を有意に改善することが明らかとなった (Figure 2-7 (B), (C)). 以上の







Figure 2-5.  Effects of compound 42a on cyclic nucleotides in mouse brain. cGMP (A) and cAMP 
(B) levels 1 h after oral administration of compound 42a (1 mg/kg, 3 mg/kg, and 10 mg/kg) were 
measured in the mouse frontal cortex (Fcx), hippocampus (Hipp), and striatum (Str). Data are 







Figure 2-6.  Effects of 42a on a novel object recognition task in rats. Vehicle or 42a (0.01, 0.1, and 
1 mg/kg) was orally administered 2 h prior to the acquisition trials. Exploration times in the 
acquisition trial (A) and the retention trial (performed 48 h after the acquisition trial) (B) were scored. 
Novelty discrimination index (NDI) (C) in the retention trial was calculated as: novel object 
interaction time/total interaction time × 100 (%). Data are presented as the mean ± S.E.M., n = 9 for 1 
mg/kg, n = 10 for the other groups; **p ≤ 0.01 vs familiar object by paired t-test, #p ≤ 0.025 vs 




Figure 2-7.  Effects of compound 42a on MK-801-induced episodic memory deficits assessed by the 
passive avoidance task in rats. Vehicle or compound 42a (1, 3, and 10 mg/kg) was orally administered 
2 h before the s.c. administration of saline or MK-801. Thirty minutes after the s.c. administration of 
saline or MK-801 (0.1 mg/kg), the rat was placed on the illuminated chamber. The latency to cross 
over into the dark chamber was recorded for up to a maximum of 300 s. The retention test was carried 
out 24 h after the acquisition trial. Data (latency to cross over into the dark compartment on the 
retention trial) are expressed as mean ± S.E.M., n = 20, **p ≤ 0.01 (versus control by Wilcoxon’s test), 
##p ≤ 0.01 (versus vehicle + MK-801 by Wilcoxon’s test). 
 
第 13 節 化合物 42a の既存抗精神病薬で見られる副作用に対する評価 92 
  序論で論じたように既存の抗精神病薬で認められる重大かつ代表的な副作用として, ド
パミン D2 受容体遮断作用による錐体外路症状や高プロラクチン血症, セロトニン 2A 受
容体やヒスタミン H1 受容体遮断作用による体重増加や耐糖能異常が知られている 15,16,18,19. 
そこで, 化合物 42a のこれら副作用に対する影響をラットを用いて検証した. 錐体外路症状
を評価する指標として, 不自然な姿勢を長時間持続する症状として知られているカタレプシ
ー (catalepsy) 反応を測定した (Figure 2-8). また, 高プロラクチン血症および体重増加に繋
がる摂食亢進の指標として, それぞれ血漿中のプロラクチン濃度 (Figure 2-9 (A)) およびグ
ルコース濃度 (Figure 2-9 (B)) を測定した. その結果, 非定型抗精神病薬であるオランザピン
が 10 mg/kg の用量でカタレプシー反応を示したのに対して, 化合物 42a は 100 mg/kg の
用量においても全くカタレプシー反応の傾向を示さなかった. さらに, 本化合物は同じ 100 
mg/kg の用量で血漿中プロラクチン濃度およびグルコース濃度に対しても全く影響を及ぼ







Figure 2-8. Effects of 42a on cataleptic response in rats. Duration of cataleptic response was 
measured using the bar test 2 h after the administration of 42a (10 or 100 mg/kg, po) and olanzapine 
(10 mg/kg, po). Data are expressed as mean + S.E.M., n = 8 for each group, **p ≤ 0.01 (versus vehicle 
by Student’s t-test). †Occurrence of animals in a cataleptic position for more than 90 s. 
 
 
Figure 2-9. Effects of 42a on plasma prolactin and glucose levels in rats. Blood samples were 
collected from the tail vein 2 h after the administration of 42a (10, 30, or 100 mg/kg, po). (A) The 
plasma prolactin concentration was determined by enzyme immunoassay kits. (B) The plasma glucose 
concentration was determined by colorimetric detection using a chemical analyzer. Data are expressed 




第 14 節 化合物の合成 
  ピラゾロ[1,5-a]ピリミジン誘導体 31 は市販の 15 とベンジルアミン 22b の縮合反応
により合成した (Scheme 2-1). 
 
Scheme 2-1.  Synthesis of Pyrazolo[1,5-a]pyrimidine Derivative 31a 
 
a Reagents and conditions: (a) EDCI·HCl, HOBt·H2O, Et3N, DMF, rt, overnight, 83%. 
 
  1,5-ナフチリジン-2(1H)-オン誘導体 33 は Scheme 2-2 記載の方法で合成した. 2-クロロ
-3-ニトロピリジン (43) に塩基性条件下, 非対称マロン酸ジエステルを求核剤として作用さ
せてジエステル付加体 44 とした後, TFA 条件下, tert-ブチルエステルの加水分解と脱炭酸を
行ってエチルエステル 45 を合成した. 続いて, ニトロ基の還元と 2,2-ジエトキシ酢酸との
縮合反応によって, アセタール 47 を 4 工程 53% の収率で合成した. 得られた 48 のアセ
タール部位を酸性条件下, ホルミル基へ変換した後, ピペリジン共存下, トルエン中加熱還
流することで, 環化およびその後の脱水反応が一挙に進行し, 所望の 1,5-ナフチリジン
-2(1H)-オン環化体 48 を得ることができた. 最後に, 48 のアルカリ加水分解, 続く右骨格の




Scheme 2-2.  Synthesis of 1,5-Naphthyridin-2(1H)-one Derivative 33a 
 
a Reagents and conditions: (a) tert-butyl ethyl malonate, KOtert-Bu, THF, 60 °C to reflux, 3 h, (taken 
on crude); (b) TFA, CH2Cl2, rt, overnight, (taken on crude); (c) H2, 10% Pd/C, EtOH, 50 psi, rt, 
overnight, (taken on crude); (d) 2,2-diethoxylacetic acid, HATU, DIEA, DMF, rt, overnight, 53% (4 
steps from 43); (e) TFA, H2O, cat. I2, 50 °C, overnight, then piperidine, toluene, reflux, 6 h, 26%; (f) 2 
M NaOH aq., EtOH, rt, 2 h, 87%; (g) 22b, HATU, DIEA, DMF, rt, 2.5 h, 46%. 
 
  ピラゾロ[1,5-b][1,2,4]トリアジン 34 は Scheme 2-3 記載の方法に従って合成した. 3-ア
ミノピラゾール (50) に対してヒドロキシアミン-O-スルホン酸 (HOSA) を作用させること
で位置異性体 51b を含む N-アミノ化体 51a を得た. 位置異性体混合物はシリカゲルカラ
ム精製により分離し, その後 NOE 実験によりそれぞれの構造を決定した. 次に, 51a を酸
性条件下, 1,3-ジカルボニル等価体である 2-オキソ-プロピオンアルデヒドとの縮合反応に付
すことによって 3-メチルピラゾロ[1,5-b][1,2,4]トリアジン (52) を得た. 続いて, Vilsmeire 
試薬 73 による 52 の位置選択的なホルミル化, 続く Pinnick 酸化 93 によりカルボン酸 54 

















































a Reagents and conditions: (a) HOSA, KOH, DMF, 0 °C to 15 °C, 2 h, 17%; (b) 
2-oxo-propionaldehyde, concd HCl, H2O, 60 °C to reflux, 1 h, 37%; (c) POCl3, DMF, 0 °C to 40 °C, 
16 h, 28%; (d) NaClO2, NaH2PO4, 2-methyl-2-butene, tert-BuOH, H2O, 30 °C, 16 h, (taken on crude); 
(e) 22b, EDCI, HOBt, Et3N, DMF, 10−15 °C, 16 h, 3% (2 steps from 53). 
 
  1,6-ナフチリジン-5(6H)-オン誘導体 35 の合成は Scheme 2-4 記載の方法で合成した. 2-
ブロモピリジン-3-カルボン酸 (55) に対する銅 (II) 触媒を用いたアセト酢酸エチルの付加
と脱アセチル化によって 56 に導き, 続いて Vilsmeire 試薬 74 を作用させることで環化体 
57 を合成した. 得られた 57 に 2,4-ジメトキシベンジルアミンを反応させることでカルボ
ン酸無水物への求核置換反応と続く環の再構築反応が進行し, 1,6-ナフチリジン-5(6H)-オン
誘導体 58 を得た. 次にベンジルアミン 22b との縮合と TFA 条件下, 2,4-ジメトキシベン




Scheme 2-4.  Synthesis of 1,6-Naphthyridin-5(6H)-one Derivative 35a 
 
a Reagents and conditions: (a) ethyl acetoacetate, Na, EtOH, Cu(OAc)2, reflux, 16 h, 54%; (b) POCl3, 
DMF, 0 °C to 5 °C, 2 h, (taken on crude); (c) 2,4-dimethoxybenzylamine, Et3N, DMF, 5 °C, 16 h, 
26% (2 steps from 56); (d) amine 22b, EDCI, HOBt, Et3N, DMF, 5 °C to 40 °C, 32 h; (e) TFA, reflux, 
16 h, 12% in 2 steps from 58. 
 
  3,4-ジヒドロピリド[2,3-b]ピラジン-2(1H)-オン誘導体 32, 36, 37a−h, 38a−e, 39a−c, 39e の
合成を Scheme 2-5 に示す. 2-クロロ-3-ニトロピリジン誘導体 60a−f にトリエチルアミン共
存下, メチルグリシンを求核剤として作用させることで 2 位置換アミノピリジン 61a−f を
得た. また, 5-ブロモピリジン 61f はマイクロウェーブ照射下, 塩化銅 (I) を作用させるこ
とによって対応するクロロ体 61g へ導いた. 得られたニトロ体 61a−e, g をパラジウムある
いは白金を用いた水素添加により還元し, 続いてエタノール中加熱することで 3,4-ジヒドロ
ピリド[2,3-b]ピラジン-2(1H)-オン環 62a−e および 62g を構築した. 標的化合物 32, 36, 
37a−h, 38a−e, 39a−c, 39e は 3,4-ジヒドロピリド[2,3-b]ピラジン-2(1H)-オン環 62 をクロロギ
酸 4-ニトロフェニル, あるいはトリホスゲンと反応させた後, トリエチルアミン共存下, ベ
ンジルアミン 22a, 22b, 99, 100, 108 を作用させて合成した. また, スルホン誘導体 38f はス
ルフィド 64 を m-クロロペルオキシ安息香酸 (m-CPBA) で酸化して合成した. 
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Scheme 2-5.  Synthesis of 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one Derivatives 32, 36, 37a−h, 
38a−e, 39a−c, and 39ea 
 
a Reagents and conditions: (a) methyl glycinate hydrochloride, Et3N, DMF or EtOH, rt−90 °C, 3−16 h, 
31%−quant.; (b) CuCl, NMP, 150 °C (microwave), 2.5 h, 64%; (c) H2 (balloon pressure), 10% Pd/C, 
EtOH, rt, 16 h or overnight, (taken on crude) (for 62a−d); (d) H2 (balloon pressure), 5% Pt/C, THF, rt, 
2−16 h, (taken on crude) (for 62e and 62g); (e) EtOH, reflux, 5−16 h, 58−99%; (f) 4-nitrophenyl 
chloroformate, pyridine, DMA, rt−80 °C, 16−24 h, 70−81% (for 63a, 63d, and 63h); (g) 
4-nitrophenyl chloroformate, DIEA, THF, 0 °C to rt, 1 h, 51% (for 63b); (h) RHS benzylamine 22b, 
99, 100, or 108, Et3N, DMF, rt−80 °C, 1−16 h, 23−96%; (i) triphosgene, THF, 40 °C, 1−5 h, then 
RHS benzylamine 22a, 99, or 100, Et3N, THF, rt−60 °C, 16 h−overnight, 3−95%; (j) m-CPBA, 
EtOAc, rt, overnight, 66%. 
 
  3,4-ジヒドロピリド[2,3-b]ピラジン-2(1H)-オン環 7 位の置換基 R2 の変換を行うにあた
り, Scheme 2-5 の合成法では置換基導入を合成初期段階で行わなければならず, 種々の 7 位
置換誘導体を効率的に合成するのには適さないと考えた. そこで著者らは, 誘導体合成の後
期段階で置換基導入が可能な効率的な新規合成法の開発を目指して検討を行った (Scheme 
2-6). ラクタム 62e のプロトン性ドナーを (2-(トリスメチルシリル)エトキシ)メチル (SEM) 
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基で保護した後, トリホスゲンを用いて SEM 保護体 65 とベンジルアミン 99, あるいは 
100 の縮合反応によってウレア体  66−68 に導いた . 母核  7 位置換基の変換  (誘導体 
69−73) は以下の 2 通りの方法で行った. すなわち, 7 位シクロプロピル誘導体 69 はヨウ
素体 66 と対応するボロン酸との鈴木－宮浦クロスカップリング反応により良好な収率で合
成した. 一方, 7 位アルコキシ誘導体 70−73 は, ヨウ素体 66 とピナコールジボランを用い
た宮浦－石山ホウ素化反応 94 により対応するボロン酸エステル体とした後, 炭素－ホウ素
結合の酸化的開裂によるヒドロキシ基への変換, 続くフェノール性水酸基のアルキル化によ
り目的の 7 位アルコキシ体を合成した. 得られた 69−73 に TFA と水の混合物を作用させ
て SEM 基の脱保護を試みたが, 全ての誘導体において, 所望の脱保護体と共に脱保護の過
程で生成するヒドロキシメチル中間体 74 が残存することが判明した. ヘミアミナール 74 
の分解を促進するため, TFA を留去した後, アンモニア/メタノール溶液を作用させることで
脱保護体 39d, f, g, 75, 76 を良好な収率で得ることができた. 光学活性体 40a−b, 41a−b, 




Scheme 2-6.  Synthesis of 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one Derivatives 39d, 39f−g, 
40a−b, 41a−b, and 42a−ba 
 
a Reagents and conditions: (a) KHMDS, DMF, DMSO, 0 °C, 20 min, then SEMCl, rt, 3 h, 38%.; (b) 
triphosgene, THF, 40 °C, 1−5 h, then RHS benzylamines 99 or 100, Et3N, THF, rt−60 °C, 16 
h−overnight, 64−95%.; (c) cyclopropylboronic acid, Pd(OAc)2, Cy3P, K3PO4, toluene, 100 °C, 
overnight, 73%; (d) B2pin2, PdCl2(dppf), KOAc, DMF, 80 °C, overnight, (taken on crude); (e) 2 M 
NaOH aq., THF, 0 °C, 30 min, then 35−36% H2O2 aq., rt, 1.5−2 h, 80−97% (2 steps from 66−68); (f) 
R2I, K2CO3, DMF, rt−70 °C, overnight, 60−82%; (g) TFA, H2O, rt, 1−3.5 h, then NH3, MeOH, rt, 10 
min−2 h, 67−93%; (h) Chiralpak IA, CO2/MeOH = 43:7 (for 40a and 40b); (i) Chiralpak AD, 
hexane/EtOH = 3:2 (for 41a and 41b); (j) Chiralpak AD, hexane/EtOH = 43:7 (for 42a and 42b). 
 
  右骨格の α-分岐ベンジルアミン合成に必要な共通中間体 86 は Scheme 2-7 記載の方
法で合成した. ケトン 86a あるいは 86b はそれぞれブロモベンゼン 77 とシクロプロピル
ボロン酸を用いた鈴木－宮浦クロスカップリング反応 72,73, あるいはアゼチジンとの 




成した. またケトン 86f はブロモベンゼン 84 とパラジウム触媒を用いたシアン化亜鉛と
のカップリング反応によりシアノ体 85 とした後, エチルグリニャール試薬と反応させて合
成した. 一方, ケトン 86h は, アルデヒド 87 へのビニルグリニャール試薬の求核付加反応
で得られた二級アルコール 88 を Dess−Martin 試薬 75 で酸化した後, パラジウム触媒を用
いたメタノールの α,β-不飽和ケトン 89 への付加反応 96 によって合成した. 86i はアルデヒ
ド 90 を Corey−Chaykovsky 反応 97 によりエポキシ体 91 へ変換した後, ナトリウムメト
キシドによるエポキシの開環および得られた二級アルコールの Dess−Martin 酸化 75 により
合成した. また 86j−l は, 83 のメチルグリニャール試薬との反応によって合成したアセトフ






Scheme 2-7.  Synthesis of Common Ketone Intermediates 86 for RHS Benzylamine Moietiesa 
 
 a Reagents and conditions: (a) cyclopropylboronic acid, PdCl2(dppf), K3PO4, DME, H2O, 85 °C, 20 h, 
78% (for 86a); (b) azetidine, Pd2(dba)3, Xantphos, NaOtert-Bu, toluene, 85 °C, 20 h, 73% (for 86b); 
(c) N,O-dimethylhydroxylamine hydrochloride, EDCI or EDCI·HCl, HOBt or HOBt·H2O, Et3N, DMF, 
0 °C−rt, 16 h, 86−96%; (d) EtMgBr, Et2O, THF, 0 °C to rt, 16 h−3 days, 69−96%; (e) ZnCN2, 
Pd2(dba)3, dppf, DMF, 100 °C, overnight, 43%; (f) vinylmagnesium bromide, THF, 0 °C, 2 h, 60%; 
(g) 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one (Dess−Martin periodinane), CH3CN, 
0 °C or rt, 1−1.5 h, 67−97%; (h) PdCl2(CH3CN)2, MeOH, CH2Cl2, 0 °C to rt, 50%; (i) (CH3)3SOI, 
NaH, DMSO, THF, rt, 1 h, 45%; (j) NaOMe, DMF, 60 °C, 2 h, 65%; (k) Br2, AcOH, 50 °C, 1 or 3 h, 
82%; (l) MeOH, Ag2CO3, BF3·OEt2, 50−60 °C, 2.5 h−overnight, 80−90%; (m) NaSMe, THF, 0 °C to 
rt, 2 h, 86%. 
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  Scheme 2-7 で得られた 86 は ヒドロキシアミンとのオキシム形成反応, 続いて金属触
媒を用いた接触還元に付すことによってベンジルアミン 99 へ導いた. アミン 99 は塩酸塩
とすることで結晶化させて 100c−f, 100h−i, 100l とした (Scheme 2-8). 
 
Scheme 2-8.  Synthesis of RHS Benzylamine Moieties 99 and 100 from Ketones 86a 
 
a Reagents and conditions: (n) hydroxylammonium chloride, Et3N, EtOH, rt−80 °C, 3−72 h, (taken on 
crude); (o) H2, 10% Pd/C or Raney Ni or 20% Pd(OH)2/C, EtOH or MeOH, rt, 4 h−overnight, (taken 
on crude); (p) BH3·THF, reflux, 20 h or overnight, (taken on crude); (q) HCl, EtOAc, rt. 
 
  アルコール分岐側鎖を有するベンジルアミン 108 は Scheme 2-9 記載の方法に従って
合成した. ブロモベンゼン 101 に対して n-ブチルリチウムを作用させてハロゲン−リチウ
ム交換を行った後, 求電子補足剤として 2-クロロ-2-オキソ酢酸エチルを作用させることで 
α-ケトエステル 102 を得た. 次に, 定法に従い, オキシムへの変換, 続くパラジウム/炭素を
用いた接触還元によりベンジルアミン 104 を合成した. さらにアミノ基を Boc で保護 
(105) した後, エステルを水素化アルミニウムリチウムで還元して一級アルコール 106 を合
成した. また, 105 はメチルグリニャール試薬を反応させることで三級アルコール 107 へ導
















































107 108  
a Reagents and conditions: (a) n-BuLi, THF, −78 °C, 50 min, then ethyl 2-chloro-2-oxoacetate, 
−78 °C to rt, overnight, 23%; (b) hydroxylammonium chloride, Et3N, EtOH, 80 °C, overnight, 27%; 
(c) H2, 10% Pd/C, EtOH, rt, overnight, 86%; (d) Boc2O, THF, rt, 2 days, (taken on crude); (e) LAH, 
THF, 0 °C, 30 min, 62%; (f) MeMgBr, THF, 0 °C, 2 h, 41%; (g) HCl, EtOAc, rt, 84%. 
 
  化合物 40a の別ルートによる合成法を Scheme 2-10 に示す. Scheme 2-8 で合成したベ
ンジルアミン 99i のアミノ基を Boc 基 で保護し, 得られた 109 を Chiralpak IC カラムを
用いて光学分割することにより, 光学活性体 110a および 110b を得た. これらに, 塩酸/酢
酸エチル溶液を加えて脱 Boc 化することでベンジルアミン 111a および 111b をそれぞれ
塩酸塩の固体として得た. なお, 111b のベンジル位の絶対立体配置は, 111a の単結晶 X 線
構造解析結果に基づいて S 体と決定した. また, 標的化合物 40a は 3,4-ジヒドロピリド







Scheme 2-10.  Alternative Synthetic Route for 40aa 
 
a Reagents and conditions: (a) Boc2O, Et3N, THF, rt, 20 h, 82%; (b) Chiralpak IC, hexane/EtOH, = 
93:7; (c) HCl, EtOAc, rt, 1 h, 96%; (d) 4-nitrophenyl chloroformate, DIEA, THF, rt, 24 h, (taken on 
crude); (e) amine 111b, Et3N, DMF, rt, 24 h, 52% (2 steps from 112). 
 
  化合物 42a の別ルートによる合成法を Scheme 2-11 に示す. Scheme 2-8 で合成した分
岐ベンジルアミン 99k のアミノ基を Boc で保護し, 得られた 113 を Chiralpak AD カラム
を用いて光学分割することにより, 光学活性体 114a および 114b を得た. 続いて, 114a に
塩酸/酢酸エチル溶液を加えて脱 Boc 化することでベンジルアミン 115 を塩酸塩の固体と
して得た. ベンジルアミンの絶対立体配置を決定する上で良質な単結晶を取得するべく, 塩
酸塩 115 を一旦脱塩 (116) し, 新たに (+)-ジ-(p-トルオイル)-D-酒石酸塩 117 を調製した. 
本結晶の X 線構造解析により, ベンジル位の絶対立体配置は S 体と決定した. また, 標的






Scheme 2-11.  Alternative Synthetic Route for 42a and Synthesis of (+)-Di-(p-toluoyl)-D-tartaric 




































































a Reagents and conditions: (a) Boc2O, Et3N, THF, rt, 16 h, 79%; (b) Chiralpak AD, hexane/EtOH, = 
19:1; (c) HCl, EtOAc, rt, 3 h, 95%; (d) NaHCO3, H2O, quant.; (e) (2S,3S)-(+)-di-(p-toluoyl)-D-tartaric 
acid, EtOH, H2O, 50 °C, overnight; (f) 4-nitrophenyl chloroformate, DIEA, THF, rt, 3 h, 88%; (g) 




第 15 節 結語 
  リード化合物 10a の PDE2A 阻害活性と PDE ファミリー選択性のさらなる向上を目
指して, 10a と PDE2A の X 線共結晶構造解析情報を基に, 以下の 4 つの薬物設計戦略を
考案した. 
戦略 1 Gln859 と明確な水素結合の形成 
戦略 2 PDE2A に特徴的な脂溶性空間を占有する p-トリフルオロメトキシフェニル基の置
換基最適化 
戦略 3 近傍の水分子や極性アミノ酸残基との相互作用を指向したエチル基側鎖の最適化 
戦略 4 母核への置換基導入と最適化 
  また, 良好な中枢移行性化合物を得るために, 脳移行性を予測する上で重要な 2 つの物
理化学的パラメータ (TPSA < 110 Å2, HBD < 3) の目標値を分子内水素結合を考慮して設定
し, 化合物設計の指標とした. 上述の戦略に基づいた構造最適化検討を行うことで, IC50 = 
0.61 nM の強力な PDE2A 阻害活性と PDE1A 阻害と比較して 4100 倍以上の優れた PDE2 
選択性および良好な中枢移行性を併せ持つ新規 3,4-ジヒドロピリド[2,3-b]ピラジン-2(1H)-オ
ン誘導体 42a を見出すことに成功した. 化合物 42a はマウスの脳内 cGMP 含量を用量依
存的に増加させ, ラットを用いた新奇物体認知試験およびマウスを用いた受動的回避試験に
おいて有意な認知機能の亢進および改善作用を示した. 一方, 既存の抗精神病薬で認められ
る副作用に関する評価試験において, 化合物 42a は良好な安全性プロファイルを有するこ
とが明らかとなった. また, 各種動物を用いた安全性試験の結果, 危惧すべき毒性所見が認





第  3 章 既存ケモタイプに特徴的な部分構造のハイブリッド化による新規 
TAK-915 バックアップ化合物の創製 
 
第 1 節 研究背景および新規リード化合物の創出 
  これまでに著者らは, 第 1 章にて HTS によりピラゾロ[1,5-a]ピリミジン環を母核とす
るヒット化合物 2 を端緒化合物として新規 PDE2A 阻害剤の探索研究を行い, 母核への置
換基導入, α-エチルベンジルアミン部位の変換および光学分割を行い, PDE2A 阻害活性およ
び PDE ファミリー選択性の向上したリード化合物 10a を見出した (Figure 3-1). さらに第 
2 章にて, リード化合物 10a の X 線共結晶構造解析の情報を基に構造最適化検討を実施し
た結果, 非常に強力な PDE2A 阻害活性と 4100 倍以上の優れた PDE ファミリー選択性を
示す臨床候補化合物 42a (TAK-915) を見出した (Figure 3-1). 42a は経口投与によって脳内 
cGMP 含量を用量依存的かつ有意に増加させ, また種々の統合失調症動物モデルにおいて有
効性を示した. 本化合物はその後, 統合失調症治療薬として臨床入りを果たすに至ったが, 
化合物探索段階においては 42a の安全性への影響も不明瞭であったことから, 不測の事態
に備えてバックアップ化合物の準備が必要と考えられた. 
  42a の発見に至る過程において, 著者らは, 化合物 118 に代表されるように, 42a とは
構造の異なる α-分岐ベンジルアミン骨格を見出していた (Figure 3-2). 化合物 118 は 42a 
と同様のエーテル側鎖を有する 38a と比べて, 同等の PDE2A 阻害活性および PDE ファ
ミリー選択性を有していたものの, P-gp による排出が強く (排出比 = 2.8), これら一連の誘
導体は中枢移行性の面で課題があった. 42a と 118 は, 両化合物共にほぼ同じ TPSA (102 Å2 
vs. 104 Å2) を有しているにも関わらず, 前者は P-gp 基質の懸念がなく良好な中枢移行性が
確認されている. 前章の第 3 節で論じたように, HBD の数は P-gp 基質プロファイルおよ
び中枢移行性に大きな影響を与える重要な因子であることが報告されており 61,62, 42a と 118 
の P-gp 基質プロファイルの違いは HBD 数の違い (42a: 2 HBDs vs. 118: 3 HBDs) に起因し
ていることが示唆された. 一方で, 第 1 章の研究過程で見出されたピラゾロ[1,5-a]ピリミジ
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ン誘導体 31 は, この時点において母核およびベンジルアミン部位が最適化されていないた
め PDE2A 阻害活性は不十分であったものの, 理想的な TPSA (69 Å2) および HBD 数 (一
つ) を反映して良好な P-gp プロファイル (排出比 = 0.43) と中枢移行性を示した. これら
の結果を基に, 著者らは, 118 の母核である 3,4-ジヒドロピリド[2,3-b]ピラジン-2(1H)-オン
環を HBD 数の 1 つ少ないピラゾロ[1,5-a]ピリミジン環に変換し, 分子全体の HBD 数を
前章で設定した 2 つまで低減したハイブリッド化合物 119 を設計し, P-gp 基質の懸念のな
い新規リード化合物の取得を目指した. その結果, ハイブリッド化合物 119 は, IC50 = 66 nM 
の良好な PDE2A 阻害活性と 150 倍以上の PDE ファミリー選択性を示し, かつ期待通り 
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Different RHS from 42a (TAK-915)
Different core from 42a (TAK-915)
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Figure 3-2.  Origin of a novel PDE2A lead compound 119. 
 
第 2 節 薬物設計戦略 
  第 1 章の第 3 節 (Table 1-1) で論じたように, 化合物 2 のピラゾロ[1,5-a]ピリミジン
環上へのメチル基導入の検討において, 6 位メチル置換体は無置換体と比べて活性が約 10 
倍向上した. 一方, 5 位メチル置換体は活性が保持したのに対し, 2 位あるいは 7 位メチル
置換体は活性が減弱する傾向を示した. これらの知見を基に, 化合物 119 のピラゾロ[1,5-a]
ピリミジン環 6 位にメチル基を導入 (120) したところ, 期待した通り, 約 13 倍の活性向
上が認められた (Figure 3-3). 化合物 10a と PDE2A との複合体 X 線結晶構造解析の結果
から, 母核 5 位置換基の方向には溶媒領域に至るまでの比較的大きな空間の存在が明らか
となっており (Figure 3-4), 5 位置換基として種々の置換基が許容される可能性が示唆されて
82 
 
いる. また, この知見は前述の Table 1-1 で 5 位メチル基が許容された結果とよく一致した. 
以上の考察を踏まえ, リード化合物 119 のさらなる活性の向上を指向して, 5 位置換基の最
適化 (Figure 3-5 の R1), ならびに 6 位メチル基の導入 (Figure 3-5 の R2) を検討すること
とした. この際, 誘導体合成の効率を優先し, 先ずは 5 位置換基の最適化検討を実施し, そ
の後, 6 位メチル基との組み合わせ検討を行うこととした. 
 
 





Figure 3-4.  X-ray crystal structure of 10a bound in the PDE2A catalytic site (PDB 5XKM). 
 
 




第 3 節 ピラゾロ[1,5-a]ピリミジン環 5 位への置換基導入と構造活性相関 
  ピラゾロ[1,5-a]ピリミジン環 5 位に炭素結合型置換基注 11) を導入した結果を Table 3-1 
に示す. また, 対照化合物として化合物 119 のプロファイルを Table 3-1 上段に掲載した. 
ピラゾロ[1,5-a]ピリミジン環 5 位置換基の許容性を検証するために, メチル基よりも嵩高い
脂肪族置換基の導入を検討した. その結果, イソプロピル誘導体 121a は, 無置換体 119 と
比べて活性に大きな変化は認められなかったのに対して, さらに嵩高く, 脂溶性の低減した
テトラヒドロ-2H-ピラニル誘導体 121b は 119 と比べて活性がおよそ 6 倍増強する傾向が
認められた. しかしながら, 121b は P-gp 基質の傾向が強く, さらに高い in vivo クリアラ
ンスを示すことが明らかとなった. 化合物 121b で見られた脂肪族へテロ環の問題点を克服
するべく, 次に芳香族へテロ環の導入を検討した. その結果, 2-ピリジル基 (121c) の導入に
よって, PDE2A 阻害活性および PDE ファミリー選択性のみならず, P-gp 基質プロファイル
および in vivo クリアランスも大幅に改善することが分かった. さらに, 3- および 4-ピリジ
ン誘導体 121d および 121e は, 2-ピリジン誘導体 121c と同様に, 活性・選択性および P-gp 
基質性の点で好ましいプロファイルを保持したが, in vivo クリアランスは悪化の傾向を示し
た. クリアランスの悪化は, ピリジン環上のメチル基, あるいはピリジン塩基性窒素の酸化
代謝に起因するものと考えられた. そこで, メチルピリジン誘導体の代謝安定性の改善を指
向して, メチル基の代謝をフッ素原子の導入により抑制し, 同時に窒素原子の塩基性を低減
したピラゾール環へ変換したジフルオロメチルピラゾール誘導体 121f を設計し, 合成した
ところ, 予想通り in vivo クリアランスが大幅に改善し, 活性・選択性および P-gp 基質性も 
2-ピリジル誘導体 121c と同等の良好なプロファイルを保持することが分かった. しかしな
がら, 一連の炭素結合型芳香族へテロ環誘導体 121c−f は, 全ての化合物において非常に強
                                                     
注 11) 導入する置換基として, ピラゾロ[1,5-a]ピリミジン環 5 位炭素原子に直接炭素原子, あるいは窒素原子が
結合する置換基を, それぞれ「炭素結合型置換基」, 「窒素結合型置換基」と称する. 
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い in vitro 光毒性ポテンシャル注 12) を示すことが明らかとなった. 光毒性は, 薬剤性光線過
敏症の一つであり, 体内に化合物が投与された後, 光照射 (紫外線や可視光) が加わること
で丘疹, 紅斑, 水泡, 蕁麻疹などの症状を引き起こす毒性所見である. 光毒性を有する化合物
は, 日焼け止めクリームやサングラス, 全身を覆う衣類を着用するなど, 日光への露出を避
けなければならず, 臨床での使用が制限される可能性があるため, 前臨床研究において光毒
性ポテンシャルのない化合物の探索が求められる 99,100. そこで著者らは, 化合物 121c−f で
認められた in vitro 光毒性ポテンシャルの軽減を目指した. 上述の検討において, ピラゾー
ル誘導体 121f は in vitro 光毒性を除く他のプロファイルで良好であったことから, 引き続
き芳香族ヘテロ 5 員環, 特に窒素結合型置換基の導入を検討することとした. その結果, 窒
素結合型ピラゾール誘導体 121g は 121f と比べて, 活性および選択性が 2−3 倍低下した
ものの, P-gp 基質性および in vivo クリアランスは良好な値を示した. さらに特筆すべき点
として, 化合物 121g の光毒性ポテンシャルが大幅に改善することが明らかとなった. 詳細
は不明であるが, 5 位置換基の結合様式によって, in vitro 光毒性の原因骨格と考えられる 5 
位置換基を含むピラゾロ[1,5-a]ピリミジン環の電子状態に変化が生じ, その結果, in vitro 光
毒性ポテンシャルの軽減に繋がったのではないかと推察している. 続いて, ピラゾール類縁
体としてメチルイミダゾール誘導体 121h を合成したところ, 本化合物は強力な活性と良好
な PDE ファミリー選択性および in vitro 光毒性ポテンシャルを示した反面, 強い P-gp 基
質であることが明らかとなった. イミダゾール環の強い塩基性がその原因と考えられたこと
から, 以下の 2 通りの方法にて塩基性低減の可能性を検討した. 一つ目のアプローチとして, 
イミダゾール環上に電子求引基であるトリフルオロメチル基の導入を試みた (121i). 二つ目
のアプローチとして, イミダゾール環にさらにもう一つの窒素原子を導入することにより塩
基性の非局在化を図った (121j, 121k). その結果, 121i−k のいずれの化合物も良好な in vitro 
                                                     




光毒性プロファイルおよび in vivo クリアランスを示し, さらに P-gp 基質性も大幅に改善


















































1300-fold 1.2 558 102.1 3.14 
a IC50 values (95% confidence intervals given in parentheses) were calculated from percent inhibition 
data (duplicate, n = 1). All values are rounded off to two significant digits. b Minimum selectivity 
(rounded off to two significant digits) over other PDEs. c MDR1 efflux ratios in P-gp overexpressing 
cells. d Plasma clearance calculated following 0.1 mg/kg, iv cassette dosing in rats (non-fasted). 
e Values (%) represent the difference between viability of cells exposed to 50 μM of the test 
compound in the absence of UV irradiation and that in the presence of UV irradiation, where cell 
viability was measured by intracellular ATP content (%) at 50 μM relative to vehicle control. A larger 















































610-fold 0.90 779 3.8 3.15 
a IC50 values (95% confidence intervals given in parentheses) were calculated from percent inhibition 
data (duplicate, n = 1). All values are rounded off to two significant digits. b Minimum selectivity 
(rounded off to two significant digits) over other PDEs. c MDR1 efflux ratios in P-gp overexpressing 
cells. d Plasma clearance calculated following 0.1 mg/kg, iv cassette dosing in rats (non-fasted). 
e Values (%) represent the difference between viability of cells exposed to 50 μM of the test 
compound in the absence of UV irradiation and that in the presence of UV irradiation, where cell 
viability was measured by intracellular ATP content (%) at 50 μM relative to vehicle control. A larger 
value is interpreted as a higher risk of phototoxicity. f Log D values at pH 7.4. g Not tested. 




第 4 節 ピラゾロ[1,5-a]ピリミジン環 5, 6 位への置換基導入と構造活性相関 
  前節において見出した化合物 121j および 121k は P-gp 基質性, in vivo クリアランス, 
および in vitro 光毒性ポテンシャルのいずれも良好なプロファイルを有していたものの, 活
性および選択性に改善の余地が残されていた. 第 1 章の第 2 節で論じたピラゾロ[1,5-a]ピ
リミジン環上への置換基の構造活性相関から, 6 位メチル体は PDE2A 阻害活性および PDE 
ファミリー選択性を大きく改善することが明らかとなっており, この知見を 121j および 
121k の両化合物に適応することとした. その結果, 122a および 122b は共に 100 pM オー
ダーの非常に強い PDE2A 阻害活性と 5000 倍を超える PDE ファミリー選択性 (Table 3-2, 
詳細は Table 3-3 参照) を示し, その他のプロファイルも 6 位メチル基の導入によって悪化
の傾向は認められなかった. 化合物 122a は in vitro 光毒性ポテンシャルを評価した 50 µM 
の濃度において析出物が観察されており, それゆえ, 過小評価の可能性は否めないが, 少な
くとも析出物が認められていない 25 µM の濃度においては, 炭素結合型誘導体 121c−f の
いずれの化合物と比較しても, 化合物 122a の in vitro 光毒性ポテンシャルは顕著に軽減さ
れていることが明らかとなった. 一方, 化合物 122a と 122b の溶解度を測定したところ 
(Table 3-4), 化合物 122a は酸性および中性のどちらの条件下においても溶解度が非常に低い
ことが明らかとなった. 化合物 122a の低溶解性は, Table 3-2 の in vitro 光毒性評価におい
て析出物が確認されていたこととも矛盾のない結果であり, この後の薬理評価および毒性試
験での経口吸収性に課題を残した. 一方で, 化合物 122b は評価したいずれの条件下におい




















120 H 5.1 (4.3−6.1) 1600-fold 0.53 2743 4.2 2.66 
122a 
 
0.31 (0.27−0.35) 5800-fold 1.2 940 13.0g 3.24 
122b 
 
0.51 (0.46−0.58) 5300-fold 1.0 1169 3.7 3.42 
a IC50 values (95% confidence intervals given in parentheses) were calculated by nonlinear regression 
analysis of percent inhibition data (n = 2). All values are rounded off to two significant digits. 
b Minimum selectivity (rounded off to two significant digits) over other PDEs. c MDR1 efflux ratios in 
P-gp overexpressing cells. d Plasma clearance calculated following 0.1 mg/kg, iv cassette dosing in 
rats (non-fasted). e Values (%) represent the difference between viability of cells exposed to 50 μM of 
the test compound in the absence of UV irradiation and that in the presence of UV irradiation, where 
cell viability was measured by intracellular ATP content (%) at 50 μM relative to vehicle control. A 





Table 3-3.  Inhibitory Activities of 122a and 122b against Human PDEsa 
 122a 122b 
PDE subtypes IC50 (nM)a selectivity ratiob IC50 (nM)a selectivity ratiob 
PDE1A 3300 11000 2700 5300 
PDE2A3 0.31 − 0.51 − 
PDE3A >10000 >32000 >10000 >20000 
PDE4D2 3300 11000 9400 18000 
PDE5A1 8800 28000 9100 18000 
PDE6AB 1800 5800 8000 16000 
PDE7B >10000 >32000 >10000 >20000 
PDE8A1 >10000 >32000 >10000 >20000 
PDE9A2 >10000 >32000 >10000 >20000 
PDE10A2 1700 5500 3100 6100 
PDE11A4 3000 9700 >10000 >20000 
a IC50 values (nM) were calculated by nonlinear regression analysis of percent inhibition data (n = 2). 
All values are rounded off to two significant digits. 
 
Table 3-4.  Thermodynamic Solubility of Compound 122a and 122b 
compd 
thermodynamic solubility (μg/mL) 
crystallinity (%) 
pH 1.2 pH 6.8 pH 6.8 + GCDCa 
122a 0.45 0.32 16 89 
122b 7 4.1 140 83 
a Solubility in a pH 6.8 solution containing sodium glycochenodeoxycholate (GCDC). This is 




第 5 節 化合物 122b と PDE2A の X 線共結晶構造解析 
  化合物 122b と PDE2A との X 線共結晶構造および化合物 10a と PDE2A との X 線
共結晶構造をそれぞれ Figure 3-6 (A) および 3-6 (B) に示す. 結晶構造解析の結果, 化合物 
122b は第 1 章で見出したリード化合物 10a と同様に, 以下の 1−5 に示す相互作用を保持
していることが明らかとなった. 
1. ピラゾロ[1,5-a]ピリミジン環 7 位の水素原子は Gln859 と CH−O の擬似的水素結合を
介して相互作用している. 
2. ピラゾロ[1,5-a]ピリミジン環は上下の Phe862 および Ile826 とそれぞれ π−π ならびに 
CH−π の相互作用により安定化している. 
3. ピラゾロ[1,5-a]ピリミジン環 6 位メチル基は Tyr827, Leu858, Ile826 で囲まれた脂溶性
空間とファンデアワールス相互作用を形成している. 
4. アミドカルボニル基は Tyr655 と水分子を介した水素結合のネットワーク, さらにもう
一つ別の水分子と水素結合を形成している (Figure 3-6 (A) には未記載. 詳細は Figure 
1-7 参照). 
5. p-トリフルオロメトキシフェニル基は PDE2A タンパクとの結合によって新たに形成さ
れた PDE2A に特異的な脂溶性空間を効果的に充填している. 
これら 5 つの相互作用に加え, 122b は PDE2A タンパクと以下の新たな相互作用を獲得し
ていることが分かった.  
6. ピラゾロ[1,5-a]ピリミジン環 5 位のトリアゾール環は上下にある Ile866 と Met847 に
挟まれる空間を効果的に充填し, ファンデアワールス相互作用をしている. また, トリア
ゾール環は Leu858 の主鎖カルボニル基と水を介して水素結合を形成している. 





  以上のように , 化合物  122b はリード化合物  10a と同様 , Gln859 との相互作用は 
TAK-915 と比べて弱いことが予想されるものの, 上述の PDE2A 特異的な新たな相互作用を
獲得することによって TAK-915 と同等の強力な PDE2A 阻害活性および 5300 倍以上の優
れた PDE ファミリー選択性を示していると考えられる. 
 
 
Figure 3-6.  (A) X-ray crystal structure of 122b bound in the PDE2A catalytic site (PDB 5VP1) and 
(B) X-ray crystal structure of 10a bound in the PDE2A catalytic site (PDB 5XKM). The 




第 6 節 化合物 122b の薬物動態プロファイル 
  化合物 122b のラットおよびマウスにおける薬物動態試験の結果を Table 3-5 に示す. 
化合物 122b をラットおよびマウスに 0.3 mg/kg の静脈内投与をしたところ, 共に良好なク
リアランスおよび分布容積を示し, 1 mg/kg 経口投与においては, それぞれ 31% および 48% 
の良好な生物学的利用率と 272.8 ng·h/mL および 628.6 ng·h/mL の血中濃度−時間曲線下総
面積値を示した. さらに, ラットの最高血中濃度到達時間における脳内と血漿中の薬物濃度
比 Kp は 0.32 で, 高い TPSA (114 Å2) を示したにも関わらず, 比較的良好な中枢移行性を
示すことが明らかとなった. 
 
Table 3-5.  PK Parameters and Kp Values of Compound 122b in Rat and Mousea 
 rat mouse 
CLtotalb (mL/h/kg) 1169 768 
Vdssc (mL/kg) 2329 1337 
Cmaxd (ng/mL) 58.1 181.0 
Tmaxe (h) 2.0 0.7 
AUC0−8hf (ng·h/mL) 272.8 628.6 
Fg (%) 31.2 48.2 
Kph 0.32 − 
a Cassette dosing at 0.1 mg/kg, iv and 1 mg/kg, po (non-fasted), in an average of 3 rats or mice. b Total 
clearance. c Volume of distribution at steady state. d Maximum plasma concentration. e Time of 
maximum concentration. f Area under the plasma concentration vs time curve (0−8 h). g Oral 




第 7 節 化合物 122b の in vivo 薬理評価 
  精査化合物 122b が標的分子に直接作用しているかどうか (target engagement) を検証す
るために, 化合物 122b の PDE2A 酵素に対する結合占有率を算出した. 結果を Figure 3-7 
に示す . 化合物  122b を経口投与することによって , 本化合物が線条体部位に発現する 
PDE2A に用量依存的に結合していることが明らかとなった. このとき, ED50 (50% 占有率の
ときの用量) は 3.9 mg/kg であった. また, 化合物 122b の PD マーカーに対する影響を確
認するために, 前頭葉, 線条体ならびに海馬の cAMP および cGMP 含量を測定した (Figure 
3-8). これまでの知見と同様に 48,55,69, 化合物 122b は上記の脳部位において用量依存的に 
cGMP 含量を増加させ, 3 mg/kg の用量から有意な変化が認められた. 一方, 化合物 122b は
これまでの結果と同様に, cAMP 含量に有意な影響を及ぼさなかった. 前述の用量−占有率相
関の結果 (Figure 3-7) から, 3 mg/kg の用量における PDE2A 酵素占有率は ~37% であるこ
とから, 動物モデルにおいても本占有率を超える用量にて薬理作用を発揮することが期待さ
れる. そこで, 脳内 cGMP 含量の増加が認められた 3 mg/kg の投与量で認知機能障害モデ
ルを用いたラット受動的回避試験を実施した (Figure 3-9). その結果, MK-801 (0.1 mg/kg) の
皮下投与によって誘発された認知機能障害作用が, 化合物 122b の経口投与 (3 mg/kg) によ
り有意に改善することが確認できた. 以上のことから, 化合物 122b は第 2 章で見出した 





Figure 3-7.  In vivo PDE2A target occupancy in the striatum measured 2 h after oral administration 






Figure 3-8.  Effects of compound 122b on cyclic nucleotides in rat brain. cGMP (A) and cAMP (B) 
levels 2 h after oral administration of compound 122b (1 mg/kg, 3 mg/kg, and 10 mg/kg) were 
measured in the rat frontal cortex (Fcx), hippocampus (Hipp), and striatum (Str). Data are presented as 





Figure 3-9.  Effects of compound 122b on MK-801-induced episodic memory deficits assessed by 
the passive avoidance task in rats. Vehicle or compound 122b (3 mg/kg) was orally administered 90 
min before the s.c. administration of saline or MK-801. Thirty minutes after the s.c. administration of 
saline or MK-801 (0.1 mg/kg), the rat was placed on the illuminated chamber. The latency to cross 
over into the dark chamber was recorded for up to a maximum of 300 s. The retention test was carried 
out 24 h after the acquisition trial. Data (latency to cross over into the dark compartment on the 
retention trial) are expressed as mean ± SEM, n = 20, **p ≤ 0.01 (versus control by Wilcoxon’s test), 




第 8 節 化合物の合成 
  三級アルコール側鎖を有するベンジルアミン 130 は Scheme 3-1 記載の方法で合成し
た. ベンズアルデヒド 123 は Bucherer−Bergs 反応 101 により対応するヒダントイン 124 へ
導いた後 , アルカリ加水分解によりアミノ酸  125 を合成した . 125 のアミノ基を 
Schotten−Baumann の条件下, Boc 基で保護し, 続いてカルボン酸 126 をメチル化すること
によってメチルエステル 127 に変換した. 得られた 127 をメチルグリニャール試薬と反応
させて三級アルコール 128 とした後, Chiralpak AD を用いた光学分割により光学活性体 
129a および 129b を取得した. 続いて, 所望の絶対配置 (決定法は後述 (Scheme 3-5)) を有
する光学活性体 129a を塩酸/酢酸エチルで脱 Boc 化することによってベンジルアミン 130 
を塩酸塩として得た. 
 

































































a Reagents and conditions: (a) KCN, (NH4)2CO3, EtOH, H2O, 50 °C to 60 °C, 3 h, (taken on crude); 
(b) KOH, water, 90 °C, 3 days, (taken on crude); (c) Boc2O, 2 M NaOH aq., THF, rt, overnight, (taken 
on crude); (d) MeI, K2CO3, DMF, rt, 2 h, 46% (4 steps from 123); (e) MeMgBr, THF, 0 °C, 1 h, 76%; 
(f) Chiralpak AD, hexane/EtOH = 95:5; (g) HCl, EtOAc, rt, 1.5 h, 84%. 
 
  化合物 119 と 120 は市販の原料 15 および 15b (Scheme 1-1 参照) とベンジルアミン 
塩酸塩 130 とのアミド化反応によって合成した (Scheme 3-2). 
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Scheme 3-2.  Synthesis of Pyrazolo[1,5-a]pyrimidine Derivatives 119 and 120a 
 
a Reagents and conditions: (a) EDCI·HCl, HOBt·H2O, Et3N, DMF, rt, overnight, 41−87%. 
 
  5 位置換ピラゾロ[1,5-a]ピリミジン誘導体 121a−k は Scheme 3-3 記載の方法で合成し
た. ピラゾロ[1,5-a]ピリミジン 132 は塩基性条件下, 5-アミノ-1H-ピラゾール 131 と 3-エト
キシアクリル酸エチルとの縮合反応により合成した. 次に, エステル 132 をアルカリ加水分
解によりカルボン酸 133 とした後, オキシ塩化リン (POCl3) を加えて 130 °C で加熱するこ
とによってビスクロロ体 134 を得た. 続いて, 右骨格のベンジルアミン 130 を作用させる
ことで鍵中間体の 5-クロロピラゾロ[1,5-a]ピリミジン誘導体 135 を合成した. ピラゾロ
[1,5-a]ピリミジン環 5 位への置換基導入は鈴木－宮浦クロスカップリング反応,72,73 あるい
は対応するアゾール環との求核置換反応を用いて行い, 標的化合物 121d−k へ導いた. また
カップリング体 136 および 137 は, 引き続きパラジウム/炭素を用いた接触還元に付し, オ
レフィン還元体 121a および 121b を得た. 一方, 2-ピリジン誘導体 121c については, 上述
の 5-クロロピラゾロ[1,5-a]ピリミジン誘導体 135 を基質とする鈴木－宮浦クロスカップリ
ング反応が進行しなかったため, 別ルートでの合成を検討した. 135 に含まれるアミドや三
級アルコール部位などの極性官能基がカップリング反応に悪影響を及ぼしている可能性が考
えられたため, ベンジルアミン部位の導入前のヒドロキシ体 132 から誘導した 5-クロロピ
ラゾロ[1,5-a]ピリミジン誘導体 138 と 2-ピリジルトリオールボレート塩 139 を銅触媒存在
下, 無水溶媒中, 80 °C で加熱することで 87% の良好な収率で所望のカップリング体 140 を
得ることができた 102. 最後に, エステル体 140 はアルカリ加水分解に次ぐベンジルアミン 
130 との縮合反応によって標的化合物 121c へ導いた. 
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Scheme 3-3.  Synthesis of 5-Substituted Pyrazolo[1,5-a]pyrimidine Derivatives 121a−ka 
 
a Reagents and conditions: (a) ethyl 3-ethoxyacrylate (cis- and trans-mixture), Cs2CO3, DMF, 
100 °C, 2 h, 91%; (b) NaOH aq., THF, EtOH, 50−60 °C, 2 h−overnight, 75−98%; (c) POCl3, DIEA, 
130 °C, 4 h, 74%; (d) RHS benzylamine 130, DIEA, CH3CN, 0 °C to rt, 16 h, 77%; (e) alkyl or 
arylboronic acid pinacolester, (Amphos)2PdCl2, K2CO3, toluene, H2O, 120−150 °C (microwave), 25 
min−2.5 h, 63−78%; (f) azole, K2CO3, DMF, 80−90 °C, 30 min−2 h, 7−74%; (g) H2, 5% 
Pd/C−ethylenediamine complex, MeOH, rt, 16 h, 83−98%; (h) POCl3, 100 °C, 16 h, 61%; (i) lithium 
4-methyl-1-pyridin-2-yl-2,6,7-trioxa-1-borabicyclo[2.2.2]octan-1-uide 139, Pd(OAc)2, Ph3P, CuI, 
DMF, 80 °C, 2 h, 87%; (j) RHS benzylamine 130, HATU, DIEA, DMF, rt, 12 h, 84%. 
 
  5,6-ジ置換ピラゾロ[1,5-a]ピリミジン誘導体 122a および 122b の合成を Scheme 3-4 に
示す. アミノピラゾール 145 は 2-シアノ酢酸 tert-ブチル (142) と tert-ブトキシビス(ジメ
チルアミノ)メタン (143) との縮合反応, 続くヒドラジンとのピラゾール環構築反応の 2 工
程, 64% の収率で合成した. 得られた 145 は 1,3-ジカルボニル等価体 148 との縮合反応に




した. また, 化合物 149 の 5 位ヒドロキシ基を DBU 共存下, ジフェニルリン酸アジドを
用いてアジド体 150 に変換した後, α-ホルミルエチリデントリフェニルホスホラン (151a) 
の互変異性体 151b との 1,3-双極子付加環化とトリフェニルホスフィンオキシドの脱離を伴
うトリアゾール環構築反応によって 1,2,3-トリアゾール体 153a を合成した 103,104. 一方で, 
149 を四塩化炭素およびトリフェニルホスフィンを用いた Appel 型反応 105 に付しクロロ体 
152 とした後, 塩基性条件下, 3-メチル-1H-1,2,4-トリアゾールの芳香族求核置換反応により 
1,2,4-トリアゾール体 153b を位置選択的に得た. 153a,b は酸性条件下での tert-ブチルエス





Scheme 3-4.  Synthesis of 6-Methyl-5-Substituted Pyrazolo[1,5-a]pyrimidine Derivatives 122a and 
122ba 
 
a Reagents and conditions: (a) neat, rt, 30 min, (taken on crude); (b) NH2NH2·H2O, MeOH, 70 °C, 
overnight, 64%; (c) Br2, EtOAc, rt, 16 h, (taken on crude); (d) NaOMe, MeOH, 70 °C, 3 h, (taken on 
crude); (e) Cs2CO3, DMF, 100 °C, 16 h, 84%; (f) DPPA, DBU, THF, 60 °C, 5 h, 74%; (g) 151, toluene, 
80 °C, 3 h, then MgCl2, 60 °C, 2 h, 97%; (h) CCl4, PPh3, 1,2-dichloroethane, 75−85 °C, 4.5 h, 88%; (i) 
3-methyl-1H-1,2,4-triazole, K2CO3, DMF, 60 °C, 2 h, 69%; (j) MsOH, CH3CN, rt−60 °C, 5.5 
h−overnight, 85−91%; (k) RHS benzylamine 130, EDCI·HCl, HOBt·H2O, Et3N, DMF, rt, 2 
h−overnight, 75−82%. 
 
  ベンジルアミン 130 の絶対立体配置を決定するために, 塩酸塩 130 を中和によりフリ
ー体 155 とした後, (+)-ジ-(p-トルオイル)-D-酒石酸との新たな塩形成によって 156 を結晶と
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して取得した (Scheme 3-5). 156 の単結晶 X 線構造解析の結果, ベンジル位の絶対立体配置
は S 体と決定した. 
 




























a Reagents and conditions: (a) NaHCO3, H2O; (b) (2S,3S)-(+)-di-(p-toluoyl)-D-tartaric acid, EtOH, 




第 9 節 結語 
  第 1 章および第 2 章の合成研究の過程で見出した誘導体 118 および 31 の化合物特
性に着目し, それぞれの部分骨格を組み合わせた化合物 119 を設計・合成した結果, TAK-915 
とは構造的に異なり, かつ PDE2A 阻害活性, PDE ファミリー選択性および P-gp プロファ
イルの優れた新規リードケモタイプを見出すことに成功した. また, 新たに見出したリード
化合物を端緒化合物として, X 線共結晶構造情報に基づき, ピラゾロ[1,5-a]ピリミジン環 5 
位および 6 位の置換基探索を行った結果, TAK-915 と同等の強力な阻害活性 (IC50 = 0.51 
nM) と優れた PDE ファミリー選択性 (5300 倍 vs. PDE1A) および in vitro プロファイルを
示す化合物 122b を見出すことに成功した. また, 炭素結合型芳香族へテロ環をピラゾロ
[1,5-a]ピリミジン環 5 位に導入することで認められた強い in vitro 光毒性ポテンシャルは, 
ピラゾール環やトリアゾール環などの窒素結合型芳香族へテロ 5 員環に変換することで劇
的に改善されることを明らかにした. さらに化合物 122b は, ラットへの経口投与によって, 
線条体における PDE2A 酵素への占有率を用量依存的に増加させ, 占有率の増加に伴いラッ
ト脳内 cGMP 含量も用量依存的に上昇させることが明らかとなった. また統合失調症の認
知機能障害を反映するモデルとされる受動的回避試験においても, 脳内 cGMP 含量を有意
に上昇させた用量にて有意な認知機能改善効果を示した. 以上のように, 化合物 122b は 
TAK-915 の構造とは異なり , かつ良好な  ADME-Tox (absorption, distribution, metabolism, 










が強く求められている. このような背景のもと, 近年, 既存の抗精神病薬とは作用機序が異
なる新規認知機能改善薬として PDE2A 阻害薬が注目を集め, 複数の製薬企業から低分子化
合物が報告されている. しかしながら, いずれの化合物も主活性・PDE 選択性・薬物動態あ
るいは中枢移行性などに課題を有しており, PDE2A が統合失調症の認知機能を改善する有望
な標的分子であるかどうかはこれまで不明であった. そこで著者らは, 非臨床および臨床に
おいて PDE2A の認知機能改善薬としての有用性を実証するべく, 構造独自性が高く, 経口
投与可能で, 良好な中枢移行性を示す安全かつ高選択的な PDE2A 阻害薬の探索研究を実施
した. その結果, 3,4-ジヒドロピリド[2,3-b]ピラジン-2(1H)-オン環を基本骨格とした臨床候補
化合物 42a (TAK-915) を見出すことに成功した. さらに, TAK-915 の開発過程における不測
の事態に備えるためにバックアップ化合物の探索研究に着手し, TAK-915 とは構造が異なり, 
かつ TAK-915 と同等の PDE2A 阻害活性・PDE 選択性および in vivo 活性を有する化合物 





  本研究で得られた知見を以下にまとめる. これらの知見は, PDE2A 阻害剤の研究のみな




1. HTS ヒット化合物 2 を端緒化合物とした合成展開において, ピラゾロ[1,5-a]ピリミジン
環上への置換基の導入, 右骨格ベンジルアミン部位の最適化検討およびベンジルアミン
側鎖部位の光学分割により, 良好な PDE2A 阻害活性 (IC50 = 24 nM) および PDE ファ
ミリー選択性 (180 倍 vs. PDE3A) を有し, 経口投与において脳内 cGMP 含量の増加を
示すリード化合物 10a を見出した. 
 
2. 化合物 10a の X 線共結晶構造解析の結果, 特徴的な結合様式が明らかとなった. 中で
も, p-トリフルオロメトキシフェニル基は PDE2A に特徴的な脂溶性空間を最安定構造に
近い配座で効果的に占有していること, ピラゾロ[1,5-a]ピリミジン環 7 位水素原子は 
PDE ファミリー共通の基質結合部位である Gln859 と CH－O の擬似的水素結合を介し
て相互作用していること, アミド NH とピラゾロ[1,5-a]ピリミジン環 4 位窒素原子が強




3. 化合物 10a のピラゾロ[1,5-a]ピリミジン骨格を Gln859 と明確な水素結合が形成可能な
縮合環へ骨格変換することで, PDE2A 阻害活性の向上した新規 3,4-ジヒドロピリド
[2,3-b]ピラジン-2(1H)-オン誘導体 32 を見出した. 
 
4. 化合物 32 の右末端フェニル基上置換基の最適化において, 種々置換基導入の構造活性
相関を明らかにし, 中でも p-トリフルオロメトキシ基の隣の位置にフッ素原子を導入す
ることで PDE2A 阻害活性がおよそ 2 倍向上した化合物 37h を見出した. 
 
5. リガンド結合サイトに存在する金属イオン周辺の極性アミノ酸残基や水分子との新たな
相互作用を指向した化合物 32 の分岐エチル側鎖への極性基導入を通じて, 4 倍強力な 
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PDE2A 阻害活性 (IC50 = 19 nM) と 310 倍の良好な PDE ファミリー選択性, かつ顕著
に脂溶性が低減 (ΔLog D = 0.66) した化合物 38a を見出した. 
 
6. 化合物 38a の 3,4-ジヒドロピリド[2,3-b]ピラジン-2(1H)-オン環上への置換基導入を通じ
て, 各部位の構造活性相関を明らかにするとともに, 7 位メトキシ基 (39f) が PDE2A 阻
害活性および PDE ファミリー選択性の両面において, 顕著な改善効果 (IC50 = 2.8 nM, 




7. 上記 3−6 で得られた知見を組み合わせ, その後分岐側鎖部位の光学分割を行うことによ
り, 強力な PDE2A 阻害活性 (IC50 = 0.61 nM) と優れた PDE ファミリー選択性 (4100 
倍以上) およびオフターゲット選択性 (6400 倍以上 vs. 96 種類のオフターゲット) を示
し, 中枢移行性の良好な化合物 42a を見出した. 本化合物は 経口投与の結果, マウス脳
内の cGMP 含量を用量依存的に増加させるとともに, 種々の薬効モデル動物において認
知機能改善効果を示した. また, 既存の抗精神病薬に特徴的な副作用の評価および各種動
物を用いた安全性試験の結果, 危惧すべき毒性所見が認められず十分な毒性マージンが
確保されたことから, 化合物 42a (開発コード: TAK-915) を臨床試験の候補化合物として
選出した. 
 
8. 上記 3−7 の化合物探索において, 我々が設定した分子内水素結合を考慮した TPSA お





9. 化合物 118 および 31 に代表される既存ケモタイプの構造特性を理解し, それぞれの部
分構造を組み合わせることで, 118 の高い P-gp 基質プロファイルおよび 31 の弱い阻害
活性の双方の問題点を同時に克服し, TAK-915 とは構造の異なる新規リード化合物 119 
を見出すことに成功した. 
 
10. 化合物 10a の X 線共結晶構造解析の情報に基づいてピラゾロ[1,5-a]ピリミジン誘導体 
119 の母核 5 および 6 位の最適化研究を行った結果, 非常に強力な PDE2A 阻害活性
と PDE1A に対して 5300 倍の PDE ファミリー選択性を示す 122b を見出した. 
 
11. 炭素結合型芳香族へテロ環を 5 位置換基として導入することで認められた強い in vitro 
光毒性ポテンシャルは, 122b の置換基に代表される窒素結合型芳香族へテロ 5 員環に置
換することで劇的に改善されることを明らかにした. π 共役系を短くする一般的な光毒性
回避の戦略とは異なる本知見は, 今後の創薬研究において有用であると考えられる.  
 
12. 化合物 122b の X 線共結晶構造解析の結果, 本化合物は第 1 章で見出したリード化合
物 10a と同様の相互作用に加えて, 5 位トリアゾール環の上下に位置する Ile866/Met847 
とのファンデアワールス相互作用と Leu858 主鎖カルボニル基との水を介した水素結合
を新たに獲得するとともに, 分岐側鎖の三級アルコール部位酸素原子とアミド NH との
分子内水素結合 , さらには  gem-ジメチル基による立体配座の固定化によって強い 
PDE2A 阻害活性と高い PDE ファミリー選択性が発現していることを明らかにした. 
 
13. 化合物 122b のラットへの経口投与によって, ラット脳内 cGMP 含量が用量依存的かつ
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    All solvents and reagents were obtained from commercial sources and were used as received. 
Microwave-assisted reactions were carried out in a single-mode reactor, Biotage Initiator 2.0 or 2.5 
microwave synthesizer. Yields were not optimized. All reactions were monitored by thin layer 
chromatography (TLC) analysis on Merck Kieselgel 60 F254 plates or Fuji Silysia NH plates, or LC–
MS (liquid chromatography–mass spectrometry) analysis. LC–MS analysis was performed on a 
Shimadzu liquid chromatography–mass spectrometer system operating in atmospheric pressure 
chemical ionization (APCI) (+ or −) or electrospray ionization (ESI) (+ or −) mode. Analytes were 
eluted using a linear gradient with a mobile phase of water/acetonitrile containing 0.05% TFA or 5 
mM ammonium acetate and detected at 220 nm. Column chromatography was carried out on silica gel 
((Merck Kieselgel 60, 70–230 mesh, Merck) or (Chromatorex NH-DM 1020, 100–200 mesh, Fuji 
Silysia Chemical, Ltd.)), or on prepacked Purif-Pack columns (SI or NH, particle size: 60 µm, Fuji 
Silysia Chemical, Ltd.). Analytical HPLC was performed using a Corona Charged Aerosol Detector or 
photo diode array detector with a Capcell Pak C18AQ (3.0 mm ID × 50 mm L, Shiseido, Japan) or 
L-column2 ODS (2.0 mm ID × 30 mm L, CERI, Japan) column at a temperature of 50 °C and a flow 
rate of 0.5 mL/min. Mobile phases A and B under neutral conditions were a mixture of 50 mmol/L 
ammonium acetate, water, and acetonitrile (1:8:1, v/v/v) and a mixture of 50 mmol/L ammonium 
acetate and acetonitrile (1:9, v/v), respectively. The ratio of mobile phase B was increased linearly 
from 5% to 95% over 3 min, and then maintained at 95% over the next 1 min. Mobile phases A and B 
under acidic conditions were a mixture of 0.2% formic acid in 10 mmol/L ammonium formate and 
0.2% formic acid in acetonitrile, respectively. The ratio of mobile phase B was increased linearly from 
14% to 86% over 3 min, and then maintained at 86% over the next 1 min. All final test compounds 
were purified to >95% chemical purity as measured by analytical HPLC. Elemental analyses were 
carried out by Takeda Analytical Laboratories, and all results were within ±0.4% of the theoretical 
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values. Melting points were determined on a BÜCHI B-545 melting point apparatus or a DSC1 system 
(Mettler-Toledo International Inc., Greifensee, Switzerland) and are uncorrected. Optical rotation was 
determined by a Jasco P-2300 polarimeter. Specific rotations [α]ଶ଴ୈ  are given in deg dL g−1 mm−1. 
Proton (1H) and carbon (13C) nuclear magnetic resonance (NMR) spectra were recorded on a Varian 
Mercury-300 (300 MHz), Bruker DPX300 (300 MHz), or Bruker Avance II+ 600 (600 MHz) 
instrument. All 1H and 13C NMR spectra were consistent with the proposed structures. All proton and 
carbon shifts are given in parts per million (ppm) downfield from tetramethysilane (δ) as the internal 
standard in deuterated solvent, and coupling constants (J) are in hertz (Hz). NMR data are reported as 
follows: chemical shift, integration, multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; quint, 
quintet; m, multiplet; dd, doublet of doublets; td, triplet of doublets; ddd, doublet of doublet of 
doublets; and brs, broad singlet), and coupling constants. Very broad peaks for protons of, for example, 




第 1 章に関する実験 
N-(1-(4-Methoxyphenyl)propyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (2). To a solution of 
pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (15) (50 mg, 0.31 mmol) in DMF (2 mL) were added 
EDCI (71 mg, 0.37 mmol), HOBt (49 mg, 0.37 mmol), and DIEA (79 mg, 0.61 mmol). Then 21a (55 
mg, 0.34 mmol) was added. After stirred at rt overnight, the reaction mixture was diluted with EtOAc 
and washed with saturated aqueous NaHCO3 and saturated aqueous NaCl. The organic layer was dried 
over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by preparative TLC 
(petroleum ether/ethyl acetate, 1:1) to give 2 (50 mg, 0.16 mmol, 52%) as a colorless oil. 1H NMR 
(400 MHz, CDCl3) δ 0.97 (3H, t, J = 7.6 Hz), 1.92–2.00 (2H, m), 3.78 (3H, s), 5.12–5.14 (1H, m), 
6.87 (2H, d, J = 8.8 Hz), 6.97–6.99 (1H, m), 7.33 (2H, d, J = 8.8 Hz), 8.19–8.21 (1H, m), 8.63–8.66 
(2H, m), 8.76–8.78 (1H, m). MS (ESI/APCI) mass calculated for [M + H]+ (C17H19N4O2) requires m/z 
311.14, found m/z 311.1. HPLC purity: 99.3%. 
N-(1-(4-Methoxyphenyl)propyl)-2-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide (3a). To a 
mixture of 15a (128 mg, 0.720 mmol), 22a (160 mg, 0.793 mmol) and Et3N (0.151 mL, 1.08 mmol) in 
DMF (5 mL) were added HOBt·H2O (133 mg, 0.868 mmol) and EDCI·HCl (166 mg, 0.866 mmol). 
The mixture was stirred at rt for 5 h and then poured into NaHCO3 aqueous solution, extracted with 
EtOAc, washed with water, dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was 
purified by column chromatography (silica gel, hexane/ethyl acetate, 2:3 to 0:100) to afford 3a (171 
mg, 0.528 mmol, 73%) as a colorless oil. 1H NMR (300 MHz, DMSO-d6) δ 0.89 (3H, t, J = 7.4 Hz), 
1.75–1.91 (2H, m), 2.62 (3H, s), 3.73 (3H, s), 4.88–5.03 (1H, m), 6.85–6.95 (2H, m), 7.21 (1H, dd, J = 
6.8, 4.2 Hz), 7.25–7.34 (2H, m), 8.43 (1H, d, J = 8.3 Hz), 8.78 (1H, dd, J = 4.2, 1.5 Hz), 9.20 (1H, dd, 
J = 7.0, 1.7 Hz). MS (ESI/APCI) mass calculated for [M + H]+ (C18H21N4O2) requires m/z 325.2, found 
m/z 325.3. HPLC purity: 100%. 
N-(1-(4-Methoxyphenyl)propyl)-5-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide (3b). To a 
mixture of 15c (98.1 mg, 0.554 mmol), 22a (123 mg, 0.610 mmol), and Et3N (0.116 mL, 0.832 mmol) 
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in DMF (5 mL) were added HOBt·H2O (102 mg, 0.666 mmol) and EDCI·HCl (127 mg, 0.662 mmol). 
The mixture was stirred at rt for 5 h and then poured into NaHCO3 aqueous solution, extracted with 
EtOAc, washed with water, dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was 
purified by column chromatography (silica gel, hexane/ethyl acetate, 1:1 to 0:100). The product was 
crystallized from hexane/ethyl acetate (5:1) to afford 3b (109 mg, 0.335 mmol, 61%) as a white solid. 
1H NMR (300 MHz, DMSO-d6) δ 0.88 (3H, t, J = 7.4 Hz), 1.73–1.96 (2H, m), 2.67 (3H, s), 3.73 (3H, 
s), 4.95 (1H, q, J = 7.2 Hz), 6.87–6.96 (2H, m), 7.16 (1H, d, J = 6.8 Hz), 7.26–7.34 (2H, m), 8.40 (1H, 
d, J = 8.3 Hz), 8.46 (1H, s), 9.15 (1H, d, J = 7.2 Hz). MS (ESI/APCI) mass calculated for [M + H]+ 
(C18H21N4O2) requires m/z 325.2, found m/z 325.3. HPLC purity: 100%. mp 89 °C. 
N-(1-(4-Methoxyphenyl)propyl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide (3c). The title 
compound was prepared in 84% yield as a yellow oil from 15b and 21a using the procedure analogous 
to that described for the synthesis of 2. 1H NMR (400 MHz, CDCl3) δ 0.97 (3H, t, J = 7.6 Hz), 1.92–
1.97 (2H, m), 2.44 (3H, s), 3.78 (3H, s), 5.11–5.13 (1H, m), 6.87 (2H, d, J = 8.8 Hz), 7.32 (2H, d, J = 
8.8 Hz), 8.16 (1H, d, J = 8.0 Hz), 8.51 (1H, d, J = 2.0 Hz), 8.55 (1H, d, J = 1.2 Hz), 8.58 (1H, s). MS 
(ESI/APCI) mass calculated for [M + H]+ (C18H21N4O2) requires m/z 325.2, found m/z 325.2. HPLC 
purity: 99.9%. 
N-(1-(4-Methoxyphenyl)propyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide (3d). The 
title compound was prepared in 53% yield as a white solid from 15d and 22a using the procedure 
analogous to that described for the synthesis of 3b. 1H NMR (300 MHz, DMSO-d6) δ 0.82–0.94 (3H, 
m), 1.75–1.94 (2H, m), 2.63 (3H, s), 2.74 (3H, d, J = 0.8 Hz), 3.73 (3H, s), 4.88–5.03 (1H, m), 6.87–
6.96 (2H, m), 7.13 (1H, d, J = 0.8 Hz), 7.24–7.36 (2H, m), 8.42–8.56 (2H, m). MS (ESI/APCI) mass 
calculated for [M + H]+ (C19H23N4O2) requires m/z 339.2, found m/z 339.2. HPLC purity: 100%. mp 
129 °C. 
6-Chloro-N-(1-(4-methoxyphenyl)propyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (3e). To a 
mixture of 15e (200 mg, 1.01 mmol) and 21a (176 mg, 1.06 mmol) in DMF (8 mL) were added 
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HOBt·H2O (186 mg, 1.21 mmol) and EDCI·HCl (233 mg, 1.21 mmol). The mixture was stirred for 2 h 
and then poured into NaHCO3 aqueous solution. The mixture was extracted with EtOAc, washed with 
water, dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by column 
chromatography (basic silica gel, hexane/ethyl acetate, 19:1 to 2:3) to afford 3e (234 mg, 0.678 mmol, 
67%) as a white solid after crystallization from hexane/ethyl acetate (5:1). 1H NMR (300 MHz, 
DMSO-d6) δ 0.89 (3H, t, J = 7.3 Hz), 1.73–1.93 (2H, m), 3.73 (3H, s), 4.96 (1H, q, J = 7.3 Hz), 6.82–
6.95 (2H, m), 7.23–7.34 (2H, m), 8.08 (1H, d, J = 8.7 Hz), 8.59 (1H, s), 8.91 (1H, d, J = 2.3 Hz), 9.75 
(1H, d, J = 2.3 Hz). MS (ESI/APCI) mass calculated for [M + H]+ (C17H18ClN4O2) requires m/z 345.1, 
found m/z 345.2. HPLC purity: 100%. mp 102 °C. Anal. Calcd for C17H17ClN4O2: C, 59.22; H, 4.97; N, 
16.25. Found: C, 59.26; H, 4.98; N, 16.10. 
6-Cyclopropyl-N-(1-(4-methoxyphenyl)propyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (3f). To a 
mixture of 11 (150 mg, 0.385 mmol), cyclopropylboronic acid (49.7 mg, 0.579 mmol) and potassium 
tert-butoxide (143 mg, 1.27 mmol) in toluene (5 mL) were added Pd(OAc)2 (4.3 mg, 0.02 mmol) and 
tricyclohexylphosphine (10.8 mg, 0.04 mmol). The mixture was stirred at 100 °C for 16 h under Ar 
and then poured into water. The mixture was extracted with EtOAc, dried over anhydrous Na2SO4 and 
concentrated in vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl 
acetate, 19:1 to 1:4) to afford 3f (13.9 mg, 0.040 mmol, 10%) as a pale yellow oil. 1H NMR (300 MHz, 
CDCl3) δ 0.74–0.84 (2H, m), 0.97 (3H, t, J = 7.4 Hz), 1.07–1.18 (2H, m), 1.84–2.07 (3H, m), 3.78 (3H, 
s), 5.12 (1H, q, J = 7.6 Hz), 6.81–6.92 (2H, m), 7.28–7.37 (2H, m), 8.17 (1H, d, J = 8.3 Hz), 8.47 (1H, 
d, J = 1.9 Hz), 8.52 (1H, d, J = 1.9 Hz), 8.58 (1H, s). MS (ESI/APCI) mass calculated for [M + H]+ 
(C20H23N4O2) requires m/z 351.2, found m/z 351.2. HPLC purity: 95.6%. 
N-(1-(4-Methoxyphenyl)propyl)-6-phenylpyrazolo[1,5-a]pyrimidine-3-carboxamide (3g). Into a 
microwave vial equipped with a magnetic stirrer were added 11 (120 mg, 0.308 mmol), phenylboronic 
acid (41.3 mg, 0.339 mmol), DME (3 mL), and water (1.5 mL), followed by Pd(Ph3P)4 (17.8 mg, 0.02 
mmol). The reaction vial was flushed with nitrogen, sealed, and heated by microwave irradiation at 
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150 °C for 20 min. The mixture was poured into water and extracted with EtOAc. The combined 
organic phases were dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was 
purified by column chromatography (silica gel, hexane/ethyl acetate, 19:1 to 2:3) to afford 3g (92 mg, 
0.239 mmol, 77%) as a pale yellow solid after crystallization from hexane/ethyl acetate (5:1). 1H NMR 
(300 MHz, DMSO-d6) δ 0.91 (3H, t, J = 7.2 Hz), 1.77–1.96 (2H, m), 3.73 (3H, s), 4.99 (1H, q, J = 7.3 
Hz), 6.84–6.98 (2H, m), 7.24–7.38 (2H, m), 7.41–7.62 (3H, m), 7.84–7.97 (2H, m), 8.22 (1H, d, J = 
8.3 Hz), 8.60 (1H, s), 9.24 (1H, d, J = 1.9 Hz), 9.68 (1H, d, J = 2.3 Hz). MS (ESI/APCI) mass 
calculated for [M + H]+ (C23H23N4O2) requires m/z 387.2, found m/z 387.1. HPLC purity: 100%. mp 
145 °C. Anal. Calcd for C23H22N4O2·0.1H2O: C, 71.15; H, 5.76; N, 14.43. Found: C, 71.15; H, 5.84; N, 
14.15. 
1-(4-Methoxyphenyl)-N-((6-methylpyrazolo[1,5-a]pyrimidin-3-yl)methyl)propan-1-amine (4). To a 
mixture of 24 (100 mg, 0.621 mmol), 22a (188 mg, 0.932 mmol), acetic acid (0.107 mL, 1.86 mmol), 
and Et3N (0.104 mL, 0.746 mmol) in CH3CN (5 mL) at rt was added sodium triacetoxyborohydride 
(263 mg, 1.24 mmol). The mixture was stirred at rt overnight. The mixture was quenched with 
saturated aqueous NaHCO3 at rt and extracted with EtOAc. The organic layer was washed with water 
and saturated aqueous NaCl, dried over anhydrous MgSO4, and concentrated in vacuo. The residue 
was purified by column chromatography (basic silica gel, hexane/ethyl acetate, 9:1 to 1:1) to give 4 
(169 mg, 0.544 mmol, 88%) as a pale yellow oil. 1H NMR (300 MHz, CDCl3) δ 0.77 (3H, t, J = 7.6 
Hz), 1.52–1.79 (2H, m), 2.36 (3H, d, J = 0.8 Hz), 3.52 (1H, dd, J = 7.9, 5.7 Hz), 3.73–3.96 (5H, m), 
6.89 (2H, d, J = 8.7 Hz), 7.19–7.31 (2H, m), 7.91 (1H, s), 8.31 (1H, d, J = 2.3 Hz), 8.41 (1H, dd, J = 
2.3, 1.1 Hz). MS (ESI/APCI) mass calculated for [M + H]+ (C18H23N4O2) requires m/z 311.2, found 
m/z 311.2 [M + H]+. HPLC purity: 100%. 
N-(1-(4-Methoxyphenyl)propyl)-N,6-dimethylpyrazolo[1,5-a]pyrimidine-3-carboxamide (5). To a 
mixture of 15b (70 mg, 0.40 mmol) and 19 (78 mg, 0.44 mmol) in DMF (5 mL) was added HATU 
(225 mg, 0.592 mmol), followed by DIEA (102 mg, 0.791 mmol). The mixture was stirred at rt 
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overnight, and then diluted with EtOAc and washed with saturated aqueous NaHCO3 and saturated 
aqueous NaCl. The organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo. The 
residue was purified by preparative TLC (petroleum ether/ethyl acetate, 1:1) to give 5 (70 mg, yield 
52%) as a yellow oil. 1H NMR (400 MHz, DMSO-d6) δ 0.91–0.94 (3H, m), 1.92–2.02 (2H, m), 2.34 
(3H, s), 2.67–2.72 (3H, m), 3.74 (3H, s), 6.92 (2H, d, J = 8.4 Hz), 7.28–7.32 (2H, brs), 8.32 (1H, s), 
8.60 (1H, d, J = 2.0 Hz), 9.04–9.05 (1H, m). MS (ESI/APCI) mass calculated for [M + H]+ 
(C19H23N4O2) requires m/z 339.2, found m/z 339.2 [M + H]+. HPLC purity: 100%. 
N-(1-(4-Methoxyphenyl)propyl)-6-methylpyrazolo[1,5-a]pyrimidine-3-sulfonamide (6). To a mixture 
of 25 (70.2 mg, 0.303 mmol) and 22a (67.0 mg, 0.33 mmol) in CH3CN (5 mL) at rt was added DIEA 
(0.127 mL, 0.741 mmol). The mixture was stirred at rt overnight. The mixture was quenched with 
water and extracted with EtOAc. The organic layer was washed with water and saturated aqueous 
NaCl, dried over anhydrous MgSO4, and concentrated in vacuo. The residue was purified by column 
chromatography (silica gel, hexane/ethyl acetate, 9:1 to 1:3) to give 6 (106 mg, 0.294 mmol, 97%) as a 
white solid. 1H NMR (300 MHz, CDCl3) δ 0.82 (3H, t, J = 7.4 Hz), 1.52–2.00 (2H, m), 2.40 (3H, d, J 
= 0.8 Hz), 3.67 (3H, s), 4.15 (1H, q, J = 7.9 Hz), 5.25 (1H, d, J = 8.3 Hz), 6.32–6.55 (2H, m), 6.66–
6.88 (2H, m), 8.18 (1H, s), 8.30–8.57 (2H, m). MS (ESI/APCI) mass calculated for [M – H]– 
(C17H19N4O3S) requires m/z 359.1, found m/z 359.0. HPLC purity: 100%. mp 136 °C. Anal. Calcd for 
C17H20N4O3S: C, 56.65; H, 5.59; N, 15.54. Found: C, 56.71; H, 5.70; N, 15.28. 
N-(1-(4-Methoxyphenyl)propyl)pyrazolo[1,5-a]pyridine-3-carboxamide (7). The title compound was 
prepared in 44% yield as a white solid from pyrazolo[1,5-a]pyridine-3-carboxylic acid (15) and 21a 
using the procedure analogous to that described for the synthesis of 3e. 1H NMR (300 MHz, CDCl3) δ 
0.96 (3H, t, J = 7.4 Hz), 1.79–2.14 (2H, m), 3.80 (3H, s), 5.07 (1H, q, J = 7.6 Hz), 5.97 (1H, d, J = 7.9 
Hz), 6.80–6.99 (3H, m), 7.28–7.40 (3H, m), 8.12 (1H, s), 8.30 (1H, d, J = 9.1 Hz), 8.47 (1H, d, J = 6.8 
Hz). MS (ESI/APCI) mass calculated for [M + H]+ (C18H20N3O2) requires m/z 310.2, found m/z 310.1 
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[M + H]+. HPLC purity: 99.2%. mp 105 °C. Anal. Calcd for C18H19N3O2: C, 69.88; H, 6.19; N, 13.58. 
Found: C, 69.77; H, 6.18; N, 13.50. 
4-(1-(4-Methoxyphenyl)propyl)-4,5-dihydro-3H-pyrazolo[4,5,1-ij][1,6]naphthyridin-3-one (8). To a 
solution of 30 (664 mg, 1.96 mmol) in DMF (20 mL) was added EDCI·HCl (413 mg, 2.15 mmol), 
followed by HOBt·H2O (330 mg, 2.15 mmol). The mixture was stirred at rt for 16 h and then poured 
into water. The mixture was extracted with EtOAc, washed with water and saturated aqueous NaCl, 
dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by column 
chromatography (silica gel, hexane/ethyl acetate, 19:1 to 0:100) to afford 8 (535 mg, 1.67 mmol, 85%) 
as a white solid after crystallization from hexane/ethyl acetate (4:1). 1H NMR (300 MHz, DMSO-d6) δ 
0.90 (3H, t, J = 7.4 Hz), 1.91–2.16 (2H, m), 3.73 (3H, s), 4.33 (1H, d, J = 18.6 Hz), 4.83 (1H, d, J = 
18.6 Hz), 5.84–5.96 (1H, m), 6.86–6.96 (2H, m), 6.96–7.05 (1H, m), 7.13–7.21 (1H, m), 7.24–7.32 
(2H, m), 8.27 (1H, s), 8.63 (1H, d, J = 6.8 Hz). MS (ESI/APCI) mass calculated for [M + H]+ 
(C19H20N3O2) requires m/z 322.2, found m/z 322.1. HPLC purity: 100%. mp 137 °C. Anal. Calcd for 
C19H19N3O2: C, 71.01; H, 5.96; N, 13.08. Found: C, 70.89; H, 6.01; N, 12.88. 
6-Methyl-N-(1-phenylpropyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (9a). The title compound was 
prepared in 28% yield as a white solid from 15b and 1-phenylpropan-1-amine using the procedure 
analogous to that described for the synthesis of 2. 1H NMR (400 MHz, CDCl3) δ 0.99 (3H, t, J = 7.6 
Hz), 1.93–2.00 (2H, m), 2.44 (3H, s), 5.16–5.22 (1H, m), 7.21–7.25 (1H, m), 7.31–7.35 (2H, m), 7.39–
7.40 (2H, m), 8.23 (1H, d, J = 8.0 Hz), 8.53 (1H, d, J = 2.0 Hz), 8.56 (1H, s), 8.58 (1H, s). MS 
(ESI/APCI) mass calculated for [M + H]+ (C17H19N4O) requires m/z 295.2, found m/z 295.1. HPLC 
purity: 100%. mp 116 °C. 
6-Methyl-N-(1-phenylethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (9b). The title compound was 
prepared in 84% yield as a white solid from 15b and 1-phenylethanamine using the procedure 
analogous to that described for the synthesis of 3e, except that silica gel was employed in place of 
basic silica gel in a column chromatographic separation. 1H NMR (300 MHz, DMSO-d6) δ 1.52 (3H, d, 
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J = 7.2 Hz), 2.38 (3H, d, J = 0.8 Hz), 5.15–5.28 (1H, m), 7.21–7.45 (5H, m), 8.21 (1H, d, J = 8.0 Hz), 
8.49 (1H, s), 8.75 (1H, d, J = 2.3 Hz), 9.15–9.21 (1H, m). MS (ESI/APCI) mass calculated for [M + 
H]+ (C16H17N4O) requires m/z 281.1, found m/z 281.2. HPLC purity: 99.6%. mp 112 °C. 
N-(2,3-Dihydro-1H-inden-1-yl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide (9c). The title 
compound was prepared in 69% yield as a white solid from 15b and 2,3-dihydro-1H-inden-1-amine 
using the procedure analogous to that described for the synthesis of 3e, except that silica gel was 
employed in place of basic silica gel in a column chromatographic separation. 1H NMR (300 MHz, 
DMSO-d6) δ 1.80–1.97 (1H, m), 2.35 (3H, d, J = 0.8 Hz), 2.51–2.64 (1H, m), 2.79–3.07 (2H, m), 5.57 
(1H, q, J = 8.2 Hz), 7.16–7.34 (4H, m), 8.12 (1H, d, J = 8.3 Hz), 8.56 (1H, s), 8.65 (1H, d, J = 1.9 Hz), 
9.15–9.20 (1H, m). MS (ESI/APCI) mass calculated for [M + H]+ (C17H17N4O) requires m/z 293.1, 
found m/z 292.7. HPLC purity: 100%. mp 160 °C. 
N-(4-Methoxybenzyl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide (9d). The title compound 
was prepared in 84% yield as a yellow oil from 15b and 1-(4-methoxyphenyl)methanamine using the 
procedure analogous to that described for the synthesis of 2. 1H NMR (400 MHz, CDCl3) δ 2.42 (3H, 
s), 3.79 (3H, s), 4.65 (2H, d, J = 5.6 Hz), 6.88 (2H, d, J = 8.8 Hz), 7.33 (2H, d, J = 8.8 Hz), 8.12 (1H, 
s), 8.43 (1H, d, J = 2.0 Hz), 8.55 (1H, s), 8.63 (1H, s). MS (ESI/APCI) mass calculated for [M + H]+ 
(C16H17N4O2) requires m/z 297.1, found m/z 297.2. HPLC purity: 98.0%. 
N-(3-Methoxybenzyl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide (9e). The title compound 
was prepared in 90% yield as a colorless oil from 15b and 2,3-dihydro-1H-inden-1-amine using the 
procedure analogous to that described for the synthesis of 3e, except that silica gel was employed in 
place of basic silica gel in a column chromatographic separation. 1H NMR (300 MHz, DMSO-d6) δ 
2.38 (3H, d, J = 0.8 Hz), 3.73 (3H, s), 4.56 (2H, d, J = 6.1 Hz), 6.78–6.86 (1H, m), 6.88–6.97 (2H, m), 
7.19–7.30 (1H, m), 8.31 (1H, t, J = 5.9 Hz), 8.52 (1H, s), 8.71 (1H, d, J = 1.9 Hz), 9.14–9.21 (1H, m). 
MS (ESI/APCI) mass calculated for [M + H]+ (C16H16N4O2) requires m/z 297.1, found m/z 297.2. 
HPLC purity: 100%. 
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N-(2-Methoxybenzyl)-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxamide (9f). The title compound 
was prepared in 69% yield as a white solid from 15b and (2-methoxyphenyl)methanamine using the 
procedure analogous to that described for the synthesis of 3c. 1H NMR (300 MHz, DMSO-d6) δ 2.38 
(3H, d, J = 0.8 Hz), 3.88 (3H, s), 4.53 (2H, d, J = 6.1 Hz), 6.85–6.94 (1H, m), 7.02 (1H, d, J = 8.0 Hz), 
7.20–7.31 (2H, m), 8.40 (1H, t, J = 5.9 Hz), 8.49 (1H, s), 8.74 (1H, d, J = 1.9 Hz), 9.14–9.20 (1H, m). 
MS (ESI/APCI) mass calculated for [M + H]+ (C16H17N4O2) requires m/z 297.1, found m/z 297.1. 
HPLC purity: 100%. mp 171 °C. 
6-Methyl-N-(4-(trifluoromethoxy)benzyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (9g). The title 
compound was prepared in 69% yield as a white solid from 15b and 
1-(4-(trifluoromethoxy)phenyl)methanamine using the procedure analogous to that described for the 
synthesis of 3e, except that silica gel was employed in place of basic silica gel in a column 
chromatographic separation. 1H NMR (300 MHz, DMSO-d6) δ 2.38 (3H, d, J = 0.8 Hz), 4.61 (2H, d, J 
= 6.1 Hz), 7.28–7.37 (2H, m), 7.43–7.51 (2H, m), 8.42 (1H, t, J = 6.1 Hz), 8.52 (1H, s), 8.71 (1H, d, J 
= 1.9 Hz), 9.15–9.21 (1H, m). MS (ESI/APCI) mass calculated for [M + H]+ (C16H14F3N4O2) requires 
m/z 251.1, found m/z 351.1. HPLC purity: 100%. mp 111 °C. 
6-Methyl-N-(1-(4-(trifluoromethoxy)phenyl]propyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (10). 
The title compound was prepared in 98% yield as a colorless oil from 15b and 
1-(4-(trifluoromethoxy)phenyl)propan-1-amine using the procedure analogous to that described for the 
synthesis of 3e, except that silica gel was employed in place of basic silica gel in a column 
chromatographic separation. 1H NMR (300 MHz, DMSO-d6) δ 0.92 (3H, t, J = 7.4 Hz), 1.78–1.96 (2H, 
m), 2.39 (3H, s), 5.04 (1H, q, J = 7.2 Hz), 7.27–7.39 (2H, m), 7.44–7.57 (2H, m), 8.28 (1H, d, J = 7.9 
Hz), 8.47 (1H, s), 8.77 (1H, d, J = 2.3 Hz), 9.14–9.23 (1H, m). MS (ESI/APCI) mass calculated for [M 
+ H]+ (C18H18F3N4O2) requires m/z 379.1, found m/z 379.1. HPLC purity: 99.0%. 
6-Methyl-N-((1R)-1-(4-(trifluoromethoxy)phenyl)propyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
(10a). 10 (1.07 g, 2.78 mmol) was chirally separated utilizing chiral chromatography with a Chiralpak 
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AD 50 mm ID × 500 mm L column, mobile phase 100% EtOH, and flow rate 60 mL/min, to afford 
10a (475 mg, tR1), which was recrystallized from hexane/ethyl acetate (5:1) to afford 10a (339 mg, 
0.896 mmol, 32%, 64% theoretical) as a white solid. Analytical HPLC analysis carried out on a 4.6 
mm ID × 250 mm L Chiralpak AD column with the same eluent as above at a flow rate of 0.5 mL/min 
indicated that 10a was of >99.9% ee. 1H NMR (300 MHz, DMSO-d6) δ 0.93 (3H, t, J = 7.3 Hz), 1.79–
1.97 (2H, m), 2.39 (3H, s), 5.04 (1H, q, J = 7.3 Hz), 7.27–7.40 (2H, m), 7.45–7.57 (2H, m), 8.29 (1H, 
d, J = 7.9 Hz), 8.48 (1H, s), 8.77 (1H, d, J = 1.9 Hz), 9.14–9.23 (1H, m). 13C NMR (151 MHz, 
DMSO-d6) δ 10.50, 14.47, 29.07, 53.01, 104.37, 120.00 (q, J = 256.0 Hz, 1C), 120.86, 128.11, 135.10, 
142.81, 144.03, 145.06, 146.98 (q, J = 1.7 Hz, 1C), 154.57, 160.65. MS (ESI/APCI) mass calculated 
for [M + H]+ (C18H18F3N4O2) requires m/z 379.1, found m/z 379.1. HPLC purity: 99.7%. Anal. Calcd 
for C18H17F3N4O2: C, 57.14; H, 4.53; N, 14.81. Found: C, 57.07; H, 4.53; N, 14.74. [α]ଶ଴ୈ  = −175.5 (c 
= 0.94 in MeOH). mp 106 °C. 
6-Methyl-N-((1S)-1-(4-(trifluoromethoxy)phenyl)propyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 
(10b). 10 (1.07 g, 2.78 mmol) was chirally separated utilizing chiral chromatography with a Chiralpak 
AD 50 mm ID × 500 mm L column, mobile phase 100% EtOH, and flow rate 60 mL/min, to afford 
10b (452 mg, tR2), which was recrystallized from hexane/ethyl acetate (5:1) to afford 10b (230 mg, 
0.609 mmol, 22%, 44% theoretical) as a white solid. Analytical HPLC analysis carried out on a 4.6 
mm ID × 250 mm L Chiralpak AD column with the same eluent as above at a flow rate of 0.5 mL/min 
indicated that 10b was of 99.7% ee. 1H NMR (300 MHz, DMSO-d6) δ 0.93 (3H, t, J = 7.3 Hz), 1.78–
1.98 (2H, m), 2.39 (3H, s), 5.04 (1H, q, J = 7.3 Hz), 7.27–7.39 (2H, m), 7.44–7.57 (2H, m), 8.29 (1H, 
d, J = 7.9 Hz), 8.48 (1H, s), 8.77 (1H, d, J = 1.9 Hz), 9.16–9.23 (1H, m). MS (ESI/APCI) mass 
calculated for [M + H]+ (C18H18F3N4O2) requires m/z 379.1, found m/z 379.1. HPLC purity: 100%. mp 




6-Bromo-N-(1-(4-methoxyphenyl)propyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (11). The title 
compound was prepared in 83% yield as an off-white solid from 15f and 21a using the procedure 
analogous to that described for the synthesis of 3e. 1H NMR (300 MHz, DMSO-d6) δ 0.88 (3H, t, J = 
7.4 Hz), 1.75–1.92 (2H, m), 3.73 (3H, s), 4.89–5.02 (1H, m), 6.83–6.96 (2H, m), 7.22–7.36 (2H, m), 
8.07 (1H, d, J = 8.3 Hz), 8.56 (1H, s), 8.93 (1H, d, J = 2.3 Hz), 9.79 (1H, d, J = 2.3 Hz). MS 
(ESI/APCI) mass calculated for [M + H]+ (C17H18BrN4O2) requires m/z 389.1, found m/z 389.0. 
Ethyl 2-Methylpyrazolo[1,5-a]pyrimidine-3-carboxylate (13a). The mixture of 11 (1.04 g, 6.16 mmol) 
and 12a (1.21 g, 7.39 mmol) in AcOH (20 mL) was stirred at 70 °C for 16 h. The mixture was 
concentrated in vacuo and then partitioned between EtOAc and NaHCO3 aqueous solution. The phases 
were separated and the aqueous phase was extracted with EtOAc. The combined organic phases were 
dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by column 
chromatography (basic silica gel, hexane/ethyl acetate, 1:1 to 0:100) to afford 13a (0.870 g, 4.24 mmol, 
69%) as a white solid after trituration with hexane/ethyl acetate (5:1). 1H NMR (300 MHz, DMSO-d6) 
δ 1.32 (3H, t, J = 7.2 Hz), 2.61 (3H, s), 4.30 (2H, q, J = 7.1 Hz), 7.22 (1H, dd, J = 6.8, 4.2 Hz), 8.77 
(1H, dd, J = 4.2, 1.9 Hz), 9.15 (1H, dd, J = 7.0, 1.7 Hz). 
Ethyl 6-Methylpyrazolo[1,5-a]pyrimidine-3-carboxylate (13b). The title compound was prepared in 
87% yield as a white solid from 11 and 12b using the procedure analogous to that described for the 
synthesis of 13a. 1H NMR (300 MHz, CDCl3) δ 1.42 (3H, t, J = 7.0 Hz), 2.44 (3H, s), 4.44 (2H, q, J = 
6.9 Hz), 8.51 (1H, s), 8.55 (1H, s), 8.66 (1H, d, J = 1.9 Hz). 
Ethyl 5-Methylpyrazolo[1,5-a]pyrimidine-3-carboxylate (13c). A mixture of 11 (1.05 g, 6.45 mmol) 
and 12c (1.71 g, 12.9 mmol) in toluene (10 mL) was stirred at 100 °C for 16 h and then concentrated 
in vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl acetate, 19:1 to 
0:100) to afford 13c (0.898 g, 4.37 mmol, 68%) as a beige solid. 1H NMR (300 MHz, DMSO-d6) δ 
1.31 (3H, t, J = 7.0 Hz), 2.62 (3H, s), 4.28 (2H, q, J = 7.2 Hz), 7.17 (1H, d, J = 7.2 Hz), 8.53 (1H, s), 
9.11 (1H, d, J = 7.2 Hz). 
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2-Methylpyrazolo[1,5-a]pyrimidine-3-carboxylic Acid (15a). To a solution of 13a (866 mg, 4.22 
mmol) in THF (20 mL) and MeOH (10 mL) was added 1 M NaOH aqueous solution (12.7 mL, 12.7 
mmol). The mixture was stirred at 50 °C for 16 h and then concentrated in vacuo. The residue was 
suspended in water and 1 M HCl aqueous solution (12.7 mL, 12.7 mmol) was added. The resulting 
solid was collected by filtration, rinsed with water and dried to afford 15a (649 mg, 3.66 mmol, 87%) 
as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 2.60 (3H, s), 7.19 (1H, dd, J = 7.2, 4.2 Hz), 8.73 
(1H, dd, J = 4.2, 1.5 Hz), 9.14 (1H, dd, J = 6.8, 1.9 Hz), 12.26 (1H, brs). MS (ESI/APCI) mass 
calculated for [M + H]+ (C8H8N3O2) requires m/z 178.1, found m/z 178.1. 
6-Methylpyrazolo[1,5-a]pyrimidine-3-carboxylic Acid (15b). A mixture of 13b (6.44 g, 31.38 mmol), 
2 M NaOH aqueous solution (23.5 mL, 47.1 mmol), THF (20 mL) and MeOH (20 mL) was stirred at 
60 °C overnight. The mixture was acidified with 10% citric acid aqueous solution. The resulting 
precipitate was collected by filtration, washed with water and dried to give 15b (3.91 g, 22.1 mmol, 
70%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 2.37 (3H, s), 8.50 (1H, s), 8.71 (1H, d, J = 
1.9 Hz), 9.09–9.15 (1H, m), 12.33 (1H, brs). MS (ESI/APCI) mass calculated for [M + H]+ 
(C8H8N3O2) requires m/z 178.1, found m/z 178.0. 
5-Methylpyrazolo[1,5-a]pyrimidine-3-carboxylic Acid (15c). The title compound was prepared in 
84% yield as a beige solid from 13c using the procedure analogous to that described for the synthesis 
of 15a. 1H NMR (300 MHz, DMSO-d6) δ 2.62 (3H, s), 7.15 (1H, d, J = 7.2 Hz), 8.49 (1H, s), 9.10 (1H, 
d, J = 7.2 Hz), 12.27 (1H, brs). MS (ESI/APCI) mass calculated for [M + H]+ (C8H8N3O2) requires m/z 
178.1, found m/z 178.1. 
5,7-Dimethylpyrazolo[1,5-a]pyrimidine-3-carboxylic Acid (15d). A mixture of 14b (502 mg, 3.75 
mmol) and 12d (394 mg, 3.94 mmol) in EtOH (8 mL) and AcOH (8 mL) was stirred at 100 °C for 1.5 
h and then concentrated in vacuo. To the residue were added EtOH (4 mL). The resulting solid was 
collected by filtration, rinsed with EtOH (2 mL) and dried to afford 15d (487 mg, 2.54 mmol, 68%) as 
a white solid. 1H NMR (300 MHz, DMSO-d6) δ 2.58 (3H, s), 2.72 (3H, d, J = 0.8 Hz), 7.10 (1H, d, J = 
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0.8 Hz), 8.51 (1H, s), 12.20 (1H, brs). MS (ESI/APCI) mass calculated for [M + H]+ (C9H10N3O2) 
requires m/z 192.1, found m/z 192.1. 
6-Chloropyrazolo[1,5-a]pyrimidine-3-carboxylic Acid (15e). To a solution of 11 (1.00 g, 6.45 mmol) 
in EtOH (15 mL) was added 2 M NaOH aqueous solution (9.67 mL, 19.3 mmol). The mixture was 
stirred at reflux for 20 h. The mixture was concentrated in vacuo (azeotroped with toluene) to give the 
crude product 14a. The residue was suspended in EtOH (2 mL) and AcOH (7 mL), and then 12e 
(0.721 g, 6.77 mmol) was added. The mixture was stirred at 80 °C for 2 h and then cooled to rt. Water 
was then added and the precipitate was filtered by filtration, rinsed with water and EtOH, and dried to 
afford 15e (0.809 g, 4.10 mmol, 64%) as a beige solid. 1H NMR (300 MHz, DMSO-d6) δ 8.61 (1H, s), 
8.86 (1H, d, J = 2.3 Hz), 9.71 (1H, d, J = 2.3 Hz), 12.54 (1H, brs). MS (ESI/APCI) mass calculated for 
[M – H]– (C7H3ClN3O2) requires m/z 196.0, found m/z 196.0. 
6-Bromopyrazolo[1,5-a]pyrimidine-3-carboxylic Acid (15f). To a solution of 14b (2.63 g, 19.64 
mmol) in EtOH (30 mL) and AcOH (30.0 mL) was added 12f (3.11 g, 20.6 mmol). The mixture was 
stirred at 80 °C for 1.5 h and then cooled to rt. The resulting solid was collected by filtration, rinsed 
with water and dried to afford 15f (3.58 g, 14.8 mmol, 75%) as a beige solid. 1H NMR (300 MHz, 
DMSO-d6) δ 8.58 (1H, s), 8.88 (1H, d, J = 2.3 Hz), 9.76 (1H, d, J = 2.3 Hz), 12.54 (1H, brs). 
N-Methoxy-N-methyl-4-(trifluoromethoxy)benzamide (16). To a solution of 16 (9.96 g, 48.3 mmol) 
in THF (200 mL) was added oxalyl chloride (5.97 mL, 62.8 mmol), followed by a drop of DMF. The 
mixture was stirred at rt for 4 h and then concentrated in vacuo (azeotroped with toluene) to afford the 
corresponding acyl chloride as a pale yellow oil. This was dissolved in DMA (150 mL) and then Et3N 
(10.1 mL, 72.5 mmol) and O,N-dimethylhydroxylamine hydrochloride (6.13 g, 62.8 mmol) were 
sequentially added. The mixture was stirred for 16 h and poured into water. The mixture was extracted 
with EtOAc, washed with water and concentrated in vacuo. The residue was purified by column 
chromatography (silica gel, hexane/ethyl acetate, 100:0 to 1:1) to afford 17 (3.64 g, 14.6 mmol, 30%) 
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as a colorless oil. 1H NMR (300 MHz, DMSO-d6) δ 3.27 (3H, s), 3.55 (3H, s), 7.44 (2H, dd, J = 8.9, 
0.9 Hz), 7.69–7.78 (2H, m). 
1-(4-(Trifluoromethoxy)phenyl)propan-1-one (18b). To a solution of 17 (3.64 g, 14.6 mmol) in THF 
(40 mL) at 0 °C was added dropwise EtMgBr (1 M in THF, 21.9 mL, 21.9 mmol). The mixture was 
stirred at rt for 2 h. LC–MS analysis indicated that the starting material still remained. Therefore, 
further EtMgBr (1 M in THF, 10.0 mL, 10.0 mmol) was added. The mixture was stirred for another 30 
min and then poured into 0.5 M HCl aqueous solution, extracted with EtOAc, dried over anhydrous 
Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography (silica gel, 
hexane/ethyl acetate, 100:0 to 3:1) to afford 18b (2.73 g, 12.5 mmol, 86%) as a colorless oil. 1H NMR 
(300 MHz, DMSO-d6) δ 1.09 (3H, t, J = 7.2 Hz), 3.07 (2H, q, J = 7.2 Hz), 7.44–7.56 (2H, m), 8.02–
8.16 (2H, m). 
1-(4-Methoxyphenyl)-N-methylpropan-1-amine (19). To a mixture of 18a (1.50 g, 9.14 mmol) and 
methylamine (27 wt % in methanol, 2.10 g, 18.3 mmol) in MeOH (20 mL) was added titanium 
tetraisopropoxide (3.11 g, 11.0 mmol) and the mixture was stirred at rt for 5 h. Then sodium 
borohydride (0.680 g, 18.3 mmol) was added. After the mixture was stirred overnight, it was diluted 
with NaOH aqueous solution and filtered. The filtrate was extracted with dichloromethane and the 
organic layer was washed with saturated aqueous NaCl, dried over anhydrous Na2SO4 and 
concentrated in vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl 
acetate, 0:100) to give 19 (0.400 g, 2.23 mmol, 25%) as a yellow oil. 1H NMR (CDCl3, 400 MHz) δ 
0.79 (3H, t, J = 7.6 Hz), 1.55–1.62 (1H, m), 1.71–1.78 (1H, m), 2.27 (3H, s), 3.29–3.33 (1H, m), 3.81 
(3H, s), 6.85–6.88 (2H, m), 7.16–7.19 (2H, m). 
1-(4-Methoxyphenyl)propan-1-amine (21a). To a solution of 18a (23.5 g, 143 mmol) and 
hydroxylammonium chloride (10.9 g, 157 mmol) in EtOH (300 mL) was added Et3N (21.9 mL, 157 
mmol) at rt. The mixture was refluxed for 3 h and then evaporated under reduced pressure to remove 
EtOH. The residue was partitioned between EtOAc and water, and the organic layer was washed with 
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saturated aqueous NaCl, dried over anhydrous Na2SO4, and concentrated in vacuo to give the crude 
product 20a (26.7 g, 149 mmol, ~quant.) as a white solid, which was subjected to the next reaction 
without further purification. A mixture of 20a (12.4 g, 69.2 mmol) and 10% Pd/C (containing 50% 
water, 8.19 g) in EtOH (300 mL) was hydrogenated under balloon pressure at rt overnight. The 
catalyst was removed by filtration and the filtrate was concentrated in vacuo. The residue was purified 
by column chromatography (basic silica gel, 200 g, hexane/ethyl acetate, 9:1 to 1:9) to give 21a (7.56 
g, 45.8 mmol, 66%) as a pale yellow oil. 1H NMR (300 MHz, DMSO-d6) δ 0.76 (3H, t, J = 7.4 Hz), 
1.30–1.64 (2H, m), 1.87 (2H, brs), 3.63 (1H, t, J = 6.7 Hz), 3.72 (3H, s), 6.74–6.91 (2H, m), 7.15–7.29 
(2H, m). MS (ESI/APCI) mass calculated for [M − NH2]+ (C10H13O) requires m/z 149.1, found m/z 
149.2. 
1-(4-(Trifluoromethoxy)phenyl)propan-1-amine (21b). The crude product 20b was prepared in 99% 
yield as a colorless oil from 18b using the procedure analogous to that described for the synthesis of 
20a. 1H NMR (300 MHz, DMSO-d6) δ 1.04 (3H, t, J = 7.6 Hz), 2.72 (2H, q, J = 7.6 Hz), 7.31–7.44 
(2H, m), 7.70–7.82 (2H, m), 11.29 (1H, s). A mixture of 20b (2.89 g, 12.4 mmol) and 10% Pd/C 
(containing 50% water, 800 mg) in MeOH (30 mL) was hydrogenated under balloon pressure at rt 
overnight. The catalyst was removed by filtration and the filtrate was concentrated in vacuo to give the 
crude product 21b (2.58 g, 11.8 mmol, 95%) as a colorless oil. This material was taken on to the next 
reaction without further purification. 1H NMR (300 MHz, DMSO-d6) δ 0.77 (3H, t, J = 7.4 Hz), 1.41–
1.68 (2H, m), 2.21 (2H, brs), 3.74 (1H, t, J = 6.6 Hz), 7.21–7.34 (2H, m), 7.41–7.52 (2H, m). 
1-(4-Methoxyphenyl)propan-1-amine Hydrochloride (22a). A mixture of 20a (26.7 g, 149 mmol) and 
10% Pd/C (containing 50% water, 15.8 g) in MeOH (200 mL) was hydrogenated under balloon 
pressure at rt overnight. The catalyst was removed by filtration and the filtrate was concentrated in 
vacuo to give the crude product 21a. The crude material 21a was diluted with EtOAc (100 mL) and 
added 1 M HCl solution in diethyl ether (150 mL). The resulting solid was collected and washed with 
EtOAc to give 22a (27.4 g, 136 mmol, 91%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 0.74 
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(3H, t, J = 7.4 Hz), 1.58–2.13 (2H, m), 3.76 (3H, s), 4.04 (1H, dd, J = 9.5, 5.3 Hz), 6.84–7.12 (2H, m), 
7.29–7.61 (2H, m), 8.44 (3H, brs). 
1-(4-(Trifluoromethoxy)phenyl)propan-1-amine Hydrochloride (22b). The crude product 21b (11.3 g, 
51.4 mmol) was dissolved in EtOAc (70 mL) and MeOH (10 mL) and then 4 M HCl solution in 
EtOAc (40 mL) was added. After 20 min of stirring (no precipitate occurred), the solvent was removed 
under reduced pressure. To the residual white solid was added Et2O and the resulting solid was 
collected by filtration, rinsed with Et2O and dried to afford 22b (10.1 g, 39.6 mmol, 67%) as a white 
solid. 1H NMR (300 MHz, DMSO-d6) δ 0.76 (3H, t, J = 7.4 Hz), 1.70–2.11 (2H, m), 4.20 (1H, dd, J = 
9.1, 5.7 Hz), 7.39–7.53 (2H, m), 7.61–7.71 (2H, m), 8.63 (3H, brs). 
6-Methylpyrazolo[1,5-a]pyrimidine-3-carbaldehyde (24). To a solution of 23 (5.91 g, 44.4 mmol) in 
DMF (50 mL) was added phosphorus oxychloride (12.4 mL, 133 mmol) at 0 °C. The mixture was 
stirred at rt for 3 h. The mixture was neutralized with 8 M NaOH aqueous solution and extracted with 
EtOAc/THF (2:1). The organic layer was dried over anhydrous MgSO4 and was passed through a 
silica gel pad (eluted with THF). The appropriate fraction was concentrated in vacuo and the obtained 
solid was collected by filtration, washed with cold EtOAc, and dried to give 24 (5.86 g, 36.4 mmol, 
82%) as a yellow solid. 1H NMR (300 MHz, CDCl3) δ 2.48 (3H, s), 8.54 (1H, s), 8.60 (1H, s), 8.66 
(1H, d, J = 1.9 Hz), 10.27 (1H, s). MS (ESI/APCI) mass calculated for [M + H]+ (C8H8N3O) requires 
m/z 162.1, found m/z 162.2. 
6-Methylpyrazolo[1,5-a]pyrimidine-3-sulfonyl chloride (25). 6-Methylpyrazolo[1,5-a]pyrimidine 
(23) (300 mg, 2.25 mmol) was added to chlorosulfonic acid (1.50 mL, 22.5 mmol). The mixture was 
stirred at 80 °C for 2 h, and then poured into iced water. The precipitate was collected, washed with 
water, and dried to give 25 (135 mg, 0.583 mmol, 26%) as a white solid. 1H NMR (300 MHz, CDCl3) 
δ 2.53 (3H, d, J = 1.1 Hz), 8.52 (1H, s), 8.66 (1H, dd, J = 2.3, 1.1 Hz), 8.82 (1H, d, J = 1.9 Hz). 
Methyl 4-(Hydroxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylate (27a). A solution of 
hydroxylamine-O-sulfonic acid (HOSA) (2.07 g, 18.3 mmol) in water (10 mL) was basified with 
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saturated aqueous NaHCO3 at 0 °C. To this mixture was added a solution of 26 (1.00 g, 9.16 mmol) in 
MeOH (10 mL) at the same temperature, and the mixture was heated at 50 °C for 16 h. The mixture 
was diluted with toluene, and concentrated in vacuo (this protocol was repeated 3 times). The residual 
solid was suspended in DMF (23 mL), to which methyl propiolate (0.897 mL, 10.1 mmol) and 
potassium carbonate (3.80 g, 27.5 mmol) were successively added at 0 °C. After vigorous stirring at rt 
for 2 h, the mixture was filtered by filtration. The filtrate was partitioned between EtOAc and water. 
The phases were separated and the aqueous phase was extracted with EtOAc. The combined organic 
phases were washed with water, dried over anhydrous Na2SO4, and concentrated in vacuo. The residue 
was purified by column chromatography (silica gel, hexane/ethyl acetate, 19:1 to 1:4) to afford 27a 
(0.556 g, 2.70 mmol, 29%) and methyl 6-(hydroxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylate 
(27b) (0.311 g, 1.51 mmol, 16%) as white solids. Data for 27a: 1H NMR (300 MHz, DMSO-d6) δ 3.80 
(3H, s), 5.04 (2H, d, J = 5.7 Hz), 5.37 (1H, t, J = 5.7 Hz), 7.10–7.21 (1H, m), 7.65 (1H, dd, J = 7.2, 1.1 
Hz), 8.44 (1H, s), 8.70–8.78 (1H, m). MS (ESI/APCI) mass calculated for [M + H]+ (C10H11N2O3) 
requires m/z 207.1, found m/z 207.1. Data for 27b: 1H NMR (300 MHz, DMSO-d6) δ 3.83 (3H, s), 
4.58 (2H, d, J = 4.9 Hz), 5.46 (1H, t, J = 5.7 Hz), 7.58 (1H, dd, J = 9.1, 1.5 Hz), 8.05 (1H, dd, J = 9.1, 
0.8 Hz), 8.43 (1H, s), 8.67–8.79 (1H, m). MS (ESI/APCI) mass calculated for [M + H]+ (C10H11N2O3) 
requires m/z 207.1, found m/z 207.1. 
Methyl 4-Formylpyrazolo[1,5-a]pyridine-3-carboxylate (28). To a suspension of 27 (550 mg, 2.67 
mmol) in CH3CN (70 mL) at 0 °C was added portionwise Dess-Martin periodinane (1.36 g, 3.20 
mmol). The mixture was stirred at rt for 1.5 h. Further Dess-Martin periodinane (500 mg) was added at 
rt. Stirring was continued for another 1 h and then NaHCO3 aqueous solution and solid Na2S2O3 were 
successively added. After stirring for 20 min, the mixture was extracted with EtOAc, washed with 
saturated aqueous NaHCO3 and saturated aqueous NaCl, dried over anhydrous Na2SO4, and 
concentrated in vacuo to afford 28 (545 mg, 2.67 mmol, 100%) as a reddish solid. This was used in the 
next reaction without further purification. 1H NMR (300 MHz, DMSO-d6) δ 3.85 (3H, s), 7.29–7.38 
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(1H, m), 8.06 (1H, dd, J = 7.6, 1.1 Hz), 8.64 (1H, s), 9.17 (1H, dd, J = 6.8, 1.1 Hz), 10.96 (1H, d, J = 
0.8 Hz). 
Methyl 4-(((1-(4-Methoxyphenyl)propyl)amino)methyl)pyrazolo[1,5-a]pyridine-3-carboxylate (29). 
To a mixture of 28 (540 mg, 2.64 mmol), 21a (612 mg, 3.70 mmol), and acetic acid (0.454 mL, 7.93 
mmol) in CH3CN (25 mL) at 0 °C was added portionwise sodium triacetoxyborohydride (1.18 g, 5.29 
mmol). The mixture was stirred at rt for 16 h and then poured into saturated aqueous NaHCO3. The 
mixture was extracted with EtOAc, dried over anhydrous Na2SO4, and concentrated in vacuo. The 
residue was purified by column chromatography (basic silica gel, hexane/ethyl acetate, 19:1 to 1:1) to 
afford 29 (739 mg, 2.09 mmol, 79%) as a colorless oil. 1H NMR (300 MHz, DMSO-d6) δ 0.68 (3H, t, 
J = 7.4 Hz), 1.36–1.73 (2H, m), 3.31–3.43 (1H, m), 3.73 (3H, s), 3.75 (3H, s), 3.90–4.16 (2H, m), 
6.78–6.95 (2H, m), 7.09 (1H, t, J = 7.0 Hz), 7.14–7.26 (2H, m), 7.34–7.45 (1H, m), 8.42 (1H, s), 8.65–
8.79 (1H, m) (one proton was not observed). MS (ESI/APCI) mass calculated for [M + H]+ 
(C20H24N3O3) requires m/z 354.2, found m/z 354.2. 
4-(((1-(4-Methoxyphenyl)propyl)amino)methyl)pyrazolo[1,5-a]pyridine-3-carboxylic Acid (30). To a 
solution of 29 (743 mg, 2.10 mmol) in THF (15 mL) and MeOH (7.5 mL) was added 1 M NaOH 
aqueous solution (6.31 mL, 6.31 mmol). The mixture was stirred at 50 °C for 30 min and then at 70 °C 
for 1.5 h. The mixture was acidified with 1 M HCl aqueous solution (12.6 mL, 12.6 mmol) and then 
evaporated under reduced pressure to remove the organic solvents. The residual aqueous solution was 
passed through HP20 (DIAIONTM, Mitsubishi Chemical) (eluted with water and then CH3CN). The 
acetonitrile fractions containing the desired product was concentrated in vacuo to afford 30 (674 mg, 
1.99 mmol, 94%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 0.61–0.77 (3H, m), 1.58–2.05 
(2H, m), 3.62–3.93 (5H, m), 3.94–4.09 (1H, m), 6.83–7.03 (3H, m), 7.12 (1H, d, J = 6.8 Hz), 7.26–
7.43 (2H, m), 8.32 (1H, s), 8.72 (1H, d, J = 6.8 Hz), 11.33 (1H, brs) (one proton was not observed). 




Enzyme Assay Protocol. Preparation of human PDE. Human PDE1A, 3A, 4D2, 5A1, 7B, 8A1, 9A2, 
and 11A4 enzymes were purchased from BPS Bioscience. Human PDE6AB enzyme was purchased 
from SB Drug Discovery. Human PDE2A3 full-length gene was transduced into Sf9 cells, and the 
enzyme was purified by His-tag affinity column and gel filtration. Human PDE10A2 was generated 
from COS-7 cells that had been transfected with the full-length gene. The enzymes were stored at 
−70 °C until use. 
PDE2A3 enzyme inhibitory assay. PDE activity was measured using an SPA (Scintillation Proximity 
Assay) (GE Healthcare). To evaluate the inhibitory activity of a compound, 10 µL of serially diluted 
compounds were incubated with 20 µL of PDE enzyme (final concentration 0.023 nM) in assay buffer 
(50 mM HEPES-NaOH, 8.3 mM MgCl2, 1.7 mM EGTA, and 0.1% bovine serum albumin (BSA) (pH 
7.4)) for 30 min at rt. The final concentration of DMSO in the reaction solution was 1%. Compounds 
were tested in duplicate in 96-well half-area plates (Corning) or a 384-well OptiPlates (PerkinElmer). 
We used an 8 concentration serial dilution dose response ranging from 100 µM to 10 pM compound 
concentrations. To start the reaction, 10 µL of substrate [3H] cGMP (final concentration 77 nM, 
PerkinElmer) were added to a total volume of 40 µL. After 60 min at rt, 20 µL of 20 mg/mL yttrium 
silicate SPA beads containing zinc sulfate were added to terminate the PDE reaction. After allowing to 
settle for an additional 60 min, the assay plates were counted in a scintillation counter (PerkinElmer) 
to allow calculation of the inhibition rate. The inhibition rate was calculated based on the 0% control 
wells with enzyme and DMSO, and the 100% control wells without enzyme. All IC50 values were 
obtained by fitting the results to the following 4 Parameter Logistic Equation: 
y = A + (B – A)/(1 + (10^((C – x)*D))) 
where A is the minimum y value, B is the maximum y value, C is Log(EC50) value, and D is the 
slope factor. 
Human PDE enzyme assay. PDE activities were measured using an SPA (GE Healthcare). To evaluate 
the inhibitory activity, 10 µL of serially diluted compounds were incubated with 20 µL of PDE 
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enzymes, except for PDE1A, in the following assay buffer: 50 mM HEPES-NaOH, 8.3 mM MgCl2, 
1.7 mM EGTA, and 0.1% BSA (pH 7.4) for 30 min at rt. The PDE1A enzyme assay was performed in 
the following assay buffer: 50 mM Tris-HCl, 8.3 mM MgCl2, 0.2 mM CaCl2, 0.1% BSA, and 30 nM 
Calmodulin (pH 7.5). The final concentration of DMSO in the assay was 1%, and compounds were 
tested in duplicate in 96-well half-area plates (Corning). We used an 4 concentration serial dilution 
dose response ranging from 10 µM to 10 nM compound concentrations. To start the reaction, 10 µL of 
substrate ([3H] cGMP (final concentration 77 nM, PerkinElmer) for PDE1A, 5A1, 6AB, 9A2, 10A2, 
and 11A4 or [3H] cAMP (final concentration 14.7 nM, PerkinElmer) for PDE3A, 4D2, 7B, and 8A1) 
was added for a final assay volume of 40 µL. After 60 min incubation at rt, 20 µL of 20 mg/mL 
yttrium silicate SPA beads containing zinc sulfate was added to terminate the PDE reaction. After 
allowing to settle for more than 120 min, the assay plates were counted in a scintillation counter 
(PerkinElmer) to allow calculation of the inhibition rate. 
Estimation of Log D at pH 7.4. Log D7.4, which is the partition coefficient of the compounds between 
1-octanol and aqueous buffer at pH 7.4, was measured using a chromatographic procedure based on a 
previously published method.68 The instruments utilized were a Waters Alliance 2795 HPLC system 
and a 2996 UV–vis detector (Milford, MA, USA). 
In Vitro Metabolic Clearance Assay. In vitro oxidative metabolic studies of the tested compounds 
were performed using hepatic microsomes obtained from humans, rats or mice. The reaction mixture 
with a final volume of 0.05 mL consisted of 0.2 mg/mL hepatic microsome in 50 mM KH2PO4–
K2HPO4 phosphate buffer (pH 7.4) and 1 µM test compound. The reaction was initiated by the 
addition of an NADPH-generating system containing 25 mM MgCl2, 25 mM glucose 6-phosphate, 2.5 
mM β-NADP+, and 7.5 unit/mL glucose 6-phosphate dehydrogenase at 20% of the volume of the 
reaction mixture. After the addition of the NADPH-generating system, the mixture was incubated at 
37 °C for 0, 15, and 30 min. The reaction was terminated by adding an equivalent volume of CH3CN. 
After the samples were mixed and centrifuged, the supernatant fractions were analyzed using liquid 
134 
 
chromatography tandem mass spectrometry (LC–MS/MS). For metabolic clearance determinations, 
chromatograms were analyzed for the disappearance rate of the parent compound from the reaction 
mixtures. All incubations were made in duplicate. 
Transcellular Transport Study Using a Transporter-Expression System. Human 
MDR1-expressing LLC-PK1 cells were cultured as reported previously with minor modifications.106 
The transcellular transport study was performed as reported previously.107 In brief, the cells were 
grown for 7 days in an HTS Transwell 96-well permeable support (pore size: 0.4 µm, surface area: 
0.143 cm2) with a polyethylene terephthalate membrane (Corning Life Sciences, Lowell, MA, USA) at 
a density of 1.125 × 105 cells/well. The cells were preincubated with M199 at 37 °C for 30 min. 
Subsequently, transcellular transport was initiated by the addition of M199 either to apical 
compartments (75 µL) or to basolateral compartments (250 µL) containing 10 µM digoxin, 200 µM 
lucifer yellow as a marker for the monolayer tightness, and 10 µM test compounds, and then 
terminated by the removal of each assay plate after 2 h. Aliquots (25 µL) from the opposite 
compartments were mixed with acetonitrile containing alprenolol and diclofenac as internal standards, 
and then centrifuged. The compound concentrations in the supernatant were measured by LC–MS/MS. 
The apparent permeability (Papp) of test compounds in the receiver wells was determined and the 
efflux ratio (ER) for the MDR1 membrane permeability test was calculated using the following 
equation: 
ER = Papp,BtoA/Papp,AtoB 
where Papp,AtoB is the apical-to-basal passive permeability–surface area product and Papp,BtoA is the 
basal-to-apical passive permeability–surface area product. 
Protein Expression and Purification. Human PDE2A catalytic domain (residues 578–919) for 
crystallographic study was purified from insect cells as a fusion protein with an N-terminal 6× 
histidine tag and adjacent tobacco etch virus (TEV) protease cleavage site. An extra His–Ala sequence 
was added prior to Ser578 of the PDE2A sequence, based on the previously described structure.108 The 
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histidine-tagged PDE2A was expressed in Sf9 insect cells, and the harvested cell pellets were 
suspended in lysis buffer (50 mM Tris-HCl (pH 8.0), 1 mM DTT, 1 mM EDTA, and 10% glycerol), 
followed by centrifugation. The supernatant was supplemented with 300 mM NaCl and 20 mM 
imidazole and loaded onto a nickel–nitrilotriacetic acid (Ni–NTA) Superflow™ cartridge (QIAGEN). 
The PDE2A bound resin was washed with wash buffer (50 mM Tris-HCl (pH 8.0), 10% glycerol, 300 
mM NaCl, and 20 mM imidazole), and eluted with wash buffer containing 250 mM imidazole. The 
eluted histidine-tagged PDE2A catalytic domain was desalted using a HiPrep 26/10 Desalting column 
(GE Healthcare) with tris-buffered saline (TBS) (pH 7.4), 0.5 mM DTT, 1 mM EDTA, and 10% 
glycerol. The histidine-tagged protein was cleaved at the TEV cleavage site by TEV protease treatment. 
After TEV cleavage, the digested protein was passed through the Ni–NTA Superflow™ cartridge to 
remove the unwanted histidine-tagged fragments and histidine-tagged TEV proteases, followed by ion 
exchange chromatography using a MonoQ 10/100 GL column (GE Healthcare) in basal buffer (50 mM 
Tris-HCl (pH 8.0), 1 mM DTT, and 10% glycerol) with a 0-500 mM NaCl linear gradient. 
Subsequently, the purified catalytic domain was further treated with HiLoad 26/60 Superdex200 
column (GE Healthcare), concentrated by ultrafiltration to 9.5 mg/mL, and stored at −80 °C until use. 
Crystallization and Structure Determination. Crystals were obtained using the sitting-drop 
vapor-diffusion method by mixing 50 nL of protein solution (9.5 mg/mL PDE2A catalytic domain in 1 
mM 10a, TBS (pH 7.4), 0.5 mM DTT, 1 mM EDTA, and 10% glycerol) and 50 nL of reservoir 
solution containing 0.1 M Tris-HCl (pH 7.5), 410 mM MgCl2, and 29.3% PEG 3350 at 20 °C. 
Complex crystals were transfered into liquid nitrogen and stored until data collection. Diffraction data 
were collected from a single crystal at the Advanced Light Source beamline 5.0.3 (Berkeley, CA) for 
compounds 10a, and processed using the program HKL2000.108 The structures were determined by 
molecular replacement using MOLREP,109 utilizing the previously reported coordinate of PDE2A with 
the PDB accession code 5XKM.110 Subsequently, the structures were refined through an iterative 
procedure utilizing REFMAC111 followed by model building with WinCoot.112 The dictionary files for 
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the inhibitors were prepared using AFITT (OpenEye Scientific Software). X-ray data collection and 
refinement statistics for the crystal structure of PDE2A in complex with compound 10a were 




Table 1-7.  X-ray Data Collection and Refinement Statistics for the Crystal Structure of PDE2A in 
Complex with Compound 10a 
 10a 
Data Collection  
X-ray source ALS BL5.0.3 
Wavelength (Å) 0.97645 
Space group P1 
Unit cell dimensions (Å) a = 72.9, b = 89.8, c = 90.3, α = 107.3, β = 113.9, γ = 89.8 
Resolution (Å) 2.20 
Unique reflections 100556 
Redundancy 1.8 
Completeness (%) 96.8 (93.4) 
I/σ(I) 8.5 (1.5) 
Rsyma 0.090 (0.554) 
Refinement  
Reflections used 95501 
RMS Bonds (Å) 0.006 
RMS Angles (°) 0.946 
Average B value (Å2) 28.6 
R-valueb 0.2061 
R freeb 0.2632 
a Rsym = ΣhΣj |<I(h)> − I(h)j| / ΣhΣj <I(h)>, where <I(h)> is the mean intensity of symmetry-related 
reflections. b R-value = Σ | |Fobs| − |Fcalc| | / Σ |Fobs|. Rfree for 5% of reflections excluded from 
refinement. Values in parentheses are for the highest resolution shell. 
Animal Experiments. The care and use of animals and the experimental protocols were approved by 
the Experimental Animal Care and Use Committee of Takeda Pharmaceutical Company Limited. 
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Pharmacokinetic Analysis in Rat or Mouse Cassette Dosing. Compound 10a was administered 
intravenously (0.1 mg/kg) or orally (1 mg/kg) by cassette dosing to nonfasted male Crl:CD(SD)(IGS) 
rats (8W, n = 3) or male ICR mice (8W, n = 3). The combination for a cassette dosing was determined 
to avoid combinations of compounds with the same molecular weight. The solution of compounds in 
dimethylacetamide containing 50% (v/v) 1,3 butanediol at 0.1 mg/mL/kg was administered 
intravenously to isoflurane-anesthetized mice via femoral vein. The suspension of compounds in 0.5% 
methyl cellulose with water was used for vehicle (1 mg/kg) and was administered orally by gavage. 
After administration, blood samples were collected via tail vein by syringes with heparin at 5, 10, 15, 
30 min, 1, 2, 4, and 8 h (iv) and 15, 30 min, 1, 2, 4, and 8 h (po), and centrifuged to obtain the plasma 
fraction. The plasma samples were deproteinized by mixing with acetonitrile followed by 
centrifugation. The compound concentrations in the supernatant were measured by LC–MS/MS with a 
standard curve. Pharmacokinetic parameters were calculated by the non-compartmental analysis. The 
area under the concentration-time curve (AUC) and the area under the first moment curve (AUMC) 
were calculated using the linear trapezoidal method. The mean residence time (MRT) was calculated 
as AUMC/AUC. The total clearance (CLtotal) was calculated as doseiv/AUCiv. The volume of 
distribution (Vdss) was calculated as CLtotal × MRTiv. Oral bioavailability (F) was calculated as 
(AUCpo/dosepo)/(AUCiv/doseiv) × 100. 
Brain and Plasma Concentrations in Rats and Mice. Compound 10a was administered orally to 
non-fasted rats or mice at 1 mg/kg. Blood and brain samples were collected 2 h or 1 h after oral 
administration to rats or mice, respectively. The blood samples were centrifuged to obtain the plasma 
fraction. The brain samples were homogenized in 0.1 M phosphate buffer (pH 7.4) to obtain the brain 
homogenate. The plasma and brain homogenate samples were deproteinized with CH3CN containing 
an internal standard. After centrifugation, the compound concentrations in the supernatant were 
measured by LC–MS/MS. 
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Measurement of Cyclic Nucleotide Content in the Mouse Brain. Animals. Five-week-old male ICR 
mice were purchased from CLEA Japan, Inc. (Japan). The mice were housed in groups of 5/cage in a 
light-controlled room (12 h light/dark cycles with lights on at 07:00). Food and water were provided 
ad libitum. After a one-week acclimation period, the six-week-old mice were used for experiments. 
Measurements. Compound 10a was suspended in 0.5% (w/v) methylcellulose in distilled water, and 
was administered at 10 mL/kg body weight for mice. Mice were administered orally either vehicle or 
10a (10, 30, or 100 mg/kg) after a habituation period of at least 30 min. A microwave fixation system 
(Muromachi Kikai, Tokyo, Japan) was used to sacrifice unanesthetized mice by exposure of the head 
to a microwave beam 30 min after administration of 10a. Brain tissues were isolated and then 
homogenized in 0.5 M HCl, followed by centrifugation. Concentration of cyclic nucleotides in the 
supernatant were measured using cyclic AMP EIA kit or cyclic GMP EIA kit (Cayman Chemical, 




第 2 章に関する実験 
N-(1-(4-(Trifluoromethoxy)phenyl)propyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (31). A mixture 
of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (15) (26.7 mg, 0.16 mmol), 
1-(4-(trifluoromethoxy)phenyl)propan-1-amine hydrochloride (22b) (46.0 mg, 0.18 mmol), EDCI·HCl 
(37.6 mg, 0.20 mmol), HOBt·H2O (30.1 mg, 0.20 mmol), and Et3N (0.027 mL, 0.20 mmol) in DMF 
(1.5 mL) was stirred at rt overnight. The mixture was poured into water and extracted with EtOAc. 
The organic layer was separated, washed with saturated aqueous NaCl, dried over anhydrous MgSO4, 
and concentrated in vacuo. The residue was purified by column chromatography (silica gel, 
hexane/ethyl acetate, 4:1 to 0:100). The desired fractions were collected and concentrated in vacuo. 
The resulting solid was triturated with i-Pr2O, collected by filtration, rinsed with i-Pr2O, and dried to 
give 31 (49.2 mg, 0.135 mmol, 83%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 0.93 (3H, t, J 
= 7.4 Hz), 1.81–1.96 (2H, m), 5.05 (1H, q, J = 7.2 Hz), 7.25–7.37 (3H, m), 7.47–7.56 (2H, m), 8.32 
(1H, d, J = 8.0 Hz), 8.56 (1H, s), 8.86 (1H, dd, J = 4.2, 1.9 Hz), 9.29–9.37 (1H, m). MS (ESI/APCI) 
m/z 365.2 [M + H]+. HPLC purity: 100%. 
2-Oxo-N-(1-(4-(trifluoromethoxy)phenyl)propyl)-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxam
ide (32). To a solution of 13a (904 mg, 2.62 mmol) in DMF (15 mL) were added 22b (736 mg, 2.88 
mmol) and Et3N (1.10 mL, 7.85 mmol). The mixture was stirred at rt for 1 h and then poured into 
NaHCO3 aqueous solution. The mixture was extracted with EtOAc, washed with 1 M HCl aqueous 
solution and saturated aqueous NaCl, dried over anhydrous Na2SO4 and concentrated in vacuo. The 
residue was purified by column chromatography (silica gel, hexane/ethyl acetate, 9:1 to 0:100) to 
afford 32 (910.6 mg, 2.31 mmol, 88%) as a white solid. 1H NMR (300 MHz, CDCl3) δ 0.96 (3H, t, J = 
7.4 Hz), 1.76–1.96 (2H, m), 4.67 (2H, s), 4.90 (1H, q, J = 7.2 Hz), 6.99 (1H, dd, J = 7.6, 4.9 Hz), 
7.12–7.25 (3H, m), 7.30–7.42 (2H, m), 7.99 (1H, dd, J = 5.1, 1.7 Hz), 9.91 (1H, s), 10.46 (1H, d, J 
=7.2 Hz). MS (ESI/APCI) mass calculated for [M + H]+ (C18H18F3N4O3) requires m/z 395.1, found m/z 





(32a). Resolution of the enantiomers of 32 was carried out chromatographically using a Chiralpak IC 
50 mm ID × 500 mm L column (hexane/ethanol, 400:600) at 60 mL/min. Resolution of 32 (907 mg, 
2.30 mmol) provided 439 mg of 32a as the first eluting enantiomer, which was triturated with 
hexane/ethyl acetate (5:1) to afford 32a (416.9 mg, 1.03 mmol, 45%, 89% theoretical) as a pale yellow 
solid. Analytical HPLC analysis carried out on a 4.6 mm ID × 250 mm L Chiralpak IC column with 
the same eluent as above at a flow rate of 0.5 mL/min indicated that 32a was of 99.7% ee. 1H NMR 
(300 MHz, DMSO-d6) δ 0.88 (3H, t, J = 7.3 Hz), 1.70–1.89 (2H, m), 4.41 (2H, s), 4.81 (1H, q, J = 6.9 
Hz), 7.10 (1H, dd, J = 7.7, 5.1 Hz), 7.25–7.37 (3H, m), 7.38–7.51 (2H, m), 8.02 (1H, dd, J = 5.1, 1.7 
Hz), 10.34 (1H, d, J = 7.5 Hz), 10.82 (1H, brs). MS (ESI/APCI) mass calculated for [M + H]+ 
(C18H18F3N4O3) requires m/z 395.1, found m/z 395.2. HPLC purity: 97.9%. Anal. Calcd for 
C18H17F3N4O3: C, 54.82; H, 4.35; N, 14.21. Found: C, 55.01; H, 4.59; N, 14.12. 
2-Oxo-N-((1S or 
1R)-1-(4-(trifluoromethoxy)phenyl)propyl)-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide 
(32b). Resolution of the enantiomers of 32 was carried out chromatographically using a Chiralpak IC 
50 mm ID × 500 mm L column (hexane/ethanol, 400:600) at 60 mL/min. Resolution of 32 (907 mg, 
2.30 mmol) provided 429 mg of 32b as the first eluting enantiomer, which was triturated with 
hexane/ethyl acetate (5:1) to afford 32b (399 mg, 1.01 mmol, 44%, 88% theoretical) as a pale yellow 
solid. Analytical HPLC analysis carried out on a 4.6 mm ID × 250 mm L Chiralpak IC column with 
the same eluent as above at a flow rate of 0.5 mL/min indicated that 32b was of >99.9% ee. 1H NMR 
(300 MHz, DMSO-d6) δ 0.88 (3H, t, J = 7.3 Hz), 1.70–1.90 (2H, m), 4.41 (2H, s), 4.81 (1H, q, J = 7.0 
Hz), 7.11 (1H, dd, J = 7.7, 5.1 Hz), 7.26–7.38 (3H, m), 7.38–7.51 (2H, m), 8.02 (1H, dd, J = 4.9, 1.5 
Hz), 10.35 (1H, d, J = 7.2 Hz), 10.83 (1H, brs). MS (ESI/APCI) mass calculated for [M + H]+ 
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(C18H18F3N4O3) requires m/z 395.1, found m/z 395.1. HPLC purity: 100%. Anal. Calcd for 
C18H17F3N4O3: C, 54.82; H, 4.35; N, 14.21. Found: C, 54.90; H, 4.50; N, 14.15. 
2-Oxo-N-(1-(4-(trifluoromethoxy)phenyl)propyl)-1,2-dihydro-1,5-naphthyridine-4-carboxamide 
(33). To a mixture of 49 (372 mg, 1.96 mmol), 22b (650 mg, 2.54 mmol) and DIEA (1.03 mL, 5.87 
mmol) in DMF (15 mL) was added HATU (1.12 g, 2.94 mmol). The mixture was stirred at rt for 2.5 h 
and then poured into water. The mixture was extracted with EtOAc, washed with water and saturated 
aqueous NaCl, dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by 
column chromatography (silica gel, hexane/ethyl acetate, 4:1 to 0:100), followed by a second column 
purification (silica gel, hexane/ethyl acetate, 4:1 to 0:100)) to afford 33 (341 mg, 0.871 mmol, 45%) as 
a white solid after recrystallization from ethyl acetate. 1H NMR (300 MHz, DMSO-d6) δ 0.95 (3H, t, J 
= 7.4 Hz), 1.78–1.92 (2H, m), 5.03 (1H, q, J = 6.9 Hz), 7.08 (1H, s), 7.30–7.40 (2H, m), 7.50–7.58 
(2H, m), 7.63 (1H, dd, J = 8.5, 4.4 Hz), 7.79 (1H, dd, J = 8.3, 1.5 Hz), 8.58 (1H, dd, J = 4.5, 1.5 Hz), 
10.47 (1H, d, J = 8.0 Hz), 12.17 (1H, brs). MS (ESI/APCI) mass calculated for [M + H]+ 
(C19H17F3N3O3) requires m/z 392.1, found m/z 392.2. HPLC purity: 95.7%. 
3-Methyl-N-(1-(4-(trifluoromethoxy)phenyl)propyl)pyrazolo[1,5-b][1,2,4]triazine-8-carboxamide 
(34). A mixture of compound 54 (30 mg, containing 50% of 52), 22b (46 mg, 0.18 mmol), HOBt (24 
mg, 0.18 mmol), EDCI (34 mg, 0.18 mmol), and Et3N (20 mg, 0.20 mmol) in DMF (3 mL) was stirred 
at 10–15 °C for 16 h. The mixture was diluted with water (15 mL), extracted with EtOAc (10 mL × 3). 
The combined organic layer was washed with saturated aqueous NaCl (10 mL), dried over anhydrous 
Na2SO4 and concentrated in vacuo. The residue was purified by preparative HPLC (column: Fuji C18 
(25 mm ID × 300 mm L), YMC (20 mm ID × 250 mm L); mobile phase A: 0.05% HCl in water; 
mobile phase B: 0.05% HCl in acetonitrile; flow rate: 25 mL/min), and most of CH3CN was removed 
under reduced pressure. The remaining solvent was removed by lyophilization to give 34 (4 mg, 3% in 
2 steps) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 0.93 (3H, t, J = 7.2 Hz), 1.81–1.92 (2H, 
m), 2.63 (3H, s), 4.97–5.06 (1H, m), 7.32 (2H, d, J = 8.0 Hz), 7.52 (2H, d, J = 8.8 Hz), 8.14 (1H, d, J 
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= 8.4 Hz), 8.56 (1H, s), 8.81 (1H, s). MS (ESI/APCI) mass calculated for [M + H]+ (C17H17F3N5O2) 
requires m/z 380.1, found m/z 380.2. HPLC purity: 100%. 
5-Oxo-N-(1-(4-(trifluoromethoxy)phenyl)propyl)-5,6-dihydro-1,6-naphthyridine-8-carboxamide 
(35). A solution of impure 59 (370 mg, 93% LC–MS purity) in TFA (3 mL) was stirred at reflux for 16 
h. After cooling to rt, the mixture was concentrated in vacuo. The residue was dissolved in CH2Cl2 (20 
mL) and the solution was washed with saturated NaHCO3 (20 mL). The organic layer was 
concentrated in vacuo. The residue was purified by column chromatography (silica gel, petroleum 
ether/ethyl acetate, 2:1 to 0:100), followed by preparative TLC (EtOAc) to afford 35 (30 mg, 0.0767 
mmol, 12% in 2 steps from 58) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 0.93 (3H, t, J = 7.2 
Hz), 1.81–1.94 (2H, m), 5.06 (1H, q, J = 7.2 Hz), 7.33 (2H, d, J = 8.0 Hz), 7.50 (2H, d, J = 8.8 Hz), 
7.66 (1H, dd, J = 8.0, 4.8 Hz), 8.20 (1H, s), 8.66 (1H, dd, J = 8.0, 2.0 Hz), 9.09 (1H, dd, J = 4.8, 2.0 
Hz), 11.01 (1H, d, J = 7.6 Hz), 12.17 (1H, brs). MS (ESI/APCI) m/z 392.0 [M + H]+. mp 185 °C. 
3-Oxo-N-(1-(4-(trifluoromethoxy)phenyl)propyl)-3,4-dihydroquinoxaline-1(2H)-carboxamide (36). 
To a solution of 63h (313 mg, 1.00 mmol) and 22b (307 mg, 1.20 mmol) in DMF (10 mL) was added 
Et3N (418 µL, 3.00 mmol) at rt. After being stirred at 80 °C for 24 h, the mixture was quenched with 
water and extracted with EtOAc. The organic layer was separated, washed with water and saturated 
aqueous NaCl, dried over anhydrous MgSO4 and concentrated in vacuo. The residue was purified by 
column chromatography (silica gel, hexane/ethyl acetate, 9:1 to 1:1) to give 36 (281 mg, 0.714 mmol, 
72%) as a white solid. 1H NMR (300 MHz, CDCl3) δ 0.88 (3H, t, J = 7.3 Hz), 1.69–1.86 (2H, m), 
4.30–4.52 (2H, m), 4.81 (1H, q, J = 7.2 Hz), 5.39 (1H, d, J = 7.2 Hz), 6.91–6.97 (1H, m), 7.07–7.37 
(7H, m), 8.02 (1H, brs). MS (ESI/APCI) mass calculated for [M + H]+ (C19H19F3N3O3) requires m/z 
394.1, found m/z 394.1. HPLC purity: 96.9%. mp 198 °C. Anal. Calcd for C19H18F3N3O3: C, 58.01; H, 
4.61; N, 10.68. Found: C, 58.17; H, 4.70; N, 10.59. 
N-(1-(4-Methoxyphenyl)propyl)-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (37a). 
To a solution of 62a (23.5 mg, 0.160 mmol) and Et3N (65.9 μL, 0.470 mmol) in THF (5.0 mL) and 
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DMA (1.0 mL) was added triphosgene (46.8 mg, 0.160 mmol) at 0 °C. After stirring at 0 °C for 2 h, 
Et3N (65.9 μL, 0.470 mmol) and 22a (159 mg, 0.790 mmol) was added at 0 °C. The mixture was 
stirred at rt for 2 h and then quenched with water. The mixture was extracted with EtOAc, washed with 
saturated aqueous NaCl, dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was 
purified by column chromatography (basic silica gel, hexane/ethyl acetate, 1:1 to 0:100) to give 37a 
(6.33 mg, 0.019 mmol, 12%) as a white solid after trituration with hexane/i-Pr2O. 1H NMR (300 MHz, 
CDCl3) δ 0.79–1.00 (3H, m), 1.76–1.97 (2H, m), 3.78 (3H, s), 4.68 (2H, s), 4.83 (1H, q, J = 7.2 Hz), 
6.86 (2H, d, J = 8.7 Hz), 6.96 (1H, dd, J = 7.7, 5.1 Hz), 7.08–7.37 (3H, m), 7.97 (1H, dd, J = 5.1, 1.3 
Hz), 9.69 (1H, brs), 10.35 (1H, d, J = 7.6 Hz). MS (ESI/APCI) mass calculated for [M − H]− 
(C18H19N4O3) requires m/z 339.2, found m/z 339.1. HPLC purity: 99.8%. 
2-Oxo-N-(1-(4-(trifluoromethyl)phenyl)propyl)-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamid
e (37b). To a solution of 63a (314 mg, 1.00 mmol) in DMF (10 mL) were added 99g (223 mg, 1.10 
mmol) and Et3N (0.418 mL, 3.00 mmol). The mixture was stirred at rt for 16 h and then concentrated 
in vacuo. The residue was diluted with water and extracted with EtOAc. The organic layer was 
separated, washed with saturated aqueous NaHCO3, water and saturated aqueous NaCl, dried over 
anhydrous MgSO4 and concentrated in vacuo. The residue was purified by column chromatography 
(silica gel, hexane/ethyl acetate, 9:1 to 3:2) to give 37b (314 mg, 0.830 mmol, 83%) as a colorless 
prisms after recrystallized from hexane/ethyl acetate. 1H NMR (300 MHz, CDCl3) δ 0.97 (3H, t, J = 
7.3 Hz), 1.89 (2H, quin, J = 7.3 Hz), 4.67 (2H, s), 4.93 (1H, q, J = 6.8 Hz), 7.01 (1H, dd, J = 7.7, 5.1 
Hz), 7.19 (1H, dd, J = 7.5, 1.5 Hz), 7.44 (2H, d, J = 8.3 Hz), 7.58 (2H, d, J = 8.3 Hz), 8.01 (1H, dd, J 
= 4.9, 1.5 Hz), 9.16 (1H, brs), 10.48 (1H, d, J = 7.2 Hz). MS (ESI/APCI) mass calculated for [M + H]+ 
(C18H18F3N4O2) requires m/z 379.1, found m/z 379.2. HPLC purity: 100%. mp 105 °C. Anal. Calcd for 
C18H17F3N4O2: C, 57.14; H, 4.53; N, 14.81. Found: C, 56.89; H, 4.55; N, 14.74. 
N-(1-(4-Cyclopropylphenyl)propyl)-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide 
(37c). The title compound was prepared as a pale yellow solid after recrystallization from hexane/ethyl 
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acetate in 23% yield from 63a and 99a using the procedure analogous to that described for the 
synthesis of 37b. 1H NMR (300 MHz, CDCl3) δ 0.61–0.70 (2H, m), 0.86–0.98 (5H, m), 1.79–1.95 (3H, 
m), 4.61–4.75 (2H, m), 4.79–4.90 (1H, m), 6.92–7.06 (3H, m), 7.10–7.24 (3H, m), 7.99 (1H, dd, J = 
5.1, 1.7 Hz), 8.36–8.67 (1H, m), 10.33 (1H, d, J = 7.2 Hz). MS (ESI/APCI) mass calculated for [M + 
H]+ (C20H23N4O2) requires m/z 351.2, found m/z 351.2. HPLC purity: 98.0%. 
N-(1-(4-(Azetidin-1-yl)phenyl)propyl)-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide 
(37d). The title compound was prepared as a colorless prisms after recrystallization from hexane/ethyl 
acetate in 80% yield from 63a and 99b using the procedure analogous to that described for the 
synthesis of 37b. 1H NMR (300 MHz, CDCl3) δ 0.91 (3H, t, J = 7.3 Hz), 1.74–1.96 (2H, m), 2.27–2.39 
(2H, m), 3.84 (4H, t, J = 7.2 Hz), 4.60–4.72 (2H, m), 4.74–4.85 (1H, m), 6.38–6.45 (2H, m), 6.90–
6.99 (1H, m), 7.09–7.21 (3H, m), 7.97 (1H, dd, J = 5.1, 1.7 Hz), 8.53 (1H, s), 10.24 (1H, d, J = 7.9 
Hz). MS (ESI/APCI) mass calculated for [M + H]+ (C20H24N5O2) requires m/z 366.2, found m/z 366.2. 
HPLC purity: 100%. mp 176 °C. Anal. Calcd for C20H23N5O2: C, 65.73; H, 6.34; N, 19.16. Found: C, 
65.73; H, 6.23; N, 18.93. 
2-Oxo-N-(1-(3-(trifluoromethoxy)phenyl)propyl)-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxam
ide (37e). To a solution of 63a (369 mg, 1.17 mmol) and 100c (335 mg, 1.31 mmol) in DMF (10 mL) 
was added Et3N (0.409 mL, 2.94 mmol) at rt. After being stirred for 16 h, the mixture was quenched 
with water and extracted with EtOAc. The organic layer was separated, washed with water and 
saturated aqueous NaCl, dried over anhydrous MgSO4 and concentrated in vacuo. The residue was 
purified by column chromatography (silica gel, hexane/ethyl acetate, 9:1 to 33:67) to give 37e (202 
mg, 0.512 mmol, 44%) as a white solid after recrystallization from hexane/ethyl acetate. 1H NMR (300 
MHz, CDCl3) δ 0.96 (3H, t, J = 7.3 Hz), 1.82–1.93 (2H, m), 4.68 (2H, s), 4.92 (1H, q, J = 6.9 Hz), 
7.00 (1H, dd, J = 7.5, 4.9 Hz), 7.09 (1H, dd, J = 7.9, 1.1 Hz), 7.14–7.20 (2H, m), 7.23–7.29 (1H, m), 
7.31–7.39 (1H, m), 8.00 (1H, dd, J = 4.9, 1.5 Hz), 8.57–8.77 (1H, m), 10.44 (1H, d, J = 7.2 Hz). MS 
(ESI/APCI) mass calculated for [M + H]+ (C18H18F3N4O2) requires m/z 395.1, found m/z 395.2. HPLC 
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purity: 99.7%. mp 110 °C. Anal. Calcd for C18H17F3N4O3: C, 54.82; H, 4.35; N, 14.21. Found: C, 
54.69; H, 4.37; N, 14.16. 
2-Oxo-N-(1-(2-(trifluoromethoxy)phenyl)propyl)-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxam
ide (37f). The title compound was prepared as a white solid in 78% yield from 63a and 100d using the 
procedure analogous to that described for the synthesis of 37e. 1H NMR (300 MHz, DMSO-d6) δ 0.89 
(3H, t, J = 7.4 Hz), 1.66–1.91 (2H, m), 4.40 (2H, s), 4.97–5.15 (1H, m), 7.11 (1H, dd, J = 7.7, 4.9 Hz), 
7.26–7.42 (4H, m), 7.44–7.53 (1H, m), 8.00 (1H, dd, J = 5.0, 1.6 Hz), 10.41 (1H, d, J = 7.7 Hz), 10.80 
(1H, s). MS (ESI/APCI) mass calculated for [M + H]+ (C18H18F3N4O2) requires m/z 395.1, found m/z 
395.2. HPLC purity: 99.4%. mp 178 °C. Anal. Calcd for C18H17F3N4O3: C, 54.82; H, 4.35; N, 14.21; 
F,14.45. Found: C, 55.00; H, 4.49; N, 14.20; F, 14.21. 
N-(1-(3-fluoro-4-(trifluoromethoxy)phenyl)propyl)-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-c
arboxamide (37g). The title compound was prepared as a white solid after crystallization from 
hexane/ethyl acetate in 63% yield from 63a and 100e using the procedure analogous to that described 
for the synthesis of 37e. 1H NMR (300 MHz, DMSO-d6) δ 0.77–0.95 (3H, m), 1.81 (2H, quin, J = 7.3 
Hz), 4.35–4.47 (2H, m), 4.81 (1H, q, J = 7.2 Hz), 7.11 (1H, dd, J = 7.7, 5.1 Hz), 7.27 (1H, d, J = 8.3 
Hz), 7.32 (1H, dd, J = 7.9, 1.5 Hz), 7.44–7.58 (2H, m), 8.02 (1H, dd, J = 4.9, 1.5 Hz), 10.30 (1H, d, J 
= 7.2 Hz), 10.81 (1H, s). MS (ESI/APCI) mass calculated for [M + H]+ (C18H17F4N4O3) requires m/z 
413.1, found m/z 413.1. HPLC purity: 100%. mp 154 °C. Anal. Calcd for C18H16F4N4O3: C, 52.43; H, 
3.91; N, 13.59. Found: C, 52.48; H, 3.89; N, 13.30. 
N-(1-(2-Fluoro-4-(trifluoromethoxy)phenyl)propyl)-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-
carboxamide (37h). The title compound was prepared as a white solid after recrystallization from 
hexane/ethyl acetate in 87% yield from 63a and 100f using the procedure analogous to that described 
for the synthesis of 37e. 1H NMR (300 MHz, DMSO-d6) δ 0.89 (3H, t, J = 7.2 Hz), 1.70–1.88 (2H, m), 
4.40 (2H, s), 5.00 (1H, q, J = 7.4 Hz), 7.11 (1H, dd, J = 7.9, 4.9 Hz), 7.22 (1H, d, J = 8.7 Hz), 7.27–
7.42 (2H, m), 7.49 (1H, t, J = 8.5 Hz), 8.02 (1H, dd, J = 4.9, 1.9 Hz), 10.43 (1H, d, J = 7.5 Hz), 10.81 
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(1H, s). MS (ESI/APCI) mass calculated for [M + H]+ (C18H17F4N4O3) requires m/z 413.1, found m/z 
413.2. HPLC purity: 97.2%. mp 173.9–176.3 °C. 
N-(2-Methoxy-1-(4-(trifluoromethoxy)phenyl)ethyl)-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-
carboxamide (38a). The title compound was prepared as a white solid after trituration with hexane in 
55% yield from 63a and 99i using the procedure analogous to that described for the synthesis of 32. 1H 
NMR (300 MHz, DMSO-d6) δ 3.28 (3H, s), 3.55–3.71 (2H, m), 4.33–4.50 (2H, m), 4.99–5.13 (1H, m), 
7.11 (1H, dd, J = 7.9, 4.9 Hz), 7.27–7.39 (3H, m), 7.42–7.53 (2H, m), 8.00 (1H, dd, J = 4.9, 1.7 Hz), 
10.51 (1H, d, J = 7.4 Hz), 10.83 (1H, brs). MS (ESI/APCI) mass calculated for [M + H]+ 
(C18H18F3N4O4) requires m/z 411.1, found m/z 411.1. HPLC purity: 99.8%. mp 163 °C. Anal. Calcd for 
C18H17F3N4O4: C, 52.69; H, 4.18; N, 13.65. Found: C, 52.83; H, 4.33; N, 13.55. 
N-(3-Methoxy-1-(4-(trifluoromethoxy)phenyl)propyl)-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H
)-carboxamide (38b). The title compound was prepared as a white solid in 25% yield from 63a and 
100h using the procedure analogous to that described for the synthesis of 37e. 1H NMR (300 MHz, 
DMSO-d6) δ 2.01 (2H, q, J = 6.0 Hz), 3.21 (3H, s), 3.25–3.33 (2H, m), 4.29–4.51 (2H, m), 5.01 (1H, q, 
J = 6.8 Hz), 7.11 (1H, dd, J = 7.9, 4.9 Hz), 7.26–7.37 (3H, m), 7.39–7.50 (2H, m), 8.02 (1H, dd, J = 
4.9, 1.5 Hz), 10.31 (1H, d, J = 7.5 Hz), 10.81 (1H, brs). MS (ESI/APCI) mass calculated for [M + H]+ 
(C18H18F3N4O4) requires m/z 424.1, found m/z 425.2. HPLC purity: 99.8%. mp 132 °C. Anal. Calcd for 
C19H19F3N4O4: C, 53.77; H, 4.51; N, 13.20; F,13.43. Found: C, 53.50; H, 4.52; N, 13.02; F, 13.37. 
2-Oxo-N-(1-(4-(trifluoromethoxy)phenyl)butyl)-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxami
de (38c). The title compound was prepared as a white solid after crystallization from hexane/ethyl 
acetate in 73% yield from 63a and 1-(4-(trifluoromethoxy)phenyl)butan-1-amine hydrochloride using 
the procedure analogous to that described for the synthesis of 37e. 1H NMR (300 MHz, CDCl3) δ 
0.86–1.01 (3H, m), 1.23–1.51 (2H, m), 1.68–1.94 (2H, m), 4.58–4.75 (2H, m), 4.96 (1H, q, J = 7.5 Hz), 
7.00 (1H, dd, J = 7.7, 5.1 Hz), 7.10–7.22 (3H, m), 7.31–7.38 (2H, m), 8.00 (1H, dd, J = 4.9, 1.5 Hz), 
8.99 (1H, s), 10.40 (1H, d, J = 7.5 Hz). MS (ESI/APCI) mass calculated for [M + H]+ (C19H20F3N4O3) 
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requires m/z 424.1, found m/z 409.2. HPLC purity: 99.7%. mp 171.7–173.7 °C. Anal. Calcd for 
C19H19F3N4O3: C, 55.88; H, 4.69; N, 13.72. Found: C, 55.94; H, 4.78; N, 13.54. 
N-(2-Hydroxy-1-(4-(trifluoromethoxy)phenyl)ethyl)-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-
carboxamide (38d). A mixture of tert-butyl 
(2-hydroxy-1-(4-(trifluoromethoxy)phenyl)ethyl)carbamate (106) (52 mg, 0.16 mmol) and 2 M HCl 
solution in EtOH (2 mL, 4.00 mmol)  was stirred at 60 °C for 2 min and then concentrated in vacuo. 
To the residue were added DMF (2 mL), Et3N (0.045 mL, 0.32 mmol), and 63a (50.9 mg, 0.16 mmol) 
at rt. The mixture was stirred at rt overnight and then poured into saturated aqueous NaCl. The mixture 
was extracted with EtOAc, washed with saturated aqueous NaCl, dried over anhydrous MgSO4, and 
concentrated in vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl 
acetate, 1:1 to 0:100), followed by a preparative HPLC purification (column: L-Column2 ODS 20 mm 
ID × 150 mm L; mobile phase A: 0.1% TFA in water; mobile phase B: 0.1% TFA in acetonitrile; flow 
rate: 20 mL/min). The desired fraction was neutralized with saturated aqueous NaHCO3, concentrated 
in vacuo to remove most of acetonitrile, and extracted with EtOAc. The organic layer was separated, 
dried over anhydrous MgSO4, and concentrated in vacuo to give 38d (32.2 mg, 0.081 mmol, 50%) as a 
white solid. 1H NMR (300 MHz, DMSO-d6) δ 3.51–3.80 (2H, m), 4.29–4.53 (2H, m), 5.09 (1H, t, J = 
5.1 Hz), 7.11 (1H, dd, J = 7.7, 5.1 Hz), 7.28–7.35 (4H, m), 7.40–7.51 (2H, m), 8.01 (1H, dd, J = 4.9, 
1.5 Hz), 10.39 (1H, d, J = 7.2 Hz), 10.79 (1H, brs). MS (ESI/APCI) mass calculated for [M + H]+ 
(C17H16F3N4O4) requires m/z 397.1, found m/z 397.1. HPLC purity: 98.8%. mp 190 °C. 
N-(2-Hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)-2-oxo-2,3-dihydropyrido[2,3-b]pyraz
ine-4(1H)-carboxamide (38e). The title compound was prepared as a white solid after trituration with 
hexane/ethyl acetate in 82% yield from 63a and 108 using the procedure analogous to that described 
for the synthesis of 37e. 1H NMR (300 MHz, CDCl3) δ 1.16 (3H, s), 1.37 (3H, s), 1.70 (1H, s), 4.55–
4.76 (2H, m), 4.91 (1H, d, J = 8.3 Hz), 7.02 (1H, dd, J = 7.9, 4.9 Hz), 7.13–7.22 (3H, m), 7.37–7.46 
(2H, m), 8.07 (1H, dd, J = 4.9, 1.5 Hz), 8.51 (1H, s), 10.93 (1H, d, J = 8.3 Hz). MS (ESI/APCI) mass 
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calculated for [M + H]+ (C19H20F3N4O4) requires m/z 425.1, found m/z 425.1. HPLC purity: 99.5%. mp 
164.7–168.5 °C.  Anal. Calcd for C19H19F3N4O4: C, 53.77; H, 4.51; N, 13.20. Found: C, 53.91; H, 
4.66; N, 13.22. 
N-(2-(Methylsulfonyl)-1-(4-(trifluoromethoxy)phenyl)ethyl)-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine
-4(1H)-carboxamide (38f). A mixture of m-CPBA (68.7 mg, 0.28 mmol) and 64 (54 mg, 0.13 mmol) 
in EtOAc (10 mL) was stirred at rt overnight. Then saturated aqueous Na2S2O3 was added at rt and the 
mixture was stirred for 5 min at the same temperature. The mixture was poured into saturated aqueous 
NaHCO3 and extracted with EtOAc. The organic layer was separated, washed with saturated aqueous 
NaHCO3 and saturated aqueous NaCl, dried over anhydrous MgSO4 and concentrated in vacuo. The 
resulting solid was triturated from hexane/ethyl acetate to give 38f (38.2 mg, 0.083 mmol, 66%) as a 
white solid. 1H NMR (300 MHz, DMSO-d6) δ 2.91 (3H, s), 3.63 (1H, dd, J = 14.7, 4.5 Hz), 4.00 (1H, 
dd, J = 14.5, 9.2 Hz), 4.26–4.56 (2H, m), 5.46 (1H, td, J = 8.5, 3.8 Hz), 7.11 (1H, dd, J = 7.9, 4.9 Hz), 
7.30 (1H, dd, J = 7.9, 1.5 Hz), 7.33–7.41 (2H, m), 7.53–7.61 (2H, m), 7.98 (1H, dd, J = 4.9, 1.5 Hz), 
10.62 (1H, d, J = 7.9 Hz), 10.82 (1H, s). MS (ESI/APCI) mass calculated for [M + H]+ 
(C18H18F3N4O5S) requires m/z 459.1, found m/z 459.2. HPLC purity: 99.7%. mp 147.2–150.8 °C. Anal. 
Calcd for C18H17F3N4O5S: C, 47.16; H, 3.74; N, 12.22. Found: C, 46.92; H, 3.80; N, 12.00. 
N-(2-Methoxy-1-(4-(trifluoromethoxy)phenyl)ethyl)-6-methyl-2-oxo-2,3-dihydropyrido[2,3-b]pyrazi
ne-4(1H)-carboxamide (39a). To a suspension of 62c (118 mg, 0.72 mmol) in THF (20 mL) was 
added triphosgene (171 mg, 0.58 mmol) at rt. The mixture was stirred at 40 °C under Ar for 1 h. After 
cooling to rt, the mixture was concentrated in vacuo. The residue was diluted with THF and 
concentrated in vacuo (this procedure was repeated three times). To a solution of the residue in THF 
(20 mL) were added 100i (235 mg, 0.87 mmol) and Et3N (0.302 mL, 2.16 mmol) at rt. The mixture 
was stirred at rt for 16 h and then poured into water. The mixture was extracted with EtOAc, dried 
over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by column 
chromatography (silica gel, hexane/ethyl acetate, 4:1 to 0:100) to give 39a (58.3 mg, 0.137 mmol, 
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19%) as a white solid after crystallization from hexane/ethyl acetate (2:1). 1H NMR (300 MHz, 
DMSO-d6) δ 2.42 (3H, s), 3.29 (3H, s), 3.56–3.70 (2H, m), 4.39 (2H, s), 4.97–5.09 (1H, m), 6.96 (1H, 
d, J = 8.3 Hz), 7.22 (1H, d, J = 8.0 Hz), 7.27–7.37 (2H, m), 7.42–7.53 (2H, m), 10.72 (1H, s), 10.80 
(1H, d, J = 7.2 Hz). MS (ESI/APCI) mass calculated for [M + H]+ (C19H20F3N4O4) requires m/z 425.1, 
found m/z 425.2. HPLC purity: 95.1%. mp 175 °C. 
N-(2-Methoxy-1-(4-(trifluoromethoxy)phenyl)ethyl)-7-methyl-2-oxo-2,3-dihydropyrido[2,3-b]pyrazi
ne-4(1H)-carboxamide (39b). The title compound was prepared as a pale yellow solid in 96% yield 
following the general procedure described for preparation of compound 37e, by using 63d and 100i. 
1H NMR (300 MHz, DMSO-d6) δ 2.26 (3H, s), 3.28 (3H, s), 3.56–3.68 (2H, m), 4.32–4.48 (2H, m), 
4.99–5.11 (1H, m), 7.14 (1H, d, J = 1.5 Hz), 7.27–7.37 (2H, m), 7.41–7.51 (2H, m), 7.85 (1H, d, J = 
1.3 Hz), 10.38 (1H, d, J = 7.4 Hz), 10.78 (1H, brs). MS (ESI/APCI) mass calculated for [M + H]+ 
(C19H20F3N4O4) requires m/z 425.1, found m/z 425.2. HPLC purity: 99.1%. mp 149 °C. 
N-(2-Methoxy-1-(4-(trifluoromethoxy)phenyl)ethyl)-8-methyl-2-oxo-2,3-dihydropyrido[2,3-b]pyrazi
ne-4(1H)-carboxamide (39c). To a solution of 63a (82.5 mg, 0.251 mmol) in DMF (5 mL) were added 
100i (68.3 mg, 0.251 mmol) and Et3N (0.096 mL, 0.689 mmol). The mixture was stirred at rt for 16 h 
and then poured into NaHCO3 aqueous solution. The mixture was extracted with EtOAc, washed with 
1 M HCl aqueous solution and saturated aqueous NaCl, dried over anhydrous Na2SO4 and 
concentrated in vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl 
acetate, 9:1 to 0:100), followed by a preparative HPLC purification (column: L-Column2 ODS 20 mm 
ID × 150 mm L; mobile phase A: 0.1% TFA in water; mobile phase B: 0.1% TFA in acetonitrile; flow 
rate: 20 mL/min). The desired fraction was neutralized with saturated aqueous NaHCO3, concentrated 
in vacuo to remove most of acetonitrile, and extracted with EtOAc. The organic layer was separated, 
dried over anhydrous Na2SO4, and concentrated in vacuo to afford 39c (73.1 mg, 0.172 mmol, 69%) as 
a white solid. 1H NMR (300 MHz, DMSO-d6) δ 2.30 (3H, s), 3.27 (3H, s), 3.56–3.68 (2H, m), 4.33–
4.49 (2H, m), 5.00–5.10 (1H, m), 7.03 (1H, d, J = 5.7 Hz), 7.27–7.36 (2H, m), 7.41–7.51 (2H, m), 7.93 
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(1H, d, J = 5.3 Hz), 10.28 (1H, d, J = 7.6 Hz), 10.35 (1H, s). MS (ESI/APCI) mass calculated for [M + 
H]+ (C19H20F3N4O4) requires m/z 425.1, found m/z 425.1. HPLC purity: 99.9%. mp 128 °C. 
7-Cyclopropyl-N-(2-methoxy-1-(4-(trifluoromethoxy)phenyl)ethyl)-2-oxo-2,3-dihydropyrido[2,3-b]p
yrazine-4(1H)-carboxamide (39d). A mixture of 69 (432 mg, 0.740 mmol) in TFA (2.1 mL) and H2O 
(0.236 mL) was stirred at rt for 3.5 h and then concentrated in vacuo. The residue was dissolved in 
DMF (10 mL) and 8 M NH3 solution in MeOH (2.0 mL, 16.0 mmol) was added. The mixture was 
stirred at rt for 1 h and then concentrated in vacuo. The residue was diluted with EtOAc. The solution 
was washed with water and saturated aqueous NaCl, dried over anhydrous Na2SO4 and concentrated in 
vacuo to give 39d (279 mg, 0.590 mmol, 80%) as a white solid after trituration with hexane/ethyl 
acetate (10:1). 1H NMR (300 MHz, DMSO-d6) δ 0.61–0.71 (2H, m), 0.93–1.05 (2H, m), 1.90–2.03 
(1H, m), 3.28 (3H, s), 3.55–3.71 (2H, m),4.30–4.49 (2H, m), 5.00–5.12 (1H, m), 6.96 (1H, d, J = 2.3 
Hz), 7.32 (2H, d, J = 7.9 Hz), 7.46 (2H, d, J = 8.7 Hz), 7.85 (1H, d,J = 1.9 Hz), 10.34 (1H, d, J = 7.5 
Hz), 10.69 (1H, s). MS (ESI/APCI) mass calculated for [M + H]+ (C21H22F3N4O4) requires m/z 425.2, 
found m/z 451.1. HPLC purity: 98.8%. mp 149 °C. 
7-Chloro-N-(2-methoxy-1-(4-(trifluoromethoxy)phenyl)ethyl)-2-oxo-2,3-dihydropyrido[2,3-b]pyrazi
ne-4(1H)-carboxamide (39e). To a solution of 57g (132.4 mg, 0.72 mmol) and Et3N (305 µL, 2.16 
mmol) in THF (6 mL) and DMA (6 mL) was slowly added a solution of triphosgene (214 mg, 0.72 
mmol) in THF (3.0 mL) at 0 °C. After stirring at 0 °C for 2 h, a mixture of Et3N (508 µL, 3.61 mmol) 
and 100i (980 mg, 3.61 mmol) in THF (3.0 mL) and DMA (6.0 mL) was added at the same 
temperature. The mixture was stirred at rt for 3 h and then quenched with water. The phases were 
separated and the aqueous phase was extracted with EtOAc. The combined organic phases were 
washed with water and saturated aqueous NaCl, dried over anhydrous Na2SO4 and concentrated in 
vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl acetate, 99:1 to 
3:2) to give 39e (10.4 mg, 0.023 mmol, 3.2%) as a pale yellow solid after trituration with hexane/ethyl 
acetate (10:1). 1H NMR (300 MHz, DMSO-d6) δ 3.29 (3H, s), 3.53–3.71 (2H, m), 4.32–4.52 (2H, m), 
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4.99–5.12 (1H, m), 7.27–7.38 (3H, m),7.48 (2H, d, J = 8.7 Hz), 8.06 (1H, d, J = 2.3 Hz), 10.13 (1H, d, 
J = 7.2 Hz), 10.93 (1H, brs). MS (ESI/APCI) mass calculated for [M + H]+ (C18H17ClF3N4O4) requires 
m/z 445.1, found m/z 445.1. HPLC purity: 96.5%. 
7-Methoxy-N-(2-methoxy-1-(4-(trifluoromethoxy)phenyl)ethyl)-2-oxo-2,3-dihydropyrido[2,3-b]pyra
zine-4(1H)-carboxamide (39f). A mixture of 70 (395 mg, 0.69 mmol) in TFA (10 mL) and water (1.1 
mL) was stirred at rt for 3 h and then concentrated in vacuo. The residue was dissolved in DMF (19 
mL) and 8 M NH3 solution in MeOH (3.73 mL, 29.8 mmol) was added. The mixture was stirred at rt 
for 2 h and then concentrated in vacuo. The residue was diluted with EtOAc. The solution was washed 
with water and saturated aqueous NaCl, dried over anhydrous Na2SO4 and concentrated in vacuo. The 
residue was purified by column chromatography (silica gel, hexane/ethyl acetate, 99:1 to 0:100) to 
give 39f (203 mg, 0.461 mmol, 67%) as a white solid after trituration with hexane/ethyl acetate (10:1). 
1H NMR (300 MHz, DMSO-d6) δ 3.28 (3H, s), 3.54–3.68 (2H, m), 3.83 (3H, s), 4.30–4.51 (2H, m), 
4.98–5.12 (1H, m), 6.96 (1H, d, J = 2.6 Hz), 7.27–7.37 (2H, m), 7.46 (2H, d, J = 8.7 Hz), 7.76 (1H, d, 
J = 2.6 Hz), 10.02 (1H, d, J = 7.5 Hz), 10.76 (1H, brs). MS (ESI/APCI) mass calculated for [M + H]+ 
(C19H20F3N4O5) requires m/z 441.1, found m/z 441.2. HPLC purity: 98.7%. 
7-Isopropoxy-N-(2-methoxy-1-(4-(trifluoromethoxy)phenyl)ethyl)-2-oxo-2,3-dihydropyrido[2,3-b]py
razine-4(1H)-carboxamide (39g). A mixture of 71 (90 mg, 0.15 mmol) in TFA (2.13 mL) and  water 
(0.239 mL) was stirred at rt for 3 h. The mixture was concentrated in vacuo. The residue was dissolved 
in DMF (4 mL) and 8 M NH3 solution in MeOH (0.808 mL, 6.46 mmol) was added. The mixture was 
stirred at rt for 2 h and concentrated in vacuo. The residue was diluted with EtOAc. The solution was 
washed with water and saturated aqueous NaCl, dried over anhydrous Na2SO4 and concentrated in 
vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl acetate, 99:1 to 
0:100) to give 39g (67.2 mg, 0.143 mmol, 95%) as a white amorphous solid. 1H NMR (300 MHz, 
DMSO-d6) δ 1.29 (6H, d, J = 6.0 Hz), 3.28 (3H, s), 3.52–3.69 (2H, m), 4.28–4.49 (2H, m), 4.60 (1H, 
dt, J = 12.1, 6.0 Hz), 5.04 (1H, d, J = 7.2 Hz), 6.94 (1H, d, J = 2.6 Hz), 7.27–7.37 (2H, m), 7.46 (2H, d, 
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J = 8.7 Hz), 7.73 (1H, d, J = 2.6 Hz), 10.01 (1H, d, J = 7.2 Hz), 10.72 (1H, s). MS (ESI/APCI) mass 
calculated for [M + H]+ (C21H24F3N4O5) requires m/z 469.2, found m/z 469.2. HPLC purity: 99.1%. 
7-Methoxy-N-((1S)-2-methoxy-1-(4-(trifluoromethoxy)phenyl)ethyl)-2-oxo-2,3-dihydropyrido[2,3-b]
pyrazine-4(1H)-carboxamide (40a). (Method A: step 39f → 40a in Scheme 2-6) Resolution of the 
enantiomers of 39f was carried out chromatographically using a Chiralpak IA 20 mm ID × 250 mm L 
column (CO2/methanol, 43:7) at 50 mL/min. Resolution of 39f (200 mg, 0.454 mmol) provided 90.0 
mg of 40a as the first eluting enantiomer, which was crystallized from hexane/ethyl acetate to afford 
40a (78.3 mg, 0.178 mmol, 39%, 78% theoretical) as a white solid. Analytical HPLC analysis carried 
out on a 4.6 mm ID × 150 mm L Chiralpak IA column (CO2/methanol, 41:9) at a flow rate of 4.0 
mL/min indicated that 40a was of 99% ee. 1H NMR (300 MHz, DMSO-d6) δ 3.28 (3H, s), 3.52–3.70 
(2H, m), 3.83 (3H, s), 4.26–4.52 (2H, m), 4.97–5.13 (1H, m), 6.96 (1H, d, J = 2.6 Hz), 7.32 (2H, d, J = 
8.3 Hz), 7.46 (2H, d, J = 8.7 Hz), 7.76 (1H, d, J = 2.6 Hz), 10.02 (1H, d, J = 7.5 Hz), 10.77 (1H, brs). 
MS (ESI/APCI) mass calculated for [M + H]+ (C19H20F3N4O5) requires m/z 441.1, found m/z 411.1. 
HPLC purity: 100%. mp 77.6–78.6 °C. Anal. Calcd for C19H19N4O5F3·0.25H2O: C, 51.30; H, 4.42; F, 
12.81; N, 12.59. Found: C, 51.58; H, 4.71; F, 12.52; N, 12.41. 
7-Methoxy-N-((1S)-2-methoxy-1-(4-(trifluoromethoxy)phenyl)ethyl)-2-oxo-2,3-dihydropyrido[2,3-b]
pyrazine-4(1H)-carboxamide (40a). (Method B: step 112 → 40a in Scheme 2-10) To a solution of 
112 (179 mg, 1.00 mmol) and 4-nitrophenyl carbonochloridate (242 mg, 1.20 mmol) in THF (10 mL) 
was added DIEA (262 µL, 1.50 mmol) at rt. After being stirred at rt for 24 h, the mixture was 
concentrated in vacuo. To a solution of the residue and 111b (299 mg, 1.10 mmol) in DMF (10 mL) 
was added Et3N (418 µL, 3.00 mmol) at rt. After being stirred at rt for 24 h, the mixture was quenched 
with water and extracted with EtOAc. The organic layer was washed with water and saturated aqueous 
NaCl, dried over MgSO4, and concentrated in vacuo. The residue was purified by column 
chromatography (silica gel, hexane/ethyl acetate, 4:1 to 1:4) to give 40a (227 mg, 0.515 mmol, 52%) 
as a white solid after recrystallization from heptane/acetone. Analytical HPLC analysis carried out on 
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a 4.6 mm ID × 150 mm L Chiralpak IA column (CO2/methanol, 41:9) at a flow rate of 4.0 mL/min 
indicated that 40a was of >99.9% ee as the first eluting enantiomer. 1H NMR (300 MHz, CDCl3) δ 
3.40 (3H, s), 3.68 (2H, d, J = 4.9 Hz), 3.87 (3H, s), 4.65 (2H, s), 5.12–5.22 (1H, m), 6.80 (1H, d, J = 
2.6 Hz), 7.13–7.21 (2H, m), 7.37–7.44 (2H, m), 7.71 (1H, d, J = 2.6 Hz), 8.90 (1H, s), 10.17 (1H, d, J 
= 7.2 Hz). MS (ESI/APCI) m/z 441.1 [M + H]+. Anal. Calcd for C19H19N4O5F3: C, 51.82; H, 4.35; N, 
12.72. Found: C, 51.65; H, 4.41; N, 12.62. 
7-Methoxy-N-((1R)-2-methoxy-1-(4-(trifluoromethoxy)phenyl)ethyl)-2-oxo-2,3-dihydropyrido[2,3-b]
pyrazine-4(1H)-carboxamide (40b). Resolution of the enantiomers of 39f was carried out 
chromatographically using a Chiralpak IA 20 mm ID × 250 mm L column (CO2/methanol, 43:7) at 50 
mL/min. Resolution of 39f (200 mg, 0.454 mmol) provided 94.0 mg of 40b as the second eluting 
enantiomer, which was crystallized from hexane/ethyl acetate to afford 40b (60.0 mg, 0.136 mmol, 
30%, 60% theoretical) as a white solid. Analytical HPLC analysis carried out on a 4.6 mm ID × 150 
mm L Chiralpak IA column (CO2/methanol, 41:9) at a flow rate of 4.0 mL/min indicated that 40b was 
of >99.9% ee. 1H NMR (300 MHz, DMSO-d6) δ 3.28 (3H, s), 3.53–3.67 (2H, m), 3.83 (3H, s), 4.27–
4.51 (2H, m), 4.96–5.16 (1H, m), 6.96 (1H, d, J = 3.0 Hz), 7.32 (2H, d, J = 8.3 Hz), 7.41–7.54 (2H, m), 
7.76 (1H, d, J = 2.6 Hz), 10.02 (1H, d, J = 7.2 Hz), 10.76 (1H, brs). MS (ESI/APCI) mass calculated 
for [M + H]+ (C19H20F3N4O5) requires m/z 441.1, found m/z 411.1. HPLC purity: 100%. 
7-Methoxy-N-((1S or 
1R)-2-methoxy-1-(4-(trifluoromethyl)phenyl)ethyl)-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-c
arboxamide (41a). Resolution of the enantiomers of 75 was carried out chromatographically using a 
Chiralpak AD 50 mm ID × 500 mm L column (hexane/ethanol, 3:2) at 80 mL/min. Resolution of 75 
(444 mg, 1.05 mmol) provided 210 mg of 41a as the first eluting enantiomer, which was crystallized 
from hexane/ethyl acetate to afford 41a (197 mg, 0.464 mmol, 44%, 88% theoretical) as a white solid. 
Analytical HPLC analysis carried out on a 4.6 mm ID × 250 mm L Chiralpak AD column 
(hexane/ethanol, 7:3) at a flow rate of 1.0 mL/min indicated that 41a was of >99.9% ee. 1H NMR (300 
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MHz, DMSO-d6) δ 3.28 (3H, s), 3.61–3.68 (2H, m), 3.83 (3H, s), 4.29–4.50 (2H, m), 5.03–5.16 (1H, 
m), 6.97 (1H, d, J = 2.6 Hz), 7.56 (2H, d, J = 8.3 Hz), 7.69 (2H, d, J = 8.3 Hz), 7.77 (1H, d, J = 2.6 
Hz), 10.07 (1H, d, J = 7.2 Hz),10.77 (1H, brs). MS (ESI/APCI) mass calculated for [M + H]+ 
(C19H20F3N4O4) requires m/z 425.1, found m/z 425.1. HPLC purity: 100%. mp 144 °C. 
7-Methoxy-N-((1R or 
1S)-2-methoxy-1-(4-(trifluoromethyl)phenyl)ethyl)-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-c
arboxamide (41b). Resolution of the enantiomers of 75 was carried out chromatographically using a 
Chiralpak AD 50 mm ID × 500 mm L column (hexane/ethanol, 3:2) at 80 mL/min. Resolution of 75 
(444 mg, 1.05 mmol) provided 210 mg of 41b as the second eluting enantiomer, which was 
crystallized from hexane/ethyl acetate to afford 41b (189 mg, 0.444 mmol, 43%, 85% theoretical) as a 
white solid. Analytical HPLC analysis carried out on a 4.6 mm ID × 250 mm L Chiralpak AD column 
(hexane/ethanol, 7:3) at a flow rate of 1.0 mL/min indicated that 41b was of >99.9% ee. 1H NMR (300 
MHz, DMSO-d6) δ 3.28 (3H, s), 3.61–3.67 (2H, m), 3.83 (3H, s), 4.30–4.50 (2H, m), 5.04–5.16 (1H, 
m), 6.97 (1H, d, J = 2.6 Hz), 7.56 (2H, d, J = 8.3 Hz), 7.69 (2H, d, J = 8.3 Hz), 7.77 (1H, d, J = 2.6 
Hz), 10.07 (1H, d, J = 7.5 Hz),10.77 (1H, s). MS (ESI/APCI) mass calculated for [M + H]+ 
(C19H20F3N4O4) requires m/z 425.1, found m/z 425.1. HPLC purity: 100%. mp 142 °C. 
N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyr
ido[2,3-b]pyrazine-4(1H)-carboxamide (42a). (Method A: step 76 → 42a in Scheme 2-6) Resolution 
of the enantiomers of 76 was carried out chromatographically using a Chiralpak AD 50 mm ID × 500 
mm L column (hexane/ethanol, 43:7) at 80 mL/min. Resolution of 76 (1.34 g, 2.93 mmol) provided 
652 mg of 42a as the first eluting enantiomer, which was crystallized from hexane/ethyl acetate to 
afford 42a (578 mg, 1.26 mmol, 43%, 86% theoretical) as a white solid. Analytical HPLC analysis 
carried out on a 4.6 mm ID × 250 mm L Chiralpak AD column (hexane/ethanol, 13:7) at a flow rate of 
1.0 mL/min indicated that 42a was of 99.8% ee. 1H NMR (300 MHz, DMSO-d6) δ 3.29 (3H, s), 3.53–
3.72 (2H, m), 3.83 (3H, s), 4.24–4.54 (2H, m), 4.95–5.16 (1H, m), 6.96 (1H, d, J = 2.6 Hz), 7.29 (1H, 
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d, J = 8.3 Hz), 7.39–7.61 (2H, m), 7.75 (1H, d, J = 2.6 Hz), 10.02 (1H, d, J = 7.5 Hz), 10.78 (1H, brs). 
13C NMR (151 MHz, DMSO-d6) δ 45.41, 52.93, 55.99, 58.42, 74.55, 110.38, 115.66 (d, J = 18.8 Hz, 
1C), 119.97 (q, J = 257.6 Hz, 1C), 123.54 (d, J = 3.3 Hz, 1C), 123.70, 124.59, 125.82, 133.80 (qd, J = 
1.7, 12.7 Hz, 1C), 135.07, 143.41 (d, J = 6.1 Hz, 1C), 152.10, 153.26 (d, J = 249.9 Hz, 1C), 153.75, 
165.32. MS (ESI/APCI) mass calculated for [M + H]+ (C19H20F3N4O4) requires m/z 459.1, found m/z 
459.2. HPLC purity: 100%. [α]ଶ଴ୈ  = −114.5 (c = 1.00 in MeOH). mp 151.2–152.2 °C. Anal. Calcd for 
C19H18F4N4O5: C, 49.79; H, 3.96; F, 16.58; N, 12.22. Found: C, 49.84; H, 4.14; F, 16.38; N, 12.12. 
N-((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyr
ido[2,3-b]pyrazine-4(1H)-carboxamide (42a). (Method B: step 112 → 42a in Scheme 2-11) To a 
suspension of 112 (2.49 g, 13.90 mmol) and DIEA (7.13 mL, 41.7 mmol) in THF (120 mL) was added 
portionwise 4-nitrophenyl chloroformate (3.64 g, 18.1 mmol) at 0 °C. The mixture was stirred at rt 
under N2 for 3 h and then concentrated in vacuo. To the residue were added i-Pr2O (200 mL) and 
saturated aqueous NaCl (150 mL) and the mixture was srirred at rt for 20 min. The resulting 
precipitate was filtered, washed with water and then i-Pr2O, and dried to give 4-nitrophenyl 
7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxylate (4.20 g, 12.2 mmol, 88%) as a 
gray solid. A mixture of 4-nitrophenyl 
7-methoxy-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxylate obtained above (4.20 g, 12.2 
mmol), DIEA (11.9 mL, 69.5 mmol), 115 (4.43 g, 15.3 mmol) and DMF (130 mL) was stirred at rt for 
16 h and concentrated in vacuo. To the residue were added EtOAc (200 mL), THF (100 mL), and 
NaHCO3 aqueous solution (200 mL). The phases were separated and the aqueous phase was extracted 
with EtOAc/THF (2:1). The phases were washed with saturated aqueous NaCl, dried over anhydrous 
Na2SO4, and concentrated in vacuo. The residue was purified by column chromatography (basic silica 
gel (200 g), hexane/ethyl acetate, 3:17) to give 42a (5.01 g, 10.9 mmol, 79%) as a pale yellow solid. 
To a solution of 42a (5.00 g, 10.9 mmol) in EtOH (200 mL) was added activated carbon (10 g). After 
the mixture was stirred at rt for 30 min, the insoluble material was removed by filtration and washed 
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with acetone several times. The filtrate was concentrated in vacuo. To a solution of the obtained 
compound (4.17g) in acetone (35 mL) was added dropwise heptane (70 mL) at 52 °C (precipitate 
occurred) and the mixture was stirred at 52 °C for 1 h. Additional heptane (35 mL) was added 
dropwise at 52 °C and then gradually cooled to rt. The mixture was stirred overnight, and then stirred 
at 5 °C for 1 h. The precipitate was collected by filtration, rinsed with acetone/heptane (7:21) to give 
42a (3.15 g, 6.87 mmol, 63%) as a white solid. Analytical HPLC analysis carried out on a 4.6 mm ID 
× 150 mm L Chiralpak ADH column (hexane/ethanol, 13:7) at a flow rate of 1.0 mL/min indicated that 
42a was of >99.9% ee as the first eluting enantiomer. 1H NMR (300 MHz, DMSO-d6) d 3.29 (3H, s), 
3.56–3.70 (2H, m), 3.83 (3H, s), 4.30–4.52 (2H, m), 4.95–5.16 (1H, m), 6.96 (1H, d, J = 2.6 Hz), 7.29 
(1H, d, J = 8.3 Hz), 7.43–7.57 (2H, m), 7.75 (1H, d, J = 3.0 Hz), 10.02 (1H, d, J = 7.2 Hz), 10.78 (1H, 
brs). MS (ESI/APCI) m/z 459.2 [M + H]+. HPLC purity: 99.9%. 
N-((1R)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyr
ido[2,3-b]pyrazine-4(1H)-carboxamide (42b). Resolution of the enantiomers of 76 was carried out 
chromatographically using a Chiralpak AD 50 mm ID × 500 mm L column (hexane/ethanol, 43:7) at 
80 mL/min. Resolution of 76 (1.34 g, 2.93 mmol) provided 680 mg of 42b as the second eluting 
enantiomer, which was crystallized from hexane/ethyl acetate to afford 42b (563 mg, 1.22 mmol, 41%, 
83% theoretical) as a white solid. Analytical HPLC analysis carried out on a 4.6 mm ID × 250 mm L 
Chiralpak AD column (hexane/ethanol, 13:7) at a flow rate of 1.0 mL/min indicated that 42b was of 
99.6% ee. 1H NMR (300 MHz, DMSO-d6) δ 3.29 (3H, s), 3.53–3.70 (2H, m), 3.83 (3H, s), 4.29–4.51 
(2H, m), 4.98–5.12 (1H, m), 6.97 (1H, d, J = 3.0 Hz), 7.29 (1H, d, J = 8.3 Hz), 7.39–7.59 (2H, m), 
7.75 (1H, d, J = 2.6 Hz), 10.02 (1H, d, J = 7.2 Hz), 10.78 (1H, brs). MS (ESI/APCI) mass calculated 
for [M + H]+ (C19H20F3N4O4) requires m/z 459.1, found m/z 459.1. HPLC purity: 98.2%. mp 151.2–
152.2 °C. Anal. Calcd for C19H18N4O5F4·0.3H2O: C, 49.21; H, 4.04; F, 16.39; N, 12.08. Found: C, 
49.17; H, 4.05; F, 16.20; N, 12.04. 
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tert-Butyl Ethyl (3-Nitropyridin-2-yl)malonate (44). To a suspension of potassium tert-butoxide (26.6 
g, 237 mmol) in THF (500 mL) at 60 °C was added dropwise tert-butyl ethyl malonate (45 mL, 237 
mmol), followed by 43 (25.0 g, 158 mmol) in THF (50 mL). The mixture was refluxed for 3 h. The 
mixture was concentrated in vacuo and the residue was diluted with 1 M HCl aqueous solution (100 
mL). The aqueous solution was extracted with EtOAc and the combined organic phase was washed 
with saturated aqueous NaCl, dried over anhydrous Na2SO4 and concentrated in vacuo to give crude 
44 (66.7 g). This was used in the next reaction without further purification. 1H NMR (400 MHz, 
CDCl3) δ 1.30 (3H, t, J = 7.2 Hz), 1.49 (9H, s), 4.29–4.33 (2H, m), 5.43 (1H, s), 7.51 (1H, dd, J = 8.4, 
4.2 Hz), 8.46 (1H, d, J = 8.4 Hz), 8.82 (1H, d, J = 5.2 Hz). 
Ethyl (3-Nitropyridin-2-yl)acetate (45). To a solution of crude 44 (66.7 g) in CH2Cl2 (300 mL) was 
added TFA (100 mL). The mixture was stirred at rt overnight. The mixture was concentrated in vacuo 
and the residue was diluted with NaHCO3 aqueous solution (100 mL). The mixture was extracted with 
EtOAc, washed with saturated aqueous NaCl, dried over anhydrous Na2SO4 and concentrated in vacuo 
to give crude 45 (29.0 g). This was used in the next reaction without further purification. 1H NMR 
(400 MHz, CDCl3) δ 1.26 (3H, t, J = 7.2 Hz), 4.20 (2H, q, J = 7.2 Hz), 4.33 (2H, s), 7.48 (1H, dd, J = 
8.0, 1.2 Hz), 8.43 (1H, dd, J = 8.4, 1.2 Hz), 8.80 (1H, dd, J = 8.4, 1.2 Hz). 
Ethyl (3-Aminopyridin-2-yl)acetate (46). A mixture of crude 45 (29.0 g) and 10% Pd/C (containing 
50% water, 2.90 g) in EtOH (400 mL) was stirred under 50 psi of H2 at rt for 3 h. The mixture was 
filtered through celite and the filtrate was concentrated in vacuo to give crude 46 (25.5 g). This was 
used in the next reaction without further purification. 1H NMR (400 MHz, CDCl3) δ 1.26 (3H, t, J = 
7.2 Hz), 3.85 (2H, s), 4.17 (2H, q, J = 7.2 Hz), 4.32 (2H, br s), 6.99–7.06 (2H, m), 7.99–8.01 (1H, m). 
Ethyl (3-((Diethoxyacetyl)amino)pyridin-2-yl)acetate (47). To a mixture of crude 46 (25.5 g, 142 
mmol) and 2,2-diethoxylacetic acid (23.0 g, 156 mmol) in DMF (300 mL) was added DIEA (70.3 mL, 
425 mmol), followed by HATU (80.7 g, 212 mmol). The mixture was stirred at rt overnight. The 
mixture was diluted with water and extracted with EtOAc (300 mL × 2). The combined organic phase 
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was washed with NaHCO3 aqueous solution and then saturated aqueous NaCl, dried over anhydrous 
Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography (silica gel, 
petroleum/ethyl acetate, 3:1) to give 47 (26.0 g, 53% in 4 steps from 43). 1H NMR (400 MHz, CDCl3) 
δ 1.27–1.33 (9H, m), 3.69–3.83 (4H, m), 3.90 (2H, s), 4.20 (2H, q, J = 7.2 Hz), 4.97 (1H, s), 7.25–7.28 
(1H, m), 8.29–8.35 (2H, m), 9.53 (1H, br s). 2,2-Diethoxylacetic acid was prepared in the following 
method. To a solution of ethyl 2,2-diethoxyacetate (17.8 g, 101 mmol)in EtOH (50 mL) was added 2 
M NaOH aqueous solution (101 mL, 202 mmol). The mixture was stirred at rt for 16 h and then EtOH 
was removed under reduced pressure. The aqueous phase was extracted with Et2O. The aqueous phase 
was acidified with 2 M HCl aqueous solution to pH 3~4, saturated with solid NaCl and extracted with 
EtOAc. The combined organic phases were dried over anhydrous Na2SO4 and concentrated in vacuo to 
afford 2,2-diethoxyacetic acid (3.37 g, 22.7 mmol, 23%) as a colorless oil. 1H NMR (300 MHz, 
DMSO-d6) δ 1.13 (6H, t, J = 7.2 Hz), 3.46–3.67 (4H, m), 4.80 (1H, s), 12.92 (1H, brs). 
Ethyl 2-Oxo-1,2-dihydro-1,5-naphthyridine-4-carboxylate (48). To a solution of 47 (3.00 g, 9.67 
mmol) in TFA (50 mL) was added H2O (2 mL), followed by 2 drops of I2 fresh solution (30 mg of I2 
was suspended in TFA (10 mL)). The mixture was heated to 50 °C overnight and then concentrated in 
vacuo. The residue was dissolved in toluene (50 mL) and piperidine (3 mL). The resulting mixture was 
refluxed for 6 h, and then concentrated in vacuo. The residue was purified by column chromatography 
(silica gel, petroleum ether/ethyl acetate, 1:1) to give 48 (550 mg, 26%). 1H NMR (400 MHz, CDCl3) 
δ 1.44 (3H, t, J = 7.2 Hz), 4.53 (2H, q, J = 7.2 Hz), 7.07 (1H, s), 7.48–7.51 (1H, m), 7.74–7.77 (1H, 
m), 8.66–8.68 (1H, m), 12.38 (1H, br s). 
2-Oxo-1,2-dihydro-1,5-naphthyridine-4-carboxylic Acid (49). To a solution of 48 (70 mg, 0.32 mmol) 
in EtOH (5 mL) was added 2 M NaOH aqueous solution (4 mL). The mixture was stirred at rt for 2 h. 
EtOH was removed under reduced pressure and the aqueous phase was acidified to pH ~5 with 1 M 
HCl aqueous solution. The precipitate was collected by filtration and dried to give 49 (53 mg, 87%) as 
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a beige solid. 1H NMR (400 MHz, DMSO-d6) δ 7.02 (1H, s), 7.64–7.67 (1H, m), 7.80 (1H, d, J = 8.8 
Hz), 8.55 (1H, d, J = 4.0 Hz), 12.26 (1H, d, J = 10.4 Hz), 14.86 (1H, br s). 
1H-Pyrazole-1,5-diamine (51a). To a vigorously stirred solution of 2H-pyrazol-3-ylamine (50) (4.00 g, 
48.2 mmol) in DMF (50 mL) cooled in an ice-salt bath was added KOH (20.0 g, 357 mmol). The 
mixture was stirred at 0 °C for 20 min. Then, HOSA (5.45 g, 48.2 mmol) was added in portions. The 
mixture was stirred vigorously at 10–15 °C for 2 h. The mixture was filtered by a cake of celite and the 
celite was washed with CH2Cl2 (50 mL × 2). The combined filtrate was concentrated in vacuo. The 
residue was purified by column chromatography (silica gel, CH2Cl2/methanol, 100:0 to 60:1) to afford 
51a (less polar, 810 mg, 17% yield) as a yellow solid and 51b (more polar, 520 mg, 11% yield) as a 
yellow solid. The structures were confirmed by nuclear overhauser effect (NOE) experiments (See 
below). 1H NMR for 51a (400 MHz, DMSO-d6) δ 4.91 (2H, brs), 5.14 (1H, d, J = 2.0 Hz), 5.66 (2H, 
brs), 6.86 (1H, d, J = 1.6 Hz). 1H NMR for 51b (400 MHz, DMSO-d6) δ 4.41 (2H, brs), 5.22 (1H, d, J 
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3-Methylpyrazolo[1,5-b][1,2,4]triazine (52). To a solution of 2-oxo-propionaldehyde (40% aqueous 
solution, 689 mg, 3.83 mmol) in H2O (4 mL) and concd HCl (0.2 mL) was added 51a (300 mg, 3.06 
mmol) in small portions at 60 °C. The mixture was heated to reflux for 1 h. After cooling to 15 °C, the 
mixture was basified to pH ~8 with saturated aqueous NaHCO3 and extracted with CH2Cl2 (10 mL × 
3). The combined organic layer was dried over anhydrous Na2SO4 and concentrated in vacuo. The 
residue was purified by preparative TLC (CH2Cl2/methanol, 10:1) to give 52 (150 mg, 37% yield) as a 
yellow solid. The structure was confirmed by heteronuclear multiple bond correlation (HMBC) 
experiments (See below). 1H NMR (400 MHz, CDCl3) δ 2.65 (3H, s), 6.79 (1H, d, J = 2.4 Hz), 8.12 
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3-Methylpyrazolo[1,5-b][1,2,4]triazine-8-carbaldehyde (53). POCl3 (800 mg, 5.26 mmol) was added 
dropwise to DMF (5 mL) at 0 °C under N2. After 30 min of stirring at 0 °C, a solution of 52 (150 mg, 
1.12 mmol) in DMF (3 mL) was added dropwise at the same temperature. The mixture was warmed to 
40 °C and stirred for 16 h. After cooling to 10 °C, the mixture was diluted with water (20 mL) and 
basified to pH ~9 with 1 M NaOH aqueous solution. The mixture was extracted with EtOAc (15mL × 
3). The combined organic layer was washed with saturated aqueous NaCl (15 mL), dried over 
anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by column chromatography 
(silica gel, petroleum ether/ethyl acetate, 5:1) to give 53 (50 mg, 28% yield) as a yellow solid. 1H 
NMR (400 MHz, CDCl3) δ 2.75 (3H, s), 8.59–8.63 (2H, m), 10.29 (1H, s). 
3-Methylpyrazolo[1,5-b][1,2,4]triazine-8-carboxylic acid (54). A mixture of 53 (50 mg, 0.31 mmol), 
NaClO2 (140 mg, 1.55 mmol), NaH2PO4 (94 mg, 0.78 mmol), and 2-methyl-2-butene (55 mg, 0.78 
mmol) in tert-BuOH (5 mL) and H2O (2 mL) was stirred at 30 °C for 16 h. The solvent was removed 
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under reduced pressure and the residue was diluted with water (10 mL). The mixture was extracted 
with CH2Cl2 (10 mL × 5). The combined organic layer was washed with saturated aqueous NaCl (10 
mL), dried over anhydrous Na2SO4, and concentrated in vacuo to give 54 (30 mg, containing 50% of 
52) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 2.57 (3H, s), 8.57 (1H, s), 8.78 (1H, s), 12.73 
(1H, brs). 
2-(2-Ethoxy-2-oxoethyl)nicotinic Acid (56). Na (2.85 g, 124 mmol) was dissolved in absolute EtOH 
(100 mL) and the solution was cooled to rt. To the resulting solution were added ethyl acetoacetate 
(9.66 g, 74.3 mmol), 2-bromonicotinic acid (55) (10.0 g, 49.5 mmol), and Cu(OAc)2 (360 mg, 1.98 
mmol). The mixture was stirred at reflux for 16 h. After cooling to rt, the mixture was acidified with 
AcOH (80 mL) and concentrated in vacuo. The residue was diluted with water (50 mL) and the 
mixture was extracted with CH2Cl2 (50 mL × 5). The extract was concentrated in vacuo. The residue 
was purified by column chromatography (silica gel, CH2Cl2/methanol, 100:0 to 10:1) to afford 56 
(5.60 g, 26.8 mmol, 54%) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 1.16 (3H, t, J = 7.2 Hz), 
4.06 (2H, q, J = 7.2 Hz), 4.17 (2H, s), 7.46 (1H, dd, J = 8.0, 4.8 Hz), 8.27 (1H, dd, J = 8.0, 2.0 Hz), 
8.66 (1H, dd, J = 4.8, 2.0 Hz), 13.35 (1H, brs). 
(8E or 8Z)-8-((Dimethylamino)methylene)-5H-pyrano[4,3-b]pyridine-5,7(8H)-dione (57). To a 
stirred solution of 56 (700 mg, 3.35 mmol) in DMF (5 mL) was added POCl3 (0.70 mL, 7.5 mmol) 
dropwise at 0 °C. The mixture was stirred at 5 °C for 2 h, and then poured into ice/water (20 mL). The 
mixture was extracted with CH2Cl2 (20 mL × 3). The extract was concentrated in vacuo to afford crude 
57 (400 mg) as a yellow solid. This was used in the next reaction without further purification. 1H 
NMR (400 MHz, CDCl3) δ 3.37 (3H, s), 3.55 (3H, s), 7.12 (1H, dd, J = 8.0, 4.8 Hz), 8.39 (1H, d, J = 
7.2 Hz), 8.57 (1H, dd, J = 4.8, 1.6 Hz), 8.79 (1H, s). 
6-(2,4-Dimethoxybenzyl)-5-oxo-5,6-dihydro-1,6-naphthyridine-8-carboxylic Acid (58). To a 
suspension of crude 57 (400 mg) in DMF (8 mL) were added Et3N (740 mg, 7.32 mmol) and 
2,4-dimethoxybenzylamine (919 mg, 5.50 mmol), and the mixture was stirred at 5 °C for 16 h. The 
164 
 
mixture was poured into ice/water (30 mL) and then acidified with 1 M HCl aqueous solution to pH ~ 
1. The precipitate was collected by filtration, washed with water (5 mL), and dried to afford 58 (300 
mg, 0.881 mmol, 26% in 2 steps from 56) as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 3.75 
(3H, s), 3.78 (3H, s), 5.16 (2H, s), 6.52 (1H, dd, J = 8.4, 2.4 Hz), 6.59 (1H, d, J = 2.4 Hz), 7.24 (1H, d, 
J = 8.4 Hz), 7.74 (1H, dd, J = 8.0, 4.8 Hz), 8.67 (1H, s), 8.73 (1H, dd, J = 8.0, 2.0 Hz), 9.06 (1H, dd, 
J = 4.8, 2.0 Hz). 
6-(2,4-Dimethoxybenzyl)-5-oxo-N-(1-(4-(trifluoromethoxy)phenyl)propyl)-5,6-dihydro-1,6-naphthyr
idine-8-carboxamide (59). A mixture of 58 (300 mg, 0.882 mmol), 22b (226 mg, 0.882 mmol), EDCI 
(253 mg, 1.32 mmol), HOBt (178 mg, 1.32 mmol) and Et3N (268 mg, 2.65 mmol) in DMF (5 mL) was 
stirred at 5 °C for 16 h and then at 40 °C for 16 h. After cooling to rt, the mixture was poured into 
water (10 mL) and extracted with CH2Cl2 (15 mL × 2). The extract was concentrated in vacuo. The 
residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate, 5:1 to 2:1) 
to afford impure 59 (500 mg, 93% LC–MS purity). 100 mg of impure 59 was further purified by 
preparative HPLC (column: YMC-pack ODS-A 4.6 mm ID × 150 mm L; mobile phase A: 0.05% HCl 
in water; mobile phase B: 0.05% HCl in acetonitrile; flow rate: 1.5 mL/min). After most of the solvent 
was removed under reduced pressure, the residue was lyophilized to afford 59 (27 mg, 0.0467 mmol, 
26%) as a yellow solid. The remaining impure 59 (370 mg, 93% LC–MS purity) was used in the next 
reaction without further purification. 1H NMR (400 MHz, DMSO-d6) δ 0.92 (3H, t, J = 7.2 Hz), 1.82–
1.91 (2H, m), 3.74 (3H, s), 3.76 (3H, s), 5.05 (1H, q, J = 7.2 Hz), 5.06–5.17 (2H, m), 6.50 (1H, dd, J 
= 8.4, 2.4 Hz), 6.58 (1H, d, J = 2.4 Hz), 7.18 (1H, d, J = 8.4 Hz), 7.32 (2H, d, J = 8.0 Hz), 7.49 (2H, 
d, J = 8.8 Hz), 7.67 (1H, dd, J = 8.0, 4.8 Hz), 8.52 (1H, s), 8.69 (1H, dd, J = 8.0, 2.0 Hz), 9.09 (1H, 
dd, J = 4.8, 2.0 Hz), 10.99 (1H, d, J = 7.6 Hz). MS (ESI/APCI) m/z 542.1 [M + H]+. 
Methyl N-(3-Nitropyridin-2-yl)glycinate (61a). The mixture of 60a (36.6 g, 231 mmol), methyl 
glycinate hydrochloride (29 g, 231 mmol), and Et3N (80 mL, 577 mmol) in DMF (231 mL) was stirred 
at 90 °C for 3 h. After cooling to rt, the mixture was poured into water. The resulting solid was 
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collected by filtration, washed with water, and dried to give 61a (49.8 g, 236 mmol, quantitative yield) 
as a yellow solid. This was used in the next reaction without further purification. 1H NMR (300 MHz, 
CDCl3) δ 3.80 (3H, s), 4.40 (2H, d, J = 5.7 Hz), 6.74 (1H, dd, J = 8.3, 4.5 Hz), 8.36–8.55 (3H, m). MS 
(ESI/APCI) mass calculated for [M + H]+ (C8H10N3O4) requires m/z 212.1, found m/z 212.1. 
Methyl N-(4-Methyl-3-nitropyridin-2-yl)glycinate (61b). To a mixture of 60b (1.51 g, 8.77 mmol) and 
methyl glycinate hydrochloride (1.16 g, 9.21 mmol) in DMF (12 mL) was added Et3N (3.06 mL, 21.9 
mmol). The mixture was stirred at 80 °C for 16 h. The solvent was evaporated and the residue was 
diluted with EtOAc. The organic layer was washed with water and saturated aqueous NaCl, dried over 
anhydrous Na2SO4. The solvent was evaporated. The residue was purified by column chromatography 
(silica gel, hexane/ethyl acetate, 19:1 to 4:1) to give 61b (0.614 g, 2.73 mmol, 31%) as a yellow solid. 
1H NMR (300 MHz, DMSO-d6) δ 2.39 (3H, s), 3.63 (3H, s), 4.14 (2H, d, J = 5.7 Hz), 6.69 (1H, dd, J = 
4.9, 0.8 Hz), 7.83 (1H, t, J = 5.9 Hz), 8.13 (1H, d, J = 4.9 Hz). MS (ESI/APCI) mass calculated for [M 
+ H]+ (C9H12N3O4) requires m/z 226.1, found m/z 226.3. 
Methyl N-(6-Methyl-3-nitropyridin-2-yl)glycinate (61c). The title compound was prepared in 94% 
yield as a yellow solid from 60c and methyl glycinate hydrochloride using the procedure analogous to 
that described for the synthesis of 61b. 1H NMR (300 MHz, DMSO-d6) δ 2.38 (3H, s), 3.66 (3H, s), 
4.29 (2H, d, J = 6.1 Hz), 6.70 (1H, d, J = 8.3 Hz), 8.34 (1H, d, J = 8.3 Hz), 8.76 (1H, t, J = 5.5 Hz). 
MS (ESI/APCI) mass calculated for [M + H]+ (C9H12N3O4) requires m/z 226.1, found m/z 226.1. 
Methyl N-(5-Methyl-3-nitropyridin-2-yl)glycinate (61d). The title compound was prepared as a 
yellow solid in 70% yield from 60d and methyl glycinate hydrochloride using the procedure analogous 
to that described for the synthesis of 61b. 1H NMR (300 MHz, DMSO-d6) δ 2.24 (3H, s), 3.64 (3H, s), 
4.28 (2H, d, J = 5.7 Hz), 8.27–8.37 (2H, m), 8.60 (1H, t, J = 5.7 Hz). 
Methyl N-(5-Iodo-3-nitropyridin-2-yl)glycinate (61e). To a solution of 60e (11.1 g, 39.0 mmol) in 
EtOH (350 mL) were added methyl glycinate hydrochloride (9.80 g, 78.1 mmol) and Et3N (13.6 mL, 
97.6 mmol) at rt. After being refluxed for 16 h, the reaction mixture was concentrated, and the residue 
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was quenched with water and extracted with EtOAc. The organic layer was separated, washed with 
water and saturated aqueous NaCl, dried over anhydrous MgSO4 and concentrated in vacuo. The 
residue was crystallized from hexane/ethyl acetate to give 61e (9.79 g, 29.0 mmol, 74%) as a yellow 
solid. 1H NMR (300 MHz, CDCl3) δ 3.79 (3H, s), 4.36 (2H, d, J = 5.5 Hz), 8.43 (1H, brs), 8.53 (1H, d, 
J = 2.1 Hz), 8.70 (1H, d, J = 2.1 Hz). MS (ESI/APCI) mass calculated for [M + H]+ (C8H9IN3O4) 
requires m/z 338.0, found m/z 337.9. 
Methyl N-(5-Bromo-3-nitropyridin-2-yl)glycinate (61f). The title compound was prepared as a dark 
yellow solid in 82% yield from 60f and methyl glycinate hydrochloride using the procedure analogous 
to that described for the synthesis of 61e. 1H NMR (300 MHz, CDCl3) δ 3.80 (3H, s), 4.37 (2H, d, J = 
5.7 Hz), 8.37–8.51 (2H, m), 8.57 (1H, d, J = 2.3 Hz). MS (ESI/APCI) mass calculated for [M + H]+ 
(C8H9BrN3O4) requires m/z 290.0, found m/z 290.0. 
Methyl 2-((5-Chloro-3-nitropyridin-2-yl)amino)acetate (61g). To a stirred solution of 61f (400 mg, 
1.38 mmol) in NMP (13.8 mL) was added copper(I) chloride (410 mg, 4.14 mmol). The mixture was 
stirred at 150 °C for 2.5 h under microwave irradiation. The mixture was partitioned between EtOAc 
and water, and the gray solid was filtered off. The phases of the filtrate were separated and the aqueous 
phase was extracted with EtOAc. The combined organic phases were washed with water and then 
saturated aqueous NaCl, dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was 
purified by column chromatography (silica gel, hexane/ethyl acetate, 99:1 to 4:1) to give 61g (181 mg, 
0.737 mmol, 53%) as a yellow solid after trituration with i-Pr2O. The filtrate was concentrated to give 
the residue. The residue was triturated with hexane/i-Pr2O (5:1) to give 61g (36.1 mg, 0.147 mmol, 
11%) as a yellow solid. 1H NMR (300 MHz, DMSO-d6) δ 3.65 (3H, s), 4.29 (2H, d, J = 5.7 Hz), 8.54 
(2H, s), 8.81 (1H, t, J = 5.5 Hz). MS (ESI/APCI) mass calculated for [M + H]+ (C8H9ClN3O4) requires 
m/z 246.0, found m/z 246.0. 
3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one (62a). A mixture of 61a (24.1 g, 114 mmol) and 10% 
Pd/C (containing 50% water, 3.0 g) in EtOH (381 mL) was stirred at rt overnight under H2. The 
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catalyst was filtered off and evaporated. A suspension of the residue in EtOH (500 mL) was refluxed 
for 16 h. After cooling to rt, the solid was collected by filtration, washed with EtOH, and dried to give 
62a (16.8 g, 113 mmol, 99%) as a gray solid. 1H NMR (300 MHz, DMSO-d6) δ 3.89 (2H, d, J = 1.5 
Hz), 6.54 (1H, dd, J = 7.5, 4.9 Hz), 6.67 (1H, s), 6.91 (1H, dd, J = 7.5, 0.8 Hz), 7.59 (1H, dd, J = 4.9, 
1.5 Hz), 10.34 (1H, brs). 
8-Methyl-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-one (62b). A mixture of 61b (610 mg, 2.71 mmol) 
and 10% Pd/C (containing 50% water, 500 mg) in EtOH (60 mL) was hydrogenated under balloon 
pressure at rt for 16 h. The catalyst was removed by filtration and the filtrate was stirred at 80 °C for 8 
h. The solvent was removed under reduced pressure. The resulting solid was triturated with 
hexane/ethyl acetate (1:2) to afford 62b (258 mg, 1.58 mmol, 58%) as a dark purple solid. 1H NMR 
(300 MHz, DMSO-d6) δ 2.14 (3H, s), 3.83 (2H, d, J = 1.9 Hz), 6.45 (1H, d, J = 5.3 Hz), 6.58 (1H, s), 
7.51 (1H, d, J = 4.9 Hz), 9.91 (1H, s). MS (ESI/APCI) mass calculated for [M + H]+ (C8H10N3O) 
requires m/z 164.1, found m/z 164.2. 
6-Methyl-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-one (62c). A mixture of 61c (3.08 g, 13.7 mmol) 
and 10% Pd/C (containing 50% water, 1.5 g) in EtOH (200 mL) was hydrogenated under balloon 
pressure at rt for 1.5 h. The catalyst was filtered off and the filtrate was stirred at 80 °C for 8 h. EtOH 
was removed to ~50 mL, to which ethyl acetate/hexane (30 mL/15 mL) were added. The resulting 
solid was collected by filtration, rinsed with hexane/ethyl acetate (2:1) and dried to afford 62c (1.911 g, 
11.71 mmol, 86%) as a gray solid. 1H NMR (300 MHz, DMSO-d6) δ 2.20 (3H, s), 3.86 (2H, d, J = 1.9 
Hz), 6.39 (1H, d, J = 7.6 Hz), 6.60 (1H, s), 6.82 (1H, d, J = 7.6 Hz), 10.25 (1H, s). MS (ESI/APCI) 
mass calculated for [M + H]+ (C8H10N3O) requires m/z 164.1, found m/z 164.2. 
7-Methyl-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-one (62d). A mixture of 61d (6.99 g, 31.0 mmol) 
and 10% Pd/C (containing 50% water, 2.0 g) in EtOH (100 mL) was stirred at rt overnight under H2. 
The catalyst was filtered off and evaporated. A suspension of the residue in EtOH (100 mL) was 
refluxed for 5 h and then concentrated to ~1/3 volume in vacuo. To the residue was added i-Pr2O (30 
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mL) and the precipitate was collected by filtration, rinsed with i-Pr2O and dried to give 62d (4.56 g, 
27.9 mmol, 90%) as a gray solid. 1H NMR (300 MHz, DMSO-d6) δ 2.09 (3H, s), 3.85 (2H, d, J = 1.5 
Hz), 6.45 (1H, s), 6.72–6.80 (1H, m), 7.39–7.48 (1H, m), 10.31 (1H, s). 
7-Iodo-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-one (62e). A mixture of 61e (6.0 g, 17.8 mmol) and 
5% Pt/C (500 mg) in THF (300 mL) was hydrogenated under balloon pressure at rt overnight. The 
catalyst was removed by filtration and the filtrate was concentrated in vacuo to give methyl 
2-((3-amino-5-iodopyridin-2-yl)amino)acetate as brown oil. This product was subjected to the next 
reaction without further purification. MS (ESI/APCI) m/z 308.0 [M + H]+. A solution of methyl 
2-((3-amino-5-iodopyridin-2-yl)amino)acetate (5.47 g, 17.8 mmol) in EtOH (200 mL) was refluxed 
for 16 h. The reaction mixture was concentrated, and the residue was triturated with i-Pr2O to give 62e 
(4.48 g, 16.3 mmol, 91%) as a gray solid. 1H NMR (300 MHz, DMSO-d6) δ 3.93 (2H, d, J = 1.5 Hz), 
6.96 (1H, br. s), 7.12 (1H, d, J = 1.1 Hz), 7.74 (1H, d, J = 1.9 Hz), 10.42 (1H, br. s). MS (ESI/APCI) 
mass calculated for [M + H]+ (C7H7IN3O) requires m/z 276.0, found m/z 276.0. 
7-Chloro-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-one (62g). A solution of 61g (181 mg, 0.74 mmol) 
in THF (12.5 mL) was hydrogenated over 5% Pt/C (20 mg) at rt for 2 h. The catalyst was filtered off 
and washed with EtOH, and the filtrate was concentrated in vacuo. The residue was dissolved in EtOH 
(10 mL), and the mixture was stirred at reflux overnight. Since the starting material remained, 2 M 
HCl solution in MeOH (1 mL) was added to the mixture, which was stirred at reflux for further 10 min. 
After the solvent was removed under reduced pressure, the residue was diluted with EtOAc and 
neutralized with saturated aqueous NaHCO3. The phases were separated and the aqueous phase was 
extracted with EtOAc. The combined organic phases were washed with saturated aqueous NaCl, dried 
over anhydrous Na2SO4 and concentrated in vacuo to give 62g (132 mg, 0.721 mmol, 98%) as a brown 
solid. This was used in the next reaction without further purification. 1H NMR (300 MHz, DMSO-d6) 
δ 3.93 (2H, d, J = 1.5 Hz), 6.92 (1H, d, J = 2.3 Hz), 6.98 (1H, s), 7.59 (1H, d, J = 2.3 Hz),10.48 (1H, s). 
MS (ESI/APCI) mass calculated for [M + H]+ (C7H7ClN3O) requires m/z 184.0, found m/z 184.0. 
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4-Nitrophenyl 2-Oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxylate (63a). To a solution of 
62a (3.0 g, 20.1 mmol) in DMA (170 mL) and pyridine (30 mL) was added 4-nitrophenyl 
chloroformate (4.87 g, 24.1 mmol) at rt. After being stirred for 20 h, the mixture was quenched with 
water and extracted with EtOAc. The organic layer was separated, washed with 1 M HCl aqueous 
solution, water and saturated aqueous NaCl, dried over anhydrous MgSO4 and concentrated in vacuo. 
The residue was crystallized from hexane/ethyl acetate to give 63a (4.83 g, 15.4 mmol, 76%) as a 
colorless needle. 1H NMR (300 MHz, DMSO-d6) δ 4.51 (2H, s), 7.26 (1H, dd, J = 7.9, 4.5 Hz), 7.40 
(1H, dd, J = 7.9, 1.5 Hz), 7.48–7.58 (2H, m), 8.11 (1H, dd, J = 4.7, 1.7 Hz), 8.26–8.35 (2H, m). MS 
(ESI/APCI) mass calculated for [M + H]+ (C14H11N4O5) requires m/z 315.1, found m/z 315.1. 
4-Nitrophenyl 8-Methyl-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxylate (63b). To a 
solution of 62b (50.5 mg, 0.31 mmol) and DIEA (0.162 mL, 0.93 mmol) in THF (4 mL) was added 
4-nitrophenyl chloroformate (81 mg, 0.40 mmol) at 0 °C. After being stirred at rt for 1 h, the mixture 
was poured into water, extracted with EtOAc, dried over anhydrous Na2SO4 and concentrated in vacuo. 
The resulting solid was triturated with hexane/ethyl acetate (2:1), collected by filtration, rinsed with 
hexane/ethyl acetate (2:1) and dried to afford 63b (51.9 mg, 0.158 mmol, 51%) as a tan solid. 1H NMR 
(300 MHz, DMSO-d6) δ 2.32 (3H, s), 4.47 (2H, s), 7.15 (1H, d, J = 4.9 Hz), 7.48–7.57 (2H, m), 8.01 
(1H, d, J = 4.9 Hz), 8.26–8.36 (2H, m), 10.52 (1H, s). MS (ESI/APCI) mass calculated for [M + H]+ 
(C15H13N4O5) requires m/z 329.1, found m/z 329.2. 
4-Nitrophenyl 7-Methyl-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxylate (63d). To a 
solution of 62d (1 g, 6.13 mmol) in DMA (40 mL) were added 4-nitrophenyl chloroformate (1.48 g, 
7.35 mmol) and pyridine (15 mL) at rt. The mixture was stirred at rt for 16 h and then water (ca. 100 
mL) was added. The resulting precipitate was collected by filtration, rinsed with water and dried to 
afford 63d (1.63 g, 4.97 mmol, 81%) as a beige solid. 1H NMR (300 MHz, DMSO-d6) δ 2.29 (3H, s), 
4.48 (2H, s), 7.20 (1H, d, J = 1.3 Hz), 7.45–7.58 (2H, m), 7.95 (1H, d, J = 1.3 Hz), 8.21–8.38 (2H, m), 
10.85 (1H, s). 
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4-Nitrophenyl 3-Oxo-3,4-dihydroquinoxaline-1(2H)-carboxylate (63h). To a solution of 62h (447 mg, 
3.02 mmol) in DMA (18 mL) and pyridine (4 mL) was added 4-nitrophenyl chloroformate (730 mg, 
3.62 mmol) at rt. After being stirred at 80 °C for 24 h, the mixture was quenched with water at rt and 
extracted with EtOAc. The organic layer was separated, washed with 1 M HCl aqueous solution, water 
and saturated aqueous NaCl, dried over anhydrous MgSO4 and concentrated in vacuo. The residue was 
crystallized from hexane/ethyl acetate to give 63h (657 mg, 2.10 mmol, 70%) as a yellow solid. 1H 
NMR (300 MHz, DMSO-d6) δ 4.44 (2H, brs), 7.00–7.10 (2H, m), 7.14–7.23 (1H, m), 7.56–7.65 (2H, 
m), 7.68–7.75 (1H, m), 8.25–8.36 (2H, m), 10.80 (1H, s). MS (ESI/APCI) mass calculated for [M − 
H]− (C15H10N3O5) requires m/z 312.1, found m/z 312.1. 
N-(2-(Methylsulfanyl)-1-(4-(trifluoromethoxy)phenyl)ethyl)-2-oxo-2,3-dihydropyrido[2,3-b]pyrazine
-4(1H)-carboxamide (64). The title compound was prepared as a white solid after crystallization from 
hexane/ethyl acetate in 46% yield from 63a and 99j using the procedure analogous to that described 
for the synthesis of 37b. 1H NMR (300 MHz, CDCl3) δ 2.05 (3H, s), 2.97 (2H, d, J = 6.0 Hz), 4.69 
(2H, s), 5.24 (1H, q, J = 6.4 Hz), 7.01 (1H, dd, J = 7.7, 5.1 Hz), 7.12–7.25 (3H, m), 7.34–7.46 (2H, m), 
8.03 (1H, dd, J = 4.9, 1.5 Hz), 9.55 (1H, brs), 10.76 (1H, d, J = 7.2 Hz). MS (ESI/APCI) mass 
calculated for [M + H]+ (C18H18F3N4O3S) requires m/z 427.1, found m/z 427.1. HPLC purity: 100%. 
mp 114.5–117.1 °C. Anal. Calcd for C18H17F3N4O3S: C, 50.70; H, 4.02; N, 13.14. Found: C, 50.78; H, 
4.18; N, 12.97. 
7-Iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-one (65). To a 
stirred solution of 62e (6.05 g, 22.0 mmol) in DMF (100 mL) and DMSO (150 mL) was added 
KHMDS (26.4 mL, 26.4 mmol) dropwise at 0 °C under N2. The mixture was stirred at 0 °C for 20 min 
and SEMCl (5.74 mL, 30.8 mmol) was added at 0 °C. The mixture was stirred at rt for 3 h and then 
poured into water. The mixture was extracted with EtOAc, washed with water and saturated aqueous 
NaCl, dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by column 
chromatography (silica gel, hexane/ethyl acetate, 100:0 to 4:1), followed by a second column 
171 
 
purification (basic silica gel, hexane/ethyl acetate, 100:0 to 4:1) to afford 65 (3.41 g, 8.41 mmol, 38%) 
as a tan solid. 1H NMR (300 MHz, DMSO-d6) δ −0.04 (9H, s), 0.86 (2H, t, J = 7.7 Hz), 3.55 (2H, t, J 
= 7.7 Hz), 4.02 (2H, d, J = 1.5 Hz), 5.26 (2H, s), 7.08 (1H, s), 7.50 (1H, d, J = 1.5 Hz), 7.88 (1H, d, J 
= 1.9 Hz). MS (ESI/APCI) mass calculated for [M + H]+ (C13H21IN3O2Si) requires m/z 406.0, found 
m/z 406.1. 
7-Iodo-N-(2-methoxy-1-(4-(trifluoromethoxy)phenyl)ethyl)-2-oxo-1-((2-(trimethylsilyl)ethoxy)methy
l)-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (66). To a stirred solution of 65 (1.11 g, 2.73 
mmol) in THF (42 mL) was added a solution of triphosgene (647 mg, 2.18 mmol) in THF (6.3 mL) 
dropwise at rt under N2. The mixture was stirred at 40 °C for 1 h under N2 and then concentrated in 
vacuo. The residue was diluted with THF and concentrated in vacuo (this procedure was repeated three 
times), and suspended in THF (21 mL). The mixture was added dropwise to a mixture of 
2-methoxy-1-(4-(trifluoromethoxy)phenyl)ethanamine hydrochloride (889 mg, 3.27 mmol) and Et3N 
(1.15 mL, 8.18 mmol) in THF (14mL) with stirring at rt. The mixture was stirred at 60 °C overnight. 
The mixture was concentrated in vacuo and the residue was diluted with EtOAc. This solution was 
washed with water and saturated aqueous NaCl, dried over anhydrous Na2SO4 and concentrated in 
vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl acetate, 99:1 to 
7:3) to give 66 (1.17 g, 1.76 mmol, 64%) as a pale orange solid. 1H NMR (300 MHz, DMSO-d6) δ 
0.00 (9H, s), 0.91 (2H, t, J = 7.7 Hz), 3.34 (3H, s), 3.52–3.76 (4H, m), 4.60 (2H, s),5.03–5.17 (1H, m), 
5.36 (2H, s), 7.37 (2H, d, J = 8.3 Hz), 7.52 (2H, d, J = 8.7 Hz), 8.01 (1H, d, J = 1.9 Hz), 8.39 (1H, d, J 
=1.9 Hz), 9.96 (1H, d, J = 7.2 Hz). MS (ESI/APCI) mass calculated for [M + H]+ (C24H31F3IN4O5Si) 
requires m/z 667.1, found m/z 667.1. 
7-Iodo-N-(2-methoxy-1-(4-(trifluoromethyl)phenyl)ethyl)-2-oxo-1-((2-(trimethylsilyl)ethoxy)methyl)
-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (67). To a solution of 65 (1.53 g, 3.77 mmol) 
in THF (60 mL) was added a solution of triphosgene (0.896 g, 3.02 mmol) in THF (8 mL) at rt. After 
being stirred at 40 °C for 5 h, the mixture was concentrated in vacuo. To a mixture of 100l (1.16 g, 
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4.53 mmol) and Et3N (1.58 mL, 11.3 mmol) in THF (60 mL) was added a solution of the residue 
obtained above in THF (10 mL) at rt. The mixture was stirred at 60 °C for 16 h, and then quenched 
with water and extracted with EtOAc. The organic layer was separated, washed with water and 
saturated aqueous NaCl, dried over anhydrous MgSO4 and concentrated in vacuo. The residue was 
purified by column chromatography (basic silica gel, hexane/ethyl acetate, 19:1 to 7:3) to give 67 
(2.18 g, 3.35 mmol, 89%) as a pale orange solid. 1H NMR (300 MHz, CDCl3) δ 0.00 (9H, s), 0.90–
0.99 (2H, m), 3.38 (3H, s), 3.59–3.73 (4H, m), 4.65 (2H, d, J = 1.1 Hz), 5.12–5.20 (1H, m), 5.27 (2H, 
s), 7.42–7.51 (2H, m), 7.53–7.62 (2H, m), 7.95 (1H, d, J = 1.9 Hz), 8.25 (1H, d, J = 1.9 Hz), 10.15 
(1H, d, J = 6.8 Hz). MS (ESI/APCI) mass calculated for [M + H]+ (C24H31F3IN4O4Si) requires m/z 
651.1, found m/z 651.1. 
N-(1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-iodo-2-oxo-1-((2-(trimethylsilyl)eth
oxy)methyl)-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (68). To a stirred solution of 65 
(3.83 g, 9.45 mmol) in THF (144 mL) was added a solution of triphosgene (2.24 g, 7.56 mmol) in THF 
(22 mL) dropwise at rt under N2. The mixture was stirred at 40 °C for 3 h under N2 and concentrated in 
vacuo. The residue was diluted with THF and concentrated in vacuo (this procedure was repeated three 
times), and suspended in THF (72 mL). The mixture was added dropwise to a mixture of 99k (2.87 g, 
11.3 mmol) and Et3N (2.66 mL, 18.9 mmol) in THF (48 mL) with stirring at rt. The mixture was 
stirred at 60 °C overnight. The mixture was concentrated in vacuo and the residue was partitioned 
between EtOAc and water. The phases were separated and the aqueous phase was extracted with 
EtOAc. The combined organic phases were washed with saturated aqueous NaCl, dried over 
anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography 
(silica gel, hexane/ethyl acetate, 99:1 to 7:3) to give 68 (6.15 g, 8.98 mmol, 95%) as a pale yellow 
amorphous solid. 1H NMR (300 MHz, DMSO-d6) δ 0.00 (9H, s), 0.85–0.97 (2H, m), 3.35 (3H, s), 
3.59–3.77 (4H, m), 4.60 (2H, s), 5.03–5.18 (1H, m), 5.37 (2H, s), 7.36 (1H, d, J = 8.7 Hz), 7.46–7.64 




y)methyl)-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (69). A mixture of 66 (683 mg, 1.03 
mmol), cyclopropylboronic acid (176 mg, 2.05 mmol), K3PO4 (802 mg, 3.59 mmol), Cy3P (117 mg, 
0.410 mmol), and Pd(OAc)2 (46.0 mg, 0.210 mmol) was stirred at 100 °C overnight under Ar. The 
mixture was filtered and the filtrate was washed with water and saturated aqueous NaCl, dried over 
anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography 
(silica gel, hexane/ethyl acetate, 99:1 to 7:3) to give 69 (432 mg, 0.743 mmol, 73%) as a pale yellow 
solid. 1H NMR (300 MHz, CDCl3) δ 0.00 (9H, s), 0.64–0.78 (2H, m), 0.90–0.99 (2H, m), 1.00–1.13 
(2H, m), 1.83–1.99 (1H, m), 3.39 (3H, s), 3.59–3.73 (4H, m), 4.65 (2H, d, J = 1.1 Hz), 5.17 (1H, d, J = 
7.5 Hz), 5.29 (2H, s), 7.17 (2H, d, J = 7.9 Hz), 7.34–7.45 (3H, m), 7.86 (1H, d, J = 1.9 Hz), 10.29 (1H, 
d, J = 7.5 Hz). MS (ESI/APCI) mass calculated for [M + H]+ (C27H36F3IN4O5Si) requires m/z 581.2, 
found m/z 581.2. 
7-Methoxy-N-(2-methoxy-1-(4-(trifluoromethoxy)phenyl)ethyl)-2-oxo-1-((2-(trimethylsilyl)ethoxy)m
ethyl)-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (70). A mixture of 66 (900 mg, 1.35 
mmol), bis(pinacolato)diboron (707 mg, 2.70 mmol), KOAc (546 mg, 5.40 mmol), and PdCl2(dppf) 
(99 mg, 0.14 mmol) in DMF (13.5 mL) was stirred at 80 °C overnight under Ar. The mixture was 
quenched with water and extracted with EtOAc. The combined organic layer was washed with 
saturated aqueous NaCl, dried over anhydrous Na2SO4 and concentrated in vacuo to afford crude 
N-(2-methoxy-1-(4-(trifluoromethoxy)phenyl)ethyl)-2-oxo-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (1.55 
g). This was used in the next reaction without further purification. MS (ESI/APCI) m/z 667.4 [M + H]+. 
To a stirred solution of the crude product obtained above (1.55 g) in THF (23 mL) was added 2 M 
NaOH aqueous solution (4.64 mL, 9.28 mmol) at 0 °C. After 30 min of stirring at 0 °C, hydrogen 
peroxide (0.813 mL, 9.28 mmol) was added to the mixture. The mixture was stirred at rt for 1.5 h and 
then quenched with ice-water at rt and extracted with EtOAc. The combined organic layer was washed 
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with saturated aqueous NaCl and dried over anhydrous Na2SO4 and concentrated in vacuo. The residue 
was purified by column chromatography (silica gel, hexane/ethyl acetate, 99:1 to 1:1) to give 
7-hydroxy-N-(2-methoxy-1-(4-(trifluoromethoxy)phenyl)ethyl)-2-oxo-1-((2-(trimethylsilyl)ethoxy)me
thyl)-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (0.678 g, 1.22 mmol, 90% in 2 steps from 
66) as a pale yellow oil. 1H NMR (300 MHz, CDCl3) δ 0.00 (9H, s), 0.89–1.01 (2H, m), 3.39 (3H, s), 
3.60–3.74 (4H, m), 4.65 (2H, s), 5.10–5.20 (1H,m), 5.27 (2H, s), 6.28 (1H, brs), 7.17 (2H, d, J = 7.9 
Hz), 7.33 (1H, d, J = 2.6 Hz), 7.37–7.47 (2H, m), 7.72 (1H, d, J = 2.6Hz), 9.96 (1H, d, J = 7.2 Hz). 
MS (ESI/APCI) mass calculated for [M + H]+ (C24H31F3N4O6Si) requires m/z 557.2, found m/z 557.3. 
To a stirred solution of 
7-hydroxy-N-(2-methoxy-1-(4-(trifluoromethoxy)phenyl)ethyl)-2-oxo-1-((2-(trimethylsilyl)ethoxy)me
thyl)-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (560 mg, 1.01 mmol) in DMF (13 mL) 
was added K2CO3 (140 mg, 1.01 mmol) and methyl iodide (95 µL, 1.51 mmol). The mixture was 
stirred at rt overnight. The mixture was quenched with water and extracted with EtOAc. The combined 
organic layer was washed with saturated aqueous NaCl, dried over anhydrous Na2SO4 and 
concentrated in vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl 
acetate, 99:1 to 3:2) to give 70 (395 mg, 0.692 mmol, 69%) as a white amorphous solid. 1H NMR (300 
MHz, CDCl3) δ 0.00 (9H, s), 0.86–1.01 (2H, m), 3.39 (3H, s), 3.58–3.73 (4H, m), 3.90 (3H, s), 4.65 
(2H, s),5.10–5.22 (1H, m), 5.29 (2H, s), 7.17 (2H, d, J = 8.3 Hz), 7.31–7.47 (3H, m), 7.75 (1H, d, J = 
2.6 Hz), 9.98 (1H, d, J = 7.2Hz). MS (ESI/APCI) mass calculated for [M + H]+ (C25H34F3N4O6Si) 
requires m/z 571.2, found m/z 571.3. 
7-Isopropoxy-N-(2-methoxy-1-(4-(trifluoromethoxy)phenyl)ethyl)-2-oxo-1-((2-(trimethylsilyl)ethoxy
)methyl)-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (71). To a stirred solution of 
7-hydroxy-N-(2-methoxy-1-(4-(trifluoromethoxy)phenyl)ethyl)-2-oxo-1-((2-(trimethylsilyl)ethoxy)me
thyl)-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (102 mg, 0.180 mmol) in DMF (2.4 mL) 
were added K2CO3 (25.6 mg, 0.180 mmol) and 2-iodopropane (28.0 μL, 0.280 mmol). The mixture 
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was stirred at 70 °C overnight. The mixture was quenched with water and extracted with EtOAc. The 
combined organic layer was washed with saturated aqueous NaCl, dried over anhydrous Na2SO4 and 
concentrated in vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl 
acetate, 99:1 to 7:3) to give 71 (90 mg, 0.150 mmol, 82%) as a colorless oil. 1H NMR (300 MHz, 
CDCl3) δ 0.00 (9H, s), 0.90–1.00 (2H, m), 1.38 (6H, d, J = 6.0 Hz), 3.39 (3H, s), 3.61–3.72 (4H, m), 
4.56 (1H, dt, J = 12.2, 6.2 Hz), 4.65 (2H, s), 5.11–5.21 (1H, m), 5.28 (2H, s), 7.17 (2H, d, J = 7.9 Hz), 
7.34 (1H, d, J = 2.6 Hz), 7.38–7.44 (2H, m), 7.73 (1H, d, J = 2.6 Hz), 9.99 (1H, d, J = 7.5 Hz). MS 
(ESI/APCI) mass calculated for [M + H]+ (C27H38F3N4O6Si) requires m/z 599.2, found m/z 599.3. 
7-Methoxy-N-(2-methoxy-1-(4-(trifluoromethyl)phenyl)ethyl)-2-oxo-1-((2-(trimethylsilyl)ethoxy)met
hyl)-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (72). A mixture of 67 (1.19 g, 1.83 mmol), 
bis(pinacolato)diboron (0.941 g, 3.67 mmol), KOAc (0.742 g, 7.34 mmol), and PdCl2(dppf) (0.137 g, 
0.18 mmol) in DMF (18 mL) was stirred at 80 °C overnight under Ar. The mixture was quenched with 
water and extracted with EtOAc. The combined organic layer was washed with water and saturated 
aqueous NaCl, dried over anhydrous Na2SO4 and concentrated in vacuo to give crude 
N-(2-methoxy-1-(4-(trifluoromethyl)phenyl)ethyl)-2-oxo-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (1.19 
g). This was used in the next reaction without further purification. MS (ESI/APCI) mass calculated for 
[M + H]+ (C30H43BF3N4O6Si) requires m/z 651.3, found m/z 651.3. To a stirred solution of the crude 
product obtained above (1.19 g) in THF (18 mL) was added 2 M NaOH aqueous solution (3.67 mL, 
7.34 mmol) at 0 °C. After 30 min of stirring at 0 °C, hydrogen peroxide (0.642 mL, 7.34 mmol) was 
added to the mixture. The mixture was stirred at rt for 2 h. The mixture was quenched with ice-water 
and acidified with 1 M HCl aqueous solution, and extracted with EtOAc. The combined organic layer 
was washed with water and saturated aqueous NaCl, dried over anhydrous Na2SO4 and concentrated in 
vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl acetate, 99:1 to 




yl)-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (0.796 g, 1.47 mmol, 80% in 2 steps from 
67) as a pink oil. 1H NMR (300 MHz, CDCl3) δ 0.00 (9H, s), 0.87–1.03 (2H, m), 3.39 (3H, s), 3.58–
3.75 (4H, m), 4.54–4.76 (2H, m), 5.13–5.23 (1H, m), 5.24–5.34 (2H, m), 7.33 (1H, d, J = 2.3 Hz), 
7.45–7.54 (2H, m), 7.54–7.63 (2H, m), 7.72 (1H, d, J = 2.6 Hz), 10.09 (1H, d, J = 7.2 Hz). MS 
(ESI/APCI) mass calculated for [M + H]+ (C24H32F3N4O5Si) requires m/z 541.2, found m/z 541.2. To a 
stirred solution of 
7-hydroxy-N-(2-methoxy-1-(4-(trifluoromethyl)phenyl)ethyl)-2-oxo-1-((2-(trimethylsilyl)ethoxy)meth
yl)-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (796 mg, 1.47 mmol) in DMF (19 mL) was 
added K2CO3 (205 mg, 1.47 mmol) and methyl iodide (139 µL, 2.21 mmol). The mixture was stirred 
at rt overnight. The mixture was quenched with water and extracted with EtOAc. The combined 
organic layer was washed with saturated aqueous NaCl, dried over anhydrous Na2SO4 and 
concentrated in vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl 
acetate, 99:1 to 11:9) to give 72 (665 mg, 1.20 mmol, 81%) as a white solid. 1H NMR (300 MHz, 
CDCl3) δ 0.00 (9H, s), 0.84–1.01 (2H, m), 3.39 (3H, s), 3.57–3.75 (4H, m), 3.90 (3H, s), 4.65 (2H, 
s),5.14–5.24 (1H, m), 5.29 (2H, s), 7.37 (1H, d, J = 2.6 Hz), 7.44–7.53 (2H, m), 7.56–7.65 (2H, m), 
7.76 (1H, d, J = 2.6 Hz),10.03 (1H, d, J = 7.2 Hz). MS (ESI/APCI) mass calculated for [M + H]+ 
(C25H34F3N4O5Si) requires m/z 555.2, found m/z 555.2. 
N-(1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-1-((2-(trimethylsilyl
)ethoxy)methyl)-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (73). A mixture of 68 (6.15 g, 
8.98 mmol), bis(pinacolato)diboron (4.61 g, 18.0 mmol), KOAc (3.64 g, 36.0 mmol), and PdCl2(dppf) 
(0.657 g, 0.90 mmol) in DMF (90 mL) was stirred at 80 °C overnight under Ar. The mixture was 
quenched with water and extracted with EtOAc. The combined organic layer was washed with water 





ide. This was used in the next reaction without further purification. MS (ESI/APCI) mass calculated 
for [M + H]+ (C30H42BF4N4O7Si) requires m/z 685.3, found m/z 685.3. To a stirred solution of the 
crude product obtained above (theoretical amount: 6.15 g, 8.98 mmol) in THF (90 mL) was added 2 M 
NaOH aqueous solution (18.0 mL, 35.9 mmol) at 0 °C. After 30 min of stirring at 0 °C, hydrogen 
peroxide (3.15 mL, 35.9 mmol) was added to the mixture. The mixture was stirred at rt for 2 h. The 
mixture was quenched with ice-water and acidified with 1 M HCl aqueous solution, and extracted with 
EtOAc. The combined organic layer was washed with water and saturated aqueous NaCl, dried over 
anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography 
(silica gel, hexane/ethyl acetate, 99:1 to 1:1) to give 
N-(1-(3-fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-hydroxy-2-oxo-1-((2-(trimethylsilyl)et
hoxy)methyl)-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (4.99 g, 8.69 mmol, 97% in 2 
steps from 68) as a brown oil. 1H NMR (300 MHz, CDCl3) δ 0.00 (9H, s), 0.86–1.02 (2H, m), 3.39 
(3H, s), 3.60–3.72 (4H, m), 4.65 (2H, d, J = 1.1 Hz), 5.12 (1H, dt, J = 7.1, 4.7 Hz), 5.28 (2H, s), 7.08–
7.27 (3H, m), 7.35 (1H, d, J = 2.5 Hz), 7.72 (1H, d, J = 2.6 Hz), 10.03 (1H, d, J =7.4 Hz). MS 
(ESI/APCI) mass calculated for [M + H]+ (C24H31F4N4O6Si) requires m/z 575.2, found m/z 575.2. To a 
stirred solution of 
N-(1-(3-fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-hydroxy-2-oxo-1-((2-(trimethylsilyl)et
hoxy)methyl)-2,3-dihydropyrido[2,3-b]pyrazine-4(1H)-carboxamide (8.47 g, 14.7 mmol) in DMF 
(189 mL) was added K2CO3 (2.05 g, 14.7 mmol) and methyl iodide (1.39 mL, 22.1 mmol). The 
mixture was stirred at rt overnight and then concentrated in vacuo. The residue was partitioned 
between EtOAc and water. The phases were separated, and the aqueous phase was extracted with 
EtOAc. The combined organic phases were washed with saturated aqueous NaCl, dried over 
anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography 
(silica gel, hexane/ethyl acetate, 99:1 to 3:2) to give 73 (5.22 g, 8.87 mmol, 60%) as a pale yellow 
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amorphous solid. 1H NMR (300 MHz, CDCl3) δ 0.00 (9H, s), 0.88–1.01 (2H, m), 3.40 (3H, s), 3.58–
3.74 (4H, m), 3.90 (3H, s), 4.65 (2H, s),5.13 (1H, dt, J = 7.2, 4.7 Hz), 5.30 (2H, s), 7.11–7.31 (3H, m), 
7.33–7.42 (1H, m), 7.76 (1H, d, J = 2.6 Hz), 10.01 (1H, d, J =7.5 Hz). MS (ESI/APCI) mass 
calculated for [M + H]+ (C25H32F4N4O6Si) requires m/z 589.2, found m/z 589.2. 
7-Methoxy-N-(2-methoxy-1-(4-(trifluoromethyl)phenyl)ethyl)-2-oxo-2,3-dihydropyrido[2,3-b]pyrazi
ne-4(1H)-carboxamide (75). A mixture of 72 (665 mg, 1.20 mmol) in TFA (17.3 mL) and water (1.93 
mL) was stirred at rt for 1 h and then concentrated in vacuo. The residue was dissolved in DMF (33 
mL) and 8 M NH3 solution in MeOH (6.46 mL, 51.7 mmol) was added. The mixture was stirred at rt 
for 10 min and concentrated in vacuo. The residue was diluted with EtOAc. The solution was washed 
with water and saturated aqueous NaCl, dried over anhydrous Na2SO4 and concentrated in vacuo to 
give 75 (474 mg, 1.12 mmol, 93%) as a white solid after trituration with hexane/ethyl acetate (10:1). 
1H NMR (300 MHz, DMSO-d6) δ 3.28 (3H, s), 3.59–3.68 (2H, m), 3.83 (3H, s), 4.25–4.55 (2H, m), 
5.00–5.17 (1H, m), 6.97 (1H, d, J = 3.0 Hz), 7.56 (2H, d, J = 8.3 Hz), 7.64–7.73 (2H, m), 7.77 (1H, d, 
J = 2.6 Hz), 10.07 (1H, d, J = 7.5 Hz), 10.77 (1H, s). MS (ESI/APCI) mass calculated for [M + H]+ 
(C19H20F3N4O4) requires m/z 425.1, found m/z 425.1. 
N-(1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)-7-methoxy-2-oxo-2,3-dihydropyrido[2
,3-b]pyrazine-4(1H)-carboxamide (76). A mixture of 73 (5.22 g, 8.87 mmol) in TFA (128 mL) and 
water (14.3 mL) was stirred at rt for 1.5 h and then concentrated in vacuo. The residue was dissolved 
in DMF (243 mL) and 8 M NH3 solution in MeOH (47.8 mL, 382 mmol) was added. The mixture was 
stirred at rt for 2 h and concentrated in vacuo. The residue was diluted with EtOAc. The solution was 
washed with water and saturated aqueous NaCl, dried over anhydrous Na2SO4 and concentrated in 
vacuo to give 76 (3.37 g, 7.36 mmol, 83%) as pale yellow solid after trituration with hexane/ethyl 
acetate (10:1). 1H NMR (300 MHz, DMSO-d6) δ 3.29 (3H, s), 3.63 (2H, tt, J = 9.6, 4.9 Hz), 3.83 (3H, 
s), 4.26–4.52 (2H, m), 4.95–5.15 (1H,m), 6.97 (1H, d, J = 2.6 Hz), 7.29 (1H, d, J = 8.3 Hz), 7.41–7.60 
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(2H, m), 7.75 (1H, d, J = 3.0 Hz), 10.02 (1H, d, J = 7.5 Hz),10.77 (1H, s). MS (ESI/APCI) mass 
calculated for [M + H]+ (C19H19F4N4O5) requires m/z 459.1, found m/z 459.1. 
N-Methoxy-N-methyl-3-(trifluoromethoxy)benzamide (81). To a mixture of 
3-(trifluoromethoxy)benzoic acid (78) (5.00 g, 24.3 mmol), EDCI (7.03 g, 36.6 mmol) and HOBt 
(4.94 g, 36.6 mmol) in DMF (50 mL) were added N,O-dimethylhydroxylamine hydrochloride (2.63 g, 
26.7 mmol) and Et3N (7.36 g, 72.9 mmol). The mixture was stirred at 10 °C for 16 h, and then poured 
into water (100 mL). The mixture was extracted with EtOAc (150 mL × 3), washed with saturated 
aqueous NaCl (400 mL × 3), dried over anhydrous Na2SO4, and concentrated in vacuo to afford 81 
(5.31 g, 21.3 mmol, 88%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ 3.37 (3H, s), 3.55 (3H, s), 
7.28–7.34 (1H, m), 7.45 (1H, t, J = 8.0 Hz), 7.57 (1H, s), 7.64 (1H, d, J = 8.0 Hz). 
N-Methoxy-N-methyl-2-(trifluoromethoxy)benzamide (82). To a mixture of 
2-(trifluoromethoxy)benzoic acid (79) (5.00 g, 24.3 mmol), EDCI (7.03 g, 36.6 mmol) and HOBt 
(4.94 g, 36.6 mmol) in DMF (50 mL) were added N,O-dimethylhydroxylamine hydrochloride (2.63 g, 
26.7 mmol) and Et3N (7.36 g, 72.9 mmol). The mixture was stirred at 10 °C for 16 h, and then poured 
into water (100 mL). The mixture was extracted with EtOAc (150 mL × 3), washed with saturated 
aqueous NaCl (300 mL × 3), dried over anhydrous Na2SO4, and concentrated in vacuo to afford 82 
(5.21 g, 20.9 mmol, 86%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 3.36 (3H, s),3.45 (3H, s), 
7.27–7.37 (2H, m), 7.39–7.50 (2H, m). 
3-Fluoro-N-methoxy-N-methyl-4-(trifluoromethoxy)benzamide (83). A mixture of 
3-fluoro-4-(trifluoromethoxy)benzoic acid (80) (15.0 g, 66.9 mmol), N,O-dimethylhydroxylamine 
hydrochloride (7.18 g, 73.6 mmol), EDCI·HCl (16.7 g, 87.0 mmol), HOBt·H2O (13.3 g, 87.0 mmol) 
and Et3N (12.1 mL, 87.0 mmol) in DMF (200 mL) was stirred at rt for 64 h. The mixture was 
quenched with water and extracted with EtOAc. The organic layer was separated, washed with water 
and saturated aqueous NaCl, dried over anhydrous MgSO4 and concentrated in vacuo. The residue was 
purified by column chromatography (silica gel, hexane/ethyl acetate, 19:1 to 4:1) to give 83 (17.6 g, 
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65.7 mmol, 98%) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 3.38 (3H, s), 3.56 (3H, s), 7.30–
7.39 (1H, m), 7.52–7.64 (2H, m). MS (ESI/APCI) m/z 268.0 [M + H]+. 
2-Fluoro-4-(trifluoromethoxy)benzonitrile (85). A mixture of dicyanozinc (4.53 g, 38.6 mmol), 
1-bromo-2-fluoro-4-(trifluoromethoxy)benzene (84) (10.0 g, 38.6 mmol), Pd2(dba)3 (1.77 g, 1.93 
mmol) and dppf (2.14 g, 3.86 mmol) in DMF (150 mL) was stirred at 100 °C overnight under N2. The 
mixture was partitioned between EtOAc and saturated aqueous NaCl. The mixture was filtered 
through a cake of celite and the filtrate was extracted with EtOAc. The extract was washed with 
saturated aqueous NaCl, dried over anhydrous MgSO4, filtered, and concentrated in vacuo. The 
residue was purified by column chromatography (basic silica gel, hexane/ethyl acetate, 49:1 to 1:1), 
followed by a second column chromatography purification (silica gel, hexane/ethyl acetate, 49:1 to 
7:3) to give 85 (3.39 g, 16.5 mmol, 43%) as an orange oil. 1H NMR (300 MHz, CDCl3) δ 7.07–7.18 
(2H, m), 7.65–7.76 (1H, m). 
1-(4-Cyclopropylphenyl)propan-1-one (86a). A mixture of 1-(4-bromophenyl)propan-1-one (77) (1.07 
g, 5.00 mmol), cyclopropylboronic acid (558 mg, 6.50 mmol, PdCl2(dppf) (183 mg, 0.25 mmol) and 
K3PO4 (2.12 g, 10.0 mmol) in DME (15 mL) and water (5 mL) was stirred at 85 °C for 20 h under N2. 
The mixture was extracted with EtOAc, washed with saturated aqueous NaCl, dried over anhydrous 
MgSO4 and concentrated in vacuo. The residue was purified by column chromatography (silica gel, 
hexane/ethyl acetate, 9:1 to 7:3) to give 86a (679 mg, 3.90 mmol, 78%) as a colorless oil. 1H NMR 
(300 MHz, CDCl3) δ 0.73–0.82 (2H, m), 1.01–1.10 (2H, m), 1.21 (3H, t, J = 7.2 Hz), 1.94 (1H, tt, J = 
8.3, 5.0 Hz), 2.97 (2H, q, J = 7.2 Hz), 7.08–7.16 (2H, m), 7.82–7.90 (2H, m). MS (ESI/APCI) m/z 
174.89 [M + H]+. 
1-(4-(Azetidin-1-yl)phenyl)propan-1-one (86b). A mixture of 77 (639 mg, 3.00 mmol), azetidine (303 
µL, 4.50 mmol), Pd2(dba)3 (137 mg, 0.15 mmol), xantphos (174 mg, 0.30 mmol) and sodium 
tert-butoxide (432 mg, 4.50 mmol) in toluene (15 mL) was stirred under N2 at 85 °C for 20 h.The 
mixture was quenched with water at rt and extracted with EtOAc. The organic layer was separated, 
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washed with water and saturated aqueous NaCl, dried over anhydrous MgSO4 and concentrated in 
vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl acetate, 19:1 to 
4:1) to give 86b (414 mg, 2.19 mmol, 73%) as a white solid. 1H NMR (300 MHz, CDCl3) δ 1.20 (3H, t, 
J = 7.3 Hz), 2.42 (2H, quin, J = 7.3 Hz), 2.90 (2H, q, J = 7.2 Hz), 3.99 (4H, t, J = 7.3 Hz), 6.32–6.39 
(2H, m), 7.82–7.90 (2H, m). 
1-(3-(Trifluoromethoxy)phenyl)propan-1-one (86c). To a solution of 81 (5.31 g, 21.3 mmol) in THF 
(50 mL) was added dropwise 3 M EtMgBr solution in Et2O (14.2 mL, 42.6 mmol) at 0 °C under N2. 
The mixture was stirred at 12 °C for 16 h and then poured into saturated aqueous NH4Cl (50 mL). The 
mixture was extracted with EtOAc (80 mL × 3). The combined organic layer was dried over anhydrous 
Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography (silica gel, 
petroleum ether/ethyl acetate, 10:1) to afford 86c (3.23 g, 14.8 mmol, 69%) as a yellow oil. 1H NMR 
(400 MHz, CDCl3) δ 1.24 (3H, t, J = 7.2 Hz), 3.01 (2H, q, J = 7.2 Hz), 7.34–7.44 (1H, m), 7.51 (1H, t, 
J = 8.0 Hz), 7.81 (1H, s), 7.85–7.92 (1H, m). 
1-(2-(Trifluoromethoxy)phenyl)propan-1-one (86d). To a solution of 82 (5.21 g, 20.9 mmol) in THF 
(30 mL) was added dropwise 3 M EtMgBr solution in Et2O (13.9 mL, 41.7 mmol) at 0 °C under N2. 
The mixture was stirred at 10 °C for 16 h and then poured into saturated aqueous NH4Cl (50 mL). The 
mixture was extracted with EtOAc (100 mL × 3). The combined organic layer was dried over 
anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography 
(silica gel, petroleum ether/ethyl acetate, 10:1) to afford 86d (3.23 g, yield: 71%) as a yellow oil. 1H 
NMR (400 MHz, CDCl3) δ 1.20 (3H, t, J = 7.2 Hz), 2.95 (2H, q, J = 7.2 Hz), 7.28–7.33 (1H, m), 7.34–
7.41 (1H, m), 7.48–7.55 (1H, m), 7.70 (1H, dd, J = 7.6, 2.0 Hz). 
1-(3-Fluoro-4-(trifluoromethoxy)phenyl)propan-1-one (86e). To a solution of 83 (5.00 g, 18.7 mmol) 
in THF (200 mL) at 0 °C was added dropwise 3 M ethylmagnesium bromide solution in Et2O (7.49 
mL, 22.5 mmol). The mixture was stirred at rt for 3 days. The mixture was poured into saturated 
aqueous NH4Cl and extracted with EtOAc. The organic layer was separated, washed with saturated 
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aqueous NaCl, dried over anhydrous MgSO4 and concentrated in vacuo. The residue was purified by 
column chromatography (silica gel, hexane/ethyl acetate, 49:1 to 7:3) to give 86e (2.60 g, 11.0 mmol, 
59%) as a pale yellow. 1H NMR (300 MHz, CDCl3) δ 1.24 (3H, t, J = 7.2 Hz), 2.98 (2H, q, J = 7.3 Hz), 
7.34–7.49 (1H, m), 7.71–7.88 (2H, m). 
1-(2-Fluoro-4-(trifluoromethoxy)phenyl)propan-1-one (86f). To a solution of 85 (3.79 g, 18.5 mmol) 
in THF (50 mL) at 0 °C was added dropwise 3 M ethylmagnesium bromide solution in Et2O (7.39 mL, 
22.2 mmol). The mixture was stirred at 0 °C for 1 h under N2. The mixture was poured into saturated 
aqueous NH4Cl and extracted with EtOAc. The organic layer was separated, washed with saturated 
aqueous NaCl, dried over anhydrous MgSO4 and concentrated in vacuo. The residue was purified by 
column chromatography (silica gel, hexane/ethyl acetate, 49:1 to 1:1) to give 86f (1.12 g, 4.75 mmol, 
26%) as a yellow oil. 1H NMR (300 MHz, CDCl3) δ 1.14–1.24 (3H, m), 3.00 (2H, qd, J = 7.2, 3.2 Hz), 
6.95–7.05 (1H, m), 7.05–7.13 (1H, m), 7.96 (1H, t, J = 8.5 Hz). 
3-Methoxy-1-(4-(trifluoromethoxy)phenyl)propan-1-one (86h). To a solution of 
1-(4-(trifluoromethoxy)phenyl)prop-2-en-1-one (89) (7.92 g, 36.6 mmol) in CH2Cl2 (92 mL) was 
added methanol (1.48 mL, 36.6 mmol) and PdCl2(CH3CN)2 (0.951 g, 3.66 mmol) at 0 °C. The mixture 
was stirred at rt overnight under Ar and concentrated in vacuo. The residue was purified by column 
chromatography (silica gel, hexane/ethyl acetate, 100:0 to 17:3) to give 86h (4.55 g, 18.3 mmol, 50%) 
as a yellow solid. 1H NMR (300 MHz, CDCl3) δ 3.22 (2H, t, J = 6.4 Hz), 3.38 (3H, s), 3.82 (2H, t, J = 
6.4 Hz), 7.22–7.36 (2H, m), 7.97–8.07 (2H, m). MS (ESI/APCI) m/z 249.0 [M + H]+. 
2-Methoxy-1-(4-(trifluoromethoxy)phenyl)ethanone (86i). (Method A: step 92 → 86i) To a solution 
of 92 (930 mg, 3.94 mmol) in CH3CN (20 mL) at 0 °C was added portionwise Dess–Martin 
periodinane (2.51 g, 5.91 mmol). The mixture was stirred at rt for 1.5 h. NaHCO3 aqueous solution 
and Na2S2O3 aqueous solution were sequentially added. After stirring for 15 min, the mixture was 
extracted with EtOAc, washed with saturated aqueous NaHCO3, dried over anhydrous Na2SO4 and 
concentrated in vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl 
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acetate, 19:1 to 3:2) to afford 86i (898 mg, 3.83 mmol, 97%) as a colorless oil. 1H NMR (300 MHz, 
DMSO-d6) δ 3.36 (3H, s), 4.80 (2H, s), 7.48–7.57 (2H, m), 8.01–8.10 (2H, m). 
2-Methoxy-1-(4-(trifluoromethoxy)phenyl)ethanone (86i). (Method B: step 96 → 86i) To a solution 
of 96 (9.91 g, 35.0 mmol) in MeOH (250 mL) was added Ag2CO3 (12.6 g, 45.5 mmol) and BF3·OEt2 
(5.96 g, 42.0 mmol) at rt. After being stirred at 50°C overnight, the mixture was filtered, and the 
filtrate was concentrated in vacuo. The mixture was diluted with water and extracted with EtOAc. The 
organic layer was separated, washed with water and saturated aqueous NaCl, dried over anhydrous 
MgSO4 and concentrated in vacuo. The residue was purified by column chromatography (silica gel, 
hexane/ethyl acetate, 100:0 to 4:1) to give 86i (6.85 g, 29.3 mmol, 84%) as a colorless oil. 1H NMR 
(300 MHz, CDCl3) δ 3.51 (3H, s), 4.67 (2H, s), 7.27–7.35 (2H, m), 7.94–8.07 (2H, m). 
2-(Methylsulfanyl)-1-(4-(trifluoromethoxy)phenyl)ethanone (86j). Sodium methanethiolate (1.24 g, 
17.7 mmol) was added to a solution of 96 (5.00 g, 17.7 mmol) in THF (150 mL) at 0 °C. The mixture 
was stirred at rt for 1 h, and then passed through a cake of basic silica gel pad (hexane/ethyl acetate, 
10:1). The appropriate fractions were concentrated in vacuo to give 86j (4.23 g, 16.9 mmol, 96%) as a 
pale yellow oil. 1H NMR (300 MHz, CDCl3) δ 2.14 (3H, s), 3.74 (2H, s), 7.27–7.36 (2H, m), 7.99–
8.10 (2H, m). 
1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethanone (86k). To a solution of 95 (4.91 g, 16.3 
mmol) in MeOH (150 mL) was added Ag2CO3 (5.85 g, 21.2 mmol) at rt. BF3·OEt2 (2.48 mL, 19.6 
mmol) was added dropwise to the mixture, which was stirred at 60 °C for 2.5 h. The mixture was 
filtered, and the filtrate was concentrated in vacuo. The residue was purified by column 
chromatography (silica gel, hexane/ethyl acetate, 19:1 to 4:1) to give 86k (3.28 g, 13.0 mmol, 80%) as 
a colorless oil. 1H NMR (300 MHz, CDCl3) δ 3.50 (3H, s), 4.63 (2H, s), 7.38–7.46 (1H, m), 7.75–7.87 
(2H, m). 
2-Methoxy-1-(4-(trifluoromethyl)phenyl)ethanone (86l). To a solution of 97 (2.50 g, 9.36 mmol) in 
MeOH (50 mL) were added Ag2CO3 (2.99 g, 12.2 mmol) and BF3·OEt2 (1.42 mL, 11.2 mmol) at rt. 
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After being stirred at 50 °C for overnight, the mixture was filtered, and the filtrate was concentrated in 
vacuo. The residue was quenched with water and extracted with EtOAc. The organic layer was 
separated, washed with water and saturated aqueous NaCl, dried over anhydrous MgSO4, and 
concentrated in vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl 
acetate, 19:1 to 4:1) to give 86l (1.84 g, 8.43 mmol, 90%) as a white solid. 1H NMR (300 MHz, 
CDCl3) δ 3.51 (3H, s), 4.70 (2H, s), 7.75 (2H, d, J = 8.3 Hz), 8.06 (2H, d, J = 7.9 Hz). 
1-(4-(Trifluoromethoxy)phenyl)prop-2-en-1-ol (88). To a solution of 
4-(trifluoromethoxy)benzaldehyde (87) (21.0 g, 110 mmol) in THF (316 mL) at 0 °C was added 
dropwise 1 M vinylmagnesium bromide solution in THF (133 mL, 133 mmol). The mixture was 
stirred at 0 °C for 2 h under Ar. The mixture was quenched with saturated aqueous NH4Cl at 0 °C and 
extracted with EtOAc. The organic layer was separated, washed with saturated aqueous NaCl, dried 
over anhydrous MgSO4 and concentrated in vacuo. The residue was purified by column 
chromatography (silica gel, hexane/ethyl acetate, 100:0 to 4:1) to give 88 (14.4 g, 66.0 mmol, 60%) as 
a yellow oil. 1H NMR (300 MHz, DMSO-d6) δ 5.00–5.15 (2H, m), 5.63 (1H, d, J = 4.5 Hz), 5.85–6.03 
(1H, m), 7.31 (2H, d, J = 8.5 Hz), 7.42–7.48 (2H, m). MS (ESI/APCI) m/z 201.0 [M + H – H2O]+. 
1-(4-(Trifluoromethoxy)phenyl)prop-2-en-1-one (89). To a solution of 88 (9.8 g, 44.9 mmol) in 
CH3CN (150 mL) was added Dess–Martin periodinane (21.0 g, 49.4 mmol) at rt. The mixture was 
stirred at rt for 1 h. The mixture was evaporated. The residue was purified by column chromatography 
(silica gel, hexane/ethyl acetate, 100:0 to 17:3) to give 89 (6.47 g, 29.9 mmol, 67%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ 5.98 (1H, dd, J = 10.5, 1.5 Hz), 6.46 (1H, dd, J = 17.1, 1.7 Hz), 7.13 
(1H, dd, J = 17.0, 10.5 Hz), 7.31 (2H, d, J = 7.9 Hz), 7.98–8.04 (2H, m). MS (ESI/APCI) m/z 217.0 
[M + H]+. 
2-(4-(Trifluoromethoxy)phenyl)oxirane (91). To a suspension of 4-(trifluoromethoxy)benzaldehyde 
(87) (5.00 g, 26.3 mmol) in DMSO (35 mL) was added portionwise trimethylsulfoxonium iodide (8.10 
g, 36.8 mmol) over 5 min. After H2 gas evolution ceased, the cloudy solution was treated with a 
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solution of 4-(trifluoromethoxy)benzaldehyde (5.00 g, 26.3 mmol) in THF (35 mL) over 15 min. After 
1 h of stirring, ethanol (1 mL) was slowly added, then the THF and ethanol were removed under 
reduced pressure. The DMSO solution was poured into water (100 mL) and then extracted with 
extracted with EtOAc. The organic layer was separated, washed with saturated aqueous NaCl, dried 
over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by column 
chromatography (silica gel, hexane/ethyl acetate, 100:0 to 7:3) to give 91 (2.44 g, 12.0 mmol, 45%) as 
a colorless oil. 1H NMR (300 MHz, CDCl3) δ 2.76 (1H, dd, J = 5.3, 2.7 Hz), 3.16 (1H, dd, J = 5.7, 4.2 
Hz), 3.87 (1H, dd, J = 3.8, 2.7 Hz), 7.14–7.24 (2H, m), 7.27–7.36 (2H, m). 
2-Methoxy-1-(4-(trifluoromethoxy)phenyl)ethanol (92). To a solution of 91 (1.00 g, 4.90 mmol) in 
DMF (5 mL) was added NaOMe (1.32 g, 24.5 mmol) at rt. After being stirred at 60 °C for 2 h, the 
mixture was partitioned between EtOAc and water, the organic layer was washed with saturated 
aqueous NaCl, dried over with anhydrous Na2SO4, and concentrated in vacuo. The residue was 
purified by column chromatography (silica gel, hexane/ethyl acetate, 19:1 to 1:9) to give 92 (0.752 g, 
3.18 mmol, 65%) as a pale yellow oil. 1H NMR (300 MHz, CDCl3) δ 2.92 (1H, br. s.), 3.40 (1H, dd, J 
= 9.8, 8.7 Hz), 3.43 (3H, s), 3.54 (1H, dd, J = 9.8, 3.7 Hz), 4.90 (1H, dd, J = 8.7, 3.0 Hz), 7.12–7.24 
(2H, m), 7.34–7.46 (2H, m). 
1-(3-Fluoro-4-(trifluoromethoxy)phenyl)ethanone (93). To a solution of 83 (13.3 g, 49.7 mmol) in 
THF (250 mL) was added 3 M MeMgBr solution in Et2O (21.5 mL, 64.6 mmol) at 0 °C. After being 
stirred at rt for 4 h, the mixture was quenched with 1 M HCl aqueous solution and extracted with 
EtOAc. The organic layer was separated, washed with water and saturated aqueous NaCl, dried over 
anhydrous MgSO4 and concentrated in vacuo. The residue was purified by column chromatography 
(silica gel, hexane/ethyl acetate, 19:1 to 4:1) to give 93 (10.2 g, 45.9 mmol, 92%) as a colorless oil. 1H 
NMR (300 MHz, CDCl3) δ 2.61 (3H, s), 7.36–7.46 (1H, m), 7.74–7.84 (2H, m). 
2-Bromo-1-(3-fluoro-4-(trifluoromethoxy)phenyl)ethanone (95). To a stirred solution of 93 (4.41 g, 
19.9 mmol) in AcOH (176 mL) was added Br2 (1.04 mL, 19.9 mmol). The mixture was stirred at 
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50 °C for 3 h and then concentrated in vacuo. The mixture was partitioned between EtOAc and 
NaHCO3 aqueous solution. The phases were separated and the aqueous phase was extracted with 
EtOAc. The combined organic phases were washed with saturated aqueous NaCl, dried over 
anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography 
(silica gel, hexane/ethyl acetate, 99:1 to 91:9) to give 95 (4.91 g, 16.3 mmol, 82%) as a pale yellow oil. 
1H NMR (300 MHz, CDCl3) δ 4.39 (2H, s), 7.36–7.51 (1H, m), 7.77–7.91 (2H, m). MS (ESI/APCI) 
m/z 300.9 [M – H]–. 
2-Bromo-1-(4-(trifluoromethoxy)phenyl)ethanone (96). To a solution of 94 (10.0 g, 49.0 mmol) in 
AcOH (100 mL) was added a solution of Br2 (2.64 mL, 51.5 mmol) in AcOH (10 mL) at rt. The 
mixture was stirred at 50 °C for 1 h. The mixture was poured into water and extracted with EtOAc. 
The organic layer was separated, washed with saturated aqueous NaHCO3 and saturated aqueous NaCl, 
dried over anhydrous MgSO4 and concentrated in vacuo to give 96 (11.3 g, 39.9 mmol, 82%). This 
was used in the next reaction without further purification. 1H NMR (300 MHz, CDCl3) δ 4.42 (2H, s), 
7.33 (2H, d, J = 7.9 Hz), 8.00–8.11 (2H, m). 
1-(4-Cyclopropylphenyl)-N-hydroxypropan-1-imine (98a). To a solution of 86a (679 mg, 3.90 mmol) 
and hydroxylammonium chloride (542 mg, 7.79 mmol) in EtOH (40 mL) was added Et3N (1.09 mL, 
7.79 mmol) at rt. After being stirred for 72 h, the mixture was concentrated in vacuo, quenched with 
water, and extracted with EtOAc. The organic layer was washed with water and saturated aqueous 
NaCl, dried over anhydrous MgSO4, and concentrated in vacuo to afford 98a (738 mg, 3.90 mmol, 
quantitative yield). This was used in the next reaction without further purification. 1H NMR (300 MHz, 
CDCl3) δ 0.66–0.76 (2H, m), 0.93–1.03 (2H, m), 1.05–1.21 (3H, m), 1.84–1.97 (1H, m), 2.49–2.85 
(2H, m), 7.07 (2H, d, J = 8.3 Hz), 7.44–7.56 (2H, m), 7.80 (1H, brs). MS (ESI/APCI) m/z 190.2 [M + 
H]+. 
1-(4-(Azetidin-1-yl)phenyl)-N-hydroxypropan-1-imine (98b). To a solution of 86b (410 mg, 2.17 
mmol) in EtOH (30 mL) were added hydroxylammonium chloride (602 mg, 8.67 mmol) and Et3N 
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(1.21 mL, 8.67 mmol) at rt. After being stirred for 20 h, the mixture was concentrated in vacuo, 
quenched with water, and extracted with EtOAc. The organic layer was washed with saturated aqueous 
NaCl, dried over anhydrous MgSO4, and concentrated in vacuo to afford 98b (443 mg, 2.17 mmol, 
quantitative yield). This was used in the next reaction without further purification. 1H NMR (300 MHz, 
CDCl3) δ 1.04–1.22 (3H, m), 2.38 (2H, quin, J = 7.3 Hz), 2.49–2.82 (2H, m), 3.91 (4H, t, J = 7.2 Hz), 
6.38–6.47 (2H, m), 7.29–7.53 (3H, m). MS (ESI/APCI) m/z 205.1 [M + H]+. 
1-(3-(Trifluoromethoxy)phenyl)propan-1-one oxime (98c). To a solution of 86c (3.23 g, 14.8 mmol) 
in EtOH (20 mL) were added hydroxylammonium chloride (1.23 g, 17.8 mmol) and Et3N (1.80 g, 17.8 
mmol). The mixture was stirred at reflux for 16 h. After cooling to rt, the solvent was removed under 
reduced pressure. The residue was partitioned between EtOAc (50 mL) and H2O (50 mL). The 
aqueous phase was extracted with EtOAc (50 mL × 3). The combined organic layer was dried over 
anhydrous Na2SO4 and concentrated in vacuo to afford 98c (3.04 g, 13.0 mmol, 88%) as a colorless oil. 
1HNMR (400 MHz, CDCl3) δ 1.18 (3H, t, J = 7.6 Hz), 2.81 (2H, q, J = 7.6 Hz), 7.18–7.25 (1H, m), 
7.42 (1H, t, J = 8.0 Hz), 7.49 (1H, s), 7.51–7.58 (1H, m), 8.44 (1H, brs). 
1-(2-(Trifluoromethoxy)phenyl)propan-1-one oxime (98d). To a solution of 86d (3.23 g, 14.8 mmol) 
in EtOH (25 mL) were added hydroxylammonium chloride (1.12 g, 16.3 mmol) and Et3N (1.65 g, 16.3 
mmol). The mixture was stirred at reflux for 16 h. After cooling to rt, the mixture was concentrated 
under reduced pressure to remove EtOH. The residue was partitioned between EtOAc (30 mL) and 
water (30 mL). The aqueous phase was extracted with EtOAc (30 mL × 3). The combined organic 
layer was dried over anhydrous Na2SO4 and concentrated in vacuo to afford 98d (2.31 g, 9.91 mmol, 
67%) as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 1.05 (3H, t, J = 7.6 Hz), 2.77 (2H, q, J = 7.6 
Hz), 7.27–7.35 (2H, m), 7.36–7.44 (2H, m), 8.28 (1H, s). 
1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-N-hydroxypropan-1-imine (98e). To a solution of 86e (2.51 
g, 10.6 mmol) in EtOH (35.4 mL) was added hydroxylammonium chloride (0.89 g, 12.8 mmol) and 
Et3N (1.78 mL, 12.8 mmol) at rt. The mixture was stirred at rt overnight. The mixture was poured into 
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water and extracted with EtOAc. The organic layer was separated, washed with saturated aqueous 
NaCl, dried over anhydrous MgSO4, and concentrated in vacuo to give 98e (2.69 g, 10.7 mmol, 
quantitative yeild) as a pale yellow oil. This was used in the next reaction without further purification. 
1-(2-Fluoro-4-(trifluoromethoxy)phenyl)-N-hydroxypropan-1-imine (98f). A mixture of 86f (1.12 g, 
4.74 mmol), hydroxylammonium chloride (0.395 g, 5.69 mmol) and Et3N (0.793 mL, 5.69 mmol) in 
EtOH (30 mL) was stirred at 80 °C for 3 h. The mixture was poured into saturated aqueous NaCl and 
extracted with EtOAc. The organic layer was separated, washed with saturated aqueous NaCl, dried 
over anhydrous MgSO4 and concentrated in vacuo to give 98f (1.27 g, 5.06 mmol, quantitative yeild) 
as a yellow oil. 1H NMR (300 MHz, CDCl3) δ 1.11 (3H, t, J = 7.7 Hz), 2.48–2.85 (1H, m), 6.93–7.14 
(2H, m), 7.19–7.53 (1H, m), 7.83–8.53 (1H, m). 
N-Hydroxy-1-(4-(trifluoromethyl)phenyl)propan-1-imine (98g). To a solution of 86g (2.00 g, 9.89 
mmol) in EtOH (100 mL) were added hydroxylammonium chloride (1.38 g, 19.8 mmol) and Et3N 
(2.76 mL, 19.8 mmol) at rt. After being stirred for 20 h, the mixture was quenched with water and 
extracted with EtOAc. The organic layer was separated, washed with saturated aqueous NaCl, dried 
over anhydrous MgSO4 and concentrated in vacuo to afford 98g (2.15 g, 9.90 mmol, quantitative 
yield). The residue was used in the next reaction without further purification. 1H NMR (300 MHz, 
CDCl3) δ 1.06–1.23 (3H, m), 2.54–2.90 (2H, m), 7.47–7.78 (4H, m), 8.14–8.53 (1H, m). 
N-Hydroxy-3-methoxy-1-(4-(trifluoromethoxy)phenyl)propan-1-imine (98h). To a solution of 86h 
(4.55 g, 18.3 mmol) in EtOH (92 mL) was added hydroxylammonium chloride (1.53 g, 22.0 mmol) 
and Et3N (3.07 mL, 22.0 mmol) at rt. The mixture was stirred at 70 °C overnight. The mixture was 
poured into water at rt and extracted with EtOAc. The organic layer was separated, washed with 
saturated aqueous NaCl, dried over anhydrous MgSO4 and concentrated in vacuo to give 98h (4.70 g, 
17.9 mmol, 97%) as a yellow oil. This was used in the next reaction without further purification. 
N-Hydroxy-2-methoxy-1-(4-(trifluoromethoxy)phenyl)ethanimine (98i). To a solution of 86i (898 mg, 
3.83 mmol) in EtOH (20 mL) were added hydroxylammonium chloride (320 mg, 4.60 mmol) and 
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Et3N (0.641 mL, 4.60 mmol). The mixture was stirred at 80 °C for 4 h and then evaporated under 
reduced pressure to remove EtOH. The residue was partitioned between EtOAc and water. The phases 
were separated and the aqueous phase was extracted with EtOAc. The combined organic phases were 
dried over anhydrous Na2SO4 and concentrated in vacuo to afford 98i (949 mg, 3.81 mmol, 99%) as a 
colorless oil. This was used in the next reaction without furthur purification. MS (ESI/APCI) m/z 
250.1 [M + H]+. 
N-Hydroxy-2-(methylsulfanyl)-1-(4-(trifluoromethoxy)phenyl)ethanimine (98j). A mixture of 86j 
(3.85 g, 15.4 mmol), triethylamine (3.11 g, 30.8 mmol) and hydroxylammonium chloride (1.39 g, 20.0 
mmol) in EtOH (100 mL) was stirred at 80 °C for 16 h. The mixture was poured into saturated 
aqueous NaCl and extracted with EtOAc. The organic layer was separated, washed with saturated 
aqueous NaCl, dried over anhydrous MgSO4 and concentrated in vacuo to give 98j (3.78 g, 14.3 mmol, 
93%) as a yellow oil. 1H NMR (300 MHz, CDCl3) δ 2.14 (3H, s), 3.83 (2H, s), 7.15–7.39 (2H, m), 
7.62–7.87 (2H, m), 8.22 (1H, brs). MS (ESI/APCI) m/z 266.0 [M + H]+. 
1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-N-hydroxy-2-methoxyethanimine (98k). To a solution of 
86k (3.28 g, 13.0 mmol) and hydroxylammonium chloride (1.81 g, 26.0 mmol) in EtOH (150 mL) was 
added Et3N (3.63 mL, 26.0 mmol) at rt. After being stirred for 60 h (over weekend), the mixture was 
concentrated in vacuo, quenched with iced water, and extracted with EtOAc. The organic layer was 
washed with water and saturated aqueous NaCl, dried over anhydrous MgSO4, and concentrated in 
vacuo to afford 98k (3.26 g, 12.2 mmol, 94%). This was used in the next reaction without further 
purification. 1H NMR (300 MHz, CDCl3) δ 3.33–3.42 (3H, m), 4.25–4.68 (2H, m), 7.27–7.63 (3H, m), 
7.68 (1H, s). MS (ESI/APCI) m/z 268.1 [M + H]+. 
N-Hydroxy-2-methoxy-1-(4-(trifluoromethyl)phenyl)ethanimine (98l). To a solution of 86l (1.84 g, 
8.43 mmol) in EtOH (100 mL) were added hydroxylammonium chloride (1.17 g, 16.9 mmol) and Et3N 
(2.35 mL, 16.9 mmol) at rt. After being stirred for 4.5 h, the mixture was concentrated, quenched with 
water, and extracted with EtOAc. The organic layer was washed with saturated aqueous NaCl, dried 
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over anhydrous MgSO4, and concentrated in vacuo to afford 98l (1.97 g, 8.43 mmol, quantitative 
yield). This was used in the next reaction without further purification. 1H NMR (300 MHz, CDCl3) δ 
3.33–3.40 (3H, m), 4.29–4.72 (2H, m), 7.58–7.83 (4H, m), 8.01–8.39 (1H, m). MS (ESI/APCI) m/z 
234.1 [M + H]+. 
1-(4-Cyclopropylphenyl)propan-1-amine (99a). To a solution of 98a (738 mg, 3.90 mmol) in THF (40 
mL) was added 1 M BH3·THF solution in THF (7.09 mL, 7.80 mmol) at rt. After being refluxed for 20 
h, the mixture was quenched with 1 M HCl aqueous solution at rt and extracted with EtOAc. The 
organic layer was separated, washed with water and saturated aqueous NaCl, dried over anhydrous 
MgSO4 and concentrated in vacuo to afford 99a (630 mg, 3.60 mmol, 92%). This was used in the next 
reaction without further purification. 
1-(4-(Azetidin-1-yl)phenyl)propan-1-amine (99b). A mixture of 98b (443 mg, 2.17 mmol) and 10% 
Pd/C (containing 50% water, 45 mg) in MeOH (15 mL) was hydrogenated under balloon pressure at rt 
for 20 h. The catalyst was removed by filtration and the filtrate was concentrated in vacuo to give 99b 
(410 mg, 2.15 mmol, 99%) as a colorless oil. This was used in the next reaction without further 
purification. 1H NMR (300 MHz, CDCl3) δ 0.85 (3H, t, J = 7.3 Hz), 1.61–1.72 (2H, m), 2.28–2.41 (2H, 
m), 3.70 (1H, t, J = 7.0 Hz), 3.86 (4H, t, J = 7.2 Hz), 6.38–6.46 (2H, m), 7.11–7.19 (2H, m). 
1-(3-(Trifluoromethoxy)phenyl)propan-1-amine Hydrochloride (99c). A mixture of 98c (1.03 g, 4.21 
mmol) and Raney Ni (300 mg) in MeOH (100 mL) was hydrogenated under 50 psi at 50 °C for 4 h. 
The suspension was filtered through a pad of Celite and the filter cake was washed with MeOH (50 
mL × 3). The combined filtrate was concentrated to afford the crude product. The residue was purified 
by preparative HPLC (column: YMC-pack ODS-A 4.6 mm ID × 150 mm L; mobile phase A: 0.05% 
HCl in water; mobile phase B: 0.05% HCl in acetonitrile; flow rate: 1.5 mL/min). After most of the 
solvent was removed under reduced pressure, the residue was lyophilized to afford 100c (330 mg, 1.29 
mmol, 31%) as a yellow solid. 1H NMR (400MHz, DMSO-d6) δ 0.75 (3H, t, J = 7.2 Hz), 1.71–1.85 
(1H, m), 1.92–2.05 (1H, m), 4.17–4.28 (1H, m), 7.34–7.42 (1H, m), 7.51–7.61(3H, m), 8.66 (3H, brs). 
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1-(4-(Trifluoromethyl)phenyl)propan-1-amine (99g). A mixture of crude 98g (2.15 g, 9.90 mmol) and 
20% Pd(OH)2/C (containing 50% water, 200 mg) in EtOH (100 mL) was hydrogenated under balloon 
pressure at rt for 5 h. The catalyst was removed by filtration and the filtrate was concentrated in vacuo 
and purified by column chromatography (basic silica gel, hexane/ethyl acetate, 9:1 to 1:1) to give 99g 
(988 mg, 4.86 mmol, 49%) as a colorless oil. 1H NMR (300 MHz, CDCl3) δ 0.87 (3H, t, J = 7.3 Hz), 
1.62–1.77 (2H, m), 3.89 (1H, t, J = 6.8 Hz), 7.44 (2H, d, J = 7.9 Hz), 7.58 (2H, d, J = 7.9 Hz). NH2 
peak was not observed. MS (ESI/APCI) m/z 204.1 [M + H]+. 
2-Methoxy-1-(4-(trifluoromethoxy)phenyl)ethanamine (99i). A mixture of 98i (948.6 mg, 3.81 
mmol) and 10% Pd/C (containing 50% water, 300 mg) in MeOH (20 mL) was hydrogenated under 
balloon pressure at rt overnight. The catalyst was removed by filtration and the filtrate was 
concentrated in vacuo to give 99i (854 mg, 3.63 mmol, 95%) as a white wax-like solid. This was used 
in the next reaction without further purification. 1H NMR (300 MHz, DMSO-d6) δ 3.25 (3H, s), 3.29–
3.38 (2H, m), 3.98–4.15 (1H, m), 7.25–7.34 (2H, m), 7.47–7.54 (2H, m). MS (ESI/APCI) m/z 236.1 
[M + H]+. 
2-(Methylsulfanyl)-1-(4-(trifluoromethoxy)phenyl)ethanamine (99j). A mixture of 1.1 M BH3·THF 
solution in THF (5.14 mL, 5.65 mmol) and 98j (500 mg, 1.88 mmol) in THF (50 mL) was stirred at 
reflux under N2 overnight and then 1 M HCl aqueous solution was added. After being stirred at rt for 
15 min, the mixture was poured into saturated aqueous NaHCO3 and extracted with EtOAc. The 
organic layer was separated, washed with saturated aqueous NaHCO3 and saturated aqueous NaCl, 
dried over anhydrous MgSO4, and concentrated in vacuo to give 99j (515 mg, 2.05 mmol, quantitative 
yeild) as a colorless oil. This was used to the next reaction without further purification. MS 
(ESI/APCI) m/z 235.0 [M + 1 – NH3]+. 
1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethanamine (99k). A solution of 98k (3.26 g, 
12.2 mmol) in EtOH (60 mL) was treated with 20% Pd(OH)2/C (containing 50% water, 1 g) under H2 
for 5 h. The catalyst was filtered off and the filtrate was concentrated in vacuo to afford 99k (2.87 g, 
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11.3 mmol, 93%) as a white solid. 1H NMR (300 MHz, CDCl3) δ 3.32–3.44 (4H, m), 3.43–3.54 (1H, 
m), 3.56–3.99 (2H, m), 4.19 (1H, brs), 6.99–7.48 (3H, m). MS (ESI/APCI) m/z 254.1 [M + H]+. 
1-(2-(Trifluoromethoxy)phenyl)propan-1-amine Hydrochloride (100d). A mixture of 98d (2.31 g, 
9.91 mmol) and Raney Ni (1.00 g) in MeOH (100 mL) was hydrogenated under 50 psi at 50 °C for 4 h. 
The suspension was filtered through a pad of Celite and the filter cake was washed with MeOH (50 
mL × 2). The combined filtrate was concentrated to afford the crude product as a white wax-like solid. 
The residue was dissolved in EtOAc (70 mL) and MeOH (10 mL). 4 M HCl solution in EtOAc (40 mL, 
160 mmol) was added to the above mixture. The mixture was stirred at 15 °C for 2 h and the solvent 
was removed under reduced pressure. The resulting solid was triturated with MTBE, collected by 
filtration, rinsed with MTBE (50 mL × 3), and dried to afford 100d (1.36 g, 5.32 mmol, 54%) as a 
white solid. 1H NMR (400 MHz, DMSO-d6) δ 0.78 (3H, t, J = 7.2 Hz), 1.76–1.89 (1H, m), 1.96–2.10 
(1H, m), 4.31–4.41 (1H, m), 7.39–7.48 (1H, m), 7.49–7.59 (2H, m), 7.84 (1H, dd, J = 6.8, 2.4 Hz), 
8.69 (3H, brs). MS (ESI/APCI) m/z 219.9 [M + H]+. 
1-(3-Fluoro-4-(trifluoromethoxy)phenyl)propan-1-amine Hydrochloride (100e). A mixture of 98e 
(2.69 g, 10.71 mmol) and 10% Pd/C (containing 50% water, 540 mg) in EtOH (36 mL) was 
hydrogenated under balloon pressure at rt overnight. The catalyst was removed by filtration and the 
filtrate was concentrated in vacuo. The residue was purified by column chromatography (silica gel, 
hexane/ethyl acetate, 7:3 to 0:100). The desired fractions were collected and evaporated. To a solution 
of the residue in EtOAc (10 mL) was added 4 M HCl solution in EtOAc (10 mL, 40 mmol). The 
mixture was concentrated in vacuo. The resulting solid was triturated with i-Pr2O, collected by 
filtration, rinsed with i-Pr2O, and dried to give 100e (1.85 g, 6.76 mmol, 63%) as a white solid. 1H 
NMR (300 MHz, DMSO-d6) δ 0.77 (3H, t, J = 7.5 Hz), 1.74–1.92 (1H, m), 1.92–2.12 (1H, m), 4.24 
(1H, dd, J = 9.0, 5.8 Hz), 7.50 (1H, d, J = 8.5 Hz), 7.67 (1H, td, J = 8.3, 0.9 Hz), 7.80 (1H, dd, J = 
11.6, 2.0 Hz), 8.76 (3H, brs). 
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1-(2-Fluoro-4-(trifluoromethoxy)phenyl)propan-1-amine Hydrochloride (100f). A mixture of 98f 
(1.27 g, 5.06 mmol) and 10% Pd/C (containing 50% water, 150 mg) in MeOH (30 mL) was 
hydrogenated under balloon pressure at rt for 2 days. LC–MS showed no reaction. After the Pd/C was 
filtered off, Raney nickel (100 mg, 0.85 mmol) was then added to the mixture. The mixture was 
hydrogenated under balloon pressure at rt for 2 days. LC–MS showed the reaction was slow with most 
of the starting material remained. After the Raney nickel was filtered off, 20% Pd(OH)2/C (containing 
50% water, 100 mg, 0.71 mmol) was added to the mixture, which was hydrogenated under balloon 
pressure at rt overnight. The mixture was passed through a cake of celite, and the filtrate was 
concentrated in vacuo. To the residue was added 4 M HCl solution in EtOAc (5 mL, 20 mmol). The 
resulting solid was triturated with i-Pr2O at 0 °C, collected by filtration, rinsed with i-Pr2O at 0 °C, and 
dried to give 100f (647 mg, 2.36 mmol, 47%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 0.79 
(3H, t, J = 7.3 Hz), 1.73–1.92 (1H, m), 1.93–2.10 (1H, m), 4.32–4.50 (1H, m), 7.41 (1H, d, J = 8.7 
Hz), 7.52 (1H, dd, J = 10.5, 1.5 Hz), 7.80 (1H, t, J = 8.5 Hz), 8.56 (2H, brs). MS (ESI/APCI) m/z 
221.0 [M + H]+. 
3-Methoxy-1-(4-(trifluoromethoxy)phenyl)propan-1-amine Hydrochloride (100h). A mixture of 98h 
(4.70 g, 17.9 mmol) and 20% Pd(OH)2/C (containing 50% water, 300 mg) in MeOH (89 mL) was 
hydrogenated under balloon pressure at rt overnight. The catalyst was removed by filtration and the 
filtrate was concentrated in vacuo. The residue was purified by column chromatography (silica gel, 
hexane/ethyl acetate/methanol, 1:1:0 to 0:100:0 to 0:3:2). The desired fractions were collected and 
evaporated. To the residue was added 4 M HCl solution in EtOAc (15 mL, 60 mmol) at rt. The mixture 
was stirred at rt for 10 min and concentrated in vacuo. The residue was triturated with hexane/i-Pr2O, 
collected by filtration, rinsed with hexane/i-Pr2O, and dried to give 100h (2.40 g, 8.40 mmol, 47%) as 
a pale yellow solid. 1H NMR (300 MHz, DMSO-d6) δ 1.92–2.08 (1H, m), 2.26 (1H, d, J = 5.3 Hz), 
3.05–3.16 (1H, m), 3.18 (3H, s), 3.25–3.36 (1H, m), 4.36 (1H, brs), 7.46 (2H, d, J = 8.1 Hz), 7.60–
7.72 (2H, m), 8.62 (3H, brs). 
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2-Methoxy-1-(4-(trifluoromethoxy)phenyl)ethanamine Hydrochloride (100i). To a 4 M HCl solution 
in EtOAc (100 mL, 400 mmol) was added a solution of 99i (4.80 g, 20.4 mmol) in EtOAc (10 mL) at 
rt. After being stirred for 2 h, the mixture was concentrated in vacuo. The resulting solid was triturated 
with i-Pr2O, collected by filtration, rinsed with i-Pr2O, and dried to afford 100i (4.20 g, 15.5 mmol, 
76%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 3.34 (3H, s), 3.58–3.74 (2H, m), 4.58 (1H, dd, 
J = 6.6, 5.5 Hz), 7.46 (2H, d, J = 8.7 Hz), 7.65 (2H, d, J = 8.3 Hz), 8.57 (3H, brs). MS (ESI/APCI) m/z 
236.1 [M + H]+. 
2-Methoxy-1-(4-(trifluoromethyl)phenyl)ethanamine Hydrochloride (100l). A mixture of 98l (1.97 g, 
8.43 mmol) and 10% Pd/C (containing 50% water, 200 mg) in EtOH (100 mL) was hydrogenated 
under balloon pressure at rt overnight. The catalyst was removed by filtration and the filtrate was 
concentrated in vacuo. To a stirred 4 M HCl solution in EtOAc (20 mL, 80 mmol) was added a 
solution of crude 2-methoxy-1-(4-(trifluoromethyl)phenyl)ethanamine obtained above (1.85 g, 8.43 
mmol) in EtOAc (5 mL) at rt. After being stirred for 30 min, the mixture was concentrated in vacuo. 
The residue was triturated with ethyl acetate, collected by filtration, rinsed with ethyl acetate, and 
dried to afford 100l (1.81 g, 7.08 mmol, 84%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 
3.26–3.41 (3H, m), 3.59–3.78 (2H, m), 4.58–4.73 (1H, m), 7.66–7.91 (4H, m), 8.69 (3H, brs). MS 
(ESI/APCI) m/z 220.1 [M + H]+. 
Ethyl Oxo(4-(trifluoromethoxy)phenyl)acetate (102). To a solution of 
1-bromo-4-(trifluoromethoxy)benzene (101) (10.0 g, 41.5 mmol) in THF (200 mL) at –78 °C was 
added dropwise 1.6 M butyllithium solution in hexane (31.1 mL, 49.8 mmol). The mixture was stirred 
at –78 °C for 50 min under N2. Then, ethyl 2-chloro-2-oxoacetate (6.23 g, 45.6 mmol) was added to 
the mixture at –78 °C. The mixture was gradually warmed to rt and stirred at the same temperature 
overnight. The mixture was poured into 1 M HCl aqueous solution at 0 °C and extracted with EtOAc. 
The organic layer was washed with water and saturated aqueous NaCl, dried over anhydrous MgSO4, 
and concentrated in vacuo. The residue was purified by column chromatography (silica gel, 
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hexane/ethyl acetate, 49:1 to 1:1) to give 102 (2.50 g, 9.54 mmol, 23%) as an orange oil, which 
contained some impurities. This was used in the next reaction without further purification. 1H NMR 
(300 MHz, CDCl3) δ 1.41–1.47 (3H, m), 4.41–4.51 (2H, m), 7.30–7.40 (2H, m), 8.04–8.19 (2H, m). 
Ethyl 2-(Hydroxyimino)-2-(4-(trifluoromethoxy)phenyl)acetate (103). A mixture of Et3N (1.60 mL, 
11.4 mmol), 102 (2.50 g, 9.54 mmol) and hydroxylammonium chloride (0.795 g, 11.4 mmol) in EtOH 
(100 mL) was stirred at 80 °C overnight. The mixture was poured into saturated aqueous NaCl and 
extracted with EtOAc. The organic layer was washed with saturated aqueous NaCl, dried over 
anhydrous MgSO4, and concentrated in vacuo. The residue was purified by column chromatography 
(silica gel, hexane/ethyl acetate, 49:1 to 1:1) to give 103 (725 mg, 2.62 mmol, 27%) as a pale yellow 
solid. 1H NMR (300 MHz, CDCl3) δ 1.36 (2H, t, J = 7.0 Hz), 1.40 (3H, t, J = 7.2 Hz), 4.36 (2H, q, J = 
7.2 Hz), 4.46 (2H, q, J = 7.2 Hz), 7.19–7.33 (4H, m), 7.53–7.64 (4H, m), 8.65 (1H, brs), 9.22 (1H, 
brs). 
Ethyl Amino(4-(trifluoromethoxy)phenyl)acetate (104). A mixture of 103 (720 mg, 2.60 mmol) and 
10% Pd/C (containing 50% water, 140 mg) in EtOH (15 mL) was hydrogenated under balloon 
pressure at rt overnight. The mixture was filtered and the filtrate was concentrated in vacuo to give 
104 (590 mg, 2.24 mmol, 86%) as a pale orange solid. 1H NMR (300 MHz, CDCl3) δ 1.18–1.28 (3H, 
m), 2.09 (2H, brs), 3.97–4.37 (2H, m), 4.63 (1H, s), 7.13–7.25 (2H, m), 7.43 (2H, d, J = 8.7 Hz). MS 
(ESI/APCI) m/z 264.1 [M + H]+. 
Ethyl ((tert-Butoxycarbonyl)amino)(4-(trifluoromethoxy)phenyl)acetate (105). A mixture of 104 
(590 mg, 2.24 mmol) and Boc2O (430 mg, 2.47 mmol) in THF (20 mL) was stirred at rt for 2 days. 
The mixture was concentrated in vacuo to give crude 105 (952 mg, 2.62 mmol, quantitative yeild) as a 
yellow oil. This was used in the next reaction without further purification. 1H NMR (300 MHz, 
CDCl3) δ 1.22 (3H, t, J = 7.2 Hz), 1.53 (9H, s), 3.99–4.33 (2H, m), 5.32 (1H, d, J = 6.8 Hz), 5.63 (1H, 
brs), 7.19 (2H, d, J = 7.9 Hz), 7.41 (2H, d, J = 8.7 Hz). 
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tert-Butyl (2-Hydroxy-1-(4-(trifluoromethoxy)phenyl)ethyl)carbamate (106). To a suspension of 
LAH (41.8 mg, 1.10 mmol) in THF (5 mL) at 0 °C was added 105 (100 mg, 0.28 mmol). The mixture 
was stirred at the same temperature for 30 min and then MgSO4 and a small amount of H2O were 
sequentially added, followed by EtOAc. The mixture was filtered through celite pad and the filtrate 
was concentrated in vacuo to give 106 (54.8 mg, 0.171 mmol, 62%) as a colorless gum. 1H NMR (300 
MHz, CDCl3) δ 1.55 (9H, s), 3.71 (1H, brs), 3.86 (2H, brs), 4.79 (1H, brs), 5.28 (1H, brs), 7.11–7.24 
(2H, m), 7.29–7.41 (2H, m). MS (ESI/APCI) m/z 320.1 [M – H]–. 
tert-Butyl (2-Hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)carbamate (107). To a 
solution of methylmagnesium bromide (1 M THF solution, 2.20 mL, 2.20 mmol) in THF (5 mL) at 
0 °C was added 105 (200 mg, 0.55 mmol). The mixture was stirred at 0 °C for 2 h. The mixture was 
poured into saturated aqueous NH4Cl and extracted with EtOAc. The organic layer was separated, 
washed with saturated aqueous NaCl, dried over anhydrous MgSO4, and concentrated in vacuo. The 
residue was purified by column chromatography (silica gel, hexane/ethyl acetate, 9:1 to 1:4) to give 
107 (78 mg, 0.224 mmol, 41%) as a pale yellow solid. 1H NMR (300 MHz, CDCl3) δ 1.05 (3H, s), 
1.36 (3H, s), 1.40 (9H, brs), 1.49 (1H, brs), 4.50 (1H, d, J = 5.3 Hz), 5.52 (1H, d, J = 5.7 Hz), 7.14–
7.23 (2H, m), 7.29–7.38 (2H, m). 
1-Amino-2-methyl-1-(4-(trifluoromethoxy)phenyl)propan-2-ol Hydrochloride (108). A mixture of 
107 (78 mg, 0.22 mmol) and 4 M HCl solution in EtOA (5 mL, 20 mmol) was stirred at rt for 1 h. The 
mixture was concentrated in vacuo to give 108 (53.3 mg, 0.187 mmol, 84%) as a pale yellow solid. 1H 
NMR (300 MHz, DMSO-d6) δ 0.97 (3H, s), 1.23 (3H, s), 4.23 (1H, s), 5.39 (1H, s), 7.38–7.52 (2H, m), 
7.55–7.71 (2H, m), 8.37 (3H, brs). MS (ESI/APCI) m/z 250.1 [M + H]+. 
tert-Butyl (2-Methoxy-1-(4-(trifluoromethoxy)phenyl)ethyl)carbamate (109). To a solution of 99i 
(10.8 g, 45.9 mmol) in THF (250 mL) were added Boc2O (11.7 mL, 50.5 mmol) and Et3N (7.68 mL, 
55.1 mmol) at rt. After being stirred for 20 h, the mixture was quenched with water and extracted with 
EtOAc. The organic layer was washed with water and saturated aqueous NaCl, dried over anhydrous 
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MgSO4, and concentrated in vacuo. The residue was purified by column chromatography (silica gel, 
hexane/ethyl acetate, 19:1 to 4:1) to give 109 (12.7 g, 37.8 mmol, 82%) as a white solid. 1H NMR (300 
MHz, CDCl3) δ 1.41 (9H, brs), 3.35 (3H, s), 3.46–3.67 (2H, m), 4.80 (1H, brs), 5.29 (1H, brs), 7.13–
7.21 (2H, m), 7.30–7.39 (2H, m). 
tert-Butyl ((1R)-2-Methoxy-1-(4-(trifluoromethoxy)phenyl)ethyl)carbamate (110a). Resolution of the 
enantiomers of 109 was carried out chromatographically using a Chiralpak IC 50 mm ID × 500 mm L 
column (hexane/ethanol, 93:7) at 85 mL/min. Resolution of 109 (12.7 g, 37.8 mmol) provided 110a as 
a white solid (5.84 g, 17.4 mmol, 46%, 92% theoretical) as the first eluting enantiomer. Analytical 
HPLC analysis carried out on a 4.6 mm ID × 250 mm L Chiralpak IC column (hexane/ethanol, 9:1) at 
a flow rate of 1.0 mL/min indicated that 110a was of 99.4% ee. 1H NMR (300 MHz, CDCl3) δ 1.41 
(9H, brs), 3.35 (3H, s), 3.49–3.67 (2H, m), 4.80 (1H, brs), 5.29 (1H, brs), 7.13–7.21 (2H, m), 7.30–
7.38 (2H, m). 
tert-Butyl ((1S)-2-Methoxy-1-(4-(trifluoromethoxy)phenyl)ethyl)carbamate (110b). Resolution of the 
enantiomers of 109 was carried out chromatographically using a Chiralpak IC 50 mm ID × 500 mm L 
column (hexane/ethanol, 93:7) at 85 mL/min. Resolution of 109 (12.7 g, 37.8 mmol) provided 110b as 
a white solid (5.95 g, 17.7 mmol, 47%, 94% theoretical) as the second eluting enantiomer. Analytical 
HPLC analysis carried out on a 4.6 mm ID × 250 mm L Chiralpak IC column (hexane/ethanol, 9:1) at 
a flow rate of 1.0 mL/min indicated that 110b was of 99.8% ee. 1H NMR (300 MHz, CDCl3) δ 1.41 
(9H, brs), 3.35 (3H, s), 3.49-3.66 (2H, m), 4.81 (1H, brs), 5.29 (1H, brs), 7.13–7.21 (2H, m), 7.30–
7.39 (2H, m).. 
(1R)-2-Methoxy-1-(4-(trifluoromethoxy)phenyl)ethanamine Hydrochloride (111a). A mixture of 
110a (5.84 g, 17.4 mmol) and 4 M HCl solution in EtOAc (30 mL, 120 mmol) was stirred at rt for 1 h. 
The mixture was concentrated in vacuo, and the residue was triturated with i-Pr2O, collected by 
filtration, rinsed with i-Pr2O, and dried to give 111a (4.52 g, 16.6 mmol, 96%) as a white solid. 1H 
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NMR (300 MHz, DMSO-d6) δ 3.33 (3H, s), 3.60–3.77 (2H, m), 4.52–4.61 (1H, m), 7.46 (2H, d, J = 
8.3 Hz), 7.68 (2H, d, J = 8.7 Hz), 8.67 (3H, brs). MS (ESI/APCI) m/z 219.0 [M + H – (NH3)]+. 
(1S)-2-Methoxy-1-(4-(trifluoromethoxy)phenyl)ethanamine Hydrochloride (111b). A mixture of 
110b (5.95 g, 17.7 mmol) and 4 M HCl solution in EtOAc (30 mL, 120 mmol) was stirred at rt for 1 h. 
The mixture was concentrated in vacuo, and the residue was triturated with i-Pr2O, collected by 
filtration, rinsed with i-Pr2O, and dried to give 111b (4.30 g, 15.8 mmol, 89%) as a white solid. 1H 
NMR (300 MHz, DMSO-d6) δ3.33 (3H, s), 3.60–3.77 (2H, m), 4.52–4.61 (1H, m), 7.46 (2H, d, J = 8.3 
Hz), 7.68 (2H, d, J = 8.7 Hz), 8.67 (3H, brs). MS (ESI/APCI) m/z 219.1 [M + H – (NH3)]+. 
tert-Butyl (1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)carbamate (113). To a solution 
of 99k (7.47 g, 29.5 mmol) in THF (200 mL) were added Boc2O (7.53 mL, 32.5 mmol) and Et3N (6.17 
mL, 44.3 mmol) at rt. After being stirred at rt for 16 h, the mixture was quenched with water and 
extracted with EtOAc. The organic layer was separated, washed with saturated aqueous NaCl, dried 
over anhydrous MgSO4, and concentrated in vacuo. The residue was purified by column 
chromatography (silica gel, hexane/ethyl acetate, 19:1 to 4:1) to give 113 (8.25 g, 23.4 mmol, 79%) as 
a white solid. 1H NMR (300 MHz, CDCl3) δ 1.42 (9H, brs), 3.35 (3H, s), 3.49–3.67 (2H, m), 4.78 (1H, 
brs), 5.34 (1H, brs), 7.08–7.29 (3H, m). MS (ESI/APCI) m/z 254.0 [M + H – (Boc)]+. 
tert-Butyl ((1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethyl)carbamate (114a). 
Resolution of the enantiomers of 113 was carried out chromatographically using a Chiralpak AD 50 
mm ID × 500 mm L column (hexane/ethanol, 19:1) at 80 mL/min. Resolution of S43 (12.5 g, 35.5 
mmol) provided 114a as a white solid (5.73 g, 16.2 mmol, 46%, 92% theoretical) as the first eluting 
enantiomer. Analytical HPLC analysis carried out on a 4.6 mm ID × 250 mm L Chiralpak AD column 
(hexane/ethanol, 19:1) at a flow rate of 1.0 mL/min indicated that 114a was of >99.9% ee. 1H NMR 
(300 MHz, CDCl3) δ 1.42 (9H, brs), 3.35 (3H, s), 3.49–3.66 (2H, m), 4.77 (1H, brs), 5.34 (1H, brs), 
7.07–7.30 (3H, m). MS (ESI/APCI) m/z 254.0 [M + H – (Boc)]+. 
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(1S)-1-(3-Fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethanamine hydrochloride (115). A 
mixture of 114a (5.73 g, 16.2 mmol) and 4 M HCl solution in EtOAc (100 mL, 400 mmol) was stirred 
at rt for 3 h. The mixture was concentrated in vacuo, and the resulting solid was triturated with i-Pr2O, 
collected by filtration, rinsed with i-Pr2O, and dried to give 115 (4.45 g, 15.4 mmol, 95%) as a white 
solid. 1H NMR (300 MHz, DMSO-d6) δ 3.33 (3H, s), 3.61–3.78 (2H, m), 4.55–4.64 (1H, m), 7.47–
7.56 (1H, m), 7.64–7.83 (2H, m), 8.74 (3H, brs). MS (ESI/APCI) m/z 254.0 [M + H]+. 
(+)-Di-(p-toluoyl)-D-tartaric acid salt of 116 (117). 115 (2.00 g, 6.90 mmol) was suspended in EtOAc 
and neutralized with saturated aqueous NaHCO3. The organic phase was dried over anhydrous Na2SO4 
and concentrated in vacuo to afford 116 (1.74 g, 6.87 mmol, quantitative yeild) as a colorless oil. 116 
(127 mg, 0.500 mmol) and (2S,3S)-(+)-di-(p-toluoyl)-D-tartaric acid (193 mg, 0.500 mmol) were 
dissolved in EtOH (200 µl) and water (200 µl) at rt. The mixture was heated to 50 °C and standed 
overnight to give (2S,3S)-2,3-bis((4-methylbenzoyl)oxy)butanedioic acid - 
(1S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-2-methoxyethanamine (1:1) (117) suitable for X-ray 
crystallography. 
Enzyme Assay Protocol. Preparation of human PDE. Human PDE1A, 3A, 4D2, 5A1, 7B, 8A1, 9A2, 
and 11A4 enzymes were purchased from BPS Bioscience. Human PDE6AB enzyme was purchased 
from SB Drug Discovery. Human PDE2A3 full-length gene was transduced into Sf9, and human 
PDE2A3 enzyme was purified by His-tag affinity column and gel filtration. Human PDE10A2 was 
generated from COS-7 cells transfected with the full-length gene. The enzymes were stored at −70 °C 
until use. 
PDE2A3 enzyme inhibitory assay. PDE activity was measured using a SPA (GE Healthcare). To 
evaluate the inhibitory activity of the compound, 10 μL of serially diluted compounds were reacted 
with 20 μL of PDE enzyme (final concentration 0.023 nM) in assay buffer (50 mM HEPES-NaOH, 8.3 
mM MgCl2, 1.7 mM EGTA, and 0.1% bovine serum albumin (BSA) (pH 7.4)) for 30 min at rt. The 
final concentration of DMSO in the reaction solution was 1%. Compounds were tested in duplicate in 
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96-well half-area plates (Corning) or a 384-well OptiPlate (PerkinElmer). We used an 8 concentration 
serial dilution dose response ranging from 100 µM to 10 pM compound concentrations. To start the 
reaction, 10 μL of substrate [3H] cGMP (final concentration 77 nM, PerkinElmer) was added to a total 
volume of 40 μL. After reaction for 60 min at rt, 20 μL of 20 mg/mL yttrium SPA beads containing 
zinc sulfate was added to terminate the PDE reaction. After allowing to settle for an additional 60 min, 
the assay plates were counted in a scintillation counter (PerkinElmer) to allow calculation of the 
inhibition rate. The inhibition rate was calculated on the basis of the 0% control wells with enzyme 
and DMSO, and the 100% control wells without enzyme. All IC50 values were obtained by fitting the 
results to the following 4 Parameter Logistic Equation: 
y = A + (B – A)/(1 + (10^((C – x)*D))) 
where A is the minimum y value, B is the maximum y value, C is Log(EC50) value, and D is the 
slope factor. 
Human PDE enzyme assay. PDE activities were measured using a SPA (GE Healthcare). To evaluate 
the inhibitory activity, 10 μL of serially diluted compounds were incubated with 20 μL of PDE 
enzymes, except for PDE1A, in the following assay buffer: 50 mM HEPES-NaOH, 8.3 mM MgCl2, 
1.7 mM EGTA, and 0.1% BSA (pH 7.4) for 30 min at rt. The PDE1A enzyme assay was performed in 
the following assay buffer: 50 mM Tris-HCl, 8.3 mM MgCl2, 0.2 mM CaCl2, 0.1% BSA, and 30 nM 
Calmodulin (pH 7.5). The final concentration of DMSO in the assay was 1%, and compounds were 
tested in duplicate in 96-well half-area plates (Corning). We used an 4 concentration serial dilution 
dose response ranging from 10 µM to 10 nM compound concentrations. To start the reaction, 10 μL of 
substrate ([3H] cGMP (final concentration 77 nM, PerkinElmer) for PDE1A, 5A1, 6AB, 9A2, 10A2, 
and 11A4 or [3H] cAMP (final concentration 14.7 nM, PerkinElmer) for PDE3A, 4D2, 7B, and 8A1) 
was added for a final assay volume of 40 μL. After 60 min incubation at rt, 20 μL of 20 mg/mL 
yttrium SPA beads containing zinc sulfate was added to terminate the PDE reaction. After allowing to 
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settle for more than 120 min, the assay plates were counted in a scintillation counter (PerkinElmer) to 
allow calculation of the inhibition rate. 
Estimation of Log D at pH 7.4. Log D7.4, which is the partition coefficient of the compounds between 
1-octanol and aqueous buffer at pH 7.4, was measured using a chromatographic procedure based on a 
published method.68 The instruments utilized were a Waters Alliance 2795 HPLC system and a 2996 
UV–vis detector (Milford, MA, USA). 
Transcellular Transport Study Using a Transporter-Expression System. Human 
MDR1-expressing LLC-PK1 cells were cultured as reported previously with minor modifications.106 
The transcellular transport study was performed as reported previously.107 In brief, the cells were 
grown for 7 days in an HTS Transwell 96-well permeable support (pore size: 0.4 μm, surface area: 
0.143 cm2) with a polyethylene terephthalate membrane (Corning Life Sciences, Lowell, MA, USA) at 
a density of 1.125 × 105 cells/well. The cells were preincubated with M199 at 37 °C for 30 min. 
Subsequently, transcellular transport was initiated by the addition of M199 either to apical 
compartments (75 μL) or to the basolateral compartments (250 μL) containing 10 μM digoxin, 200 
μM lucifer yellow as a marker for the monolayer tightness, and 10 μM test compounds, and then 
terminated by the removal of each assay plate after 2 h. The aliquots (25 μL) in the opposite 
compartments were mixed with acetonitrile containing alprenolol and diclofenac as an internal 
standard and then centrifuged. The compound concentrations in the supernatant were measured by 
LC–MS/MS. The apparent permeability (Papp) of test compounds in the receiver wells was determined 
and the efflux ratio (ER) for the MDR1 membrane permeability test was calculated using the 
following equation: ER = Papp,BtoA/Papp,AtoB 
where Papp,AtoB is the apical-to-basal passive permeability–surface area product and Papp,BtoA is the 
basal-to-apical passive permeability–surface area product. 
In Vitro Metabolic Clearance Assay. In vitro oxidative metabolic studies of the test compounds were 
carried out using hepatic microsomes obtained from humans, rats, or mice. The reaction mixture with 
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a final volume of 0.05 mL consisted of 0.2 mg/mL hepatic microsomes in 50 mM KH2PO4–K2HPO4 
phosphate buffer (pH 7.4) and 1 μM test compound. The reaction was initiated by the addition of an 
NADPH-generating system containing 25 mM MgCl2, 25 mM glucose 6-phosphate, 2.5 mM 
β-NADP+, and 7.5 units/mL glucose 6-phosphate dehydrogenase at 20 vol% of the reaction mixture. 
After addition of the NADPH-generating system, the mixture was incubated at 37 °C for 0, 15, and 30 
min. The reaction was terminated by addition of an equivalent volume of acetonitrile. After the 
samples were mixed and centrifuged, the supernatant fractions were analyzed using LC–MS/MS. For 
metabolic clearance determinations, chromatograms were analyzed to determine the disappearance of 
the parent compound from the reaction mixtures. All incubations were carried out in duplicate. 
Protein Expression and Purification. The PDE2A catalytic domain (578–919) was cloned into a 
pFastBac vector, for expression in Sf9 cells, utilizing an N-terminal 6× poly-histidine tag containing a 
TEV cleavage site. Large-scale production of recombinant protein was carried out in Sf9 cells. The 
pellet from 10L of baculovirus-infected Sf9 cells was resuspended in 600 mL of lysis buffer containing 
25 mM Tris (pH 7.6), 1 M NaCl, 20 mM imidazole, 5% glycerol, and 3 Roche cOmplete Protease 
Inhibitor tablets. The cell suspension was homogenized with the Polytron PT-3100, centrifuged for 1 h 
at 13,000 rpm (JA-14 rotor), and the clarified supernatant was brought to 800 mL with lysis buffer 
before batch binding with 10 mL of Probond Ni resin (Invitrogen) and rolling for 2 h at 4 °C. The 
beads were collected by low speed centrifugation (3,500 rpm, JS-4.2 rotor), loaded into a gravity 
column, and washed slowly overnight with 2 L of wash buffer containing 25 mM Tris (pH 7.6), 1 M 
NaCl, 20 mM imidazole, and 5% glycerol. The following day, the protein was eluted with buffer 
containing 25 mM Tris (pH 7.9), 50 mM NaCl, 250 mM imidazole, and 10% glycerol. The 1.5 mL 
sample eluted from the Nickel capture step was brought to 9 mL with Mono Q buffer A containing 25 
mM Tris (pH 7.9), and 10% glycerol. After the full sample volume was bound to the Mono Q column, 
a salt gradient was applied from 0 to ~800 mM NaCl in 40 mL. Fractions corresponding to the 
unphosphorylated protein (identified by MS with MW = 40178 Da) were pooled for further 
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purification by size-exclusion chromatography (SEC) on a Superdex 200 column equilibrated in 
1XTBS pH 7.4, 0.5 mM DTT, 1 mM EDTA, and 10% glycerol. Peak SEC fractions were collected and 
concentrated to 12 mg/mL for crystallization. 
Crystallization and Structure Determination. Crystals suitable for data collection were first grown 
in hanging drops using the vapor diffusion method at rt by adding 0.5 µL of protein solution with 1 
mM of IBMX59 and 0.5 µL of reservoir solution (30% PEG 3350, 0.1 M Tris pH 7.5, and 0.2 M 
MgCl2). PDE2A IBMX crystals were soaked in a drop containing 5 mM of 42a, 31% PEG 3350, 0.1 
M Tris (pH 7.5), and 0.2 M MgCl2 for 6 days. Crystals were transferred through a fresh cryo-protected 
soak drop immediately before being harvested and flash frozen in liquid nitrogen. X-ray diffraction 
data were collected at ALS beamline 5.0.2 using a Pilatus3 6M (Dectris) detector from a single 
cryogenically protected crystal (100 K) at a wavelength of 1 Å. The crystals belong to space group 
C121 and contain three enzyme molecules per asymmetric unit. X-ray diffraction data were reduced 
using the HKL2000108 software package. The structure was determined by molecular replacement with 
PHASER within the CCP4 program suite and refined with REFMAC.111 Several cycles of model 
building using MIfit113 and refinement using REFMAC were performed to improve the quality of the 
model. The coordinates and structure factors have been deposited in the PDB with accession code 
5VP0. 
Animal Experiments. The care and use of animals and the experimental protocols were approved by 
the Experimental Animal Care and Use Committee of Takeda Pharmaceutical Company Limited. 
Pharmacokinetic Analysis in Rat or Mouse Cassette Dosing. Compound 42a was administered 
intravenously (0.1 mg/kg) or orally (1 mg/kg) by cassette dosing to nonfasted male Crl:CD(SD)(IGS) 
rats (8W, n = 3) or male ICR mice (8W, n = 3). The combination for a cassette dosing was determined 
to avoid combinations of compounds with the same molecular weight. The solution of compounds in 
dimethylacetamide containing 50% (v/v) 1,3 butanediol at 0.1 mg/mL/kg was administered 
intravenously to isoflurane-anesthetized mice via femoral vein. The suspension of compounds in 0.5% 
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methyl cellulose with water was used for vehicle (1 mg/kg) and was administered orally by gavage. 
After administration, blood samples were collected via tail vein by syringes with heparin at 5, 10, 15, 
30 min, 1, 2, 4, and 8 h (iv) and 15, 30 min, 1, 2, 4, and 8 h (po), and centrifuged to obtain the plasma 
fraction. The plasma samples were deproteinized by mixing with acetonitrile followed by 
centrifugation. The compound concentrations in the supernatant were measured by LC–MS/MS with a 
standard curve. Pharmacokinetic parameters were calculated by the non-compartmental analysis. The 
area under the concentration-time curve (AUC) and the area under the first moment curve (AUMC) 
were calculated using the linear trapezoidal method. The mean residence time (MRT) was calculated 
as AUMC/AUC. The total clearance (CLtotal) was calculated as doseiv/AUCiv. The volume of 
distribution (Vdss) was calculated as CLtotal × MRTiv. Oral bioavailability (F) was calculated as 
(AUCpo/dosepo)/(AUCiv/doseiv) × 100. 
Brain and Plasma Concentration in Rats and Mice. Compound 42a was suspended in 0.5% (w/v) 
methylcellulose in distilled water, and was administered at a volume of 2 mL/kg body weight for rats 
and 10 mL/kg for mice. Seven-week-old male SD rats (Charles River Laboratories Japan, Inc., 
Yokohama, Japan) and seven-week-old male ICR mice (CLEA Japan Inc., Tokyo, Japan) were 
euthanized 2 h after oral administration of 42a (10 mg/kg). Blood was centrifuged and the 
supernatants were collected as plasma. Brain was homogenized in physiological saline. Concentrations 
of 42a were measured in aliquots of rat plasma and tissues, which were mixed well with acetonitrile 
containing internal standards and then centrifuged. The supernatants were diluted with solvents for 
LC–MS/MS analysis (mobile phase A: 10 mM ammonium formate/formic acid (100/0.2, v/v), mobile 
phase B: acetonitrile/formic acid (100/0.2, v/v)). The diluted solutions were injected into an LC–
MS/MS (API5000, AB Sciex, Foster City, CA) equipped with a Shimadzu Shim-pack XR-ODS 
column (2.2 μm packing particle size, 2.0 mm ID × 30 mm L) maintained at 50 °C. The 
chromatographic separation was performed using gradient elution at a flow rate of 0.7 mL/min. The 
LC time program was as follows: Mobile phase B was held at 5% for 0.2 min, and increased linearly 
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to 99% in 1.1 min. After maintaining B at 99% for another 0.7 min, it was brought back to 5% in 0.01 
min, followed by re-equilibration for 0.59 min. The total cycle time for one injection was 2.6 min. 
Compound 42a was detected using multiple reaction monitoring mode and the transition m/z 459.20 
→ 223.01. AnalystTM software (version 1.4.2) was used for data acquisition and processing. 
Measurement of Cyclic Nucleotide Contents in Mouse Brains. Animals. Four-week-old male ICR 
mice were purchased from CLEA Japan, Inc. (Japan). After one week acclimation period, the 
five-week-old mice were used for the experiment. The mice were housed in groups of 5/cage in a 
light-controlled room (12 h light/dark cycles with lights on at 07:00). Food and water were provided 
ad libitum. 
Measurements. Compound 42a was suspended in 0.5% (w/v) methylcellulose in distilled water and 
administered at a volume of 10 mL/kg body weight for mice. Either vehicle or compound 42a was 
administered orally to mice after a habituation period of more than 30 min. Compound 42a was 
administered at 3 and 10 mg/kg. A microwave fixation system (Muromachi Kikai, Tokyo, Japan) was 
used to sacrifice unanesthetized mice by exposure of the head to the microwave beam at 60 min after 
administration of 42a. Hippocampi were isolated and homogenized in 0.5 mol/L HCl, followed by 
centrifugation. The cGMP concentration in the supernatant was quantified using a cyclic GMP EIA kit 
(Cayman Chemical, USA) according to the manufacturer’s instructions. Values were expressed as 
pmol/mg tissue weight. 
Compound 42a was suspended in 0.5% (w/v) methylcellulose in distilled water, and was administered 
in a volume of 10 mL/kg body weight for mice. Either vehicle or compound 42a (1, 3, and 10 mg/kg) 
was administered orally to mice after a habituation period of more than 1 h. A microwave fixation 
system (Muromachi Kikai, Tokyo, Japan) was used to sacrifice unanesthetized mice by exposure of 
the head to the microwave beam at 60 min after administration of 42a. Brain tissues were isolated and 
homogenized in 0.5 mol/L HCl, followed by centrifugation. The concentration of cyclic nucleotides in 
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the supernatant was quantified using a cyclic cAMP or GMP EIA kit (Cayman Chemical, USA) 
according to the manufacturer’s instructions. Values were expressed as pmol/mg tissue weight. 
Effects of 42a on the Novel Object Recognition Task in Rats. Animals. Six-week-old male Long–
Evans rats were purchased from Japan SLC Inc. Rats were acclimated for one week prior to the 
experiment. The rats were housed in groups of 2 or 3/cage in a light-controlled room (12 h light/dark 
cycles with lights on at 07:00). Food and water were provided ad libitum. 
Measurements. Compound 42a was suspended in 0.5% (w/v) methylcellulose in distilled water, and 
administered at a volume of 2 mL/kg body weight for rats. On day 1, rats were allowed to habituate to 
the behavioral test room for over 1 h, and then they were allowed to habituate individually to the 
empty test box (a gray-colored polyvinyl chloride box (40 × 40 × 50 cm)) for 10 min. The test was 
comprised of two, 3 min trials called the acquisition and retention trials, separated by a 48 h inter-trial 
interval. On day 2, in the acquisition trial, rats were allowed to explore two identical objects (A1 and 
A2) for 3 min. Object exploration was defined as rats’ licking, sniffing, or touching the object with 
forelimbs while sniffing. Leaning against the object to look upward and standing or sitting on the 
object were excluded. The exploration time of rats for each object (A1 and A2) was scored manually. 
Rats that scored less than 10 s of total exploration time during the acquisition trials were excluded 
from further study. On day 4, in the retention trial, rats were again allowed to explore a familiar object 
(A3) and a novel object (B) for 3 min. Exploration times for the familiar and novel objects were 
manually scored in the same way as in the acquisition trial. Vehicle or 42a (0.01, 0.1, and 1 mg/kg) 
was administered orally 2 h prior to the acquisition trial. The novelty discrimination index (NDI) was 
calculated using the following equation: novel object interaction time/total interaction time × 100 
(%).Forty rats were prepared in total, and then one rat treated with 1 mg/kg was excluded because its 
total exploration time in the acquisition trial was less than 10 s (6.95 s). Numbers of rats treated with 




Determination of the Absolute Stereochemistry of Amine 111a. The absolute configuration of 111a 
was determined by X-ray crystallography. 
Crystal data for 111a: C10H13F3NO2+·Cl–·0.25C7H8, MW = 294.70; crystal size, 0.20 × 0.09 × 0.06 
mm; colorless, block; triclinic, space group P1, a = 7.2413(3) Å, b = 14.4003(6) Å, c = 14.4361(6) Å, 
α = 105.170(8)°, β = 103.917(8)°, γ = 92.350(7)°, V = 1401.53(12) Å3, Z = 4, Dx = 1.397 g/cm3, T = 
100 K, μ = 2.736 mm-1, λ = 1.54187 Å, R1 = 0.051, wR2 = 0.133, Flack Parameter114 = 0.036(13). 
All measurements were made on a Rigaku R-AXIS RAPID-191R diffractometer using graphite 
monochromated Cu-Kα radiation. The structure was solved by direct methods with SHELXS-97115 and 
was refined using full-matrix least-squares on F2 with SHELXL-97.115 All non-H atoms were refined 
with anisotropic displacement parameters. 
CCDC 1548480 for compound 111a contains the supplementary crystallographic data for this paper. 





Figure 2-10.  ORTEP of 111a, thermal ellipsoids are drawn at 20% probability. 
Determination of the Absolute Stereochemistry of Amine 114a. The absolute configuration of 114a 
was determined by X-ray crystallography of its (+)-di-(p-toluoyl)-D-tartaric acid salt 117. 
Crystal data for 117: C10H12F4NO2+·C20H17O8–, MW = 639.55; crystal size, 0.20 × 0.11 × 0.09 mm; 
colorless, block; monoclinic, space group P21, a = 7.88545(14) Å, b = 25.3299(5) Å, c = 15.2262(3) Å, 
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α = γ = 90°, β = 90.330(7)°, V = 3041.20(10) Å3, Z = 4, Dx = 1.397 g/cm3, T = 100 K, μ = 1.044 mm-1, 
λ = 1.54187 Å, R1 = 0.060, wR2 = 0.160, Flack Parameter114 = 0.01(15). 
All measurements were made on a Rigaku R-AXIS RAPID-191R diffractometer using graphite 
monochromated Cu-Kα radiation. The structure was solved by direct methods with SIR92116 and was 
refined using full-matrix least-squares on F2 with SHELXL-97.115 All non-H atoms were refined with 
anisotropic displacement parameters. 
CCDC 1548479 for compound 117 contains the supplementary crystallographic data for this paper. 
These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via  
http://www.ccdc.cam.ac.uk/Community/Requestastructure/Pages/DataRequest.aspx?. 
 




第 3 章に関する実験 
(S)-N-(2-hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)pyrazolo[1,5-a]pyrimidine-3-carb
oxamide (119). A mixture of pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (15) (43.8 mg, 0.268 mmol), 
130 (84.3 mg, 0.295 mmol), EDCI·HCl (61.7 mg, 0.321 mmol), HOBt·H2O (49.3 mg, 0.321 mmol), 
and TEA (0.045 mL, 0.321 mmol) in DMF (1.5 mL) was stirred at rt overnight. The mixture was 
poured into water and extracted with EtOAc. The organic layer was washed with saturated aqueous 
NaCl, dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by column 
chromatography (silica gel, hexane/ethyl acetate/methanol, 4:1:0 to 0:100:0 to 0:9:1) to give 119 (43.6 
mg, 0.111 mmol, 41%) as a white solid after trituration with i-Pr2O. 1H NMR (300 MHz, DMSO-d6) δ 
1.03 (3H, s), 1.26 (3H, s), 4.87–5.00 (2H, m), 7.24–7.36 (3H, m), 7.46–7.59 (2H, m), 8.52 (1H, s), 
8.81–8.95 (2H, m), 9.33 (1H, dd, J = 7.0, 1.7 Hz). MS (ESI/APCI) m/z 395.0 [M + H]+. HPLC purity: 
100%. mp 148 °C. 
(S)-N-(2-Hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)-6-methylpyrazolo[1,5-a]pyrimidi
ne-3-carboxamide (120). A mixture of 6-methylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid (15b) 
(53.1 mg, 0.300 mmol), 130 (94.3 mg, 0.330 mmol), EDCI·HCl (69.0 mg, 0.360 mmol), HOBt·H2O 
(55.1 mg, 0.360 mmol), and Et3N (50.2 µl, 0.360 mmol) in DMF (1.5 mL) was stirred at rt overnight. 
The mixture was poured intowaterand extracted with EtOAc. The organic layer was washed with 
saturated aqueous NaCl, dried over anhydrous MgSO4 and concentrated in vacuo. The residue was 
purified by column chromatography (basic silica gel, hexane/ethyl acetate, 9:1 to 1:9) to give 120 (107 
mg, 0.262 mmol, 87%) as a white solid after trituration with i-Pr2O. 1H NMR (300 MHz, DMSO-d6) δ 
1.02 (3H, s), 1.25 (3H, s), 2.40 (3H, s), 4.89 (1H, s), 4.94 (1H, d, J = 8.7 Hz), 7.28 (2H, d, J = 7.9 Hz), 
7.51 (2H, d, J = 8.7 Hz), 8.43 (1H, s), 8.76-8.86 (2H, m), 9.18 (1H, dd, J = 1.9, 1.1 Hz). MS 
(ESI/APCI) m/z 409.2 [M + H]+. HPLC purity: 100%. mp 208 °C. 
N-((1S)-2-Hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)-5-isopropylpyrazolo[1,5-a]pyri
midine-3-carboxamide (121a). A mixture of 136 (38.6 mg, 0.09 mmol) and 5% Pd/C–ethylenediamine 
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complex (10 mg) in MeOH (5 mL) was hydrogenated under balloon pressure at at rt for 16 h. The 
catalyst was removed by filtration and the filtrate was concentrated in vacuo. The residue was purified 
by column chromatography (silica gel, hexane/ethyl acetate, 19:1 to 0:100) to afford 121 (32.1 mg, 
0.074 mmol, 83%) as a white amorphous solid. 1H NMR (300 MHz, DMSO-d6) δ 0.99–1.08 (3H, m), 
1.27 (3H, s), 1.41 (3H, d, J = 4.5 Hz), 1.43 (3H, d, J = 4.5 Hz), 3.20–3.34 (1H, m), 4.81–5.00 (2H, m), 
7.22–7.34 (3H, m), 7.48–7.61 (2H, m), 8.44 (1H, s), 9.07 (1H, d, J = 8.7 Hz), 9.19 (1H, d, J = 7.2 Hz). 
MS (ESI/APCI) m/z 437.1 [M + H]+. HPLC purity: 98.9%. 
N-((1S)-2-Hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)-5-(tetrahydro-2H-pyran-4-yl)py
razolo[1,5-a]pyrimidine-3-carboxamide (121b). A mixture of 137 (84.4 mg, 0.177 mmol) and Pd/C 
(en) (15 mg) in MeOH (10 mL) and THF(dry) (2 mL) was hydrogenated under balloon pressure at rt 
for 16 h. The catalyst was removed by filtration and the filtrate was concentrated in vacuo. The residue 
was purified by column chromatography (silica gel, hexane/ethyl acetate, 19:1 to 0:100) to afford 
121b (82.9 mg, 0.173 mmol, 98%) as a white amorphous solid. 1H NMR (300 MHz, DMSO-d6) δ 1.04 
(3H, s), 1.28 (3H, s), 1.86–2.11 (4H, m), 3.13–3.28 (1H, m), 3.45–3.59 (2H, m), 3.97–4.10 (2H, m), 
4.88–4.99 (2H, m), 7.24–7.34 (3H, m), 7.50–7.61 (2H, m), 8.45 (1H, s), 9.03 (1H, d, J = 8.7 Hz), 9.21 
(1H, d, J = 7.2 Hz). MS (ESI/APCI) m/z 479.1 [M + H]+. HPLC purity: 99.6%. 
N-((1S)-2-Hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)-5-(pyridin-2-yl)pyrazolo[1,5-a]
pyrimidine-3-carboxamide (121c). A mixture of crude 141 (79.0 mg, 0.329 mmol), 130 (94.0 mg, 
0.329 mmol), HATU (163 mg, 0.428 mmol), DIEA (0.172 mL, 0.987 mmol), and DMF (3 mL) was 
stirred at rt for 12 h. The mixture was diluted with water and extracted with EtOAc. The organic layer 
was separated, washed with saturated aqueous NaCl, dried over anhydrous Na2SO4 and concentrated 
in vacuo. The residue was purified by column chromatography (basic silica gel, hexane/ethyl acetate, 
100:0 to 0:100) to give 121c (130 mg, 0.276 mmol, 84% (63% yield in 2 steps from 141)) as a pale 
yellow amorphous solid. 1H NMR (300 MHz, CDCl3) δ 1.21 (3H, s), 1.49 (3H, s), 1.96 (1H, s), 5.14 
(1H, d, J = 8.3 Hz), 7.14–7.22 (2H, m), 7.44–7.56 (3H, m), 7.88–7.97 (1H, m), 8.26 (1H, d, J = 7.4 
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Hz), 8.64 (1H, s), 8.75–8.88 (3H, m), 9.25 (1H, d, J = 8.3 Hz). MS (ESI/APCI) m/z 472.1 [M + H]+. 
HPLC purity: 97.3%. Anal. Calcd for C23H20F3N5O3: C, 58.60; H, 4.28; N, 14.86. Found: C, 58.61; H, 
4.51; N, 14.86. 
N-((1S)-2-Hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)-5-(6-methylpyridin-3-yl)pyrazol
o[1,5-a]pyrimidine-3-carboxamide (121d). The title compound was prepared as a pale yellow solid 
after trituration with hexane/ethyl acetate (5:1) in 63% yield from 135 and 
2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine using the procedure analogous to 
that described for the synthesis of 137, except that basic silica gel was employed in a column 
chromatography purification in place of silica gel. 1H NMR (300 MHz, DMSO-d6) δ 1.03 (3H, s), 1.33 
(3H, s), 2.60 (3H, s), 4.93 (1H, d, J = 8.3 Hz), 5.19 (1H, s), 7.23–7.33 (2H, m), 7.48–7.59 (3H, m), 
7.98 (1H, d, J = 7.5 Hz), 8.50 (1H, s), 8.81 (1H, dd, J = 8.3, 2.3 Hz), 9.24 (1H, d, J = 8.7 Hz), 9.41 
(1H, d, J = 7.5 Hz), 9.54 (1H, d, J = 2.3 Hz). MS (ESI/APCI) m/z 486.1 [M + H]+. HPLC purity: 100%. 
mp 237 °C. 
N-((1S)-2-Hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)-5-(2-methylpyridin-4-yl)pyrazol
o[1,5-a]pyrimidine-3-carboxamide (121e). A mixture of 135 (130 mg, 0.303 mmol), 
2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (100 mg, 0.455 mmol), 
(Amphos)2PdCl2 (21.5 mg, 0.0303 mmol), K2CO3 (62.9 mg, 0.455 mmol), toluene (2 mL) and water 
(0.2 mL) was heated at 120 °C under microwave irradiation for 2.5 h. After being cooled to rt, the 
reaction mixture was directly purified by column chromatography (basic silica gel, ethyl 
acetate/methanol, 100:0 to 19:1) to give 121e (115 mg, 0.237 mmol, 78%) as an off-white solid after 
recrystallization from heptane/ethyl acetate. 1H NMR (300 MHz, CDCl3) δ 1.21 (3H, s), 1.50 (3H, s), 
1.73 (1H, s), 2.72 (3H, s), 5.13 (1H, d, J = 8.5 Hz), 7.13–7.20 (2H, m), 7.46–7.54 (3H, m), 7.91 (1H, 
dd, J = 5.1, 1.3 Hz), 8.09 (1H, s), 8.67 (1H, s), 8.75 (1H, d, J = 5.3 Hz), 8.88 (1H, d, J = 7.4 Hz), 9.19 
(1H, d, J = 8.3 Hz). MS (ESI/APCI) m/z 486.1 [M + H]+. HPLC purity: 100%. mp 192 °C. Anal. Calcd 




propyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (121f). The title compound was prepared as a white 
amorphous solid in 77% yield from 135 and 
1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole using the procedure 
analogous to that described for the synthesis of 137, except that the crude material was purified by 
basic silica gel column chromatography followed by silica gel column chromatography. 1H NMR (300 
MHz, DMSO-d6) δ 1.04 (3H, s), 1.36 (3H, s), 4.89 (1H, d, J = 8.3 Hz), 5.28 (1H, s), 7.23–7.35 (2H, m), 
7.49–7.59 (2H, m), 7.73 (1H, d, J = 7.5 Hz), 7.97 (1H, t, J = 59.0 Hz), 8.45 (1H, s), 8.81 (1H, s), 9.29 
(1H, s), 9.32–9.42 (2H, m). MS (ESI/APCI) m/z 511.1 [M + H]+. HPLC purity: 100%. 
N-((1S)-2-Hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)-5-(1H-pyrazol-1-yl)pyrazolo[1,
5-a]pyrimidine-3-carboxamide (121g). To a mixture of 135 (126.3 mg, 0.295 mmol) and 1H-pyrazole 
(24.1 mg, 0.353 mmol) in DMF (4 mL) was added K2CO3 (48.8 mg, 0.353 mmol). The mixture was 
stirred at 90 °C for 30 min and then poured into water. The mixture was extracted with EtOAc, washed 
with water and saturated aqueous NaCl, dried over anhydrous Na2SO4 and concentrated in vacuo. The 
residue was purified by column chromatography (silica gel, hexane/ethyl acetate, 19:1 to 0:100) to 
afford 121g (102 mg, 0.222 mmol, 75%) as a white solid after trituration with hexane/ethyl acetate 
(5:1). 1H NMR (300 MHz, DMSO-d6) δ 1.02 (3H, s), 1.36 (3H, s), 4.86 (1H, d, J = 8.3 Hz), 5.34 (1H, 
s), 6.75–6.81 (1H, m), 7.23–7.33 (2H, m), 7.48–7.58 (2H, m), 7.76 (1H, d, J = 7.5 Hz), 8.05 (1H, d, J 
= 1.5 Hz), 8.46 (1H, s), 9.02–9.14 (2H, m), 9.37 (1H, d, J = 7.5 Hz). MS (ESI/APCI) m/z 461.1 [M + 
H]+. HPLC purity: 100%. mp 241 °C. 
N-((1S)-2-Hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)-5-(4-methyl-1H-imidazol-1-yl)p
yrazolo[1,5-a]pyrimidine-3-carboxamide (121h). The title compound was prepared as a pale yellow 
solid after trituration with hexane/ethyl acetate (5:1) in 70% yield from 135 and 
4-methyl-1H-imidazole using the procedure analogous to that described for the synthesis of 121g, 
except that a preparative HPLC (column: L-Column2 ODS 20 mm ID × 150 mm L; mobile phase A: 
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0.1% TFA in water; mobile phase B: 0.1% TFA in acetonitrile; flow rate: 20 mL/min) was employed in 
place of silica gel column chromatography. 1H NMR (300 MHz, DMSO-d6) δ 1.02 (3H, s), 1.35 (3H, 
s), 2.24 (3H, s), 4.87 (1H, d, J = 8.3 Hz), 5.31 (1H, s), 7.24–7.33 (2H, m), 7.47–7.57 (2H, m), 7.73 (1H, 
d, J = 7.9 Hz), 8.07 (1H, s), 8.45 (1H, s), 8.85 (1H, d, J = 0.8 Hz), 9.00 (1H, d, J = 8.3 Hz), 9.46 (1H, 
d, J = 7.5 Hz). MS (ESI/APCI) m/z 475.1 [M + H]+. HPLC purity: 99.2%. mp 130 °C. 
(S)-N-(2-Hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)-5-(4-(trifluoromethyl)-1H-imida
zol-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (121i). The title compound was prepared as a pale 
yellow solid after trituration with hexane/ethyl acetate (5:1) in 70% yield from 135 and 
4-(trifluoromethyl)-1H-imidazole using the procedure analogous to that described for the synthesis of 
121g. 1H NMR (300 MHz, DMSO-d6) δ 1.02 (3H, s), 1.34 (3H, s), 4.86 (1H, d, J = 8.3 Hz), 5.36 (1H, 
s), 7.23–7.33 (2H, m), 7.47–7.58 (2H, m), 7.89 (1H, d, J = 7.5 Hz), 8.53 (1H, s), 8.92–9.02 (2H, m), 
9.15 (1H, s), 9.62 (1H, d, J = 7.5 Hz). MS (ESI/APCI) m/z 529.1 [M + H]+. HPLC purity: 100%. mp 
220 °C. 
N-((1S)-2-Hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)-5-(4-methyl-1H-1,2,3-triazol-1-
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (121j). A mixture of 135 (430 mg, 1.00 mmol), 
4-methyl-1H-1,2,3-triazole (100 mg, 1.20 mmol) and K2CO3 (208 mg, 1.50 mmol) in DMF (4 mL) 
was stirred at 80 °C for 2 h. The mixture was quenched with water at rt and extracted with EtOAc. The 
organic layer was separated, washed with water and saturated aqueous NaCl, dried over anhydrous 
MgSO4 and concentrated in vacuo (508.7 mg). The residue was purified by  using preparative HPLC 
(column: L-Column2 ODS 20 mm ID × 150 mm L; mobile phase A: 0.1% TFA in water; mobile phase 
B: 0.1% TFA in acetonitrile; flow rate: 20 mL/min). The first eluting factions (tR1) were concentrated 
to dryness, and washed with saturated aqueous NaHCO3, extracted with EtOAc. The organic layer was 
separated, washed with water and saturated aqueous NaCl, dried over anhydrous MgSO4 and 
concentrated in vacuo. The residue (42.7 mg) was crystallized from hexane/ethyl acetate to give 121j 
(34.4 mg, 0.072 mmol, 7.2%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 1.04 (3H, s), 1.37 
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(3H, s), 2.44 (3H, s), 4.87 (1H, d, J = 8.3 Hz), 5.39 (1H, s), 7.23–7.34 (2H, m), 7.48–7.58 (2H, m), 
7.93 (1H, d, J = 7.5 Hz), 8.55 (1H, s), 8.88 (1H, d, J = 0.8 Hz), 9.07 (1H, d, J = 8.3 Hz), 9.50 (1H, d, J 
= 7.5 Hz). MS (ESI/APCI) m/z 476.2 [M + H]+. HPLC purity: 99.4%. mp 260 °C. 
N-((1S)-2-Hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)-5-(3-methyl-1H-1,2,4-triazol-1-
yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (121k). The title compound was prepared as a white 
solid after trituration with i-Pr2O in 35% yield from 135 and 3-methyl-1H-1,2,4-triazole using the 
procedure analogous to that described for the synthesis of 121g, except that basic silica gel was 
employed in a column chromatography purification in place of silica gel. 1H NMR (300 MHz, 
DMSO-d6) δ 1.02 (3H, brs), 1.36 (3H, s), 2.47 (3H, brs), 4.86 (1H, d, J = 8.1 Hz), 5.43 (1H, s), 7.21–
7.35 (2H, m), 7.47–7.59 (2H, m), 7.63 (1H, d, J = 7.5 Hz), 8.52 (1H, s), 9.06 (1H, d, J = 8.1 Hz), 9.46 
(1H, d, J = 7.5 Hz), 9.55 (1H, s). MS (ESI/APCI) m/z 476.1 [M + H]+. HPLC purity: 100%. 
(S)-N-(2-Hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)-6-methyl-5-(4-methyl-1H-1,2,3-t
riazol-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (122a). To a mixture of 154a (2.81 g, 10.9 
mmol) and 130 (3.26 g, 11.4 mmol) in DMF (250 mL) were added HOBt·H2O (2.06 g, 13.1 mmol), 
EDCI·HCl (2.55 g, 13.1 mmol) and TEA (7.65 mL, 54.4 mmol). The mixture was stirred at rt 
overnight and then quenched with water at rt. The mixture was extracted with EtOAc, washed with 
saturated aqueous NaHCO3, water, and then saturated aqueous NaCl, dried over anhydrous Na2SO4, 
and concentrated in vacuo. The residue was purified by column chromatography (silica gel, 
hexane/ethyl acetate, 100:0 to 3:17) to give 122a (3.86 g, 7.89 mmol, 73%) as a white solid. 1H NMR 
(300 MHz, CDCl3) δ 1.17 (3H, s), 1.48 (3H, s), 1.74 (1H, s), 2.50 (3H, d, J = 0.8 Hz), 2.84 (3H, d, J = 
0.8 Hz), 5.05(1H, d, J = 8.3 Hz), 7.17 (2H, d, J = 7.9 Hz), 7.38–7.48 (2H, m), 8.60 (1H, s), 8.69–8.82 
(3H, m). The obtained product (3.86 g, 7.89 mmol) was dissolved in EtOAc (277 mL) at 50–60 °C. To 
this solution was added hexane (150 mL) at the same temperature and a white solid precipitated. After 
2 h of stirring at rt, further hexane (88 mL) was added to the mixture, which was stirred at rt for 10 
min. The white precipitate was collected by filtration, washed with hexane/ethyl acetate, and dried to 
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give 122a (3.17 g, 6.48 mmol, 82 %) as a white solid. 1H NMR (300 MHz, CDCl3) δ 1.17 (3H, s), 1.48 
(3H, s), 1.74 (1H, s), 2.50 (3H, d, J = 0.8 Hz), 2.84 (3H, d, J = 0.8 Hz), 5.05(1H, d, J = 8.3 Hz), 7.17 
(2H, d, J = 8.3 Hz), 7.39–7.48 (2H, m), 8.60 (1H, s), 8.69–8.83 (3H, m). MS (ESI/APCI) m/z 490.2 [M 
+ H]+. HPLC purity: 100%. mp 238–239 °C. Anal. Calcd for C22H22F3N7O3: C, 53.99; H, 4.53; F, 
11.64; N, 20.03. Found: C, 53.82; H, 4.42; F, 11.64; N, 19.81. 
(S)-N-(2-Hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)-6-methyl-5-(3-methyl-1H-1,2,4-t
riazol-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide (122b). To a suspension of 154b (606 mg, 2.35 
mmol) in DMF (12 mL) were added 130 (805 mg, 2.82 mmol), EDCI·HCl (540 mg, 2.82 mmol), 
HOBt·H2O (431 mg, 2.82 mmol), and TEA (0.392 mL, 2.82 mmol) at rt. The mixture was stirred at rt 
for 2 h. The mixture was poured into water and extracted with EtOAc. The organic layer was separated, 
washed with saturated aqueous NaCl, dried over anhydrous MgSO4 and concentrated in vacuo. The 
residue was purified by column chromatography (basic silica gel, hexane/ethyl acetate, 4:1 to 1:9) to 
give 122b (858 mg, 1.75 mmol, 75%) as a white solid after recrystallization from i-Pr2O/ethyl acetate. 
1H NMR (300 MHz, DMSO-d6) δ 1.00 (3H, s), 1.31 (3H, s), 2.46 (3H, s), 2.64 (3H, d, J = 0.8 Hz), 
4.87 (1H, d, J = 8.0 Hz), 5.32 (1H, s), 7.27 (2H, d, J = 8.0 Hz), 7.51 (2H, d, J = 8.7 Hz), 8.49 (1H, s), 
8.85 (1H, d, J = 8.3 Hz), 9.46–9.53 (2H, m). 13C NMR (151 MHz, DMSO-d6) δ 13.81, 16.90, 27.23, 
28.42, 59.79, 70.72, 104.48, 112.33, 119.99, 120.00 (q, J = 256.0 Hz, 1C), 130.07, 139.82, 140.56, 
142.33, 145.40, 146.18, 147.05 (q, J = 1.7 Hz, 1C), 148.11, 159.97, 162.02. MS (ESI/APCI) m/z 490.3 
[M + H]+. HPLC purity: 100%. [α]ଶ଴ୈ  = −363.2 (c = 1.00 in MeOH). mp 212 °C. Anal. Calcd for 
C22H22F3N7O3: C, 53.99; H, 4.53; N, 20.03. Found: C, 54.11; H, 4.50; N, 20.04. 
2-Amino-2-(4-(trifluoromethoxy)phenyl)acetic Acid (125). The solution of potassium cyanide (19.4 g, 
299 mmol) in water (170 mL) at 50 °C was added dropwise to a solution of 4-trifluoromethoxy 
benzaldehyde (123) (34.1 mL, 239 mmol) and ammonium carbonate (62.0 g, 645 mmol) in EtOH (273 
mL) and water (109 mL). The mixture was stirred at 60 °C for 3 h. After cooling to rt, EtOH was 
removed under reduced pressure. To the mixture was acidified to pH ~1 with concd HCl at 0 °C. The 
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solid was filtered off and washed with water. To a solution of potassium hydroxide (66.2 g, 1000 
mmol) in water (250 mL) was added the product at rt. The mixture was stirred at 90 °C overweekend. 
After cooling to rt, the mixture was neutralized with concd HCl. The resulting solid was filtered off, 
washed with water, and dried to give 125 (56.0 g, 238 mmol, 100 %) as a pale yellow solid. This was 
used in the next reaction without further purification. MS (ESI/APCI) m/z 234.0 [M − H]−. 
((tert-Butoxycarbonyl)amino)(4-(trifluoromethoxy)phenyl)acetic Acid (126). To a solution of 125 
(56.0 g, 238 mmol) in THF (476 mL) was added Boc2O (82.9 mL, 357 mmol) and 2 M NaOH aqueous 
solution (357 mL, 714 mmol) at rt. The mixture was stirred at rt. The mixture was poured into water at 
rt and extracted with Et2O. The aqueous layer was acidified to pH ~3 with 1 M HCl aqueous solution 
at 0 °C and then extracted with EtOAc. The organic layer was washed with saturated aqueous NaCl, 
dried over anhydrous MgSO4 and concentrated in vacuo to afford 126 (63.3 g, 189 mmol) as a pale 
yellow solid. This was subjected to the next reaction without further purification. MS (ESI/APCI) m/z 
333.9 [M − H]−. 
tert-Butyl (2-Hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)carbamate (127). To a 
solution of 126 (63.3 g, 189 mmol) in DMF (378 mL) were added MeI (14.2 mL, 227 mmol) and 
K2CO3 (31.3 g, 227 mmol) at rt. The mixture was stirred at rt for 2 h. The mixture was poured into 
water at rt and extracted with EtOAc. The organic layer was separated, washed with saturated aqueous 
NaCl, dried over anhydrous MgSO4 and concentrated in vacuo. The residue was purified by column 
chromatography (silica gel, hexane/ethyl acetate, 100:0 to 4:1) to give 127 (38.7 g, 111 mmol, 46 % 
from 21) as an off-white solid. 1H NMR (300 MHz, CDCl3) δ 1.26–1.53 (9H, m), 3.73 (3H, s), 5.27–
5.41 (1H, m), 5.54–5.75 (1H, m), 7.20 (2H, d, J = 8.3 Hz), 7.35–7.44 (2H, m). MS (ESI/APCI) m/z 
348.1 [M − H]−. 
tert-Butyl (2-Hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)carbamate (128). To a 
solution of 127 (23.5 g, 67.3 mmol) in THF (336 mL) was added dropwise MeMgBr (269 mL, 269 
mmol) at 0 °C. The mixture was stirred at 0 °C under Ar for 1 h. The mixture was quenched with 
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saturated aqueous NH4Cl at 0 °C and extracted with EtOAc. The organic layer was separated, washed 
with saturated aqueous NaCl, dried over anhydrous MgSO4 and concentrated in vacuo. The residue 
was purified by column chromatography (silica gel, hexane/ethyl acetate, 19:1 to 2:3) to give 128 
(17.9 g, 51.2 mmol, 76 %) as a white solid. 1H NMR (300 MHz, CDCl3) δ 1.05 (3H, s), 1.30–1.47 
(12H, m), 4.50 (1H, d, J = 6.4 Hz), 5.53 (1H, d, J = 8.7 Hz), 7.18 (2H, d, J = 7.9 Hz), 7.33 (2H, d, J = 
8.7 Hz). MS (ESI/APCI) m/z 348.0 [M − H]−. 
tert-Butyl ((1S)-2-Hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)carbamate (129a). 
Resolution of the enantiomers of 128 was carried out chromatographically using a Chiralpak AD 20 
mm ID × 250 mm L column (hexane/ethanol, 19:1) at 80 mL/min. Resolution of 128 (22.3 g, 63.8 
mmol) provided 129a as a white solid (10.2 g, 29.1 mmol, 46%, 91% theoretical) as the first eluting 
enantiomer. Analytical HPLC analysis carried out on a 4.6 mm ID × 250 mm L Chiralpak AD column 
with the same eluent as above at a flow rate of 1.0 mL/min indicated that 129a was of >99.9% ee. 1H 
NMR (300 MHz, CDCl3) δ 1.05 (3H, s), 1.36 (3H, s), 1.40 (9H, brs), 1.51 (1H, brs), 4.50 (1H, d, J = 
7.5 Hz), 5.53 (1H, d, J = 8.3 Hz), 7.13–7.23 (2H, m), 7.29–7.39 (2H, m). 
(1S)-1-Amino-2-methyl-1-(4-(trifluoromethoxy)phenyl)propan-2-ol Hydrochloride (130). 
A mixture of 129a (10.2 g, 29.3 mmol) and 4 M HCl solution in EtOAc (70.0 mL, 280 mmol) was 
stirred at rt for 1.5 h. The mixture was concentrated in vacuo and the resulting solid was triturated with 
hexane/i-Pr2O, collected by filtration, rinsed with hexane/i-Pr2O, and dried to afford 130 (7.00 g, 24.5 
mmol, 84 %) as a pale red solid. 1H NMR (300 MHz, DMSO-d6) δ 0.98 (3H, s), 1.23 (3H, s), 4.23 (1H, 
brs), 5.39 (1H, s), 7.37–7.48 (2H, m), 7.63 (2H, d, J = 8.7 Hz), 8.46 (3H, brs). 
Ethyl 5-Hydroxypyrazolo[1,5-a]pyrimidine-3-carboxylate (132). To a mixture of ethyl 
3-amino-1H-pyrazole-4-carboxylate (131) (30.0 g, 193 mmol) and ethyl 3-ethoxy-2-propenoate (cis- 
and trans-mixture, 41.9 mL, 290 mmol) in DMF (387 mL) was added cesium carbonate (113 g, 348 
mmol). The mixture was stirred at 100 °C for 2 h, diluted with water and then acidified to pH ~5 with 
AcOH. The resulting solid was filtered by filtration, washed with water and dried to afford 132 (36.4 g, 
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176 mmol, 91 %) as a beige solid. 1H NMR (300 MHz, DMSO-d6) δ 1.28 (3H, t, J = 7.1 Hz), 4.28 (2H, 
q, J = 7.1 Hz), 6.15 (1H, d, J = 7.9 Hz), 8.13 (1H, s), 8.57 (1H, d, J = 7.9 Hz), 11.73 (1H, brs). 
5-Hydroxypyrazolo[1,5-a]pyrimidine-3-carboxylic Acid (133). To a solution of 132 (20.8 g, 100 
mmol) in THF (223 mL) and EtOH (111 mL) was added 2 M NaOH aqueous solution (201 mL, 401 
mmol). The mixture was stirred at 50 °C overnight. The mixture was evaporated under reduced 
pressure to remove solvents and then neutralized with 2 M HCl aqueous solution (201 mL, 401 mmol). 
The resulting solid was collected by filtration, rinsed with water/EtOH and dried to give 133 (17.7 g, 
99 mmol, 98 %) as a beige solid. 1H NMR (300 MHz, DMSO-d6) δ 6.14 (1H, d, J = 7.9 Hz), 8.09 (1H, 
s), 8.56 (1H, d, J = 7.9 Hz). 
5-Chloropyrazolo[1,5-a]pyrimidine-3-carbonyl Chloride (134). To cooled (0 °C) POCl3 (71.0 mL, 
762 mmol) were added 133 (5.00 g, 27.9 mmol) and DIEA (16.1 mL, 92.1 mmol). The mixture was 
stirred at 130 °C for 4 h and then concentrated in vacuo. The residue was diluted with toluene and 
water at 0 °C, and then extracted with EtOAc. The organic layer was separated, dried over anhydrous 
Na2SO4, filtered through a cake of silica gel pad (eluted with ethyl acetate) and concentrated in vacuo. 
The resulting solid was triturated with heptane, collected by filtration, washed with heptane and dried 
to give 134 (4.46 g, 20.7 mmol, 74%) as a beige solid. 1H NMR (300 MHz, CDCl3) δ 7.16 (1H, d, J = 
7.2 Hz), 8.65 (1H, s), 8.70 (1H, d, J = 7.2 Hz). 
5-Chloro-N-((1S)-2-hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)pyrazolo[1,5-a]pyrimid
ine-3-carboxamide (135). To a cooled (0 °C) mixture of 134 (1.48 g, 6.85 mmol) and CH3CN (30 mL) 
were added 130 (1.96 g, 6.85 mmol) and DIEA (3.58 mL, 20.6 mmol), and the mixture was stirred at 
0 °C to rt for 16 h. The mixture was poured into water and extracted with EtOAc. The organic layer 
was separated, washed with saturated aqueous NaCl, dried over anhydrous Na2SO4, and concentrated 
in vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl acetate, 100:0 
to 0:100) to give 135 (2.27 g, 5.29 mmol, 77%) as white amorphous solids. 1H NMR (300 MHz, 
CDCl3) δ 1.19 (3H, s), 1.40 (3H, s), 1.88 (1H, s), 5.12 (1H, d, J = 8.7 Hz), 6.99 (1H, d, J = 7.2 Hz), 
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7.17–7.23 (2H, m), 7.45–7.53 (2H, m), 8.56 (1H, d, J = 8.7 Hz), 8.62 (1H, s), 8.67 (1H, d, J = 7.2 Hz). 
MS (ESI/APCI) m/z 429.1 [M + H]+. 
N-((1S)-2-Hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)-5-(prop-1-en-2-yl)pyrazolo[1,5-
a]pyrimidine-3-carboxamide (136). Into a microwave vial equipped with a magnetic stirrer were 
added 135 (76.1 mg, 0.177 mmol), 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (46.6 
mg, 0.266 mmol), K2CO3 (36.8 mg, 0.266 mmol), toluene (4 mL) and water (0.4 mL), followed by 
(Amphos)2PdCl2 (12.6 mg, 0.0177 mmol). The reaction vial was flushed with nitrogen, sealed and 
heated by microwave irradiation at 150 °C for 25 min. The mixture was purified by column 
chromatography (basic silica gel, hexane/ethyl acetate, 19:1 to 1:4), followed by a second column 
purification (silica gel, hexane/ethyl acetate, 19:1 to 1:4) to afford 136 (48.8 mg, 0.112 mmol, 63%) as 
a yellow amorphous solid. 1H NMR (300 MHz, DMSO-d6) δ 1.00 (3H, s), 1.27 (3H, s), 2.37 (3H, s), 
4.88–4.98 (2H, m), 5.80 (1H, s), 6.36 (1H, s), 7.24–7.34 (2H, m), 7.49–7.58 (2H, m), 7.65 (1H, d, J = 
7.5 Hz), 8.45 (1H, s), 9.02 (1H, d, J = 8.7 Hz), 9.22 (1H, d, J = 7.5 Hz). MS (ESI/APCI) m/z 435.2 [M 
+ H]+. 
5-(3,6-Dihydro-2H-pyran-4-yl)-N-((1S)-2-hydroxy-2-methyl-1-(4-(trifluoromethoxy)phenyl)propyl)p
yrazolo[1,5-a]pyrimidine-3-carboxamide (137). Into a microwave vial equipped with a magnetic 
stirrer were added 135 (142 mg, 0.330 mmol), 
2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (104 mg, 0.495 mmol), K2CO3 
(68.5 mg, 0.495 mmol), toluene (4 mL) and water (0.4 mL), followed by (Amphos)2PdCl2 (23.4 mg, 
0.0330 mmol). The reaction vial was flushed with nitrogen, sealed, and heated by microwave 
irradiation at 150 °C for 25 min. The mixture was purified by column chromatography (silica gel, 
hexane/ethyl acetate, 19:1 to 1:4) to afford 137 (110 mg, 0.230 mmol, 70%) as a yellow solid. 1H 
NMR (300 MHz, DMSO-d6) δ 1.00 (3H, s), 1.28 (3H, s), 2.67–2.94 (2H, m), 3.84–3.97 (2H, m), 4.35–
4.43 (2H, m), 4.86–5.00 (2H, m), 7.24–7.34 (3H, m), 7.49–7.56 (2H, m), 7.59 (1H, d, J = 7.5 Hz), 8.42 
(1H, s), 9.06 (1H, d, J = 8.7 Hz), 9.20 (1H, d, J = 7.5 Hz). MS (ESI/APCI) m/z 477.2 [M + H]+. 
220 
 
Ethyl 5-Chloropyrazolo[1,5-a]pyrimidine-3-carboxylate (138). POCl3 (30 mL, 322 mmol) was added 
to 132 (5.54 g, 26.7 mmol) and the mixture was stirred at 100 °C for 16 h. After POCl3 was removed 
under reduced pressure, the residue was partitioned between EtOAc and NaHCO3 aqueous solution. 
The phases were separated and the aqueous phase was extracted with EtOAc. The combined organic 
phases were washed with water and saturated aqueous NaCl, dried over anhydrous Na2SO4 and 
concentrated in vacuo. The residue was purified by column chromatography (silica gel, hexane/ethyl 
acetate, 19:1 to 1:1) to afford 138 (3.69 g, 16.3 mmol, 61%) as a white solid. MS (ESI/APCI) m/z 
226.1 [M + H]+. 
Ethyl 5-(Pyridin-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate (140). A mixture of ethyl 138 (300 mg, 
1.33 mmol), lithium 4-methyl-1-(pyridin-2-yl)-2,6,7-trioxa-1-borabicyclo[2.2.2]octan-1-uide (139) 
(566 mg, 2.66 mmol), Ph3P (139 mg, 0.532 mmol), copper(I) iodide (127 mg, 0.665 mmol) and 
Pd(OAc)2 (29.9 mg, 0.133 mmol) in DMF (5 mL) was stirred at 80 °C for 2 h under Ar. The mixture 
was filtered through a cake of basic silica gel pad (eluted with ethyl acetate), followed by a cake of 
silica gel pad (eluted with ethyl acetate). The appropriate fractions were concentrated in vacuo. The 
resulting solid was triturated with hot ethyl acetate and insoluble materials were filtered off. After 
concentration of the filtrate, the residue was purified by column chromatography (basic silica gel, 
hexane/ethyl acetate, 100:0 to 3:7) to give 140 (309 mg, 1.15 mmol, 87 %) as a pale yellow solid after 
trituration with i-Pr2O. 1H NMR (300 MHz, CDCl3) δ 1.47 (3H, t, J = 7.1 Hz), 4.46 (2H, q, J = 7.1 Hz), 
7.40–7.47 (1H, m), 7.86–7.95 (1H, m), 8.25 (1H, d, J = 7.4 Hz), 8.59 (1H, s), 8.71–8.76 (2H, m), 8.80 
(1H, d, J = 7.4 Hz). MS (ESI/APCI) m/z 269.1 [M + H]+. 
5-(Pyridin-2-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid (141). A mixture of 140 (117 mg, 0.436 
mmol), 4 M NaOH aqueous solution (0.545 mL, 2.18 mmol), THF (3.5 mL) and EtOH (3.5 mL) was 
stirred at 60 °C for 2 h. After being cooled to 0 °C, the mixture was acidified with 6 M HCl aqueous 
solution (0.363 mL) and concentrated in vacuo to give crude 141 (79.0 mg, 0.329 mmol, 75%). This 
was used in the next reaction without further purification. 
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tert-Butyl 2-cyano-3-(dimethylamino)acrylate (144). A mixture of tert-butyl 2-cyanoacetate (142) 
(24.3 g, 172 mmol) and tert-butoxy bis(dimethylamino)methane (143) (35.5 mL, 172 mmol) was 
stirred at rt for 30 min. The mixture was evaporated to give 144 as a pale yellow solid. This was used 
in the next reaction without further purification. 1H NMR (300 MHz, CDCl3) δ 1.50 (9H, s), 3.17 (3H, 
s), 3.36 (3H, s), 7.62 (1H, s). 
tert-Butyl 3-Amino-1H-pyrazole-4-carboxylate (145). A mixture of 144 (33.8 g, 172 mmol) and 
hydrazine monohydrate (8.39 mL, 172 mmol) in MeOH (344 mL) was stirred at 70 °C overnight. 
After cooling to rt, the mixture was poured into water at rt and extracted with EtOAc. The organic 
layer was separated, washed with saturated aqueous NaCl, dried over anhydrous MgSO4 and 
concentrated in vacuo. The residue was crystallized from i-Pr2O  to give 145 (20.0 g, 109 mmol, 
64%) as a pale orange solid. 1H NMR (300 MHz, DMSO-d6) δ 1.47 (9H, s), 4.86–6.14 (2H, m), 7.07–
7.92 (1H, m), 11.44–12.34 (1H, m). MS (ESI/APCI) m/z 184.1 [M + H]+. 
Methyl 2,3-Dibromo-2-methylpropanoate (147). To a solution of methyl methacrylate (60.1 g, 600 
mmol) in EtOAc (353 mL) at 0 °C was added a solution of bromine (30.7 mL, 600 mmol) in EtOAc 
(30 mL). The mixture was stirred at rt for 16 h and then saturated aqueous Na2S2O3 was added. The 
mixture was diluted with water and extracted with EtOAc. The combined organic phases were washed 
with saturated aqueous NaCl, dried over anhydrous Na2SO4 and concentrated in vacuo to afford 147 
(152 g, 584 mmol, 97%) as a colorless oil. 1H NMR (300 MHz, DMSO-d6) δ 1.95 (3H, s), 3.76 (3H, s), 
4.08–4.14 (1H, m), 4.16–4.22 (1H, m). 
Methyl 3,3-Dimethoxy-2-methylpropanoate (148). A suspension of sodium methoxide (28% MeOH 
solution, 226 g, 1.17 mol) in MeOH (234 mL) was heated to 70 °C and then a solution of 147 (152 g, 
584 mmol) in MeOH (20 mL) was added rapidly. The mixture was stirred at 70 °C for 3 h. After 
cooling to rt, the mixture was filtered and washed with MeOH, and then the filtrate was concentrated 
in vacuo. The residue was partitioned between Et2O and water. The organic layer was washed with 
water and saturated aqueous NaCl, dried over anhydrous MgSO4, filtered, and concentrated in vacuo 
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to give 148 (54.5 g, 336 mmol, 58%) as a pale yellow oil. This was used in the next reaction without 
further purification. 1H NMR (300 MHz, CDCl3) δ 1.17 (3H, d, J = 7.2 Hz), 2.71–2.85 (1H, m), 3.35 
(3H, s), 3.38 (3H, s), 3.70 (3H, s), 4.50 (1H, d, J = 7.6 Hz). 
tert-Butyl 5-Hydroxy-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxylate (149). To a mixture of 145 
(20.0 g, 109 mmol) and 148 (26.6 g, 164 mmol) in DMF (219 mL) was added cesium carbonate (64.2 
g, 197 mmol). The mixture was stirred at 100 °C for 16 h, diluted with water and then acidified to pH 
~4 with AcOH. The resulting solid was filtered by filtration, washed with water and dried to afford 
149 (22.6 g, 91.8 mmol, 84%) as a white solid. 1H NMR (300 MHz, DMSO-d6) δ 1.53 (9H, s), 1.96 
(3H, d, J = 1.1 Hz), 7.97 (1H, s), 8.53 (1H, d, J = 1.1 Hz), 11.22 (1H, brs). MS (ESI/APCI) m/z 250.1 
[M + H]+. 
tert-Butyl 5-Azido-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxylate (150). To a suspension of 149 
(4.99 g, 20.0 mmol) in THF (100 mL) was added DBU (4.52 mL, 30.0 mmol) and DPPA (5.17 mL, 
24.0 mmol) at rt. The mixture was stirred at 60 °C under Ar for 3 h. DBU (1.51 mL, 10.0 mmol) and 
DPPA (1.72 mL, 8.00 mmol) were added thereto. The mixture was stirred at 60 °C under Ar for 2 h. 
The mixture was poured into water at rt and extracted with a 1:1 mixture of hexane and EtOAc. The 
organic layer was separated, washed with saturated aqueous NaCl, dried over anhydrous MgSO4, 
filtered through a short pad of silica gel, eluted with a 1:1 mixture of hexane and EtOAc, and 
concentrated in vacuo. The resulting solid was triturated with hexane to give 150 (4.03 g, 14.7 mmol, 
74%) as a pale green solid. 1H NMR (300 MHz, DMSO-d6) δ 1.51–1.65 (9H, m), 2.12–2.55 (3H, m), 
8.38–8.49 (1H, m), 8.85–9.11 (1H, m). MS (ESI/APCI) m/z 275.1 [M + H]+. 
tert-Butyl 5-Chloro-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxylate (152). Carbon tetrachloride 
(9.73 mL, 100 mmol) was added to a solution of PPh3 (27.1 g, 100 mmol) in 1,2-dichloroethane (223 
mL) at rt. The mixture was stirred at the same temperature under N2 for 30 min. To this mixture was 
added a suspension of 149 (5.0 g, 20.1 mmol) in 1,2-dichloroethane (111 mL) at rt and the resulting 
mixture was stirred under N2 at 75–85 °C for 4.5 h, and then concentrated in vacuo. The residue was 
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partitioned between EtOAc and water. The phases were separated and the aqueous phase was extracted 
with EtOAc. The combined organic phases were washed with saturated aqueous NaCl, dried over 
anhydrous Na2SO4, and concentrated in vacuo. The residue was purified by column chromatography 
(silica gel, hexane/ethyl acetate, 100:0 to 7:3) to give 152 (4.75 g, 17.7 mmol, 88%) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 1.62 (9H, s), 2.42 (3H, d, J = 0.9 Hz), 8.40 (1H, s), 8.52 (1H, d, J = 0.9 
Hz). 
tert-Butyl 6-Methyl-5-(4-methyl-1H-1,2,3-triazol-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate 
(153a). A mixture of 150 (4.36 g, 15.9 mmol) and 151 (6.07 g, 19.1 mmol) in toluene (79 mL) was 
stirred at 80 °C for 3 h. To the mixture was added MgCl2 (4.54 g, 47.7 mmol). After 15 min, to the 
mixture was added MgCl2 (3.03 g, 31.8 mmol). The mixture was stirred at 60 °C under Ar for 2 h. The 
solid was filtered off, washed with hot toluene. The filtrate was evaporated. The residue was purified 
by column chromatography (silica gel, hexane/ethyl acetate, 19:1 to 9:11) to give 153a (4.83 g, 15.4 
mmol, 97%) as a white solid. 1H NMR (300 MHz, CDCl3) δ 1.64 (9H, s), 2.46 (3H, d, J = 0.8 Hz), 
2.78 (3H, d, J = 1.1 Hz), 8.46–8.50 (2H, m), 8.71–8.73 (1H, m). MS (ESI/APCI) m/z 315.2 [M + H]+. 
tert-Butyl 6-Methyl-5-(3-methyl-1H-1,2,4-triazol-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylate 
(153b). To a solution of 152 (1.08 g, 4.03 mmol) in DMF (20 mL) was added 
3-methyl-1H-1,2,4-triazole (0.469 g, 5.65 mmol) and K2CO3 (0.781 g, 5.65 mmol) at rt. The mixture 
was stirred at rt overnight and warmed to 60 °C for 2 h. After cooling to rt, water was added to the 
mixture. The solid was collected by filtration, washed with water, and dried to give 153b (0.870 g, 
2.77 mmol, 69%) as a tan solid. 1H NMR (300 MHz, DMSO-d6) δ 1.56 (9H, s), 2.43 (3H, s), 2.54 (3H, 
d, J = 1.1 Hz), 8.56 (1H, s), 9.10 (1H, s), 9.43 (1H, d, J = 1.1 Hz). MS (ESI/APCI) m/z 315.2 [M + 
H]+. 
6-Methyl-5-(4-methyl-1H-1,2,3-triazol-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid (154a). To 
a stirred suspension of 153a (2.64 g, 8.40 mmol) in CH3CN (84 mL) was added methanesulfonic acid 
(2.78 mL, 42.0 mmol) at 0 °C. The mixture was stirred at rt overnight. The starting material remained 
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on TLC and further methanesulfonic acid (0.555 mL, 8.40 mmol) was added. The mixture was stirred 
at rt for 1 h and then neutralized with 1 M NaOH aqueous solution at 0 °C. The organic solvent was 
evaporated under reduced pressure and then diluted with water. The resulting solid was collected by 
filtration, washed with water and then hexane, and dried to give 154a (1.98 g, 7.67 mmol, 91%) as a 
white solid. 1H NMR (300 MHz, DMSO-d6) δ 2.40 (3H, s), 2.52 (3H, d, J = 0.8 Hz), 8.50 (1H, d, J = 
1.1 Hz), 8.62 (1H, s), 9.50 (1H, d, J= 1.1 Hz), 12.52 (1H, brs). MS (ESI/APCI) m/z 259.2 [M + H]+.  
6-Methyl-5-(3-methyl-1H-1,2,4-triazol-1-yl)pyrazolo[1,5-a]pyrimidine-3-carboxylic Acid (154b). To 
a suspension of 153b (0.87 g, 2.77 mmol) in CH3CN (14 mL) was added MsOH (1.26 mL, 19.4 mmol) 
at 0 °C. After being stirred at rt for 5 h, the mixture was warmed to 60 °C for 30 min. 1 M NaOH 
aqueous solution (19.4 mL, 19.4 mmol) was added thereto at 0 °C. CH3CN was evaporated. The solid 
was collected by filtration, washed with water, dried to give 154b (0.606 g, 2.35 mmol, 85%) as a tan 
solid. 1H NMR (300 MHz, DMSO-d6) δ 2.42 (3H, s), 2.48–2.53 (3H, m), 8.60 (1H, s), 9.09 (1H, s), 
9.44 (1H, d, J = 1.1 Hz), 12.49 (1H, brs). MS (ESI/APCI) m/z 259.1 [M + H]+. 
(+)-Di-(p-toluoyl)-D-tartaric acid salt of 155 (156). 
(1S)-1-amino-2-methyl-1-(4-(trifluoromethoxy)phenyl)propan-2-ol hydrochloride (130) (2.00 g, 7.00 
mmol) was suspended in EtOAc and neutralized with saturated aqueous NaHCO3. The organic phase 
was dried over anhydrous Na2SO4 and concentrated in vacuo to afford 
(1S)-1-amino-2-methyl-1-(4-(trifluoromethoxy)phenyl)propan-2-ol (155) (1.74 g, 6.98 mmol, 
quantitative yeild) as a colorless oil. 155 (125 mg, 0.500 mmol) and 
(2S,3S)-(+)-di-(p-toluoyl)-D-tartaric acid (193 mg, 0.500 mmol) were dissolved in EtOH (500 µl) and 
water (500 µl) at rt. The mixture was standed at rt overnight to give 
(2S,3S)-2,3-bis((4-methylbenzoyl)oxy)butanedioic acid - 




Enzyme Assay Protocol. Preparation of human PDE. Human PDE1A, 3A, 4D2, 5A1, 7B, 8A1, 9A2, 
and 11A4 enzymes were purchased from BPS Bioscience. Human PDE6AB enzyme was purchased 
from SB Drug Discovery. Human PDE2A3 full-length gene was transduced into Sf9 cells, and the 
enzyme was purified by His-tag affinity column and gel filtration. Human PDE10A2 was generated 
from COS-7 cells that had been transfected with the full-length gene. The enzymes were stored at 
−70 °C until use. 
PDE2A3 enzyme inhibitory assay. PDE activity was measured using an SPA (GE Healthcare). To 
evaluate the inhibitory activity of a compound, 10 µL of serially diluted compounds were incubated 
with 20 µL of PDE enzyme (final concentration 0.023 nM) in assay buffer (50 mM HEPES-NaOH, 8.3 
mM MgCl2, 1.7 mM EGTA, and 0.1% bovine serum albumin (BSA) (pH 7.4)) for 30 min at rt. Final 
concentration of DMSO in the reaction solution was 1%. Compounds were tested in duplicate in 
96-well half-area plates (Corning) or 384-well OptiPlates (PerkinElmer). We used an 8 concentration 
serial dilution dose response ranging from 100 µM to 10 pM compound concentrations. To start the 
reaction, 10 µL of substrate [3H] cGMP (final concentration 77 nM, PerkinElmer) were added to a 
total volume of 40 µL. After 60 min at rt, 20 µL of 20 mg/mL yttrium silicate SPA beads containing 
zinc sulfate were added to terminate the PDE reaction. After resting undisturbed for an additional 60 
min, the assay plates were counted in a scintillation counter (PerkinElmer) to allow calculation of the 
inhibition rate. Inhibition rate was calculated based on 0% control wells with enzyme and DMSO, and 
100% control wells without enzyme. All IC50 values were obtained by fitting the results to the 
following 4 Parameter Logistic Equation: 
y = A + (B – A)/(1 + (10^((C – x)*D))) 
where A is the minimum y value, B is the maximum y value, C is Log(EC50) value, and D is the 
slope factor. 
Human PDE enzyme assay. PDE activities were measured using an SPA (GE Healthcare). To evaluate 
the inhibitory activity, 10 µL of serially diluted compounds were incubated with 20 µL of PDE 
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enzymes (except for PDE1A) in assay buffer (50 mM HEPES-NaOH, 8.3 mM MgCl2, 1.7 mM EGTA, 
and 0.1% BSA (pH 7.4)) for 30 min at rt. The PDE1A enzyme assay was performed in a different 
assay buffer (50 mM Tris-HCl, 8.3 mM MgCl2, 0.2 mM CaCl2, 0.1% BSA, and 30 nM Calmodulin 
(pH 7.5)). The final concentration of DMSO in the assay was 1%. Compounds were tested in duplicate 
in 96-well half-area plates (Corning). We used an 4 concentration serial dilution dose response ranging 
from 10 µM to 10 nM compound concentrations. To start the reaction, 10 µL of substrate ([3H] cGMP 
(final concentration 77 nM, PerkinElmer) for PDE1A, 5A1, 6AB, 9A2, 10A2, and 11A4 or [3H] cAMP 
(final concentration 14.7 nM, PerkinElmer) for PDE3A, 4D2, 7B, and 8A1) were added for a final 
assay volume of 40 µL. After 60 min incubation at rt, 20 µL of 20 mg/mL yttrium silicate SPA beads 
containing ZnSO4 were added to terminate the PDE reaction. After resting undisturbed for more than 
120 min, the assay plate was counted in a scintillation counter (PerkinElmer) to allow calculation of 
the inhibition rate. 
Transcellular Transport Study Using a Transporter-Expression System. Human 
MDR1-expressing LLC-PK1 cells were cultured as reported previously with minor modifications.106 
The transcellular transport study was performed as reported previously.107 In brief, the cells were 
grown for 7 days in HTS Transwell 96-well permeable support (pore size 0.4 µm, 0.143 cm2 surface 
area) with polyethylene terephthalate membrane (Corning Life Sciences, Lowell, MA, USA) at a 
density of 1.125 × 105 cells/well. The cells were preincubated with M199 at 37 °C for 30 min. 
Subsequently, transcellular transport was initiated by the addition of M199 either to apical 
compartments (75 µL) or to basolateral compartments (250 µL) containing 10 µM digoxin, 200 µM 
lucifer yellow (as a marker for the tightness of the monolayer), and 10 µM test compounds. The assay 
was terminated by the removal of each assay plate after 2 h. Aliquots (25 µL) from the opposite 
compartments were mixed with CH3CN containing alprenolol and diclofenac as internal standards, and 
then centrifuged. The compound concentrations in the supernatant were measured by LC–MS/MS. The 
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apparent permeability (Papp) of test compounds in the receiver wells was determined and the efflux 
ratio (ER) for the MDR1 membrane permeability test was calculated using the following equation: 
ER = Papp,BtoA/Papp,AtoB 
where Papp,AtoB is the apical-to-basal passive permeability-surface area product and Papp,BtoA is the 
basal-to-apical passive permeability-surface area product. 
Phototoxicity Test. Phototoxicity assay was carried out as described in the OECD guideline No. 
432117 with some modifications for a high-throughput screening. BALB/c 3T3 cells were cultured at 
37 °C under 5% CO2 in DMEM supplemented with 10% fetal bovine serum, 50 IU/mL penicillin and 
50 mg/mL streptomycin. Cells were seeded at 2.5 × 103 cells/well in 384-well white plates, and 
cultured in DMEM supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium 
pyruvate, 50 IU/mL penicillin, and 50 μg/mL streptomycin for 1 day. Two 384-well plates per test 
compound (50 μM) in Earle’s Balanced Salt Solution (EBSS) supplemented with 1 mM HEPES were 
preincubated for 1 h. One of the two plates was irradiated (+UV) for 60 min with 1.4–1.7 mW/cm2 (5–
6 J/cm2), whereas the other plate was kept in the dark (−UV). In both plates the treatment medium was 
replaced with the culture medium and after another 24 h of culture, the cell viability was determined 
by measuring the cellular ATP content. The cellular ATP content was measured using the 
Celltiter-Glo™ assay kit (Promega) following the manufacture’s instruction. ATP content was 
calculated as follows. ATP content (% of control) = (relative light unit (RLU) of test compound/RLU 
of 1% DMSO) × 100. 
Estimation of Log D at pH 7.4. Log D7.4, which is the partition coefficient of the compounds between 
1-octanol and aqueous buffer at pH 7.4, was measured using a chromatographic procedure based on a 
published method.68 The instruments utilized were a Waters Alliance 2795 HPLC system and a 2996 
UV–vis detector (Milford, MA, USA). 
Thermodynamic Solubility Measurement Using the Shake-Flask Method. The measurement of 
thermodynamic solubility was carried out as previously described.68 Briefly, the drug substances were 
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weighed into Thomson filter vials (Chrom Tech, Inc., Minnesota, U.S.A.). JP1 (pH 1.2), JP2 (pH 6.8), 
and JP2-containing 20 mM GCDC were added to the vials. The vials were incubated at 37 °C for 18 h 
and the resulting suspensions were filtered by compressing the vials. The drug concentration of the 
filtrates was determined using a UHPLC system. 
Powder X-ray Diffraction (PXRD) and Crystallinity Calculation. PXRD patterns were collected 
using a RINT UltimaIV powder X-ray diffractometer (Rigaku Corp., Tokyo, Japan) according to 
previously described conditions.68 The peak intensities of the crystalline (Ic) and non-crystalline (Ia) 
fractions were integrated from the baseline collection according to Herman’s method.118,119 The 
crystallinity was calculated using the following equation with an autocrystallinity calculation software 
(Rigaku, Tokyo, Japan).119,120 
Crystallinity = Ic × 100 / (Ic + Ia) × 100 
Protein Expression and Purification. The PDE2A catalytic domain (578–919) was cloned into a 
pFastBac vector, for expression in Sf9 cells, utilizing an N-terminal 6× poly-histidine tag containing a 
TEV cleavage site. Large scale production of recombinant protein was carried out in Sf9 cells. The 
pellet from 10L of baculovirus infected Sf9 cells was resuspended in 600 mL lysis buffer containing 
25 mM Tris pH 7.6, 1 M NaCl, 20 mM imidazole, 5% glycerol, and 3 Roche cOmplete Protease 
Inhibitor tablets. The cell suspension was homogenized with the Polytron PT-3100, centrifuged for 1 h 
at 13,000 rpm (JA-14 rotor), and the clarified supernatant was brought to 800 mL with lysis buffer 
before batch binding with 10 mL of Probond Ni resin (Invitrogen) for 2 h at 4 °C, rolling. The beads 
were collected by low speed centrifugation (3,500 rpm with JS-4.2 rotor), loaded into a gravity column, 
and washed slowly overnight with 2 L of wash buffer containing 25 mM Tris pH 7.6, 1 M NaCl, 20 
mM imidazole, 5% glycerol. The following day the protein was eluted with buffer containing 25 mM 
Tris pH 7.9, 50 mM NaCl, 250 mM imidazole, 10% glycerol. The 1.5 mL sample eluted from the 
Nickel capture step was brought to 9 mL with Mono Q buffer A containing 25 mM Tris pH 7.9, and 
10% glycerol. After the full sample volume was bound to the Mono Q column, a salt gradient was 
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applied from 0 M NaCl to ~800 mM NaCl in 40 mL. Fractions corresponding to the unphosphorylated 
protein (identified by MS with MW = 40178 Da) were pooled for further purification by 
size-exclusion chromatography on a Superdex 200 column equilibrated in 1XTBS pH 7.4, 0.5 mM 
DTT, 1 mM EDTA, 10% glycerol. Peak SEC fractions were collected and concentrated to 12 mg/mL 
for crystallization. 
Crystallization and Structure Determination. Crystals suitable for data collection were first grown 
using the vapor diffusion method in hanging drops at room temperature by adding 0.5 µL protein 
solution with 1 mM IBMX59 and 0.5 µL reservoir solution (30% PEG 3350, 0.1 M Tris pH 7.5, and 0.2 
M MgCl2). PDE2A IBMX crystals were soaked in a drop containing 5 mM compound 122b, 31% 
PEG 3350, 0.1 M Tris pH 7.5, and 0.2 M MgCl2 for 3 days. Crystals were transferred through a fresh 
cryo-protected soak drop immediately before being harvested and flash frozen in liquid nitrogen. 
X-ray diffraction data was collected at ALS beamline 5.0.2 using a Pilatus3 6M (Dectris) detector 
from a single cryogenically protected crystal (100K) at a wavelength of 1 Å. The crystals belong to the 
space group C121 and contain three enzyme molecules per asymmetric unit. X-ray diffraction data 
was reduced using the HKL2000108 software package. The structure was determined by molecular 
replacement with PHASER within the CCP4 program suite and refined with REFMAC.111 Several 
cycles of model building using MIfit113 and refinement using REFMAC were performed for improving 
the quality of the model. The coordinates and structure factors have been deposited in the Protein Data 
Bank with accession code 5VP1. 
Animal Experiments. The care and use of animals and the experimental protocols were approved by 
the Experimental Animal Care and Use Committee of Takeda Pharmaceutical Company Limited. 
Pharmacokinetic Analysis in Rat or Mouse Cassette Dosing. Compound 122b was administered 
intravenously (0.1 mg/kg) or orally (1 mg/kg) by cassette dosing to nonfasted male Crl:CD(SD)(IGS) 
rats (8W, n = 3) or male ICR mice (8W, n = 3). The combination for a cassette dosing was determined 
to avoid combinations of compounds with the same molecular weight. The solution of compounds in 
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dimethylacetamide containing 50% (v/v) 1,3 butanediol at 0.1 mg/mL/kg was administered 
intravenously to isoflurane-anesthetized mice via femoral vein. The suspension of compounds in 0.5% 
methyl cellulose with water was used for vehicle (1 mg/kg) and was administered orally by gavage. 
After administration, blood samples were collected via tail vein by syringes with heparin at 5, 10, 15, 
30 min, 1, 2, 4, and 8 h (iv) and 15, 30 min, 1, 2, 4, and 8 h (po), and centrifuged to obtain the plasma 
fraction. The plasma samples were deproteinized by mixing with acetonitrile followed by 
centrifugation. The compound concentrations in the supernatant were measured by LC–MS/MS with a 
standard curve. Pharmacokinetic parameters were calculated by the non-compartmental analysis. The 
area under the concentration-time curve (AUC) and the area under the first moment curve (AUMC) 
were calculated using the linear trapezoidal method. The mean residence time (MRT) was calculated 
as AUMC/AUC. The total clearance (CLtotal) was calculated as doseiv/AUCiv. The volume of 
distribution (Vdss) was calculated as CLtotal × MRTiv. Oral bioavailability (F) was calculated as 
(AUCpo/dosepo)/(AUCiv/doseiv) × 100. 
Brain and Plasma Concentration in Rats. Compound 122b was administered orally to Long–Evans 
rats (male, non-fasted, 7-week old) at 10 mg/kg. Blood and whole brain samples were collected 2 h 
after oral administration. The blood samples were centrifuged to obtain the plasma fraction. The brain 
samples were homogenized in saline to obtain the brain homogenate. Compound concentrations were 
measured in aliquots of rat plasma and brain, which were mixed well with acetonitrile containing an 
internal standard and then centrifuged. The supernatants were diluted with solvents for LC–MS/MS 
analysis (mobile phase A: 10 mM ammonium formate/formic acid (100/0.2, v/v), mobile phase B: 
acetonitrile/formic acid (100/0.2, v/v)). The diluted solutions were injected into an LC–MS/MS 
(API5000, AB Sciex, Foster City, CA) equipped with a Shimadzu Shim-pack XR-ODS column (2.2 
μm packing particle size, 2.0 mm ID × 30 mm L) maintained at 50°C. The chromatographic separation 
was performed using gradient elution at a flow rate of 0.7 mL/min. The LC time program was as 
follows: Mobile phase B was held at 5% for 0.1 min, and increased linearly to 95% in 0.1 min. After 
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maintaining B at 95% for another 0.8 min, it was decreased to 5% in 0.01 min, followed by 
re-equilibration for 0.59 min. The total cycle time for one injection was 1.6 min. Compound 122b was 
detected using multiple reaction monitoring mode and the transition m/z 490.01 → 240.96. AnalystTM 
software (version 1.4.2) was used for data acquisition and processing. 
In Vivo Occupancy Study. In vivo target occupancy study of compound 122b was conducted using 
LC–MS/MS. Compound 122b was suspended in 0.5% (w/v) methylcellulose in distilled water, and 
PF-05270430121 was dissolved in dimethylacetamide and 1,3-butanediol (1:1). SD rats were pretreated 
with vehicle (po, n = 6) or compound 122b (0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, and 30 mg/kg, 
po, n = 4 in each group) 2 h before sampling. PF-05270430 (0.1 mg/mL/kg) was administered by 
bolus intravenous injection via lateral tail vein 30 min before sampling. Rats were decapitated, and 
blood and brain samples (striatum as target tissue and cerebellum as reference tissue) were collected. 
Brain samples were weighed and saline was added (20% weight/volume), followed by 
homogenization with Lysing Matrix I beads (MP Biomedicals). Homogenized samples were stored at 
–30°C until quantification of tracer (PF-05270430) using LC–MS/MS. The supernatants were diluted 
with solvents for LC–MS/MS analysis (mobile phase A: 10 mM ammonium formate/formic acid 
(100/0.2, v/v), mobile phase B: acetonitrile/formic acid (100/0.2, v/v)). The diluted solutions were 
injected into an LC–MS/MS (API5000, AB Sciex, Foster City, CA) equipped with a Shimadzu 
Shim-pack XR-ODS (2.2 μm packing particle size, 2.0 mm ID × 30 mm L) maintained at 50°C. The 
chromatographic separation was performed using gradient elution at a flow rate of 0.7 mL/min. The 
LC time program was as follows: Mobile phase B was held at 5% for 0.1 min, and increased linearly 
to 95% in 0.1 min. After maintaining B at 95% for another 0.8 min, it was decreased to 5% in 0.01 min, 
followed by re-equilibration for 0.59 min. The total cycle time for one injection was 1.6 min. 
PF-05270430 was detected using multiple reaction monitoring mode and the transition m/z 432 → 
386. AnalystTM software (version 1.4.2) was used for data acquisition and processing. Specific tracer 
binding (BSP) in the striatum was represented as the difference between the tracer concentration in 
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striatum and that in cerebellum. PDE2A occupancy was calculated using the following equation: 
Occupancy (%) = (BSP,base − BSP,drug)/BSP,base × 100, where BSP,base and BSP,drug are the concentrations at 
baseline (vehicle treatment) and at drug treatment, respectively. Curve fitting of the saturation curve 
was carried out by nonlinear regression using GraphPad Prism 5.02 (GraphPad Software, Inc., San 
Diego, CA). 
Measurement of Cyclic Nucleotide Contents in Rat Brain. Animals. Five-week-old male Long–
Evans rats were purchased from Japan SLC, Inc. (Japan). The rats were housed in groups of 3/cage in 
a light-controlled room (12 h light/dark cycles with lights on at 07:00). Food and water were provided 
ad libitum. After a one week acclimation period, the six-week-old rats were used for experiments. 
Measurements. Compound 122b was suspended in 0.5% (w/v) methylcellulose in distilled water, and 
was administered in a volume of 2 mL/kg body weight for rats. Rats were administered orally with 
either vehicle or compound 122b (1 mg/kg, 3 mg/kg, and 10 mg/kg) after >1 h of habituation. A 
microwave fixation system (Muromachi Kikai, Tokyo, Japan) was used to sacrifice unanesthetized rats 
by exposure of the head to the microwave beam at 2 h after administration of 122b. Brain tissues were 
isolated and then homogenized in 0.5 mol/L HCl, followed by centrifugation. The concentration of 
cyclic nucleotides in the supernatant was measured using a cyclic AMP EIA kit or cyclic GMP EIA kit 
(Cayman Chemical, USA) following the manufacturer’s instructions. Values were expressed as 
pmol/mg tissue weight.  
Step-through Passive Avoidance Task. This task was performed as previously described122 with some 
modifications. This experiment was conducted in 7–8-week-old male Long–Evans rats. The apparatus 
(Brainscience idea, Osaka, Japan) consisted of an illuminated chamber (25 × 10 × 25 cm) connected to 
a dark chamber (30 × 30 × 30 cm) by a sliding door (8 × 8 cm). On the training day, each animal was 
subjected to a single pre-training trial 4–6 h before the acquisition trial. The rat was placed in the light 
chamber, and the sliding door was opened 30 s later. As soon as the rat entered the dark chamber with 
all four paws, the door was closed. The rat was then allowed to remain in the dark chamber for 30 s 
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before being returned to its home cage. In the acquisition trial, the rat was placed in the light chamber, 
and the sliding door was opened. The time required for the rat to enter the dark chamber was then 
recorded. As soon as the rat entered the dark chamber, the door was closed, and an electric shock (0.5 
mA, 3 s) was delivered from the floor grid. The rat was then returned to its home cage. The retention 
test was conducted 24 h later. The rat was again placed in the light chamber with the sliding door. 
After 30 s, the door was opened and the latency for the rat to cross over into the dark compartment 
was recorded. If the animal did not enter the dark chamber within 300 s, the retention test was 
terminated, and the animal was given a ceiling score of 300 s. Vehicle or compound 122b (3 mg/kg) 
was administered po 2 h prior, and saline or MK-801 (0.1 mg/kg) was administered sc 30 min prior to 
the acquisition trial. The statistical significance of differences between group latency scores was 
determined by Wilcoxon’s test with significance set at p ≤ 0.05. 
Determination of the Absolute Stereochemistry of RHS Amine 155. The absolute configuration of 
free base of 130 (i.e. 155) was determined by X-ray crystallography of its (+)-di-(p-toluoyl)-D-tartaric 
acid salt 156. 
Crystal data for 156: C11H15F3NO2+·C20H17O8–, MW = 635.59; crystal size, 0.21 × 0.13 × 0.07 mm; 
colorless, block; monoclinic, space group C2, a = 25.4050(5) Å, b = 7.84709(14) Å, c = 15.9718(3) Å, 
α = γ = 90°, β = 95.114(7)°, V = 3171.37(11) Å3, Z = 4, Dx = 1.331 g/cm3, T = 100 K, μ = 0.950 mm−1, 
λ = 1.54187 Å, R1 = 0.029, wR2 = 0.077, Flack Parameter114 = –0.11(10). 
All measurements were made on a Rigaku R-AXIS RAPID-191R diffractometer using graphite 
monochromated Cu-Kα radiation. The structure was solved by direct methods with SIR2008116 and 
was refined using full-matrix least-squares on F2 with SHELXL-97.115 All non-H atoms were refined 
with anisotropic displacement parameters. 
CCDC 1548481 for compound 156 contains the supplementary crystallographic data for this paper. 
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